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ABSTRACT 
 
The PINK1/Parkin pathway is genetically linked to recessive forms of Parkinson’s 
disease (PD) and plays a central role in the maintenance of mitochondrial 
homeostasis. Following toxification with the membrane uncoupler CCCP, PINK1, a 
serine/threonine kinase, becomes stabilised on the outer membrane of damaged 
mitochondria. This stabilisation is necessary for the translocation of Parkin, an E3-
ubiquitin ligase, to mitochondria prior to their removal via mitophagy. In order to identify 
novel pathway components upstream of Parkin translocation, we performed a genome-
wide RNAi screen using Drosophila S2R+ cells. Upon completion, we validated primary 
screen hits with multiple rounds of secondary screening, assessing a range of 
mitochondrial homeostatic processes. In follow-up screens, corresponding human 
orthologs were assessed for their ability to influence Parkin translocation and 
mitophagy in HeLa cells, demonstrating conserved pathway function. Human screen 
hits selected for in depth analysis included several genes acting in a common 
lipogenesis pathway. These are the transcription factor and master pathway regulator 
SREBF1, the Skp1-Cul1-F-box E3-ligase protein FBXW7 and the serine/threonine 
kinase GSK3A. Follow-up analyses of these genes suggest a role for SREBP-
dependent lipid synthesis in PINK1/Parkin-mediated mitophagy, likely acting upstream 
of PINK1. Importantly, SREBF1 has recently been identified as a risk locus for sporadic 
forms of PD (Do et al, 2011). Hence, this study reveals a novel mechanistic link 
between familial- and sporadic causes of PD, with mitochondrial dysfunction at its 
centre.  
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ABBREVIATIONS 
 
 
[Ca2+]IC  Intracellular calcium concentration 
∆Ψm  Mitochondrial membrane potential 
AbFM  Antibiotic-free MEM 
ATP  Adenosine Tri-Phosphate 
CCCP  Carbonyl cyanide m-chlorophenyl hydrazone 
CL  Cardiolipin 
CNS  Central nervous system 
CT  Threshold cycle 
DA  Dopamine 
DDC  DOPA decarboxylase 
ddH2O  Double-distilled water 
DMSO  Dimethly sulfoxide 
dsRNA  Double-stranded RNA 
EMS  ethyl methanesulfonate 
ER  Endoplasmic reticulum 
ETC  Electron Transport Chain 
FBS  Fetal bovine serum 
FOV  Field of view 
GD  Gaucher’s disease 
HeLa  Henrietta Lacks [cells] 
IBR  Inbetween RING 
IMS  Intermembrane space 
L-DOPA L-3,4-dihydroxyphenylalanine 
LB  Luria-Bertani [broth] 
MAD  Median absolute deviation 
MEF  Mouse embryonic fibroblast [cells] 
MEM  Modified Eagle’s Media 
MIM  Mitochondrial inner membrane 
MOM  Mitochondrial outer membrane 
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mPTP  Mitochondrial permeability transition pore 
MTR  MitoTracker Red 
MTS  Mitochondrial targeting sequence 
NCM  Normal culture medium 
PBS  Phosphate Buffered Saline 
PD  Parkinson’s disease 
PE  Phosphatidylethanolamine 
RBR  RING-between-RING 
RING  Really interesting new gene [domain] 
RISC  RNA-induced silencing complex 
ROS  Reactive oxygen species 
RPE1  Retinal Pigmented Epithelial 1 [cells] 
S2R+  Schneider 2 receptor plus [cells] 
SAbFM  Serum and antibiotic-free MEM 
SFSM  Serum-free Schneider’s Medium 
siRNA  Small interfering RNA 
SM  Schneider’s Medium 
SNpc  Substantia Nigra pars compacta 
SRSF  Sheffield RNAi Screening Facility 
SSD  Sterol sensing domain 
TH  Tyrosine hydroxylase 
TM   Transmembrane 
UBL  Ubiquitin-like 
UPR  Unfolded protein response 
UPS  Ubiquitin-proteasome system 
VDRC  Vienna Drosophila RNAi Centre 
  
! 4 
 
 5 
 
1. INTRODUCTION 
  
 6 
  
 7 
1.1  PARKINSON’S DISEASE 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder 
after Alzheimer’s disease, affecting 1 in 5000 people, with a mean age of onset of 55 
(Dauer and Przedborski, 2003). Incidence of the disease increases dramatically with 
age, affecting ~1 in 1000 people between the ages of 70 - 79 (Lees et al., 2009). First 
described by the physician, James Parkinson in 1817 (Parkinson, 2002), Parkinson’s 
disease is a progressive movement disorder, with a mean duration from diagnosis to 
death of 15 years (Lees et al., 2009). Pathology targets a multitude of neuronal 
populations of the central nervous system (CNS), including somatomotor, limbic, and 
autonomic regions (Braak et al., 2004). However, the hallmark lesions are the selective 
loss of pigmented dopaminergic neurons in the substantia nigra pars compacta (SNpc) 
of the midbrain (Figure 1.1 A & B), an area involved in fine motor control; and the 
appearance of proteinaceous inclusions, or Lewy bodies in surviving neurons (Figure 
1.1 C). The cumulative loss of neuronal mass in PD manifests itself as a decrease in 
SNpc pigmentation, and results in a range of characteristic motor symptoms including 
bradykinesia, muscle rigidity, resting tremor, and postural instability.  
 
Dopamine (DA) is a catecholamine neurotransmitter produced primarily in the midbrain 
from the amino acid, L-tyrosine. L-tyrosine is first converted into L-3,4-
dihydroxyphenylalanine (L-DOPA) by the enzyme tyrosine hydroxylase (TH), before 
transformation into dopamine by DOPA decarboxylase (DDC). The majority of 
dopaminergic neurons reside in the ventral mesencephalon, and form four major 
dopaminergic pathways throughout the central nervous system. Of fundamental 
importance to PD is the nigrostriatal pathway, originating in the SNpc and extending to 
the caudate nucleus and putamen, which constitute the striatum (Figure 1.1 A). This 
pathway controls the initiation and execution of voluntary movement, hence why 
Parkinson’s disease patients present motor dysfunction (Chinta and Andersen, 2005). 
Patients also experience wide-ranging non-motor symptoms including, but not limited 
to depression, hallucinations, dementia, sleep disorders, gastrointestinal issues and 
sensory disturbances (Chaudhuri et al., 2006). Often, symptoms such as olfactory 
disturbances are noted at early stages (Braak stage 1) of Parkinson’s disease, before 
the classic motor symptoms begin, making these potential diagnostic markers for pre-
clinical PD sufferers (Braak et al., 2004). 
 
Diagnosing a patient with Parkinson’s disease is difficult, and can only be definitively 
confirmed following the discovery of Lewy bodies in post-mortem substantia nigra brain 
tissue. In the living patient, the presence of bradykinesia, plus one or more additional 
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Figure 1.1 Hallmarks of Parkinson’s disease. A) Schematic of normal dopaminergic innervation from the Substantia 
Nigra pars compacta (SNpc) of the midbrain, to the striatum (Putamen and Caudate) via the nigrostriatal pathway (red). 
Arrows indicate neuromelanin-pigmented dopaminergic neurons of the SNpc. B) Schematic of the Parkinson’s disease-
state, where arrows indicate a loss of pigmented dopaminergic neurons, resulting in a reduced innervation of the 
striatum (dashed & thin red line). C) Demonstration of Lewy body pathology in surviving dopaminergic neurons. 
Immunostaining for α-synuclein and ubiquitin. Figure from Dauer and Przedborski, (2003). 
  
‘classic’ PD motor symptoms will often lead to a positive diagnosis of Parkinson’s 
disease. Additionally, alleviation of symptoms following treatment with L-DOPA 
supports this diagnosis. In some cases, a disease with similar symptoms to PD will be 
termed a ‘parkinsonism.’ This often relates to cases where the etiology of the 
syndrome is distinct to that of PD, or where Lewy bodies are absent at autopsy, such is 
the case with some familial forms of PD (Hardy et al., 2006).  
 
 
1.2  HALLMARKS OF PARKINSON’S DISEASE 
 
PD pathology is dominated by the loss of neuromelanin-containing neurons of the 
nigrostriatal dopaminergic pathway, and the presence of proteinaceous inclusions or 
Lewy bodies in surviving neurons. However, neuronal death and Lewy body pathology 
Review
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Figure 1. Neuropathology of Parkinson’s
Disease
(A) Schematic representation of the normal
nigrostriatal pathway (in red). It is composed
of dopaminergic neurons whose cell bodies
are located in the substantia nigra pars com-
pacta (SNpc; see arrows). These neurons
project (thick solid red lines) to the basal gan-
glia and synapse in the striatum (i.e., putamen
and caudate nucleus). The photograph dem-
onstrates the normal pigmentation of the
SNpc, produced by neuromelanin within the
dopaminergic neurons.
(B) Schematic representation of the diseased
nigrostriatal pathway (in red). In Parkinson’s
disease, the nigrostriatal pathway degener-
ates. There is a marked loss of dopaminergic
neurons that project to the putamen (dashed
line) and a much more modest loss of those
that project to the caudate (thin red solid line).
The photograph demonstrates depigmenta-
tion (i.e., loss of dark-brown pigment neuro-
melanin; arrows) of the SNpc due to the
marked loss of dopaminergic neurons.
(C) Immunohistochemical labeling of intra-
neuronal inclusions, termed Lewy bodies, in a
SNpc dopaminergic neuron. Immunostaining
with an antibody against !-synuclein reveals
a Lewy body (black arrow) with an intensely
immunoreactive central zone surrounded by
a faintly immunoreactive peripheral zone (left
photograph). Conversely, immunostaining
with an antibody against ubiquitin yeildsmore
diffuse immunoreactivity within the Lewy
body (right photograph).
synaptic DA clearance in the striatum seems to be more the cerebral cortex (especially cingulate and entorhinal
cortices), olfactory bulb, and autonomic nervous sys-dependent on DAT than in the prefrontal cortex, where
other monoaminergic transporters and the synaptic en- tem. Degeneration of hippocampal structures and cho-
linergic cortical i put contribute to the high rate ofzyme c techol-O-methyltransferas play a gr ater role
in terminating the actions ofDA (Giros et al., 1996; Gogos dementia that accompanies PD, particularly in older pa-
tients. However, the clinical correlates of lesions to theet al., 1998; Mundorf et al., 2001). The prefrontal cortex
is a primary site of projection for VTA dopaminergic serotonergic and noradrenergic pathways are not as
clearly characterized as are lesions in the dopaminergicneuro s, so this difference may be of importance in
understanding the relative resistance of VTA neurons to systems. Thus, while involvement of these neurochemi-
cal systems is generally thought to occur in more severePD-related degeneration. Differences in neuronal milieu
have also been identified surrounding SNpc dopaminer- or late-stage disease, the temporal relationship of dam-
age to specific neurochemical systems is not well estab-gic cell bodies. The neuropil of the substantia nigra,
composed of axon projections fro the striatum and lished. For example, some patients develop depression
months or years prior to the onset of PD motor symp-globus pallidus, stains strongly for calbindin D28K, and
most dopaminergic cell bodies reside within this calbin- to s, which could be due to early involvement of nondo-
paminergic pathways.din-rich neuropil (Damier et al., 1999a). However, the
susceptible neurons in PD t nd to be in calbindin-poor In life, the dia nosis of PD ismade on clinical grounds,
but definite diagnosis requires the identification of bothareas of the substantia nigra (Damier et al., 1999b).
Although it is commonly thought that the neuropathol- LB and SNpc dopaminergic neuron loss. LBs are not
specific for PD, however, and are also found in AD, inogy of PD is characterized solely by dopaminergic neu-
ron loss, the neurodegeneration extends well beyond a condition called “dementia with LB disease,” and as
an incidental pathologic finding in people of advanceddopaminergic neurons (reviewed by Hornykiewicz and
Kish, 1987). Neurodegeneration and LB formation are age at a greater frequency than the prevalence of PD
(Gibb and Lees, 1988). The role of LB in neuronal cellfound in noradrenergic (locus coeruleus), serotonergic
(raphe), and cholinergic (nucleus basalis of Meynert, death is controversial, as are the reasons for their in-
creased frequency in AD and the relationship of inciden-dorsal motor nucleus of vagus) systems, as well as in
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are not confined to SNpc neurons alone, with cells as far reaching as the neocortex 
being affected at late stages of disease. Despite this promiscuity, significant population 
losses are restricted to the dopaminergic neurons of the SNpc and the noradrenergic 
neurons of the locus coeruleus, with a decrease of ~80% as the disease reaches 
terminal progression (Sulzer, 2007). 
 
1.2.1  NEURODEGENERATION 
 
In 2004, Braak and colleagues split the progression of sporadic PD into 6 stages, by 
analysing the presence of Lewy bodies in different regions of the brain. They found that 
in pre-clinical stages, Lewy bodies first appear in the brainstem, moving up into the 
substantia nigra and on to the neocortex in late stages of the disease. Usually, at 
Braak stages 3 and 4 the disease becomes symptomatic, by which time ~70% of the 
SNpc dopaminergic neurons are lost (Braak et al., 2004).  
 
1.2.2  SELECTIVE VULNERABILITY OF DOPAMINERGIC NEURONS 
 
A topic of ongoing discussion in the PD field is the reason/s behind the largely 
dopamine-specific neuronal loss. The loss of these neurons is undoubtedly the cause 
of motor symptoms observed in PD sufferers, as these are greatly ameliorated by 
treatment with L-DOPA. Many theories regarding the cause of selective DA neuron loss 
in PD have been proposed, including an increase in oxidative stress following the 
metabolism of DA itself. Here, cytoplasmic DA is readily oxidised, causing increased 
production of reactive oxygen species (ROS), and resulting in nucleic acid, protein and 
lipid damage (Sulzer and Zecca, 2000). However, there are some discrepancies with 
this argument, notably that L-DOPA, the gold-standard treatment for PD, does not 
negatively affect symptoms or progression of the disease (Fahn et al., 2004). 
Additionally, PD-related cell death is not exclusively limited to DA-containing neurons, 
indicating that DA-metabolism cannot be the sole cause of PD.  
 
Alternatively, the architecture of vulnerable PD neurons may contribute to their 
selective loss. Here, dopaminergic neurons exhibit extremely long, unmyleinated 
axons, requiring them to endure slow, myelin-free action potentials over huge axonal 
distances. Additionally each neuron is required to innervate a plethora of targets via 
~370,000 synapses (Braak et al., 2004). Such energy-intensive characteristics, 
together with the vast number of energy-reliant synapses at axon termini, place a great 
burden upon the mitochondrial population (Surmeier et al., 2010). Therefore another 
putative source of selective vulnerability is an elevation of intracellular ROS from 
 10 
overworked mitochondria, combined with a chronic energy deficit. Notably, elevated 
lipid peroxidation has been detected in postmortem brain tissue from PD patients, 
confirming the incidence of increased oxidative stress (Jenner et al., 1992). 
 
Other theories are built around the unusual ‘pace making’ behavior of SNpc neurons 
(Grace and Bunney, 1983), whereby action potentials are fired regularly, in the 
absence of external stimuli. The reason for this is thought to be in maintaining a 
constant supply of DA to the striatal region of the brain. However, chronic neuronal 
depolarisation via calcium influx carries high-energy costs to the cell. This calcium 
must be pumped back across the plasma membrane via ATP hydrolysis, or buffered by 
the endoplasmic reticulum (ER) and mitochondria, to maintain low cytoplasmic 
concentrations. However, mitochondrial calcium buffering causes the mitochondrial 
membrane potential (∆Ψm) to collapse, thereby halting ATP production and producing 
a potentially fatal energy deficit (Chan et al., 2009). Additionally, increases in 
intracellular calcium stimulate DA production (Sutoo et al., 1989), perhaps contributing 
to DA oxidation and cell damage, as discussed previously. 
 
Whether the cause of selective dopaminergic vulnerability is one, or a combination of 
the theories outlined above remains to be elucidated. However, it is likely to arise from 
both the oxidative damage of cellular components and mitochondrial dysfunction, to 
levels beyond that which the cell can cope with. This coincides with an increased risk 
of PD with aging, as cellular damage increases over time. 
 
1.2.3  LEWY BODIES 
 
Together with dopaminergic neurodegeneration, the second hallmark of PD is the 
occurrence of widespread intraneuronal proteinaceous inclusions or Lewy bodies. 
Typically 15  µm in diameter, Lewy bodies have a characteristic structure with a dense 
hyaline core and an outer halo of radiating fibrils (Figure 1.1 C). They are found 
intraneuronally, in multiple locations of the PD brain, displaying a characteristic and 
predictable topography as the disease progresses (Braak et al., 2004). Typically, they 
are found in both sporadic and familial forms of PD; but are notably absent in a small 
number of familial PD patients, including most cases of parkin and PINK1-related 
autosomal recessive PD (Hardy, 2010; Klein and Westenberger, 2012). 
 
The major component of Lewy bodies is the pre-synaptic protein, α-synuclein 
(Spillantini et al., 1997), together with ubiquitin and other cellular lipids and proteins. In 
health, α-synuclein is thought to play a role in synaptic plasticity (George et al., 1995), 
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however in both familial and sporadic forms of PD it is believed to aggregate into small 
cytotoxic protofibrils capable of forming intracellular pore-like structures. These 
structures are proposed to initiate permeabilisation of intracellular organelles, ultimately 
leading to neuronal death (Lashuel et al., 2002; Volles and Lansbury, 2002). Lewy 
bodies are therefore considered to be the byproduct of a protective mechanism, 
whereby cytotoxic protofibrils are aggregated into fibrillar masses for proteolytic 
removal (Conway et al., 2001; Volles and Lansbury, 2003). Of note, DA has been 
shown to inhibit the formation of aggregated α-synuclein inclusions from the cytotoxic 
protofibrils, again implicating DA in the mechanism of pathology (Conway et al., 2001).  
 
1.2.4  PRION THEORY OF PARKINSON’S DISEASE PROGRESSION 
 
An emerging theory for PD progression is the spread of α-synuclein throughout the 
brain in a prion-like fashion. Key to this theory is the observation that Lewy bodies are 
not only found in surviving midbrain dopaminergic neurons, but also in more peripheral, 
non-dopaminergic cell types. Braak and colleagues have proposed that Lewy bodies 
first appear in the medulla oblongata and olfactory bulb of the brainstem at a pre-
clinical stage of PD, before ascending to the SN, and on to regions such as the 
neocortex as the disease progresses (Braak et al., 2003). Evidence for a non-cell-
autonomous prion-like spreading of α-synuclein came from the observation that 
embryonic grafts in the brains of PD suffers contained Lewy bodies a number of years 
post-transplantation (Kordower et al., 2008; Li et al., 2008). This suggested that Lewy 
pathology may propagate from cell to cell over time. In support of this, recent evidence 
has shown that a proportion of newly-synthesised monomeric and aggregated α-
synuclein is packaging into vesicles and exocytosed from SH-SY5Y neuroblastoma 
cells (Lee et al., 2005). Additionally, fibrillar α-synuclein can undergo endocytosis, 
followed by the formation of insoluble inclusions in axons and cell bodies of primary 
neurons (Volpicelli-Daley et al., 2011). Taken together, these studies demonstrate the 
ability of α-synuclein to leave host cells, and enter unaffected cells, supporting the idea 
of neural Lewy body transmission. However, it remains to be elucidated whether the 
presence of alpha-synuclein aggregates are the cause of neuronal death in PD, or a 
harmless byproduct of a cell-protective process; and why neuronal death is observed 
even in the absence of Lewy bodies. 
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1.3  TREATMENT OF PARKINSON’S DISEASE 
 
Currently, the neurodegeneration observed in PD patients cannot be prevented or 
cured by pharmacological intervention. The gold standard treatment, L-DOPA, acts to 
replace the lost dopamine following SNpc neurodegeneration, hence alleviating the 
associated symptoms. Most patients are responsive to this treatment, seeing a great 
improvement in associated motor symptoms over a 3-month period. However, 
extended L-DOPA treatment is not without issues. Many patients experience 
extrapyramidal, involuntary movements or dyskinesias after chronic treatment periods. 
During these times, a substitution of dopamine agonists or monoamine oxidase B 
inhibitors (an enzyme involved in the breakdown of DA) can be used instead of L-
DOPA, although the efficacy is usually lower (Lees et al., 2009). For advanced patients 
suffering from severe L-DOPA side effects, an alternative, surgical intervention called 
‘deep brain stimulation’ in the subthalamic nucleus has shown great clinical benefits 
(Rascol et al., 2011). This method involves the implantation of a pacemaker producing 
high frequency electrical stimulation to the brain, through which normal midbrain 
activity is restored. 
 
One of the issues with treating PD patients is that often, at the time of clinical diagnosis 
~70% of SNpc neurons have already been lost (Lesage and Brice, 2009). By this 
stage, the disease has progressed beyond the point of preventive measures. Future 
research is likely to focus on replacement of lost neurons through grafts and stem cell 
therapies. However, to date, these approaches have either failed to produce significant 
beneficial results, or presented worrying side effects such as the presence of Lewy 
bodies in embryonic grafts, as mentioned previously (Rascol et al., 2011). 
 
 
1.4  ETIOLOGY OF PARKINSON’S DISEASE 
 
Approximately 90% of PD cases are ‘sporadic’, with no known genetic or 
environmental cause. However, the remaining 10% of disease sufferers have a clear 
monogenetic inheritance. These genetic cases have experienced intense study since 
the discovery of the first disease-related gene, SNCA, encoding α-synuclein, in 1996 
(Polymeropoulos et al., 1996; Polymeropoulos et al., 1997). Insights gained from 
studying monogenic PD cases are hoped to enhance our understanding of common 
sporadic PD, with the ultimate goal of developing more effective treatments and even 
pre-clinical tests for the disease. Importantly, recent work indicates that ‘sporadic’ PD 
cases often carry genetic risk variants of monogenic PD genes including α-synuclein, 
and more commonly LRRK2, highlighting a crossover between the two disease groups. 
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1.4.1  ENVIRONMENTAL RISK FACTORS 
 
A number of non-genetic risk factors have been linked to the occurrence of PD via 
epidemiology studies. However, most of these risk factors are yet to be supported by 
sufficient evidence to define them as ‘causal’ to disease development (Kieburtz and 
Wunderle, 2013). Two exceptions are ‘age’ and ‘gender’, both of which consistently 
confer risk; with PD being more common in aged males (Bower et al., 1999; Van Den 
Eeden et al., 2003).  
 
A number of chemicals have been linked to the development of parkinsonian 
syndromes, with the most famous example being the administration of MPTP in a 
group of American drug-users. Here, the MPTP metabolite, MPP+ was found to induce 
a severe, parkinsonian syndrome via mitochondrial complex I inhibition, a matter of 
weeks following exposure (Langston et al., 1983). This case offered clear evidence that 
environmental determinates have the potential to play a role in PD etiology. 
Additionally, toxin-induced animal models of PD implicate common pesticides such as 
paraquat and rotenone as putative causal factors of parkinsonian neuropathology 
(Betarbet et al., 2000; Norris et al., 2007; Thiruchelvam et al., 2003). Both compounds 
share similarities with MPTP. For example, the herbicide and redox-cycling compound 
paraquat has a similar chemical structure to MPTP; and rotenone, an insecticide and 
fish poison, acts as a mitochondrial complex I inhibitor. Importantly, both pesticides 
have been implicated as causative factors in the development of sporadic PD in case-
control studies (Costello et al., 2009; Tanner et al., 2011). Additionally, epidemiology 
studies have identified a link between rural living and Parkinson’s disease risk. Aspects 
investigated included pesticide exposure, well-water consumption and connections to 
farming. However, the strongest risk factor was again, pesticide-related (Gorell et al., 
1998; Hancock et al., 2008). 
 
Other environmental factors able to modify the risk of PD development are dose-
dependent exposure to tobacco, through cigarette smoking (Allam et al., 2004; Hernan 
et al., 2001) and caffeine, through coffee drinking (Ascherio et al., 2004; Hernan et al., 
2002), both of which have been shown to reduce disease incidence. 
 
Despite the identification of a number of potential environmental risk factors, much of 
the data are inconclusive or have an unexplained relationship to PD. In recent history, 
focus has turned away from environmental, and towards genetic risk factors of PD, 
some of which are now being identified as contributing towards sporadic forms of the 
disease. 
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1.4.2  GENETIC RISK FACTORS 
 
Besides the large proportion of sporadic PD sufferers, a small number of familial PD 
cases with monogenic inheritance have been identified; often associated with features 
atypical of sporadic PD, such as early onset, slow disease progression and the 
absence of Lewy bodies. To date, 18 genetic regions or ‘loci’ have been found to have 
a putative link to Parkinsonian syndromes (Table 1.1), of which 8 are unequivocally 
associated with PD (Lesage and Brice, 2012). This association has established a clear 
genetic component to at least a small proportion (~10%) of PD cases. Thus far, 
characterisation of these loci has greatly increased our understanding of the molecular 
pathways thought to play a role in common PD (Klein and Westenberger, 2012) 
 
Of the 8 confirmed PD loci, four genes are responsible for autosomal dominant forms 
of PD, and four for autosomal recessive PD. Within the autosomal dominant group, 
PARK1&4/SNCA (Farrer et al., 1999; Polymeropoulos et al., 1996; Polymeropoulos et 
al., 1997) and PARK8/LRRK2 (Funayama et al., 2002; Paisan-Ruiz et al., 2004), have 
been studied in great depth; whereas PARK17/VPS35 (Vilarino-Guell et al., 2011; 
Zimprich et al., 2011) and PARK18/EIF4G1 (Chartier-Harlin et al., 2011), have only 
recently been identified. Interestingly, in addition to the familial link, both SNCA and 
LRRK2 variants are strongly implicated as causative risk factors of sporadic PD (Ahn et 
al., 2008; Paisan-Ruiz et al., 2008; Troiano et al., 2008). 
 
Of the four confirmed autosomal recessive genes, PARK2/parkin (Kitada et al., 1998), 
PARK6/PINK1 (Valente et al., 2004a) and PARK7/DJ1 (Bonifati et al., 2003b) produce 
an early onset form of Parkinsonism, often lacking Lewy bodies, and PARK9/ATP13A2 
produces an atypical form of PD called Kufor-Rakeb syndrome (Ramirez et al., 2006). 
Again, heterozygous mutations in Parkin, PINK1, and DJ1 are suggested to increase 
the risk of late onset PD in combination with additional unknown factors (Choi et al., 
2006; Klein et al., 2007). 
 
1.4.3  PARKINSON’S DISEASE-CAUSING GENE LOCI 
 
The 18 genetic loci identified as causal or susceptibility factors for familial Parkinson’s 
disease have each been assigned a ‘PARK1-18’ annotation, numbered according to 
their date of discovery (Table 1.1). These include a mixture of autosomal dominant and 
recessive monogenic modes of inheritance, plus a handful of loci with an unknown 
mechanism of inheritance. The causative PD genes within a number of the PARK loci 
have been identified, whereas others remain elusive. These PD loci and genes have
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Table 1.1 PARK-designated PD-related loci. Table of PARK loci from PARK1-PARK18 (symbol), together with the 
chromosomal position (Gene locus), equivalent disorder, form of inheritance, known causal gene and the mode of loci 
identification. Table adapted from Klein and Westenberger, (2012). 
 
been identified via gene mapping approaches, such as linkage studies and genome 
wide association studies, plus candidate gene methodologies (Klein and 
Westenberger, 2012). In this section, literature regarding the most well-studied PD 
genes will be reviewed in brief. 
 
1.4.4  AUTOSOMAL DOMINANT FAMILIAL PARKINSON’S DISEASE 
 
1.4.4.1  PARK1/4 - ALPHA-SYNUCLEIN (SNCA) 
 
SNCA, encoding the protein α-synuclein, was the first familial Parkinson’s disease 
gene identified, more than 15 years ago (Polymeropoulos et al., 1996; Polymeropoulos 
et al., 1997). Only four pathogenic point mutations have been identified in SNCA, all of 
which are rare and follow an autosomal dominant pattern of inheritance (Berg et al., 
2005; Proukakis et al., 2013). SNCA-related PD cases show earlier onset than 
sporadic PD, with additional, non-parkinsonian symptoms including cognitive decline. 
As well as causing monogenic PD, SNCA risk alleles have been found to significantly 
contribute to the development of sporadic PD, strengthening the link between familial 
and sporadic disease etiologies (Lesage and Brice, 2012). In addition to SNCA 
mutations, a number of gene duplication and triplication cases have been found to 
Symbol Gene locus Disorder Inheritance Gene Mode of identification
PARK1 4q21-22 EOPD AD SNCA Linkage analysis
PARK2 6q25.2-a27 EOPD AR parkin Linkage analysis
PARK3 2p13 Classical PD AD Unknown Linkage analysis
PARK4 4q21-q23 EOPD AD SNCA Linkage analysis
PARK5 4p13 Classical PD AD UCHL1 Functional candidate gene approach
PARK6 1p35-p36 EOPD AR PINK1 Linkage analysis
PARK7 1p36 EOPD AR DJ-1 Linkage analysis
PARK8 12q12 Classical PD AD LRRK2 Linkage analysis
PARK9 1p36
Kufor-Rakeb syndrome; atypical PD with 
dementia, spasticity, and supranuclear gaze 
palsy
AR ATP13A2 Linkage analysis
PARK10 1p32 Classical PD Risk factor Unknown Linkage analysis
PARK11 2q36-27 Late-onset PD AD Unknown, not GIGYF2 Linkage analysis
PARK12 Xq21-q25 Classical PD Risk factor Unknown Linkage analysis
PARK13 2p12 Classical PD AD or risk factor HTRA2 Candidate gene approach
PARK14 22q13.1 Early-onset, dystonia-parkinsonism AR PLA2G6 Linkage analysis (homozygosity mapping)
PARK15 22q12-q13 Early-onset, parkinsonian-pyramidal syndrome AR FBXO7 Linkage analysis
PARK16 1q32 Classical PD Risk factor Unknown Genome-wide association studies
PARK17 16q11.2 Classical PD AD VPS35 Exome sequencing
PARK18 3q27.1 Classical PD AD EIF4G1 Linkage analysis
AD - autosomal dominant, AR - autosomal recessive, EOPD - early-onset Parkinson's disease
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cause PD, with disease severity and onset occurring in a dose-dependent manner 
(Fuchs et al., 2007; Ibanez et al., 2004; Singleton et al., 2003). 
 
α-synuclein is a soluble protein with undefined structure, found in association with 
synaptic vesicles in the presynapsis of CNS neurons (George, 2002). The normal 
function of α-synuclein is not fully elucidated, however evidence indicates that it may 
be involved in synaptic transmission via the regulation of vesicular release (Bellani et 
al., 2010). However, both wild-type, and particularly mutant forms of α-synuclein can 
form stable β-sheet structures which are the building blocks for toxic, soluble 
oligomers, and insoluble filaments making up Lewy bodies (Bertoncini et al., 2005; 
Conway et al., 2000). Importantly, in PD patients, α-synuclein is the major component 
of Lewy bodies (Spillantini et al., 1997), indicating a toxic gain of function role for this 
protein.  
 
1.4.4.2  PARK 8 - LEUCINE-RICH REPEAT KINASE 2 (LRRK2) 
 
The second confirmed autosomal dominant form of PD is that resulting from mutations 
in leucine-rich repeat kinase 2 (LRRK2) (Funayama et al., 2002; Paisan-Ruiz et al., 
2004; Zimprich et al., 2004). Mutations in this gene are the most prolific known genetic 
cause of PD, accounting for ~7% of all familial cases (Mata et al., 2006), with the 
common G2019S variant alone accounting for ~4% of familial cases, and contributing 
to ~1% of sporadic cases (Xiong et al., 2012). LRRK2-related PD is similar in onset, 
pathogenesis, and progression to sporadic forms of the disease, setting it aside from 
PARK loci with atypical features, such as PARK2/parkin (Healy et al., 2008).  
 
LRRK2 is a very large gene, more than 9 kilobases in size and comprising 51 exons. 
The multidomain protein includes a series of leucine rich repeats in the N-terminus, a 
ROC (Ras of complex proteins) GTPase domain, a COR (C-terminal of ROC) 
regulatory domain and a kinase domain. With the exception of the leucine rich repeats, 
all aforementioned domains contain pathogenic mutations. However, the most common 
mutation, G2019S, resides in the kinase domain of the protein, implicating its 
importance in the development of PD (Xiong et al., 2012). Despite LRRK2 being the 
most prevalent disease-causing gene, little is known about the exact wild-type function 
of the protein. However, analysis of LRRK2 protein domains indicates a participation in 
protein-protein interactions via its scaffold domains, and a role in pathway signaling via 
its kinase and GTPase domains (Kumar and Cookson, 2011). Additionally, LRRK2 has 
been found to associate with a range of intracellular membranes including the 
mitochondrial outer membrane (MOM) and autophagic vesicles. However, the 
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significance of this it not yet understood (Alegre-Abarrategui et al., 2009; Biskup et al., 
2006). 
 
1.4.5  AUTOSOMAL RECESSIVE FAMILIAL PARKINSON’S DISEASE 
 
1.4.5.1  PARK2 - PARKIN 
 
The PARK2 locus was first identified in 1997, in 11 consanguineous families displaying 
an autosomal recessive parkinsonian disease with early onset (typically <40 years) 
(Matsumine et al., 1997). Later, using positional cloning, the causative gene at the 
PARK2 locus was identified and named ‘parkin’ (Kitada et al., 1998). Parkin is the most 
prevalent cause of autosomal recessive Parkinson’s disease, and accounts for ~50% 
of early onset cases under 45 and more than 70% of cases under 20 (Lucking et al., 
2000). However, despite this high frequency of mutation in early onset cases, parkin 
only accounts for approximately 1 - 2% of the total number of PD cases (Hardy, 2010). 
The parkinsonian syndrome conferred by parkin mutation is similar to sporadic PD, 
aside from the early age of onset, slow disease progression, and often, but not always 
a lack of Lewy body pathology (Farrer et al., 2001; Pramstaller et al., 2005; Takahashi 
et al., 1994). Despite this, classic PD motor symptoms are often present, together with 
a good response to L-DOPA therapy. Perturbations in the parkin gene include point 
mutations and exon rearrangements, and arise as either homozygous, or compound 
heterozygous mutations (Farrer et al., 2001; Lucking et al., 2000). Additionally, 
heterozygous parkin mutations have been identified in subjects with later onset PD, 
closely phenocopying sporadic forms of the disease. This suggests that there could 
also be a link between single parkin mutations, haploinsufficiency and sporadic PD risk 
(West et al., 2002).  
 
parkin encodes a 464-amino acid E3-ubiquitin protein ligase, capable of 
autoubiquitination and subsequent degradation (Shimura et al., 2000; Zhang et al., 
2000). The protein contains an N-terminal ubiquitin-like (UBL) domain, a RING0 
domain, and a C-terminal RING-between-RING (RBR) domain, consisting of two RING 
finger domains surrounding an inbetween RING (IBR) domain (Figure 1.2, Chaugule et 
al., 2011; Hristova et al., 2009). Pathogenic point mutations and rearrangements span 
to entirety of the protein (Walden and Martinez-Torres, 2012), including the RBR 
domain; responsible for protein interactions and E3-ligase activity (Beasley et al., 2007) 
and the UBL domain; believed to inhibit the autoubiquitination of the RBR domain 
(Figure 1.2, Chaugule et al., 2011). 
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Figure 1.2 Schematic representation of parkin transcript and protein, with associated PD mutations. parkin 
transcript, made up of 12 exons is represented in grey. Equivalent Parkin protein is shown below, with functional 
domains highlighted (UBL domain in yellow, RING domains in green, IBR domain in blue). PD-related point mutations 
are indicated by arrows; with frameshift, nonsense and splice mutations represented by red arrows, and missense 
mutations represented by blue arrows. Figure from Corti et al., (2011). 
 
Within the E3-ligase family, there are RING-E3 ligases and HECT-E3 ligases, with the 
mode of ubiquitin ligation being the distinguishing feature. Recent reports have 
indicated that Parkin may act as a RING/HECT hybrid, whereby interaction with the E2-
conjugating enzyme occurs via the RING1 domain, and transfer of a thioester-linked 
ubiquitin moiety occurs via an active cysteine in the RING2 domain (Lazarou et al., 
2013; Wenzel et al., 2011). The significance of this discovery in the context of the 
PINK1/Parkin-pathway will become apparent in later sections. 
 
E3-ubiquitin ligases act together with E1-activating and E2-conjugating enzymes to add 
ubiquitin moieties to specific target proteins. This modification can affect a number of 
different outcomes, but commonly leads to either proteasomal degradation of the target 
protein, or the stimulation of intracellular signaling cascades (Pickart and Fushman, 
2004). Parkin is known to be involved in poly-, mono- and multimono-ubiquitination 
events (Hampe et al., 2006; Moore et al., 2008; Olzmann et al., 2007), conferring 
alternative outcomes in a protein specific manner. Parkin has a number of known 
substrates (Table 1.2), including an apparent enrichment for mitochondria-linked
FIGURE 3. Schematic representation of parkin on transcript level and the functional domains of the parkin
protein with A) pathogenic frameshift mutations above the transcript and protein organizations and missense
mutations below; B) exonic deletions above the transcript (red lines) and exonic duplications (green lines) or
triplications (blue lines) below the transcript; a deletion of exons 1 of both parkin and the neighboring parkin
coregulated gene (PACRG) is also shown. Only homozygous or compound heterozygous mutations are listed.
Parkin is a 465-amino acid protein that contains an NH2-terminal ubiquitin-like (UBL) domain followed by three
RING (re lly interesting new gene) finger domains (RING 0–2) separated by a 51-residue IBR (in-between-ring)
domain in the COOH-terminal part. Numbers under the protein line indicate the boundaries of each domain.
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proteins including Mitofusin 1 and 2, VDAC1, Miro and PARIS (Walden and Martinez-
Torres, 2012), suggesting a role for Parkin in the regulation of the mitochondrial 
proteasome. 
 
1.4.5.2  PARK6 - PTEN-INDUCED KINASE 1 (PINK1) 
 
PINK1 was originally identified as a putative tumour suppressor, acting in the 
Phosphatase and tensin homolog (PTEN) pathway (Matsushima-Nishiu et al., 2001). 
This was later found to be a spurious connection (Unoki and Nakamura, 2001), but left 
behind the legacy of the name, PTEN-Inducted Kinase 1 or PINK1. Since these 
studies, the PARK6 locus and corresponding gene, PINK1, were identified as the 
second autosomal recessive region linked to early onset familial Parkinson’s disease 
(Valente et al., 2004a; Valente et al., 2001). Mutations in PINK1 produce symptoms 
synonymous with those observed in parkin-linked PD (Gasser et al., 2011), and are the 
second most common cause of recessive PD, accounting for between 1 - 9% of cases 
(Thomas and Beal, 2007). Perturbations in PINK1 are extensive across the whole 
gene, and include missense mutations, exon rearrangements and truncations (Figure 
1.3, Hatano et al., 2004; Valente et al., 2004a). Like with parkin, homozygous and 
compound heterozygous PINK1 mutations have been attributed to familial PD, most 
notably clustering around, and within the C-terminal kinase, highlighting the 
significance of this domain in pathogenicity (Hatano et al., 2004; Sim et al., 2006). In 
support of this, analysis of PINK1-autophosphorylation of disease-relevant mutants 
G309D and L347P, saw a significant reduction in kinase activity, suggesting the cause 
of PINK1-related PD to be due to a loss of phosphorylation events (Beilina et al., 
2005).  
 
In addition to familial PD, heterozygous PINK1 mutations have been suggested to 
contribute towards increased sporadic PD risk with later onset (Valente et al., 2004b). 
Interestingly, one case of digenic inheritance has been recorded where heterozygous 
mutations in PINK1 and DJ-1 (see section 1.4.5.3) were found to be the cause of a 
novel, autosomal recessive form of PD (Tang et al., 2006). This may suggest 
cooperation between PINK1 and DJ-1 in cellular protection. 
 
PINK1 encodes a 581-amino acid protein kinase, localised to the mitochondria and 
comprising of an N-terminal mitochondrial targeting sequence (MTS), a hydrophobic 
transmembrane (TM) domain, a large C-terminal serine/threonine kinase, and a 
putative regulatory C-terminal portion (Figure 1.3, Silvestri et al., 2005; Sim et al., 
2006; Valente et al., 2004a). Wild-type, but not pathologically mutated PINK1 confers 
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Figure 1.3 Schematic representation of PINK1 transcript and protein, with associated PD mutations. PINK1 
transcript, made up of 8 exons is represented in grey. Equivalent PINK1 protein is shown below, with functional domains 
highlighted (MTS domain in yellow, TM domain in blue, kinase domain in green). PD-related point mutations are 
indicated by arrows; with frameshift and nonsense mutations represented by red arrows, and missense mutations 
represented by blue arrows. Figure from Corti et al.,(2011). 
 
cellular protection in cultured dopaminergic neurons following toxic insult (Petit et al., 
2005; Valente et al., 2004a), whereas PINK1 siRNA reduces cell viability; an effect 
further exacerbated by complex I inhibition (Deng et al., 2005). The protective effect of 
PINK1 has been attributed to its serine/threonine kinase domain (Sim et al., 2006), a 
claim supported by data whereby the kinase domain of PINK1 alone was sufficient to 
prevent MPTP-induced cell death (Haque et al., 2008). Therefore PINK1 is likely 
conferring cellular protection via the phosphorylation of target substrates.  
 
Until recently, the sub-cellular and sub-mitochondrial localisations of PINK1 have been 
the subject of long-standing debate within the field. This confusion can be partly 
attributed to 1) difficulties in detection due to the rapid turnover of processed isoforms, 
2) the motile nature of the PINK1 lifecycle, 3) the re-distribution of PINK1 under 
conditions of cellular stress and 4) poor antibodies resulting in most studies being 
performed in overexpression systems. As alluded to, PINK1 exists as a number of 
isoforms, enduring several proteolytic events during its lifetime. Under basal conditions, 
following translation, the 63 kDa full-length ‘precursor’ PINK1 protein (PINK1-FL) is 
targeted to the mitochondria via its N-terminal MTS domain (Valente et al., 2004a). The 
MTS alone is responsible for this mitochondrial localisation, as a MTS-fusion with 
ECFP is sufficient for organelle specificity (Silvestri et al., 2005). Like most proteins 
with a mitochondrial presequence, once at the mitochondrial surface, PINK1 is 
imported into the intermembrane space (IMS) and then the mitochondrial inner 
membrane (MIM) via the translocase pore complexes, TOM and TIMM23 respectively 
PINK1 is a tumor suppressor with an NH2-terminal i-
tochondrial targeting signal (MTS) motif, a putative
transmembrane (TM) region, and a serine-threonine ki-
nase domain (FIG. 4), supporting the hypothesis that mi-
tochondrial dysfunction and oxidative stress may play a
role in the pathogenesis of PD. Some mutations destabi-
lize the protein, whereas others may decrease kinase ac-
tivity (23).
Mutations in the DJ-1 gene are the least common of he
known causes of autosomal recessive parkinsonism
(!1% of early-onset PD). A large homozygous deletion
and a homozygous missense mutation, L166P, were first
identified in DJ-1 at PARK7 in two consanguineous fam-
ilies from the Netherlands and Italy (38). Missense mu-
tations in coding and promoter regions, frame-shift and
splice site mutations, and exonic deletions have also been
found in some (FIG. 5) (4, 126, 221, 242, 387, 619), but
not in all studies in different populations (77, 237, 254,
373, 425, 488, 611, 627).
TheDJ-1-related phenotype, with early-onset and slow dis-
ease progression, closely resembles that of patients with
parkin or PINK1 mutations, but genotype/phenotype cor-
relations could not be meaningfully performed, however,
due to the small number of DJ-1 patients. The presence of
heterozygous mutations in the DJ-1 and PINK1 genes in
two members of a Chinese family who developed PD in
their 30s is suggestive of digenic inheritance; it was not fully
penetrant, however, since a 42-year-old sibling with the
same genotype was unaffected (618).
DJ-1 was initially described in association with oncogenesis
a d male infertility in rats. It is a member of the ThiJ/Pfp1
family of molecular chaperones, which are induced during
oxidative stress. Like the GAT sup rfamily members, hu-
man DJ-1 has a highly conserved cysteine at position res-
idue 106. The oxidation state of the Cys-106 residue
appears to have an important role in the chaperone ac-
tivity of DJ-1. Oxidative conditions induce formation of
a sulfinic acid of Cys-106, the most sensitive cysteine
residue to oxidative stress (12). In the presence of oxida-
tive stress, DJ-1 translocates from the cytoplasm to the
outer mitochondrial membrane and is thought to play a
role in neuroprotection (51). The L166P DJ-1 mutant
destabilizes the protein, inducing rapid proteasomal deg-
radation, probably interfering with the neuroprotective
mechanism (429, 435, 606).
FIGURE 4. Schematic representation of PINK1 on transcript level and the functional domains of the PINK1
protein with pathogenic frameshift mutations above the transcript and protein organizations and missense
mutations below the protein; rare deletions (above, red lines) including a deletion of the whole gene are also
represented. Only homozygous or compound heterozygous mutations are listed. PINK1 is a 581-amino acid
protein with an NH2-terminal mitochondrial targeting signal (MTS) motif, a putative transmembrane (TM)
region, and a serine-threonine kinase. Numbers under the protein line indicate the boundaries of each domain.
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(Jin and Youle, 2012; Neupert and Herrmann, 2007). A ‘stop transfer’ sequence in the 
TM domain of PINK1 halts import, preventing release into the mitochondrial matrix, and 
embedding PINK1 laterally in the MIM (Jin and Youle, 2012; Lin and Kang, 2010; 
Neupert and Herrmann, 2007; Zhou et al., 2008). Here, the matrix protease, 
mitochondrial processing peptidase (MPP), is responsible for the removal of the MTS 
domain from the N-terminus, producing a protein of ~60 kDa (Greene et al., 2012). 
Following MTS cleavage, PARL, an intramembrane protease in the MIM, is responsible 
for a second cleavage event in the TM domain at A103 (Deas et al., 2011; Jin et al., 
2010; Meissner et al., 2011; Whitworth et al., 2008), releasing a short, 52 kDa PINK1 
isoform into the cytoplasm (Yamano and Youle, 2013). Following PARL-dependent 
cleavage, the exposed N-terminus phenylalanine (F) acts as a type-2 degradation 
signal or degron (Sriram et al., 2011), leading to N-end rule pathway proteolysis via 
UBR1, UBR2 and UBR4 E3-ubiqutin ligases (Figure 1.4). The activation of the 
cytoplasmic N-end rule pathway allows for the rapid turnover of the 52 kDa isoform of 
PINK1 (Yamano and Youle, 2013). 
 
Aside from PINK1 autophosphorylation (Nakajima et al., 2003), at least five proteins 
are putatively phosphorylated in a PINK1-dependent manner; all of which reside in, or 
are associated with mitochondria. The first identified PINK1 substrate was the IMS 
chaperone, TNF-associated receptor 1 (TRAP1). Here, kinase assays demonstrated 
that PINK1 directly phosphorylates TRAP1 both in vitro and in vivo; and this event is 
increased in the presence of the oxidative stressor, hydrogen peroxide. This 
phosphorylation was proposed to inhibit the release of the pro-apoptotic protein, 
cytochrome C, through the mitochondrial permeability transition pore (mPTP), hence 
performing an anti-apoptotic cell-protective function (Pridgeon et al., 2007).  
 
In the same year, another mitochondrial protein, High Temperature requirement A2 
(HtrA2), was identified as a putative PINK1 substrate (Plun-Favreau et al., 2007). 
HtrA2 is an IMS serine protease involved in the induction of apoptotic cell death upon 
release into the cytoplasm (Suzuki et al., 2001). In 2005, HtrA2 was assigned to the 
locus ‘PARK13’, due to its involvement in a parkinsonian-like syndrome (Plun-Favreau 
et al., 2007; Strauss et al., 2005). However, this association could not be replicated, 
casting doubt over the involvement of this protein in disease etiology (Simon-Sanchez 
and Singleton, 2008). Nevertheless, HtrA2 has been shown to bind to PINK1, and 
become phosphorylated in a PINK1-dependent manner under conditions of cellular 
stress (Plun-Favreau et al., 2007). 
 23 
 
 
 
Figure 1.4 PINK1 proteolytic turnover under basal conditions. Schematic representation of PINK1 import into 
mitochondria via the TOM and TIMM23 complexes, subsequent cleavage events via MPP and PARL, and release into 
the cytosol for proteolytic N-end rule degradation via the proteasome. OMM – outer mitochondrial membrane, IMM – 
inner mitochondrial membrane, IMS – intermembrane space. Figure adapted from Yamano et al.,(2013). 
 
Two further substrates of PINK1 are the MOM GTPases, Mitofusin 2 (Mfn2), involved 
in mitochondrial fusion (Chen and Dorn, 2013), and Miro, involved in mitochondrial 
transport (Wang et al., 2011). Here, coordinated PINK1-dependent phosphorylation 
and subsequent Parkin-dependent ubiquitination triggers the removal of these proteins 
from dysfunctional mitochondria via the proteasomal degradation pathway. Together, 
these events are suggested to sequester and isolate failing mitochondria prior to 
removal from the cell; a subject covered in greater detail in later sections. 
 
Finally, using an in vitro bacterial system, Kondapalli and colleagues recently screened 
17 proteins including previously reported PINK1 interactors and genes residing at the 
PARK loci, with a view to reproduce, and/or identify new PINK1 substrates. Where the 
phosphorylation of TRAP1, HtrA2, Miro and Mfn2 could not be replicated, a novel 
PINK1-dependent phosphorylation was observed in the UBL domain of Parkin. This in 
vitro phosphorylation event was recapitulated in a mammalian system, where the 
phosphorylation site was identified as Ser65 (Kondapalli et al., 2012). As discussed 
later, these data have greatly enhanced our understanding of how PINK1 and Parkin 
interact with each other in a common pathway. 
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with Fugene HD (Promega, E2311) at a 1:3 ratio in Opti-MEM 
(GIBCO, 31985070). After 10 min incubation, the complex was 
added to each well containing cells and medium. For pink1−/− 
MEFs, Lipofectamine LTX (Invitrogen, 15338100) was used 
according to the manufacturer’s instruction. Valinomycin, car-
bonyl cyanide m-chlorophenyl hydrazone (CCCP), and MG132 
were used at final concentrations of 10 μM, 20 μM, and 10 μM, 
respectively. Stable cell lines were established by recombinant ret-
rovirus infection as follows. DNA fragments encoding wild-type 
or F104M mutant PINK1-YFP were cloned into NotI/ClaI sites 
of a pRetroX-IRES-DsRed-Express vector. Vector particles were 
produced in HEK293T cells grown in poly-lysine coated plates 
by cotransfection with Gag-Pol, VSV-G and the aforementioned 
plasmid. After 12 h of transfection, the media were changed and 
the cells were further incubated for 24 h. The viral supernatants 
were then infected into HCT116 or HeLa cells grown in 6-well 
plates with 8 μg/ml polybrene (Sigma, 107689).
Antibodies
The following antibodies were used for immunoblotting: 
rabbit anti-GFP (Invitrogen, A-11122), mouse anti-SQSTM1 
(clone 2C11, Novus Biologicals, H00008878-M01), rabbit anti-
LC3B (Sigma, L7543), mouse anti-α-Tubulin (clone B-5-1-2, 
Invitrogen, 32-2500) and mouse anti-Actin (clone AC-40, Sigma, 
A4700), rabbit anti-TOMM20 (Santa Cruz Biotechnology, Inc., 
sc-11415), rabbit anti-PINK1 (Novus Biologicals, BC100-494), 
mouse anti-TIMM23 (clone 32, BD Transduction Laboratories, 
611222), mouse anti-Cytochrome c (clone 7H8.2C12, BD 
Transduction Laboratories, 556433), rabbit anti-HTRA2/
mitochondrial precursor proteins can laterally diffuse away from 
the contact site between the TOM and the TIM23 complexes 
soon after the TIM23 complex recognizes the hydrophobic TM 
segment, thereby pulling the C-terminal domain into the IMS 
using lateral diffusion as a driving force. Thus, the TM segment 
of PINK1 may be cleaved very rapidly by PARL after release 
from or perhaps while within the TIM23 complex allowing the 
cleaved PINK1 to be released back to the cytosol with minimal or 
no force driving export to the cytosol. Alternatively, other mito-
chondrial proteins such as CLPX/ClpXP or m-AAA proteases 
may coordinate with PARL to facilitate PINK1 retrotransloca-
tion and/or to preclude PINK1 import further into IMS.13
The ephemeral life of PINK1 enables this sophisticated sensor 
to monitor and regulate dysfunctional mitochondrial through a 
well-orchestrated proteolytic cascade.
Materials and Methods
Cell culture and transfection
HeLa and MEF cells were cultured in Dulbecco’s modified 
Eagles medium (DMEM) (GIBCO, 31053028) supplemented 
with 10% (v/v) fetal calf serum, 10 mM HEPES buffer, 1 mM 
sodium pyruvate, 1 mM glutamine and nonessential amino acids. 
HCT116 cells were cultured in McCoy’s 5A medium (GIBCO, 
16600082) supplemented with 10% (v/v) fetal calf serum, 1 mM 
glutamine and nonessential amino acids. Cells were cultured at 
37°C in a 5% CO2 incubator. To transfect HeLa and parl
−/− MEF 
cells for immunoblotting and microscopy, plasmids were mixed 
Figure 7. Schematic model of PINK1 tra!cking o damaged or healthy mitochondria. Newly synt sized PINK1 precursor is accumulated on the outer 
membrane of damaged mitochondria, which ca  induce PARKIN recruitment from the cytosol to mitochondria. On the other ha d, the N-terminal part 
of PINK1 precursor can be imported into the inner membrane of healthy mitochondria via TOM and TIMM23 translocator complexes. The N-terminal 
MTS and TM segment are cleaved by MPP and PARL, respectively. Subsequently, the cleaved PINK1 is released to the cytosol where the N-end rule spe-
ci"c E3 enzymes UBR1, UBR2 and UBR4 recognize the destabilizing N-terminal phenylalanine residue of cleaved PINK1 for proteasomal degradation.
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1.4.5.3.  PARK 7 - DAISUKE-JUNKO-1 (DJ-1) 
 
Daisuke-Junko-1 (DJ-1), the third autosomal recessive gene to be linked to early onset 
PD, was found to be responsible for PARK7-linked PD cases in 2003 (Bonifati et al., 
2003a; Bonifati et al., 2003b; van Duijn et al., 2001). Point mutations and exon 
deletions in DJ-1 are very rare, accounting for less than 1% of all monogenic forms of 
PD (Pankratz et al., 2006). 
 
First described as an oncogene, DJ-1 is ubiquitously expressed, and localises mostly 
in the cytosol, with trace amounts detectable in mitochondrial and nuclear fractions 
(Canet-Aviles et al., 2004; Miller et al., 2003; Nagakubo et al., 1997). The expression of 
DJ-1 is increased in the presence of ROS accumulation, suggesting a possible anti-
oxidant role for this protein (Mitsumoto and Nakagawa, 2001). Further evidence for an 
anti-oxidant role came from SH-SY5Y human neuroblastoma cells, after the application 
of the oxidative stressor hydrogen peroxide. Here, wild type, but not PD-linked 
pathogenic variants of DJ-1 underwent oxidation, prior to promoting the elimination of 
hydrogen peroxide from these cells. This elimination protected cells from ROS-induced 
cell death, hence highlighting the cytoprotective function of DJ-1 (Taira et al., 2004).  
 
In PD brain tissue, there is an increase in DJ-1 oxidation compared to control samples, 
indicating increased levels of oxidative stress in the diseased state (Bandopadhyay et 
al., 2004). DJ-1 oxidation was also observed in M17 neuroblastoma cells, following the 
application of the ROS-producing herbicide, paraquat. Here, paraquat triggered 
oxidised DJ-1 to translocate from the cytoplasm to the MOM (Canet-Aviles et al., 2004) 
via the mitochondrial chaperone, Grp75 (Li et al., 2005). Importantly, mice carrying a 
DJ-1 deficiency have heightened sensitivity to oxidative stressors such as MPTP, 
leading to the demise of dopaminergic neurons (Kim et al., 2005). Taken together 
these data suggest that DJ-1 is a potent anti-oxidant and neuroprotectant, which 
scavenges cells for neurotoxic compounds, and neutralises their effect. It also 
highlights an interaction with mitochondria, once again implicating these organelles in 
the etiology of PD. 
 
1.4.6  GENETIC SUCEPTABILITY TO SPORADIC PD 
 
Monogenic forms of PD account for only a small fraction of the total number of PD 
cases. In such cases, a clear pattern of Mendelian inheritance is often apparent, 
whereby the gene mutation alone is responsible for the development of the disease. 
However, in sporadic cases, the cause of disease development is likely to be a 
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combination of multiple genetic risk variants, perhaps with an environmental risk 
element. Early efforts to identify polymorphisms of genes involved in sporadic PD took 
a candidate gene approach, whereby monogenic PD genes, and genes associated 
with other neurodegenerative diseases were analysed. Subsequently, a small number 
of these genes has been confirmed following modern, meta-analysis techniques. For 
example, both SNCA (Kruger et al., 1999; Tan et al., 2004) and LRRK2 (Bonifati, 2007; 
Mata et al., 2005) polymorphisms, as well as microtubule-associated protein tau 
(MAPT) polymorphisms (Golbe et al., 2001; Healy et al., 2004), the gene closely linked 
to Alzheimer’s disease pathology, were found to be linked to sporadic PD. Additionally, 
SNCA mutations and multiplications associated with monogenic PD have been 
identified in some apparently ‘sporadic’ cases, suggesting either reduced penetrance 
or the occurrence of de novo mutation in the population (Lesage and Brice, 2009; 
Lesage and Brice, 2012). 
 
Another common risk factor for sporadic PD, particularly in the Ashkenazi Jew 
population, is the presence of heterozygous mutations in the lysosomal enzyme, 
glucocerebrosidase (GBA) (Lesage et al., 2011; Sidransky et al., 2009). In the case of 
homozygous mutations, GBA causes a recessive lysosomal storage disease called 
Gaucher’s disease (GD), characterized by the deposition of lipids within the cell. 
Importantly, it was observed that together with clinical features including anaemia, liver 
and spleen enlargement, and diminishing platelet numbers, GD patients occasionally 
display parkinsonian-like symptoms, with the presence of Lewy bodies (Tayebi et al., 
2003). This observation prompted investigation into a putative link between the two 
syndromes. Of interest, a disproportionate number of relatives of GD-sufferers develop 
PD, suggesting increased risk in heterozygous carriers of GBA mutations (Goker-Alpan 
et al., 2004). This was confirmed following a large number of worldwide, single- and 
multi-centre collaborative approaches, where the prevalence of PD in people with 
heterozygous GBA mutations was 5-fold higher than the control group (Sidransky and 
Lopez, 2012; Sidransky et al., 2009). How these mutations confer the disease is still 
unknown, but may be related to disrupted lysosomal degradation pathways, and 
accumulation of dysfunctional cellular components. 
 
Genome-wide association studies (GWAS) are a relatively recent technique, which 
analyse a vast number of genetic markers or single nucleotide polymorphisms (SNPs) 
to identify common disease risk variants. The benefit of this approach is the ability to 
compare thousands of disease-specific samples against thousands of control samples, 
allowing the identification of very rare variants with a mild or moderate effect. Such 
polymorphisms would be likely missed, or fall out of significance in the smaller-scale 
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genetic linkage techniques, which employ much smaller sample numbers (Hardy and 
Singleton, 2009). Using this approach, SNCA, LRRK2 and MAPT polymorphisms have 
been strongly implicated as conferring risk for the development of sporadic PD (Satake 
et al., 2009; Simon-Sanchez et al., 2009). Additionally, GBA has also been identified as 
a risk factor, together with a number of de novo regions including HLA, GAK and 
SREBF1 (Do et al., 2011; Liu et al., 2011; Nalls et al., 2011). 
 
With the first ‘mega-meta-analyses’ now underway (J. Hardy, personal 
correspondence), increasing numbers of case-group samples enable GWAS 
techniques to become even more powerful. This should act to increase confidence in 
the strength of previously discovered risk loci, whilst removing spurious results. 
 
 
1.5  MITOCHONDRIA AND PARKINSON’S DISEASE 
 
A number of theories have been put forward regarding the etiology of Parkinson’s 
disease. These include aberrant build-up and aggregation of proteins, oxidative 
damage and mitochondrial dysfunction. One emerging theory centres on the 
‘mitochondrial dysfunction’ model of PD, supported by an increasing body of evidence 
from an array of sources. Mitochondria are double membrane-bound organelles 
responsible for oxidative respiration; the major source of cellular energy or adenosine 
triphosphate (ATP). Alongside energy production, mitochondria also provide a calcium 
buffering facility, play a central role in a range of catabolic and anabolic processes 
such as fatty acid β-oxidation, and are responsible for the initiation of the apoptosis 
cascade via the release of cytochrome c and other pro-apoptotic proteins. 
Mitochondrial respiratory complexes are responsible for generating high levels of 
reactive oxygen species (ROS) via the synthesis of superoxide anions; a byproduct of 
the electron transport chain. Not only do cellular ROS cause general cellular damage 
to proteins and lipids, it specifically damages mitochondria themselves, probably due to 
their close proximity to the ROS source. Due to this, mitochondria require tightly 
controlled anti-oxidant mechanisms in order to prevent a build-up of damaged 
components.  
 
Healthy mitochondria, able to overcome adverse oxidative environments can be easily 
distinguished from those that have succumbed to damage, through the maintenance of 
their mitochondrial electrochemical membrane potential (∆Ψm). This potential is 
produced by the electron transport chain (ETC), via the pumping of protons from the 
matrix to the IMS as electrons flow between the respiratory complexes. This differential 
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electrochemical gradient across the MIM leads to ATP production via oxidative 
phosphorylation, as protons re-enter the matrix through ATP-Synthase. However, when 
mitochondrial damage reaches a critical threshold, the electron transport chain no 
longer maintains efficient electron transfer, leading to the collapse of the 
electrochemical gradient. This occurrence is commonly used to assess the health of a 
mitochondrial population, and taken as a marker for mitochondrial dysfunction. 
Importantly, ROS can cause mitochondrial damage leading to the loss of ∆Ψm, 
demonstrating how both oxidative damage and mitochondrial dysfunction theories of 
PD could be closely linked to one another. 
 
Mitochondria were first implicated in PD following the onset of Parkinsonian symptoms 
in drug users exposed to the ETC complex I inhibitor, MPTP (Langston et al., 1983). 
The supposed outcome of this complex I inhibition was the uncoupling of the ETC, 
leading to an energy deficit, increased ROS production and eventual cell death. As a 
result of these cases, analysis of respiratory complexes in brain and blood samples of 
PD patients highlighted a marked decrease in mitochondrial complex I activity 
(Janetzky et al., 1994; Mann et al., 1992; Mizuno et al., 1989; Parker et al., 1989; 
Schapira et al., 1990), as well as a higher burden of somatic mtDNA mutations, 
compared to control samples (Bender et al., 2006). As mtDNA encodes 13 respiratory 
complex genes, this increase in mtDNA point mutations and deletions is likely to 
reduce the efficiency of oxidative respiration, perhaps accounting for the observed 
decrease in complex I activity in PD patients. To add further weight to the mitochondrial 
model of PD, epidemiology studies identified a link between exposure to pesticides, 
such as the complex I inhibitor rotenone, and the development of sporadic PD (Gorell 
et al., 1998; Tanner et al., 2011). Importantly, in animal models of Parkinson’s disease, 
both MPTP and rotenone closely recapitulate pathological and clinical hallmarks of PD, 
including dopaminergic neuron loss and Lewy body pathology (Betarbet et al., 2000; 
Langston et al., 1984).  
 
Mitochondrial involvement in PD etiology was strengthened following the observation 
that the monogenic autosomal recessive PD genes, parkin, PINK1 and DJ-1, all 
localise to mitochondria under basal or stress-induced conditions (Canet-Aviles et al., 
2004; Miller et al., 2003; Narendra et al., 2008; Valente et al., 2004a). Analysis of 
parkin- and PINK1-null animals has greatly enhanced our understanding of how 
dysregulation of mitochondrial homeostasis may contribute to disease pathology. First, 
parkin-null Drosophila melanogaster models were found to have shortened life-spans, 
severe motor dysfunction, progressive myofibril degeneration with abnormal wing 
posture, dopaminergic neuron loss and swollen mitochondria with irregular cristae 
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(Greene et al., 2003; Pesah et al., 2004; Whitworth et al., 2005). As well as 
demonstrating the reproducibility of human disease phenotypes in an invertebrate 
model, these studies provided clear evidence for mitochondrial involvement in disease 
pathology. Further evidence for a mitochondrial role came from cellular studies, where 
apoptosis was induced by ceramide; an endogenous lipid which assembles into pores 
in the MOM allowing the release of pro-apoptotic IMS proteins (Siskind, 2005). Here, 
Parkin overexpression prevented ceramide-induced cell death by slowing mitochondrial 
swelling and the consequent release of cytochrome c (Darios et al., 2003). Importantly, 
parkin-null mice also exhibited deficits in mitochondrial respiratory complex subunits, 
despite maintaining apparently normal mitochondrial architecture and dopaminergic 
neuron numbers (Goldberg et al., 2003; Palacino et al., 2004). One possible reason for 
a lack of dopaminergic neuron degradation in the parkin-null mouse model is the 
initiation of early compensatory events, such as the upregulation of protective and/or 
redundant genes, which shield aged animals against PD pathology (Dawson et al., 
2010). In support of this, conditional knockout (KO) of parkin in adult mice avoids 
developmental compensatory effects, resulting in significant and progressive DA 
neuron loss (Shin et al., 2011).  
 
Second, PINK1-null and PINK1 RNAi-expressing Drosophila exhibit equivalent 
phenotypes to the parkin-null fly model, again displaying swollen mitochondria, with 
abnormal cristae and a concomitant reduction in ATP production (Clark et al., 2006; 
Park et al., 2006; Yang et al., 2006). Importantly, overexpression of wild type, but not 
C-terminally truncated PINK1 rescued the aberrant phenotypes described (Yang et al., 
2006), highlighting the importance of the kinase domain in PINK1 cellular protection. 
Furthermore, data from primary patient fibroblasts carrying homozygous PINK1 
mutations showed reduced complex I activity coupled with increased oxidative damage 
(Hoepken et al., 2007). However, where PINK1-null mice displayed progressive 
mitochondrial dysfunction together with a mild locomotor defect, neuronal degeneration 
and Lewy body pathology were absent following post mortem analysis (Gautier et al., 
2008; Gispert et al., 2009; Kitada et al., 2007), again, possibly due to compensatory 
mechanisms.  
 
Finally, whilst data from DJ-1-deficient animal models have been inconsistent, a recent 
study reported locomotor defects and progressive mitochondrial dysfunction, together 
with decreased ATP-production in aged DJ-1-null mice and Drosophila (Hao et al., 
2010). These data again highlight the mitochondrial theme running through PARK loci 
gene function. 
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Taken together, these data offer an overwhelming body of evidence indicating the 
central involvement of aberrant mitochondrial homeostasis in the etiology of PD. 
Whether the observed mitochondrial defects are the cause or effect of disease 
sequelae remains an open question. However, given that mitochondrial swelling in 
Drosophila PINK1- and parkin-mutants is a relatively early pathogenic event, this 
indicates that mitochondrial dysfunction could be the primary cause of disease (Clark 
et al., 2006; Greene et al., 2003; Whitworth et al., 2005). 
 
1.5.1  THE PINK1/PARKIN-PATHWAY 
 
Following the observation that both parkin- and PINK1-null Drosophila models carry 
near-identical pathological phenotypes, it was suggested that these genes might act in 
a common molecular pathway. In agreement with this, double knockout Drosophila 
models lacking both PINK1 and parkin developed comparable disease phenotypes to 
those observed in the single mutants, consistent with an involvement in a mutual linear 
pathway. Additionally, overexpression of parkin in a PINK1-null background 
ameliorated mutant phenotypes; a finding that was not true for the reverse. Taken 
together these data indicate that PINK1 acts upstream of parkin in the same linear 
pathway, hereafter called the PINK1/Parkin-pathway (Clark et al., 2006; Park et al., 
2006; Yang et al., 2006; Yang et al., 2008). These studies represent a significant 
discovery in the field, as it was the first demonstration that genes attributed to PARK 
loci acted together in a common pathway with a clear function. Such a finding greatly 
strengthened the reputation of the mitochondrial theory of disease, and prompted 
increased interest in the study of recessive PD genes. 
 
Importantly, data from Drosophila studies were substantiated by studies in human 
cells, whereby PINK1 deficiency resulted in a fall in ∆Ψm and a change in 
mitochondrial morphology, the latter of which was rescued by parkin overexpression 
(Exner et al., 2007). This placed mammalian PINK1 upstream of parkin in a common 
pathway, confirming previous data from Drosophila models. 
 
1.5.2  MITOCHONDRIAL DYNAMICS 
 
Rather than existing as discrete, individual organelles, mitochondria form a dynamic, 
ever-changing network throughout the cytoplasm of the cell. Mitochondria utilise fusion, 
fragmentation (fission) and trafficking machinery in order to alter their shape, size and 
position within the cell. Each of these events depend upon the energy requirements of 
distinct subcellular locations, as well as the overall health of the mitochondria 
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themselves. The core proteins involved in mitochondrial fusion and fission are 
dynamin-like GTPases, comprehensively studied in yeast and mammalian systems, 
and found to be highly conserved across species. In a mammalian setting, 
mitochondrial fusion is mediated by two MOM GTPases, mitofusin 1 and mitofusin 2 
(MFN1/MFN2), which catalyse fusion of the outer membrane; and optic atrophy 1 
(OPA1), a MIM GTPase that facilitates fusion of the inner membrane. Mitochondrial 
fission is performed principally by dynamin-related protein 1 (DRP1), a cytosolic 
GTPase which forms a constrictive ring at the MOM, possibly following mitochondrial 
recruitment by fission 1 (FIS1), a tail anchored MOM protein (Westermann, 2010). 
When the mitochondrial morphology balance is tipped towards increased fusion, the 
mitochondrial network adopts an interconnected ‘string-like’ appearance. In contrast, 
when the morphology balance is tipped towards fission, mitochondria adopt a more 
punctate ‘dot-like’ appearance. 
 
1.5.2.1  Mitochondrial Dynamics and Disease 
 
Mutations in pro-fusion genes have been attributed to two distinct progressive 
neuropathies. Heterozygous MFN2 mutations produce a peripheral axonal 
sensorimotor neuropathy known as Charcot-Marie-Tooth disease, type 2a, 
characterised by distal muscle weakness and wasting (Zuchner et al., 2004). Also, 
heterozygous mutations in OPA1 cause autosomal dominant optic atrophy type 1, a 
disease leading to the loss of visual acuity and blindness via optic nerve deterioration 
(Delettre et al., 2000). Additionally, despite the lack of a known disease caused by core 
fission genes, a heterozygous mutation in pro-fission DRP1 has been reported to 
cause neonatal lethality with neurological features (Waterham et al., 2007). Taken 
together these data highlight the importance of a careful balance between 
mitochondrial fission and fusion for the maintenance of cell health.  
 
The first suggestion of a PINK1/Parkin-involvement in mitochondrial dynamics came 
from the observation that mitochondria from PINK1- and parkin-null Drosophila exhibit 
an abnormal, enlarged morphology in flight muscle and testes (Clark et al., 2006; 
Greene et al., 2003; Park et al., 2006; Yang et al., 2006). Leading on from this, groups 
studying the role of the PINK1/Parkin-pathway scrutinised the effects of altering fission 
and fusion gene dosage on Drosophila PINK1 (dPINK1)- and parkin (dparkin)-null 
phenotypes. Here, functional rescue of climbing and flight defects, muscle 
degeneration with abnormal wing posture, DA reduction and aberrant mitochondrial 
morphology were observed following increased dDrp1, or reduced dOpa1 or dmfn 
gene dosage (Deng et al., 2008; Poole et al., 2008; Yang et al., 2008). Additionally, 
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quantification of mitochondrial morphology phenotypes in cultured Drosophila DA 
neurons and S2R+ cells showed an increase in punctate mitochondria following PINK1 
and/or parkin overexpression, and an increase in tubular mitochondria following PINK1 
and/or parkin RNAi silencing (Yang et al., 2008; Ziviani et al., 2010). Finally, 
overexpression of PINK1 in the Drosophila visual system produced toxicity resulting in 
a ‘rough eye’ phenotype. However, increased mitochondrial fusion, or decreased 
mitochondrial fission ameliorated this phenotype; whilst the opposite manipulation 
caused an exacerbation (Poole et al., 2008). Taken together, these data indicated that 
Drosophila PINK1 and parkin promote fission and/or inhibit fusion. 
 
Whilst the morphological data from Drosophila models are relatively clear-cut, the 
same cannot be said for mammalian cell systems. In general, it is agreed that PINK1 
and parkin can influence mitochondrial morphology, however the mode of influence is a 
matter of dispute. In contrast to Drosophila data, PINK1 siRNA knockdown in cultured 
human SH-SY5Y and HeLa cells has been shown to evoke excess mitochondrial 
fragmentation (Dagda et al., 2009; Exner et al., 2007). One explanation for the disparity 
could be that compensatory mechanisms are in place to account for the loss of key 
genes in more complex systems. For example, reduced expression of pro-fission 
PINK1 may result in excess fission as alternative genes take on the role. In a less 
complex system such as Drosophila, these compensatory mechanisms may not exist, 
resulting in an excessively fused mitochondrial network, as observed. Nevertheless, 
this opposing phenotype is not always observed in mammalian cell types. For example, 
in agreement with Drosophila data, COS-7 fibroblast cells and rat dopaminergic and 
hippocampal neurons exhibited punctate, fragmented mitochondria following 
overexpression-, and tubular, fused mitochondria following siRNA-silencing of PINK1 
and/or parkin (Yang et al., 2008; Yu et al., 2011). In complete contrast to the above 
studies, one group reported a total lack of mitochondrial morphology defects in PINK1-
null Drosophila neuromuscular junctions and mouse fibroblasts (Morais et al., 2009). 
Taken together, these data imply a cell-specific response to PINK1 and parkin gene 
loss. It has been suggested that transformed cell-lines such as HeLa cells may behave 
differently to post-mitotic cells such as neurons, due to differences in cell-cycle input 
and a greater reliance upon glycolysis, perhaps accounting for these discrepancies (Yu 
et al., 2011) 
 
1.5.2.2  Functions of Mitochondrial Dynamics 
 
Establishing the purpose of a highly dynamic mitochondrial network, and how it 
benefits cellular health is fundamental to understanding the role of the PINK1/Parkin-
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pathway. Critically, new mitochondria are not synthesised de novo; rather they are 
brought about by the expansion of existing organelles. For this, mtDNA multiplication 
and increased synthesis of nuclear- and mitochondrial-encoded proteins and lipids 
must occur. With this expansion, concomitant mitochondrial fission creates a greater 
number of solitary mitochondria, which relocate to serve different areas of the cell 
(Westermann, 2010). This biogenesis is crucial for maintaining a complete and healthy 
network of mitochondria, particularly following the elimination of dysfunctional 
mitochondria from the cell (see later sections).  
 
Another function of mitochondrial dynamics is the ability of individual mitochondria to 
fuse with the network and initiate matrix content mixing. This mixing has been 
demonstrated elegantly through the use of mitochondrial matrix-targeted 
photoactivatable GFP (Twig et al., 2008a). Here, a small portion of the mitochondrial 
population was laser-activated, producing isolated GFP fluorescence. However, after 
45 minutes, homogenous distribution of GFP was observed across the entire 
mitochondrial population. The purpose of this content mixing is thought to be in the 
maintenance of mitochondrial network health via the replenishment, repair and 
complementation of intact mitochondrial components, together with the removal of 
dysfunctional factors (Youle and van der Bliek, 2012). In support of this, fusion-
deficient MFN1/2 double knock-out and OPA1-RNAi expressing mouse embryonic 
fibroblasts (MEFs) produce a heterogeneous mitochondrial population, with some 
organelles exhibiting a well-maintained ∆Ψm, and others showing either diminished or 
lost ∆Ψm (Chen et al., 2005). As the ∆Ψm status is typically regarded as a read-out for 
mitochondrial health, a lack of fusion, and subsequent content mixing therefore 
produces a mixed population of healthy and dysfunctional organelles. In support of this, 
another study showed that prevention of fusion led to a significant decrease in the 
ATP-producing capacity of mitochondria (Liu et al., 2009). In part, this is likely due to 
the instability and loss of respiratory-complex encoding mtDNA, as documented in 
optic atrophy type 1 patients with heterozygous OPA1 mutations (Amati-Bonneau et 
al., 2008; Hudson et al., 2008). 
 
Mitochondrial dynamics are also important for the segregation of damaged 
mitochondrial components for removal from the network. This relies upon mitochondrial 
fission in order to isolate less active mitochondria from the network. Here, fission is 
likely a permissive event, allowing solitary mitochondria exhibiting a sustained 
reduction in ∆Ψm, to become separated from the healthy mitochondrial population 
(Figure 1.5). Importantly, these mitochondria lose their capacity to re-fuse with 
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Figure 1.5 Mitochondrial fission as a pre-requisite for mitophagy. Schematic of the mitochondrial life-cycle whereby 
mitochondria exist as ‘solitary’ post-fission organelles, or ‘networked’ post-fusion organelles. The fusion period is brief, 
and leads quickly to a fission event, whereby heterogeneous daughter mitochondria with hypo- or hyperpolarised 
membranes are produced. Those in a hyperpolarised state will remain able to re-fuse with the network (red line), 
whereas those in a hypo-polarised state will lose their fusion ability (green line) and become directed down the 
degradative autophagy route. In some circumstances, mitochondria are able to recover their ∆Ψm, allowing them to re-
join the healthy mitochondrial population, hence avoiding degradation (arrows). Image from Twig et al., (2008b). 
 
neighbouring mitochondria, probably through the loss of pro-fusion factors OPA1 (Twig 
et al., 2008a) and Mitofusin (Ziviani and Whitworth, 2010), allowing efficient 
segregation for degradation via the macroautophagy route. This process is known as 
mitochondrial autophagy or ‘mitophagy’, and involves the packaging of dysfunctional 
mitochondria in a double-membrane autophagosome, before fusion with the lysosome 
for hydrolytic degradation. 
 
Distinct from the process of mitophagy is the recent discovery of mitochondria-derived 
vesicles (MDVs), which package specific cargo into small ~100 nm vesicles for delivery 
to peroxisomal (Neuspiel et al., 2008) and lysosomal (Soubannier et al., 2012) 
pathways. This process is DRP1-independent, indicating a dynamic process distinct 
from that of the core morphology genes. The role of MDVs is believed to be in the 
removal of ROS-damaged mitochondrial proteins and lipids, in order to maintain a 
healthy network. Such quality control measures are proposed to occur prior to 
widespread network fragmentation, and independently of mitophagy, supposedly acting 
as a first-line defence in the event of increased oxidative stress (Neuspiel et al., 2008; 
Soubannier et al., 2012)  
to fusion in the undisturbed cell has not been addressed. The
present study is the first demonstration in living cells
that mitochondrial fusion occurs preferentially between
mitochondria with higher Dcm, and generates an isolated
subpopulation of non-fusing mitochondria. Moreover, these
results demonstrate that a physiologically relevant reduction
in Dcm impacts the prevalence of fusion. As each fusing
mitochondrion requires intact Dcm to achieve matrix fusion,
the process is unlikely to rescue dysfunctional units with
altered Dcm. Yet, the selectivity of the fusion process does not
rule out the view that mitochondrial fusion serves as an inter-
mitochondrial complementary route for metabolites and
mtDNA between mitochondria with intact Dcm (Nakada
et al, 2001).
Conversely, Dcm is influenced when fusion is inhibited
(Olichon et al, 2003; Chen et al, 2005), suggesting that
reduced fusion capacity could be either the cause or the
result of Dcm depolarization. Experiments presented here
conclude that depolarization occurs immediately subsequent
to fission and not as a delayed consequence of reduced fusion
capacity. The stability of Dcm of the individual mitochondria
at all times other than the immediate post-fission period, as
reported here, further supports the conclusion that reduced
fusion over a period of an hour does not compromise the
bioenergetic parameters of the individual unit.
OPA1 as a mechanism for selective fusion
In addition to having reduced Dcm, non-fusing mitochondria
were characterized by depletion in OPA1 immunoreactivity,
providing a possible explanation for the reduced fusion
capacity (Figure 5). Recently, a protonophore-induced com-
plete collapse of Dcm of the entire cell mitochondria was
shown to trigger proteolytic cleavage or degradation of OPA1
long (l-)isoforms (Griparic et al, 2004; Duvezin-Caubet et al,
2006; Ishihara et al, 2006; Song et al, 2007). Here we show
that minute and physiological depolarization of the indivi-
dual mitochondrion in the context of the intact cell is
accompanied by reduced OPA1 levels and diminished fusion
capacity. These results further emphasize that depletion of
OPA1 in the individual mitochondrion within the intact cell
may preclude fusion and metabolic complementation even if
surrounded by fusion-competent mitochondria (Figure 1).
The dependency of OPA1 proteolysis on ATP concentration
may explain how small changes in Dcm may lead to such
profound reduction in fusion capacity (Herlan et al, 2004).
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Finally, another proposed function of mitochondrial dynamics is the division of 
mitochondria for efficient transport and spatial re-distribution to locations of high-energy 
demand. This intracellular transport is particularly important in very large cells such a 
neurons, where the cell body and synapses, both of which expend large amounts of 
energy, can be separated by tens of centimetres or more in humans. In this respect, 
individual, fragmented mitochondria are much more amenable to transport than a fused 
and interconnected mitochondrial network. In support of this, primary neuronal culture 
from DRP1-null mice showed a lack of mitochondria in cell termini such as synapses 
and dendrites, and an accumulation in the cell body (Ishihara et al., 2009). Thus, for 
motor proteins to efficiently deliver their cargo, mitochondria must undergo some 
degree of fission. 
 
With both mitochondrial fission and fusion performing crucial and distinct roles in the 
maintenance of a healthy mitochondrial population, a tightly regulated balance between 
the two processes is key. It is conceivable that an aberrant shift in either direction could 
produce cellular pathologies with devastating consequences, as demonstrated by 
section 1.5.2.1. 
 
1.5.3  MITOCHONDRIAL TRAFFICKING 
 
Mitochondria, particularly those in cells such as neurons, with a large size and high-
energy demand, must be delivered to areas of ATP-requirement, such as synapses, for 
efficient energy provision. Here, mitochondria are essential for the production of ATP 
required for the repolarisation of the plasma membrane, as well as the buffering of high 
intracellular calcium ([Ca2+]IC) levels (Schwarz, 2013). Mitochondrial components have 
short half-lives in the order of days to weeks (Lipsky and Pedersen, 1981; Vincow et 
al., 2013), therefore requiring continuous mitochondrial trafficking and replenishment. 
Here, a constant supply of healthy mitochondria with intact membrane potentials are 
brought to the synapses, coupled with the retrotransport of damaged mitochondria to 
the cell body for recycling (Miller and Sheetz, 2004). For mitochondria to be 
transported in anterograde (away from the cell body) and retrograde (towards the cell 
body) directions, the motor proteins kinesin and dynein are employed respectively, to 
taxi organelles along microtubule tracks.  
 
For the linkage of mitochondria to microtubules, motor proteins must interact with both 
mitochondrial and cytoplasmic adapter proteins. The core proteins involved in 
anterograde mitochondrial transport are the heavy chain of kinesin (KHC) (Tanaka et 
al., 1998), the cytoplasmic adapter milton (Stowers et al., 2002), and the MOM GTPase 
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Miro (Guo et al., 2005). milton was first discovered in Drosophila following an EMS 
screen, which identified defective synaptic transmission in milton mutant animals. This 
defective physiology was attributed to the absence of axonal and synaptic 
mitochondria, despite the presence of somal mitochondria. This aberrant distribution 
phenotype was caused by defective, mitochondria-specific transport; a claim 
substantiated by the association of Milton with both mitochondria and the anterograde 
mitochondrial motor protein, KHC (Stowers et al., 2002). This association implied that 
Milton acts as an adapter protein, bridging the gap between mitochondria and 
microtubule-associated motor proteins.  
 
Following the discovery of Milton, a third protein was found to be involved in the 
mitochondrial transport complex. This was the mitochondrial GTPase Miro, initially 
discovered in Drosophila models whereby EMS-induced mutation produced 
comparable mitochondrial distribution defects as those observed in milton mutants 
(Guo et al., 2005). Importantly, Milton and Miro were found to physically interact with 
each other, suggesting that Miro may act as an anchor-point for Milton at the 
mitochondrial surface (Glater et al., 2006). As well as anterograde transport, milton and 
miro have also been shown to play a role in dynein-related retrograde transport (van 
Spronsen et al., 2013). Here the two mammalian milton orthologs, TRAK1 and TRAK2, 
show differential motor protein preference, determining the direction of mitochondrial 
transport. 
 
The crucial question is how the mitochondrial motility complex coordinates the 
movement of mitochondria. The structure of Miro has provided valuable insight into 
how mitochondrial movements may be regulated by this complex. First, Miro contains a 
C-terminal transmembrane domain, which inserts into the MOM, providing an anchor 
for Milton to bind. Second, the amino-portion of the protein, which faces the cytoplasm, 
comprises two GTPase domains, flanking two EF-hand calcium-sensing domains (Reis 
et al., 2009). One of the known intracellular signals influencing the progression of 
mitochondria is a change in local [Ca2+]IC; where high [Ca2+]IC blocks mitochondrial 
transport. Increases in [Ca2+]IC are often found at energy-intensive synapses, or areas 
of the cell where the local ATP-provision and mitochondrial calcium buffering abilities 
are deficient. Therefore, incoming mitochondria are able to accumulate in these areas, 
rectifying the deficit. This accumulation was found to occur through the calcium sensing 
EF-hands of Miro. Here, high [Ca2+]IC is suggested to cause a conformational change in 
Miro, allowing a direct, Milton-independent interaction with the motor domain of KHC. 
This interaction causes the dissociation of KHC from the microtubules, hence 
reversibly halting progress (Figure 1.6, Wang and Schwarz, 2009). 
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Figure 1.6 Mitochondrial transport and calcium regulation.  Schematic representation of mitochondrial anterograde 
transport in the presence and absence of high intracellular calcium. Mitochondria are linked to the microtubule tracks via 
the anterograde motor protein kinesin heavy chain (KHC - red), the cytoplasmic adapter protein Milton (green) and the 
MOM GTPase, Miro (yellow). Transport of mitochondria can be regulated by changes in intracellular calcium levels, 
whereby high concentrations cause a transient transport block. This transport block is controlled by the calcium sensing 
EF-hands of Miro (blue), which bind directly to the N-terminal motor domain of KHC, hence disconnecting the complex 
from the microtubules. Figure from Wang and Schwarz,(2009). 
 
The trafficking of mitochondria is not only essential for efficient cellular energy supply 
and calcium buffering, but also in the process of mitochondrial fusion, as discussed in 
earlier sections. Importantly, for fusion to take place, some form of mitochondrial 
movement must be involved. For example, the inhibition of mitochondrial transport by 
nocodazole; a microtubule de-polymerisation agent, also prevents mitochondrial fusion 
and concomitant matrical mixing. This lack of matrix complementation manifests itself 
as a reduction in oxidative phosphorylation and subsequent ATP production (Liu et al., 
2009). These data reinforce the idea that mitochondrial dynamics and spatial 
distribution are not mutually exclusive processes; with both being fundamental to the 
maintenance of mitochondrial homeostasis. 
 
1.5.3.1  Mitochondrial Trafficking and the PINK1/Parkin-Pathway 
 
A growing body of evidence has implicated the PINK1/Parkin-pathway in the regulation 
of intracellular mitochondrial trafficking. This involvement is believed to be a critical 
step in mitochondrial quality control, functioning to permanently separate dysfunctional 
organelles from the network as a whole. Therefore the mechanism of trafficking arrest 
imposed by the PINK1/Parkin-pathway is distinct from that described previously, 
whereby high [Ca2+]IC produces a reversible pause in transport.  
 
The first indication of a pathway contribution to mitochondrial trafficking came following 
the discovery that PINK1, Milton and Miro form a complex capable of physical and 
functional interaction (Weihofen et al., 2009). Interestingly, the overexpression of 
PINK1 or parkin significantly arrested mitochondrial movement in both anterograde and 
2005). The Miro homolog of yeast, GEM1p, controls mitochon-
drial distribution in that orga ism in a kinesin-independent
manner (Frederick et al., 2004) and these additional functions
of Miro may be present in higher eukaryotic cells as well (Frans-
son et al., 2006; Guo et al., 2005). Another potential pathway
for regulating mitochondrial mobility may be mediated by the
enzyme O-GlcNAc tr nsferase (OGT). OGT has been sh wn to
bind to milton and glycosylate it in both mammals (Iyer and
Hart, 2003) and Drosophila (Glater et al., 2006). Elsewhere,
OGT activity has been shown to reflect glucose concentrations
and the metabolic stat of the cell (Murrey nd Hsieh-Wilson,
2008), opening the possibility that the interactions of milton
and OGT may permit mitochondrial distribution to be tailored
by the availability of substrates for glycolysis and ATP produc-
tion. Thus the mot r/adaptor complex discussed here may be
the nexus of multiple control pathways in addition to the Ca2+-
sensing role of Miro and is likely to transduce information about
local energy supply and demand. These converging signaling
pathways will likely regulate mitochondrial dynamics to achieve
th most efficient supply and use of energy by the cell.
EXPERIMENTAL PROCEDURES
Constructs
The following constructs were used: pLPS-RFP-mito (Colwill et al., 2006),
(No. 11702, Addgene, Cambridge, MA); human Miro, pRK5Myc-Miro1 and
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retrograde directions (Wang et al., 2011). Additionally, knockdown of trafficking 
complex components in Drosophila rescues PINK1-null phenotypes, indicating a clear 
genetic interaction between these genes (Liu et al., 2012). Importantly, a direct 
interaction between PINK1, Parkin and Miro results in a PINK1-dependent Miro 
phosphorylation event, leading to its proteasomal degradation in a Parkin-dependent 
manner (Figure 1.7, Liu et al., 2012; Wang et al., 2011). Miro degradation results in 
mitochondrial dissociation from the KHC-linked microtubules, therefore producing 
stationary mitochondria. All aforementioned processes are increased upon exposure to 
the mitochondrial uncoupler, CCCP (Carbonyl cyanide m-chlorophenyl hydrazone) (Liu 
et al., 2012; Wang et al., 2011), indicating that the PINK1/Parkin-pathway inhibits 
trafficking in order to isolate damaged mitochondria from the mitochondrial network.  
 
To prevent re-fusion with the mitochondrial network, the PINK1/Parkin-pathway must 
not only prevent trafficking, but also fusion events from occurring. Importantly, a well 
documented target of Parkin-dependent ubiquitination and proteasomal degradation is 
the MOM pro-fusion factor Mitofusin (Poole et al., 2010; Tanaka et al., 2010; Ziviani et 
al., 2010). Interestingly, recent work has reported a physical interaction between 
Mitofusin and the Milton/Miro complex, as well as disrupted bi-directional mitochondrial 
transport upon mitofusin mutation (Misko et al., 2010). These observations were 
seemingly distinct from a general defect in mitochondrial fusion, again suggesting 
interplay between the homeostatic mechanisms governing mitochondrial quality 
control.  
 
One frequent observation following prolonged CCCP-exposure is the redistribution and 
aggregation of mitochondria in the perinuclear region of the cell, in a PINK1 & parkin-
dependent manner (Vives-Bauza et al., 2010). This mitochondrial perinuclear 
clustering was dependent upon both microtubules and the retrograde motor protein 
dynein, and resulted in mitophagy (Lee et al., 2010), indicating that organelle 
repositioning occurs prior to degradation. This repositioning may occur due to the high 
concentration of both lysosomes and autophagosomes in the perinucleus of the cell, 
increasing the efficiency of the degradation process.  
 
1.5.4  THE MITOPHAGY PATHWAY 
 
Determined from evidence amassed over the last 5 years, the overriding theme of the 
PINK1/Parkin-pathway is the maintenance of mitochondrial homeostasis by the 
removal of dysfunctional mitochondria. Whole mitochondria are degraded and recycled 
via the autophagy-lysosomal pathway in a process known as mitophagy. Mitophagy is
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Figure 1.7 PINK1/Parkin-mediated mitochondrial trafficking inhibition, Schematic representation of a permanent 
trafficking block following irreversible mitochondrial damage. A) Mitochondrial trafficking under basal conditions as in 
Figure 1.6. B) Irreversible damage caused by a toxic insult such as CCCP application leads to membrane depolarisation 
and subsequent Miro phosphorylation by PINK1. C) Following this phosphorylation event, Parkin translocates to 
mitochondria, and Miro is ubiquitinated in a Parkin-dependent manner. D) This ubiquitination results in the proteasomal 
degradation of Miro and the subsequent arrest of mitochondrial movement along the microtubules. Figure adapted from 
Wang et al.,(2011). 
 
a form of selective autophagy, which involves the engulfment of cargo in a double 
membrane vesicle known as an autophagosome, before fusion with the lysosome for 
hydrolytic degradation. The first demonstration of whole mitochondria contained within 
double-membrane vacuoles came in 1957 from electron micrographs of neonatal 
mouse kidneys (Clark, 1957).  Since this observation, growing evidence suggests that 
this engulfment is a selective process with the purpose of eliminating dysfunctional and 
aged organelles, rather than a non-specific bulk-autophagy event, such as that initiated 
following starvation. 
 
Relatively little is known about the mechanisms involved in mitophagy, other than the 
absolute requirement for the core bulk-autophagy machinery (Kanki et al., 2009a). 
These genes have been given the universal ‘autophagy-related gene’ (ATG) 
nomenclature, which currently ranges from ATG1-34, and encompasses 15 genes 
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(A and B) Expression of PINK1-Flag (A) or YFP-Parkin (B) at a 3:1 ratio to wild-type Miro arrested mitochondria.
(C and D) Expression of PINK1-Flag (C) or YFP-Parkin (D) at a 3:1 ratio to MiroS156A did not arrest mitochondria.
(E) From kymographs as in (A)–(D), the percent of time each mitochondrion was in motion was determined and averaged. n = 85–153 mitochondria from eight
axons and four separate transfections per genotype.
(F) Schematic representation of the proposed mechanism of PINK1/Parkin-dependent mitochondrial arrest. Mitochondrial depolarization stabilizes PINK1 on the
surface of the mitochondrion, promotes its interaction with Miro, and causes PINK1 to phosphorylate Ser156 of Miro. Subsequent interaction of Parkin with Miro
and likely ubiquitination causes Miro to be removed from the membrane and degraded by the proteasome, releasing milton and kinesin from the organelle.
Error bars represent mean ± SEM. Scale bars, 10 mm. See also Figure S6 and Table S4.
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common to both bulk and selective forms (Kanki et al., 2011). Much of the data 
regarding the autophagy pathway have come from studies in yeast, where the 
mitophagy-specific factor Atg32 has been identified as a possible receptor for cargo 
recognition genes such as Atg11 (Kanki et al., 2009b; Okamoto et al., 2009). 
Surprisingly, despite the high degree of conservation between yeast and mammalian 
core ATG genes, a clear homolog of Atg32 is lacking in mammals. However, one 
mitophagy-specific mammalian gene of the MOM, Nix, has been identified as a 
mitophagy receptor in developing reticulocytes (Novak et al., 2010; Sandoval et al., 
2008; Schweers et al., 2007). Nevertheless, whether the participation of Nix in 
mitophagy is restricted to reticulocyte maturation, or plays a wider role in the whole 
organism is currently unclear (Kanki, 2010). Additionally, two studies showed that p62, 
an autophagy adapter that relocates to CCCP-compromised mitochondria, is essential 
for mitophagy (Geisler et al., 2010a; Lee et al., 2010). Here it recognises both MOM 
protein-ubiquitination and the autophagosomal membrane constituent, Atg8/LC3, 
hence leading to selective degradation of mitochondria. However, conflicting data from 
a subsequent study found that despite p62-induced mitochondrial aggregation, 
mitophagy could proceed normally in p62-null murine fibroblasts and p62-silenced 
HeLa cells (Narendra et al., 2010a). These data call into question the necessity for p62 
in the induction of mitophagy, and may highlight differences in autophagy processes 
between model systems. 
 
1.5.4.1  Mitophagy and the PINK1/Parkin-Pathway 
 
Despite conflicting evidence surrounding the relationship between p62 and mitophagy, 
one common theme was the recruitment of p62 following Parkin-dependent 
ubiquitination of MOM proteins (Geisler et al., 2010a; Narendra et al., 2010a). A 
seminal study in 2008 revealed a clear and central role for the PINK1/Parkin-pathway 
in mitophagy (Narendra et al., 2008). Here, endogenous and overexpressed Parkin 
relocated from a cytoplasmic distribution to a subset of dysfunctional mitochondria 
following uncoupling with CCCP for 4 hours; a phenomenon that was demonstrated in 
several cell lines. Critically, prolonged toxification for 12 and 48 hours led first to the 
perinuclear aggregation of mitochondria, and then global degradation in an autophagy-
dependent manner. Importantly, persistent exposure to CCCP failed to induce the 
autophagy of other cellular organelles such as peroxisomes, indicating that Parkin acts 
in a selective manner to induce mitophagy (Narendra et al., 2008). Critical to 
PINK1/Parkin-pathway involvement, all aforementioned processes have been shown to 
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Figure 1.8 PINK1/Parkin-mediated mitophagy. Schematic of PINK1/Parkin-induced mitophagy following the loss of 
∆Ψm in failing mitochondria. 1) PINK1 is no longer imported into the MIM for proteasomal degradation, but becomes 
stabilised on the MOM, associated with the TOM complex. 2) Parkin translocates from the cytoplasm to the 
mitochondria in a PINK1-dependent manner, where it ubiquitinates MOM proteins including Mitofusin and Miro. 3) 
Ubiquitination of MOM proteins triggers mitophagy via mechanism including their proteasomal degradation and 
autophagy adapter recruitment. Figure adapted from Narendra et al.,(2012). 
 
require the expression of both PINK1 and parkin to proceed (Geisler et al., 2010b; 
Matsuda et al., 2010; Narendra et al., 2010b; Vives-Bauza et al., 2010; Ziviani et al., 
2010). Specifically, Parkin translocation requires the stabilisation of full-length PINK1 
on the MOM of mitochondria with a reduced or lost ∆Ψm (Figure 1.8, Matsuda et al., 
2010; Narendra et al., 2010b). This ∆Ψm-dependent PINK1 stabilisation is proposed to 
occur through the loss of TOM-mediated protein import, and the consequential 
absence of PARL-dependent PINK1 cleavage (Jin et al., 2010). Through this, PINK1 is 
no longer rapidly degraded via the N-end rule pathway (Yamano and Youle, 2013). 
Once stabilised, PINK1 has been shown to associate with the TOM complex on the 
outer membrane (Lazarou et al., 2012). Rather than performing a mitophagy-specific 
function, this association is suggested to allow rapid re-import and degradation of 
PINK1 in the event of mitochondrial repolarisation, hence preventing mitophagy 
induction. Exogenous expression of a non-cleavable, MOM-targeted form of PINK1 is 
able to cause Parkin translocation, indicating that PINK1 MOM stabilisation is not only 
necessary, but sufficient for this event (Narendra et al., 2010b). Additionally, a kinase-
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dead version of PINK1 failed to target Parkin to the mitochondria, highlighting the 
importance of kinase activity in this process (Geisler et al., 2010b; Matsuda et al., 
2010). In agreement, a recent study revealed that Parkin translocation required the 
autophosphorylation of PINK1 following ∆Ψm (Okatsu et al., 2012). 
 
Once at the MOM, Parkin is suggested to physically interact with PINK1 (Geisler et al., 
2010a; Vives-Bauza et al., 2010) via its kinase domain (Geisler et al., 2010b). 
Importantly, PINK1 has been shown to activate the ubiquitin ligase activity of Parkin 
(Kondapalli et al., 2012; Matsuda et al., 2010), through the addition of a phosphate 
group at the highly conserved Ser65 of the UBL domain (Kondapalli et al., 2012; Shiba-
Fukushima et al., 2012). How this phosphorylation event activates Parkin is yet to be 
ascertained. However, reports that the UBL-domain confers autoinhibition of the 
catalytic RBR domain indicate that phosphorylation may alleviate the negative 
regulation, perhaps via a conformational change in tertiary protein structure, hence 
activating Parkin (Chaugule et al., 2011; Trempe et al., 2013). Additionally, as 
mentioned in previous sections, Parkin has been designated as a HECT/RING-hybrid 
E3 ligase (Wenzel et al., 2011). A recent study proposed that for Parkin to translocate 
to mitochondria, stably attach to MOM and activate its ubiquitin ligase activity, PINK1 
locally activates Parkin; probably by phosphorylation at Ser65; leading to HECT-
independent, RBR-dependent Parkin self-binding. This self-binding causes a 6-fold 
increase in Parkin-complex size, and was suggested to be a prerequisite for both 
mitochondrial translocation and the activation of Parkin’s HECT-like ubiquitin ligase 
activity (Lazarou et al., 2013). Such events are responsible for Parkin-dependent 
ubiquitination of MOM proteins, and for the stable association of Parkin with the outer 
surface of the mitochondria (Figure 1.9). Interestingly, upon mutation of the cysteine 
residue responsible for Parkin’s HECT-like activity (Cys431), Parkin no longer stably 
associates with mitochondria, indicating that HECT-domain activation is required for 
this process (Lazarou et al., 2013).  
 
As well as an absolute dependence on PINK1 for translocation, it has recently been 
shown that Parkin translocation and subsequent downstream events including 
mitophagy are influenced by another PD-linked gene, FBXO7/PARK15 (Burchell et al., 
2013). Here following CCCP-treatment, FBXO7, associated with the SCF-complex, 
relocates to mitochondria in a PINK1-dependent manner, via a putative mitochondrial 
targeting sequence. Silencing of FBXO7 causes a significant decrease in Parkin 
translocation, leading to the suggestion that FBXO7 may be involved in chaperoning 
Parkin to mitochondria. Strikingly, FBXO7 overexpression rescued parkin- but not 
PINK1-null Drosophila phenotypes, indicating that PINK1 activity is necessary for 
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Figure 1.9 Parkin self-association and HECT domain activation. Schematic of Parkin translocation and MOM 
substrate ubiquitination in wild-type (WT) and mutant (C431S) situations. In wild-type conditions, Parkin self-association 
is activated by PINK1, which precedes HECT-domain activation, possibly via Ser65 phosphorylation, and stable 
association with the mitochondrial surface via the ubiquitination of MOM substrates. In the mutant situation, Parkin self-
association occurs, but stable association with the mitochondrial surface is not observed due to the inactivity of the 
HECT-domain, and an inability to ubiquitinate target substrates. Figure from Lazarou et al.,(2013). 
 
FBXO7-related function. This finding is supported by a lack of FBXO7-rescue in 
PINK1/parkin double knockout animals. Additionally, the rescue of parkin-null 
phenotypes by FBXO7 overexpression would suggest the involvement of a novel 
Parkin-redundant E3-ligase in this pathway. 
 
The significance of the Parkin translocation event became clear following the 
identification of two Parkin substrates, Mitofusin and Miro, both of which reside in the 
MOM. Following mitochondrial toxification, the MOM pro-fusion factor Mitofusin 
undergoes Parkin-dependent ubiquitination and subsequent proteasomal degradation, 
possibly via the ATPase, p97. This process has been demonstrated in Drosophila, 
mammalian and PD-patient fibroblast systems, revealing a high degree of conservation 
across species (Gegg et al., 2010; Glauser et al., 2011; Poole et al., 2010; Rakovic et 
al., 2011; Tanaka et al., 2010; Ziviani et al., 2010). Additionally, recent data indicate 
that the MOM GTPase Miro, involved in trafficking mitochondria along microtubules, 
also undergoes Parkin-dependent ubiquitination and degradation (Liu et al., 2012). 
Importantly, this as well as the Parkin-dependent ubiquitination of Mfn2, occurs 
following a coordinated PINK1-dependent phosphorylation event, demonstrating the 
degree of built-in regulation in this degradation pathway (Chen and Dorn, 2013; Liu et 
al., 2012; Wang et al., 2011). 
  
The Parkin-dependent decrease in protein levels of both Mitofusin and Miro following 
CCCP-treatment is substantial when compared to other reported Parkin substrates 
such as VDAC1 (Chan et al., 2011). Using a non-biased proteomics approach, Chan 
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Figure 5. Parkin self-association. (A) HeLa cells expressing FRB-Fis1, C431N FKBP-mCherry-Parkin, and C431N YFP–Parkin were treated with 500 nM 
rapalog for 1 h followed by the addition f either DMSO or 10 µM CCCP for a further 6 h. Cells were fixed and immunostained with the mitochondrial-
specific marker HtrA2/Omi. Cells were counted for C431N YFP–Parkin colocalizing with both mitochondria and C431N FKBP-mCherry-Parkin. The graph 
represents means ± SD of counts in >150 cells per sample in three independent experiments. Bar, 10 µm. (B) Normalized autocorrelation curves for 
cytosolic C431N YFP–Parkin (left) and YFP alone (right) before and after 10 µM CCCP treatment for 6 h. The solid lines are fits of the dataset to a single 
species diffusion model. FCS measurements were repeated in six cells in three independent experiments. (C) Model of PINK1 activation of Parkin and 
mitochondrial translocation.
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and colleagues showed that both Mitofusin and Miro protein levels decreased, together 
with a concomitant increase in members of the ubiquitin-proteasome system (UPS). 
Importantly, as well as UPS induction, adapters of mitophagy including p62 and 
Atg8/LC3 were enriched on mitochondria, indicating a co-operative role for both 
systems in the initiation and execution of mitochondrial degradation. In further support, 
an additional elegant non-biased proteomics study identified both Mitofusin and Miro as 
Parkin binding partners whose Parkin-dependent ubiquitination states altered under 
CCCP-toxification conditions (Sarraf et al., 2013). Crucially, to date only Mitofusin and 
Miro have been shown to be ubiquitinated by endogenous, as well as overexpressed 
exogenous Parkin (Narendra et al., 2012), highlighting their physiological significance 
as effectors of the PINK1/Parkin-pathway. As the key role of the pathway appears to 
be in the maintenance of bioenergetic efficiency via quarantine and removal of 
unhealthy mitochondria, co-degradation of Mitofusin and Miro prevent transport-
dependent re-fusion of failing mitochondria, hence contributing to this function. 
 
Interestingly, Parkin has recently been linked to an increase in mitochondrial 
biogenesis, by UPS-mediated degradation of PARIS (Shin et al., 2011). In this study, 
PARIS was found to be a transcriptional repressor of PGC1-α, a transcriptional 
coactivator involved in mitochondrial biogenesis. Therefore, these data indicate that not 
only is Parkin involved in the degradation of failing mitochondria, it also plays a putative 
role in the increased biogenesis of the mitochondrial pool, hence replacing those lost. 
 
To date, the majority of data regarding PINK1/Parkin-mediated mitophagy have 
originated from studies in cultured cell systems. However, a recent study in Drosophila 
has demonstrated for the first time the occurrence of PINK1/Parkin-mediated 
mitophagy in an in vivo system (Vincow et al., 2013). These data represent a 
significant advance in our understanding of mitophagy in a physiological context, 
particularly compared to cancer cell studies where the reliance on mitochondrial 
oxidative phosphorylation is greatly diminished compared to most post-mitotic tissues. 
 
1.5.5  PINK1/PARKIN-PATHWAY MODEL 
 
In summary of the evidence outlined in previous sections, the PINK1/Parkin-pathway 
has a clear central role in the maintenance of mitochondrial homeostasis, principally 
through the mitophagic removal of dysfunctional mitochondria. Under basal conditions, 
the E3-ubiquitin ligase Parkin remains diffusely localised throughout the cytoplasm, 
whereas the N-terminal portion of PINK1 is imported into the mitochondria. At the MIM, 
the MTS is removed by the matrical protease, MPP, followed by the cleavage of the 
TM domain by the intramembrane protease PARL. This cleavage releases the short 
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Figure 1.10 PINK1/Parkin-mediated mitophagy. Following mitochondrial membrane depolarisation, dysfunctional 
mitochondria (1) lose the ability to re-fuse with the healthy mitochondrial network via a down-regulation of OPA1. These 
mitochondria accumulate full-length PINK1 on their MOM (2), leading to Parkin translocation (3). At the mitochondrial 
surface, Parkin ubiquitinates a number of MOM substrates including Mitofusin and Miro (4), which are degraded by the 
proteasome. In the absence of Mitofusin and Miro, dysfunctional mitochondria become isolated via fission (5) and are 
transported to the juxtanuclear region (6) where mitophagy proceeds (7). Highlighted at each pathway step are 
mechanistic questions requiring resolution (red arrows). 
 
form of PINK1 into the cytoplasm, where an exposed phenylalanine motif stimulates its 
proteasomal degradation via the N-end-rule pathway. However, upon mitochondrial 
damage, such as that inflicted by the application of CCCP, a drop in ∆Ψm prevents 
PINK1 mitochondrial import through the TOM/TIMM23 complexes, blocking the two 
intramitochondrial cleavage events outlined. PINK1 is stabilised on the MOM, and able 
to activate the self-association of Parkin, possibly through the phosphorylation of the 
UBL domain. This acts to alleviate Parkin’s autoinhibition, and promotes translocation 
to the mitochondrial surface. Here, the activation of latent HECT domain activity allows 
Parkin to stably associate with mitochondria, leading to the poly-ubiquitination of MOM 
substrates including Mitofusin and Miro. The subsequent UPS-related degradation of 
these proteins both halts the transport of mitochondria through the cell, as well as 
inhibiting re-fusion with neighboring mitochondria. Now isolated, dysfunctional 
6.  Mitochondria are transported in a 
retrograde direction to perinuclear regions 
5.  Fission segregates dysfunctional 
mitochondria from the network 
4.  Mitofusin and Miro are ubiquitinated and 
degraded in a Parkin-dependent manner 
1.  Dysfunctional mitochondria 
2.  PINK1 is stabilised on the MOM 
3.  PINK1 recruits Parkin from the cytoplasm 
7.  Mitochondrial removal via mitophagy 
How are dysfunctional 
mitochondria recognised? 
What causes 
mitochondrial dysfunction? 
How is PINK1 
stabilisation initiated? 
How is Parkin recruited? 
What is the function of 
Parkin at the mitochondria? 
How are damaged 
mitochondria transported? 
Does degradation only 
occur in the perinucleus? 
What are the mitophagy-
specific degradation proteins? 
The PINK1/Parkin-pathway 
 45 
mitochondria undergo mitophagy in a process that is yet to be fully understood, but 
which may involve the autophagy adapter p62 for cargo selectivity (Figure 1.10, grey). 
 
Despite great advances made in the PINK1/Parkin field over the last 5 years, many 
outstanding processes require full resolution (Figure 1.10, red arrows). These include 
the source of mitochondrial damage, and how mitochondrial dysfunction is recognised; 
the exact mechanism behind PINK1 stabilisation and the mode of Parkin translocation 
in the absence of a MTS. Additionally, many of the processes downstream of Parkin 
translocation require clarification including the way in which segregated mitochondria 
are ultimately eliminated. 
 
1.5.6  CCCP TOXIFICATION IN THE PINK1/PARKIN-FIELD 
 
CCCP is used frequently in the PINK1/Parkin-field, in order to cause a potent toxic 
insult to the mitochondrial population. Here, CCCP acts as a proton transporter, 
delivering H+ ions to the mitochondrial matrix, hence uncoupling the ETC. Through this, 
CCCP mimics the loss of ∆Ψm in unhealthy mitochondria, across the entire cellular 
population. While this is a harsh cellular insult, and one that is unlikely to occur under 
physiological conditions, it allows the analysis of processes that may otherwise require 
the lengthy build-up of toxicity, or occur with such rarity that study is impractical. 
 
 
1.6  DROSOPHILA AS A MODEL ORGANISM 
 
In 1910, Thomas Hunt Morgan first discovered the Drosophila melanogaster sex-linked 
‘white’ mutation conferring a change in eye colour from red to white. This discovery 
paved the way for the use of Drosophila as a model organism in the study of genetics, 
and later development. However, the introduction of ethyl methanesulfonate-induced 
mutagenesis in the 1960s resulted in a plethora of genetic mutant flies, leading to the 
discovery of gene function across the breadth of the genome. Importantly, the 
development of balancer chromosomes in the late 1920s allowed the easy 
maintenance of gene mutations in heterozygous fly stocks (Bellen et al., 2010). 
 
Despite being an invertebrate model, the study of human disease in Drosophila has 
provided great insight into the mechanisms behind many disorders including the two 
most prevalent neurodegenerative disorders, Alzheimer’s disease and Parkinson’s 
disease. In 2000, the Drosophila genome was sequenced revealing ~13,600 genes, 
which were found the share a high degree of genetic conservation to the human 
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genome (Adams et al., 2000). Additionally, ~60% of known human disease-causing 
genes were found to have a clear homolog in Drosophila, making this relatively simple 
organism amenable to manipulation in a human-disease context (Rubin et al., 2000). 
Also, unlike many murine models of disease, Drosophila often recapitulate the 
symptoms of their human counterparts, perhaps due to a low degree of genetic 
redundancy compared higher organisms (Guo, 2012). Taken together, these 
characteristics make Drosophila an attractive species for modeling human disease. 
 
With regards to practicalities, Drosophila offer many advantages over higher, more 
complex organisms. Specifically, Drosophila produce a large number of offspring, with 
a short development time of 10 - 12 days. This allows for the generation of large 
numbers of complex genetic combinations over a relatively short period. Additionally, 
fly stocks are maintained in small vials, which can be racked and shelved, allowing a 
great number to be held in a relatively small space. Many genetically divergent 
Drosophila lines can be purchased from a number of central repositories, and for little 
cost, making genetic studies in Drosophila comparatively inexpensive compared to 
mammalian models. Finally, Drosophila offer a great number of excellent genetic tools 
for the manipulation of pathways at both developmental and adult stages, and in a 
number of tissues. Specifically, the GAL4/UAS system, developed in 1993, allows gene 
upregulation and downregulation in the whole fly or specific tissues according to the 
GAL4 ‘enhancer’ or ‘driver’ employed (Brand and Perrimon, 1993). This system works 
by crossing two flies, one of which contains the yeast transcriptional activator GAL4, 
and the other which contains the gene of interest, flanked upstream by the ‘upstream 
activating sequence’ or ‘UAS’ promoter. This promoter contains five GAL4 binding 
sites, therefore undergoing transcriptional activation only in tissues expressing the 
GAL4 protein. In the offspring of these animals, genetic combinations with both GAL4- 
and UAS-containing alleles will express the gene of interest through the activation of 
UAS by GAL4 (Figure 1.11). Importantly, the accumulation of a wide range of tissue- 
and stage-specific GAL4 drivers means that gene expression can be spatially and 
temporally controlled. Not only is this useful for studying the effects of ectopically 
expressed genes, it also allows functional studies of genes whose whole-body 
expression would otherwise be lethal, preventing the easy maintenance of stocks. 
Additionally, a common practice is to utilise the GAL4/UAS system in the expression of 
fluorescently tagged proteins, increasing the ease of live-imaging via fluorescence 
microscopy analysis. 
 
This system is also used to drive RNAi expression, allowing for loss of function 
analyses. This is useful where a genetic null is lacking, or when the effect of eliminating 
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Figure 1.11 GAL4-UAS system in Drosophila. Schematic representation of the GAL4/UAS system involved in 
spatially and temporally regulating exogenous gene expression in Drosophila. This technique involves crossing parental 
flies with either an integrated, tissue specific GAL4 enhancer, or a gene of interest (Gene X) flanked upstream by a UAS 
promoter. Resultant offspring will express Gene X in tissues where GAL4 is driven. Figure from Brand and 
Perrimon,(1993). 
 
expression completely causes a severe or fatal phenotype. A number of groups have 
created in vivo RNAi libraries, able to target the vast majority of the Drosophila genome 
(Dietzl et al., 2007; Ni et al., 2009). These RNAi stocks are readily available and 
provide an excellent tool for large-scale analyses such as genetic screening. 
 
For many years, Drosophila have been used in the study of a number of different 
diseases, particularly those linked to neurological disorders. These include 
Huntington’s disease, Alzheimer’s disease, Tauopathies, Parkinson’s disease and 
Prion disease. Whilst these models often lack the full extent of pathology seen in 
human patients, in many cases neurodegeneration is observed together with aberrant 
accumulation of disease-relevant proteins and toxic inclusions (Jeibmann and Paulus, 
2009). In particular, Drosophila models of Parkinson’s disease are able to faithfully 
recreate many of the pathological features of its human counterpart. Specifically, loss 
of either dPINK1 or dparkin produces a set of phenotypes including DA neuron loss, 
mitochondrial dysfunction and locomotor difficulties (Clark et al., 2006; Greene et al., 
2003; Park et al., 2006; Pesah et al., 2004; Whitworth et al., 2005; Yang et al., 2006). 
402 A. H. Brand and N. Perrimon
Fig. 1. Directed gene expression in Drosophila.
To generate transgenic lines expressing GAL4
in numerous cell- and tissue-specific patterns,
the GAL4 gene is inserted randomly into the
genome, driving GAL4 expression from
numerous different genomic enhancers. A
GAL4-dependent target gene can then be
constructed by subcloning any sequence behind
GAL4 binding sites. The target gene is silent in
the absence of GAL4. To activate the target
gene in a cell- or tissue-specific pattern, flies
carrying the target (UAS-Gene X) are crossed to
flies expressing GAL4 (Enhancer Trap GAL4).
In the progeny of this cross, it is possible to
activate UAS-Gene X in cells where GAL4 is
expressed and to observe the effect of this
directed misexpression on development.
Fig. 2. (A) Vectors for directed gene expression. The
vectors pGaTB, pGawB and pUAST are illustrated. To
target GAL4 expression to specific cells, promoters can be
subcloned upstream of GAL4 at the unique BamHI site of
pGaTB. pGawB is an enhancer detection vector that directs
expression of GAL4 in a genomic integration site-dependent
fashion. pUAST is designed to direct GAL4-dependent
transcription of a gene of choice. The sequence is subcloned
into a polylinker situated downstream of five tandemly
arrayed, optimized GAL4 binding sites, and upstream of the
SV40 small t intron and polyadenylation site. Unique
restriction sites are indicated in bold letters. (B) GAL4-
dependent expression of β-galactosidase in the ocelli. To
direct expression of GAL4 to the photoreceptor cells of the
ocelli, the promoter of the Rh2 gene was subcloned
upstream of GAL4 in pGaTB. Flies heterozygous for this
gene construct (Rh2-7-2) were crossed to a line homozygous
for the UAS-lacZ gene. In the progeny of this cross approx.
50% of the flies express β-galactosidase in the ocelli, as
assayed by staining with X-Gal. On the left is the head of a
fly that carries both the Rh2-GAL4 fusion gene and the UAS-
lacZ reporter construct, on the right is the head of a fly that
carries only the UAS-lacZ construct.
A
B
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Importantly, work in Drosophila revealed for the first time that PINK1 acts upstream of 
Parkin in the same linear pathway, with mitochondrial dysfunction central to the 
pathology (Clark et al., 2006; Deng et al., 2005; Greene et al., 2003; Park et al., 2006; 
Yang et al., 2006). This discovery has revolutionised the ideas behind the etiology of 
PD, and steered the field towards mitochondrial biology, rather than the protein 
accumulation and ROS theories of earlier years. 
 
1.7  HIGH CONTENT RNAi SCREENING 
 
High content RNA interference (RNAi) screening techniques have offered a powerful, 
unbiased way of identifying novel genes involved in a wide array of different processes. 
RNAi approaches use synthetic oligonucleotides to ‘silence’ gene expression, allowing 
the analysis of ‘loss of function’ phenotypes. This technique takes advantage of 
endogenous cellular machineries whose role is to degrade foreign double-stranded 
RNA (dsRNA) from external sources such as viruses. The mechanism by which RNAi 
transiently silences genes in a post-transcriptional manner is well defined, and largely 
conserved across all eukaryotes. Briefly, long dsRNA sequences are broken into small 
fragments known as small interfering RNA (siRNA), by the RNase enzyme Dicer. 
These siRNAs are unwound into single-stranded fragments following ATP-hydrolysis, 
and integrated into the RNA-induced silencing complex (RISC), where target mRNA 
recognition and Argonaute-dependent degradation takes place (reviewed in Hannon 
and Rossi, 2004). From an experimental point of view, Drosophila cells exposed to 
exogenous dsRNA sequences efficiently activate this pathway, producing a gene-
specific silencing effect. However, in a manner divergent from Drosophila, mammalian 
systems exposed to dsRNA activate a concomitant interferon immune response, 
leading to non-specific RNA degradation together with a decrease in protein synthesis. 
In order to circumvent these non-specific effects, it was found that exposure to short, 
21 bp siRNA sequences could produce a gene-specific silencing effect in the absence 
of immune-system activation (Elbashir et al., 2001). Therefore, experiments in 
Drosophila systems typically incorporate long dsRNA sequences, whereas mammalian 
systems are limited to siRNA sequences. 
 
The ease of RNAi-dependent gene silencing, coupled with the completion of human 
and Drosophila whole-genome sequencing has led to the development of high-
throughput RNAi screening techniques for forward-genetic approaches in cultured cell 
systems. The most frequently utilised cell-types are those derived from Drosophila and 
mammalian systems. Each presents its own advantages and disadvantages. For 
example, many Drosophila cell lines will take up dsRNA without the need for 
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transfection reagents (Clemens et al., 2000), whereas mammalian cells require siRNA 
delivery across the plasma membrane. Such delivery not only substantially increases 
the cost of high-throughput screening, but often causes intracellular toxicity which 
demands significant optimisation. Additionally the low redundancy of the Drosophila 
genome compared to the human genome can facilitate data interpretation. However, 
whilst high conservation exists between Drosophila and human genomes, divergent 
pathways and processes do occur, ultimately making human cell systems more 
relevant in a human-disease setting. 
 
The first Drosophila dsRNA library was developed by Norbert Perrimon and colleagues 
in 2004 (Boutros et al., 2004). This library covers almost every gene in the Drosophila 
genome, and has since undergone complete re-design and modification to reduce off-
target effects (Horn et al., 2010). Importantly, these dsRNA sequences have been 
incorporated into an in vivo Drosophila library, allowing easy transition between cell-
based and whole-organism analysis.  
 
To date, very few RNAi cell-based screens focusing on PD etiology have been 
published. Of these, a whole genome RNAi screen in HeLa cells identified the HECT-
domain ubiquitin ligase, SMURF1 as playing a role in the promotion of Parkin-
dependent mitophagy. Here, SMURF1 is predicted to interact with p62, suggesting a 
role in selective mitophagy (Orvedahl et al., 2011). Additionally, a recent whole 
genome screen also in HeLa cells assessed modifiers of Parkin translocation following 
CCCP-toxification. Here, ATPase inhibitory factor 1 (ATPIF1) was identified as an 
essential factor for Parkin translocation, whose absence led to the reversal of ATP-
synthase and the maintenance of the ∆Ψm (Lefebvre et al., 2013). Finally, a further 
HeLa cell screen looking at Parkin translocation identified the glycolysis-related gene, 
Hexokinase 2 as important for this process. This finding links the regulation of 
metabolic pathways to the activation of PINK1/Parkin-mediated mitophagy. As 
techniques develop and technologies such as high-throughput microscopy and 
automated data capture improve, we are likely to see many more of these high-
throughout approaches in both the PD field and other disciplines.  
 
 
1.8  AIMS OF THE THESIS 
 
The aim of this thesis is to identify novel promoters of PINK1/Parkin-mediated 
mitophagy by the means of whole-genome RNAi screening in Drosophila S2R+ cells. 
Specifically, I aim to identify genes acting upstream of Parkin translocation following a 
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short toxification with CCCP. Predicted hits from this screen would be genes involved 
in the identification of dysfunctional mitochondria for degradation, as well as those 
involved in the relocation of Parkin from the cytoplasm to the mitochondrial surface. 
 
Following the completion of the primary whole genome screen, hits will be tested for an 
ability to influence other aspects of mitochondrial homeostasis in a series of secondary 
screens. As highlighted, both PINK1- and parkin deficiency cause a hyperfused 
mitochondrial network in Drosophila systems. Taking advantage of this observation, 
hits will be assessed for their ability to either phenocopy, or produce an alternative 
mitochondrial morphology to PINK1- or parkin loss. Additionally, prior to mitophagy, 
mitochondria are frequently observed as an aggregated mass in the perinuclear region. 
Importantly, loss of PINK1 or parkin prevents this phenomenon, with mitochondria 
remaining diffusely distributed throughout the extent of the cytoplasm. Therefore, hits 
will be assessed for an ability to prevent perinuclear aggregation following toxification, 
thus phenocopying the effect observed following PINK1 and parkin silencing. Finally, to 
ensure that Parkin translocation is dependent on general mitochondrial damage rather 
than CCCP-specific effects, hits will be assessed for their ability to block paraquat-
induced translocation.  
 
Upon completion of secondary screen analysis, a final list of Drosophila screening hits 
will be collated, comprising of genes able to influence a diverse set of mitochondrial 
homeostatic processes with clear links to the PINK1/Parkin-pathway. 
 
To evaluate the ability of final Drosophila hits to influence PINK1/Parkin-mediated 
mitochondrial quality control in a more complex system, human orthologs will be 
identified, and screening will switch to a HeLa cell-based system. Here, both CCCP-
induced Parkin translocation and mitophagy will be assessed, producing an overall hit 
list of human genes with a clear influence on both of these processes. After 
bioinformatic scrutiny, a small number of human hit genes will be selected for low-
throughput analysis whereby a functional involvement in the PINK1/Parkin-pathway 
itself will be tested. For this, both in vivo Drosophila, and cell-based biochemical 
techniques will be employed, in order to elucidate the relationship between hit genes, 
PINK1 and parkin. 
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2. MATERIALS AND METHODS 
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2.1  CELL CULTURE TECHNIQUES 
 
2.1.1  DROSOPHILA CELL LINES 
 
For the purpose of Drosophila melanogaster whole genome screening, Schneider 2 
receptor plus cells (S2R+), an isolate of Schneider 2 cells, were chosen for their 
increased ability to adhere to culture surfaces (Yanagawa et al, 1998). S2R+ cells were 
derived from a primary culture of late-stage embryonic tissue and are suggested to be 
of a macrophage-like lineage (Schneider, 1972). When compared to other available 
Drosophila cell lines. S2R+ cells are ideal for the visualisation of cytoplasmic structures 
due to their relatively large size (~15 µm diameter) and flattened appearance. 
 
2.1.1.1  Cell culture 
 
Drosophila S2R+ cells have a doubling time of approximately 39 hours, and were 
grown at 25 ºC in the absence of CO2. Both S2R+ and Parkin-GFP.S2R+ cell lines 
were passaged in T75 flasks (Greiner, 658170) every 3 - 4 days, at a ratio of 1:5. 
Normal culture media (NCM) consisted of Schneider’s Drosophila Medium 1X liquid 
with L-Glutamine (SM) (Gibco, 21720-024), 10% fetal bovine serum (FBS) (v/v) (Sigma, 
F4135) and 1% Penicillin-Streptomycin (v/v) (Sigma, P4333). Media was filtered 
(Millipore, SCGPU05RE) and stored at 4ºC. 
 
Whole genome screening required the creation of an S2R+ cell line stably expressing 
pMK33-Parkin-GFP (Parkin-GFP.S2R+). This population was maintained through the 
addition of 300 µg/ml Hygromycin B (Invitrogen, 10687-010) to NCM. 
 
Cells were routinely maintained to a maximum of 25 - 30 passages. Following this, a 
fresh aliquot of cells would be defrosted, and aged to a passage number of 2 - 3 before 
being applied to an experimental scenario. 
 
2.1.1.2  Freezing cell cultures for long-term storage 
 
Cell cultures were expanded and grown to full confluency in T75 flasks. Following 
manual detachment and re-suspension, cultures were transferred to 15 ml falcons 
(Starlab, E1415-0800) and pelleted by centrifugation at 1200 rpm. Media was aspirated 
and cells re-suspended in 1 ml of freezing medium (20% FBS (v/v), 10% Dimethly 
sulfoxide (DMSO) (v/v) (Sigma, D2650) in SM; filtered). Cultures were transferred to 
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cryovials (Nalgene, V4757) and placed at -80 ºC for 24 hours in propan-2-ol, before 
being submerged in liquid nitrogen. 
 
2.1.2  HUMAN CELL LINES 
 
For the purpose of human cell screening and subsequent follow-up data, two human 
cell lines were implemented: HeLa cells; derived from cervical cancer tissue, and 
retinal pigment epithelial 1 (RPE1) cells, derived from retinal pigmented epithelium.  
 
HeLa and RPE1 cell lines stably expressing pLVX-Puro-YFP-Parkin were a kind gift 
from Dr Jon Lane (University of Bristol). They were made using a YFP-Parkin plasmid 
(Addgene - 23955, Narendra et al, 2008), sub-cloned into pLVX-Puro (Clontech, 
632164) and delivered using Lenti-XTM HT Packaging System (Clontech, 632160). 
Cells were selected using 10 - 15 µg/ml Puromycin (Sigma, P8833) and FACs sorted. 
 
2.1.2.1  Cell culture 
 
Human cells were grown at 37 ºC in 95% air, 5% CO2. Both HeLa and RPE1 cell lines 
were passaged in T75 flasks every 3 - 4 days, at a ratio of 1:5. When passaging, all 
reagents were heated to 37 ºC to avoid cell shock. Existing media was aspirated and 
cell cultures washed with 5 ml phosphate buffered saline (PBS) (Thermo Scientific, 
OXBR0014G) to remove traces of serum. 2.5% Trypsin (Gibco, 15090-046) (2 ml per 
flask) was added and cells returned to the incubator for 10 - 20 minutes. Cells were re-
suspended by manual pipetting, and passaged following the addition of 10 ml NCM. 
 
Cells were maintained for a maximum of 25 passages before being replaced by a 
freshly defrosted aliquot. These were aged to passage number of 2 - 3 before being 
applied to an experimental scenario. 
 
2.1.2.2  HeLa cells 
 
HeLa cells have a doubling time of 24 hours. Normal culture medium consisted of MEM 
with HEPES & GlutaMAX™ (Gibco, 42360-032), with 10% FBS (v/v) and 1% Penicillin-
Streptomycin (v/v), which was filtered and stored at 4ºC. 
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2.1.2.3  RPE1 cells 
 
RPE1 cells have a doubling time of 19 hours. Normal culture medium, contained 
DMEM/Nutrient mixture F-12 Ham (Sigma, D8062), with 10% FBS (v/v) and 1% 
Penicillin-Streptomycin (v/v), which was filtered and stored at 4ºC. 
 
2.1.2.4  Freezing cell cultures for long-term storage 
 
Cell cultures were frozen following the protocol detailed in 2.1.3. Freezing medium 
consisted of 50% FBS (v/v) and 10% DMSO (v/v) in the appropriate medium (see 
above). 
 
 
2.2  GENE KNOCKDOWN 
 
The following protocols are designed for use in a 12-well format. For other formats, 
volumes were adjusted according to culture surface area. 
 
2.2.1  GENE SILENCING - DROSOPHILA CELLS 
 
dsRNA was seeded at 5 µg per well. Media was aspirated from cells, and replaced with 
serum-free SM (SFSM). Cells were manually re-suspended and counted using a 
haemocytometer. 200,000 cells per well were plated in 500 µl of SFSM and incubated 
at 25 ºC for 1 hour. Following this, 500 µl of 2x FBS-containing media was added, and 
cells were incubated at 25 ºC for 3 - 4 days.  
 
2.2.2  GENE SILENCING - HUMAN CELLS 
 
A number of siRNA delivery techniques have been implemented in order to optimise 
knockdown for various cell types. These include Dharmafect1 (Dharmacon, T2001-02), 
Lipofectamine 2000 (Invitrogen, 11668-027) and Effectene (Qiagen, 301425) 
transfection reagents. In each case, the transfection protocol was performed according 
to manufacturers instructions. 
 
Both forward and reverse delivery techniques have been investigated, but largely, 
reverse transfection was employed. Additionally, a range of siRNA concentrations have 
been used, from 25 - 100 nM. Following optimisation, a concentration of 25 nM was 
chosen for screening purposes and follow-up experiments. 
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2.2.2.1  Reverse transfection 
 
In general, siRNA was seeded in culture plates at a final concentration of 25 nM. 
Transfection reagents were mixed and incubated with siRNA in situ, in serum and 
antibiotic-free media (SAbFM). Cells were plated directly into culture plates at an 
appropriate density, in antibiotic-free media (AbFM), and incubated at 37 ºC. 
Depending on the reagent, media was replaced with NCM 6 - 20 hours post-
transfection to reduce cytotoxicity, and plates incubated for a further 3 - 4 days.  
 
2.2.2.2  Forward transfection 
 
In general, cells were seeded in culture plates and incubated overnight in NCM. 
Transfection reagents and siRNA were mixed in a microcentrifuge tube and incubated 
according to manufacturers instructions. Existing media was aspirated and replaced 
with AbFM, and transfection complexes were added drop-wise to culture plates. 
Depending on the reagent, media was replaced with NCM 6 - 20 hours post-
transfection to reduce cytotoxicity, and plates incubated for a further 2 - 3 days.  
 
 
2.3  PLASMID TRANSFECTION 
 
For both Drosophila and human cells, plasmids were delivered using Effectene 
transfection reagent. Briefly, in a 12-well plate, 0.3 µg of expression plasmid was 
delivered following the protocols detailed in 2.2.2.1 and 2.2.2.2. Expression of most 
plasmids could be detected 12 - 24 hours post-transfection. 
 
 
2.4  HIGH CONTENT RNAi SCREENING 
 
2.4.1  WHOLE GENOME SCREENING - DROSOPHILA CELLS 
 
A Drosophila whole genome RNAi library was purchased from the Sheffield RNAi 
Screening Facility (SRSF). This consisted of 18,434 dsRNA amplicons, arrayed in 53 
clear-bottomed 384-well plates (PerkinElmer, 60017460). Each well contained 5 µl of 
dsRNA at a concentration of 50 µg/ml, giving 250 ng of dsRNA per well. 
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2.4.1.1  Protocol 
 
Prior to screening, eight pre-defined user controls were spiked into columns 9 and 17 
of each plate. On the day of screening, plates were defrosted and centrifuged briefly. 
Parkin-GFP.S2R+ cells, at a density of 6,000 cells per well, were dispensed in 30 µl of 
SFSM, and plates were incubated at 25 ºC. After 1 hour, 30 µl of 2x FBS-containing 
media was added, and cells were incubated for a further 3 days. A solution of copper 
sulphate (final concentration, 500 µM) in SM was added to each well, inducing the 
expression of Parkin-GFP via the metallothionein promoter. After 16 hours, cells were 
toxified with Carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-containing SM at a 
final concentration of 10 µM and incubated for a further 2 hours before fixation and 
nuclear staining with Hoechst-containing formaldehyde. Plates were washed 3x with 
PBS, sealed and imaged using an ImageXpress Micro widefield high content screening 
microscope (Molecular Devices). 
 
2.4.1.2  Stock solutions 
 
Copper sulphate:  100 mM Copper (III) Sulphate (Sigma, C1297) in water. 
CCCP: 10 mM CCCP (Sigma, C2759) in ethanol. 
Formaldehyde solution: 3.7% formaldehyde solution (Sigma, F1635) in PBS with 2 
mg/ml Hoechst (Invitrogen, 33342). 
 
2.4.1.3  Equipment 
 
All solutions apart from CCCP-containing SM were dispensed using either a Multidrop 
Combi Reagent Dispenser or Multidrop 384 Reagent Dispenser (Thermo Scientific, 
5840300 & 5840150). CCCP-containing SM was dispensed using a MICROLAB® 
STAR Liquid Handling robot (Hamilton). Plates were sealed using a PlateLoc® thermal 
plate sealer (Velocity11) after each protocol step. Following toxification, all liquid 
aspiration steps were carried out using an ELx405 Select Deep Well Microplate 
Washer (BioTek). For automated plate imaging, plates were stacked onto an 
‘Automate.it Scara’ system (PAA) and loaded systematically onto the microscope by a 
robotic arm.  
 
All high-content screening images were acquired using an ImageXpress Micro 
widefield high content screening microscope (Molecular Devices). The chosen 
magnification for whole genome screening was 40x (CFI S Plan Fluor ELWD 40X, 
Nikon), with 9 fields of view (FOV) being acquired per fluorophore, per well. Parkin-
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GFP was imaged using a GFP filter cube (1-6300-0450, Molecular Devices) and 
Hoechst was imaged via a DAPI filter cube (1-6300-0442, Molecular Devices). 
 
2.4.1.4  Data analysis 
 
Microscopy images were analysed automatically using the pre-programmed ‘Transfluor’ 
application (Molecular devices). Here, parameters were optimised to enable the 
detection of puncta between 0.6 – 1 µm in size, and 60 grey levels above local 
background intensity. From this, each FOV was assigned a corresponding  ‘mask’ 
image, and value for ‘average number of puncta per cell.’ Across the 9 FOV, the ‘mean 
number of puncta per cell’ was found, producing one value per well. Following analysis 
of the entire dataset, data were normalised using the ‘robust z-score’ incorporating the 
‘median absolute deviation’, where a z-score of zero represented the median (Fisher et 
al, 2012). Primary hits were defined as those with a z-score ≤ -3. 
 
2.4.2  CONFIRMATION SCREENING - DROSOPHILA CELLS 
 
The confirmation library was synthesised by matching hit dsRNA amplicons to their 
unique ‘BKN’ identifier, allowing stock PCR templates to be located. PCR-picking was 
automated, using a MICROLAB® STAR Liquid Handling robot. Additional, amplicon 
templates from the kinome / phosphatome subset library were hand picked and spiked 
into the appropriate locations within the destination plate. The template library was 
printed into plates containing the ‘in vitro transcription’ reaction outlined in 2.6.1, and 
dsRNA synthesis could proceed. Upon completion, dsRNA underwent dilution to 
reduce the possibility of pipetting errors, before being transferred to deep-well mother 
plates. Here, the stock dsRNAs underwent further dilution to achieve a working 
concentration of 5 ng/µl, before the printing of multiple copies of the confirmation library. 
 
2.4.2.1 Protocol 
 
The ‘confirmation’ assay protocol was identical to that outlined in 2.4.1.1, where Parkin-
GFP.S2R+ cells were toxified for 2 hours with CCCP (10 µM).  
 
2.4.2.2 Data analysis 
 
Image acquisition and analysis was automated as in 2.4.1.3 and 2.4.1.4. Per 
confirmation round, a hit amplicon was any dsRNA with an average puncta score within 
two standard deviations (SD) of the mean of the ‘No CCCP’ control. Over four rounds 
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of screening, each time an amplicon appeared in the hit list it was given a score of 1. 
Upon completion of the four repeat screens, the score from each screening round was 
totalled, producing an overall ‘score’ for each dsRNA. If a gene had more than one 
dsRNA amplicon in any one of the four hit lists, that gene would gain an extra ‘multiples 
score’ of 0.5, producing a maximum screen score of 4.5. For a hit to become 
‘confirmed,’ an arbitrary cut-off of 2.5 was defined.  
 
2.4.3  SECONDARY SCREENING - DROSOPHILA CELLS 
 
2.4.3.1  Paraquat-induced Parkin translocation 
 
Confirmation library plates were defrosted and briefly centrifuged. 6,000 Parkin-
GFP.S2R+ cells per well were plated in SFSM, and incubated for 1 hour at 25 ºC. 2x 
FBS-containing media was added, and cells incubated for a further 48 hours at 25 ºC. 
Parkin-GFP expression was induced for 16 hours with 200 µM copper sulphate, before 
toxification with 10 mM paraquat (Sigma Aldrich, 856177) for 24 hours. Samples were 
fixed with ice-cold methanol, and processed for imaging. This included the application 
of 0.2 µg/ml anti-ATP5A (MS507, Mitosciences), 2 µg/ml anti-Alexa Fluor 594 (A-11005, 
Molecular Probes), and 2 mg/ml Hoechst (Invitrogen, 33342). 
 
Parkin translocation images were acquired as in 2.4.1.3, and data quantified as in 
2.4.1.4. The assay was performed in triplicate. Per screening round, a hit amplicon was 
any dsRNA with a raw puncta score within 2 SD of the mean of the vehicle-treated 
negative control dsRNA. Over three rounds of screening, each time an amplicon 
appeared in the hit list, it was given a score of 1. Upon completion of the three screens, 
the score from each round was totalled, producing an overall ‘score’ for each dsRNA. 
Assay hits required a minimum score of 2 out of 3. 
 
2.4.3.2  Mitochondrial morphology analysis 
 
Confirmation library plates were defrosted and briefly centrifuged. 4,000 S2R+ cells per 
well were plated in SFSM, and incubated for 1 hour at 25 ºC. 2x FBS-containing media 
was added, and cells incubated for a further 96 hours at 25ºC. Media was then 
aspirated, and replaced with NCM, containing 150 nM of MitoTracker Red (MTR) (M-
7512, Molecular Probes) and Hoechst (2 mg/ml). After an incubation of 15 minutes, 
media was replaced, and live cells were imaged immediately on the high content 
screening microscope. 
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Morphology images were acquired as in 2.4.1.3, using a Texas Red® filter cube (1-
6300-0449, Molecular Devices) for MTR detection, and a DAPI filter cube (as in 
2.4.1.3) for Hoechst detection. Data were quantified manually using a 4-point 
morphology scoring system, where 1 = fragmented, 2 = wild-type, 3 = fused and 4 = 
clumped mitochondria (Pogson et al., manuscript in preparation). Here, each FOV was 
assigned an overall population score, which was averaged over 9 FOV producing an 
‘average mitochondrial morphology score’ for each dsRNA amplicon. This assay was 
performed in isolation, with hits defined as any dsRNA with an ‘average mitochondrial 
morphology score’ ± 2 SD of the mean of the negative control dsRNA. 
 
2.4.3.3  Mitochondrial perinuclear aggregation 
 
Mitochondrial perinuclear aggregation was assessed using the protocol outlined in 
2.4.3.1. Here, perinuclear aggregation images were acquired as in 2.4.1.3 using a 
Texas Red® filter cube (as in 2.4.3.2) for ATP5A detection, and a DAPI filter cube (as 
in 2.4.1.3) for Hoechst detection. Per condition, 4 FOV were acquired using a 10x 
objective (10x Plan Fluor NA 0.30, Nikon). Data were quantified manually using a 3-
point scoring system, where 1 = diffuse mitochondria, 2 = mixture of diffuse and 
aggregated mitochondria and 3 = aggregated mitochondria. Here each FOV was 
assigned an overall population score, which was averaged over 4 FOV producing an 
‘average mitochondrial perinuclear aggregation score’ for each dsRNA amplicon. This 
assay was performed in triplicate. Per screening round, a hit amplicon was any dsRNA 
with a mitochondrial perinuclear aggregation score ± 2 SD of the mean of the paraquat-
treated negative control dsRNA. Over three rounds of screening, each time an 
amplicon appeared in the hit list, it was given a score of 1. Upon completion of the 
three screens, the score from each round was totalled, producing an overall ‘score’ for 
each dsRNA. Assay hits required a minimum score of 2 out of 3. 
 
2.4.4  HUMAN CELL SCREENING 
 
A custom library of human siRNA probes was ordered, comprising a total of 98 
siGENOME SMARTpool siRNAs (Dharmacon), including 8 control wells. siRNAs were 
supplied as 0.1 nmol dry pellets, arrayed over two 96-well plates. Resuspension 
involved the addition of 50 µl RNase-free water per well, for a final stock concentration 
of 2 µM. Prior to the addition of water, plates were briefly centrifuged to collect the 
siRNA pellet at the bottom of each well, and the foil lid sterilised with 70% ethanol. In a 
laminar flow cabinet, the foil lid was removed and 50 µl of water was added to each 
well by multi-channel pipette. Plates were then resealed, and placed on an orbital 
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mixer for 2 hours at room temperature to ensure total resuspension. Six copies of the 
library were printed into 96-well clear-bottomed assay plates (Greiner, 655090), 
allowing a final siRNA concentration of 25 nM (1.25 µl/well). Assay plates were 
barcoded with a plate identifier and placed at -20 ºC until required.  
 
2.4.4.1  Parkin translocation 
 
To assess Parkin translocation, plates were defrosted, and centrifuged briefly. A 
solution of ‘Dharmafect 1’ (DF1) transfection reagent (0.2 µl / well) (Dharmacon, T-
2001) in SAbFM (18.55 µl / well) was arrayed across assay plates using a multi-
channel pipette, and left to complex with the siRNA for 30 minutes at room temperature. 
4,000 YFP-Parkin.HeLa cells in 80 µl AbFM were plated per well, and incubated for 24 
hours at 37 ºC. Media was replaced with NCM, and plates incubated for a further 72 
hours. Media was exchanged for vehicle- or CCCP-containing media (10 µM) for 4 
hours, before fixation with ice-cold methanol for 10 minutes. Samples were processed 
for imaging by the addition of anti-ATP5A, anti-AlexaFluor 594 and Hoechst, as in 
2.4.3.1. 
 
Images were captured using the ImageXpress Micro widefield high content screening 
microscope (Molecular Devices), with a 10x objective (10x Plan Fluor NA 0.30, Nikon). 
Three channels were acquired using a YFP filter cube (1-6300-0448, Molecular 
devices) for YFP-Parkin detection, a Texas Red® filter cube (as in 2.4.3.2) for ATP5A 
detection, and a DAPI filter cube (as in 2.4.1.3) for Hoechst detection. 9 FOV were 
acquired per well.  Each FOV was analysed manually using a five-point system. Here, 
0 = dead or low-YFP expressing cells, 1 = < 10% of cells with Parkin translocation, 2 = 
between 10 - 50% of cells with Parkin translocation, 3 = between 50 - 90% of cells with 
Parkin translocation, and 4 = > 90% of the cells with Parkin translocation. Over the 9 
FOV, the ‘average Parkin translocation score’ per well was calculated. This assay was 
performed in triplicate. Per screen, hits were siRNAs with a score ± 3 SD of the mean 
of the CCCP-treated negative control siRNA. Each time a siRNA appeared in the hit list, 
it achieved a score of 1. Upon completion of the three screens, the score from each 
round was totalled, producing an overall ‘score’ for each siRNA. For a siRNA to be 
deemed an overall ‘hit’, a minimum score of 2 out of 3 was required. 
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2.4.4.2  Mitophagy 
 
Protocol as in 2.4.2.2 but with the following deviations: seed-cell density; 10,000 cells 
per well, post media-change incubation duration; 48 hours, toxification duration; 24 
hours. 
 
Each FOV was analysed manually using a five-point system. Here, 0 = dead or low-
YFP expressing cells, 1= a full complement of mitochondria, 2 = an overall reduced 
mitochondrial signal, 3 = a reduced mitochondrial signal, plus ~ 10% of cells with no 
mitochondria, and 4 = a reduced mitochondrial signal plus > 20% of cells with no 
mitochondria. Over the 9 FOV, the ‘average mitophagy score’ per well was calculated. 
Hits were defined as in 2.4.4.1. 
 
2.4.5  BIOINFORMATICS 
 
The ‘DRSC Interactive Ortholog Prediction Tool’ (DIOPT) was used to convert 
Drosophila genes into human orthologs (Hu et al, 2011). Known and predicted protein 
interactions were assessed using STRING 9.0 (‘Search Tool for the Retrieval of 
Interacting Genes/Proteins’) (Jensen et al, 2009). Gene symbol, name and function 
were acquired from a number of sources including FlyBase, Uniprot and NCBI gene.  
 
 
2.5  MOLECULAR BIOLOGY - DNA 
 
2.5.1  POLYMERASE CHAIN REACTION (PCR) 
 
General DNA amplification was performed in a ‘Mastercycler personal’ thermal cycler 
(Eppendorf) using standard protocols. Either ‘Platinum Taq’ (Invitrogen, 10966018) or 
‘Phusion High Fidelity’ (Thermo Scientific, F-530) DNA polymerase was employed 
depending on the assay. Efficiency and fidelity of the PCR reaction was checked using 
a ‘NanoDrop 1000’ spectrophotometer (Thermo Scientific), and gel electrophoresis. 
 
Amplification of DNA templates from the ‘Sheffield RNAi Screening Facility’ (SRSF) for 
the synthesis of dsRNA required a touchdown PCR protocol, and incorporated 
‘Reddymix PCR mastermix’ (Thermo Scientific, AB-0575) and a standardised set of 
primers incorporating a T7 tag (uppercase – see section 2.6.1), upstream of a library 
position-specific primer sequence (lowercase): 
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TU TAATACGACTCACTATAGGGtggcgcccctagatg 
T1 TAATACGACTCACTATAGGGcgacgcccgctgata 
T2 TAATACGACTCACTATAGGGtaggtctagccccgc 
T3 TAATACGACTCACTATAGGGcgcatgtagcctgcc 
T4 TAATACGACTCACTATAGGGtagcctccctagcgc 
 
2.5.2  TRANSFORMATIONS 
 
Plasmid preparations were expanded using bacterial transformation of ‘Library 
Efficiency® DH5α™ competent cells’ (Invitrogen, 18263-012). This process involved 
incubating 50 µl defrosted competent cells with 1 µl plasmid DNA on wet ice for 30 
minutes, before heat shocking at 42 ºC for 45 seconds. The mixture was then returned 
to ice for 2 minutes, before the addition of 200 µl pre-warmed Luria-Bertani (LB) broth. 
The transformation was transferred to a shaker, set at 37 ºC, 225 rpm for ~ 60 minutes, 
before being streaked onto pre-warmed LB agar plates containing the appropriate 
antibiotic. Plasmid-containing bacterial colonies were grown on LB agar plates for 16 
hours at 37 ºC before bacterial expansion in suspension culture. 
 
2.5.3  PLASMID PREPARATION 
 
Following plasmid transformation into bacterial cells, clonal colonies were picked and 
grown on in mini- or midi-suspension cultures depending on the amount of plasmid 
required. Small-volume mini-cultures (~5 ml of LB) were purified using the ‘QIAprep 
Spin Miniprep Kit’ (Qiagen, 27104), and large-volume midi-cultures (~100 ml of LB) 
were purified using the ‘HiSpeed Plasmid Midi Kit’ (Qiagen, 12643). Each format was 
executed as per the manufacturers instructions. In each case, plasmids were eluted in 
PCR-grade water (Sigma, W4502) and assessed using gel electrophoresis for product 
specificity, and NanoDrop spectrophotometry for product concentration. 
 
2.5.4  PLASMIDS UTILISED 
Below is a table of all expression plasmids used in this project. 
 
 
Transgene Vector Species Source
Mitofusin-FLAG pAct-PPA Drosophila Elena Ziviani
Mito-GFP pAct-PPA Drosophila Elena Ziviani
Parkin-GFP pMK33 Drosophila Elena Ziviani
PINK1-Myc pMK33 Drosophila Venus Ho
YFP-Parkin pEYFP-C1 Human Richard Youle
PINK1-GFP pEGFP-N1 Human Emma Deas
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2.6  MOLECULAR BIOLOGY - RNA 
 
2.6.1  GENERATION OF dsRNA 
 
For Drosophila gene silencing, dsRNA probes were synthesised. For this, PCR 
templates flanked by the T7 promoter sequence are utilised. These PCR templates 
were either synthesised ‘in house’ or acquired from the SRSF as described in 2.5.1. 
dsRNA probes were synthesised using an in vitro transcription ‘MEGAscript’ kit 
(Ambion, AM1334), performed to manufacturers instructions. Following in vitro 
transcription, dsRNA preparations were purified by the addition of 1 µl TURBO DNase 
for 30 minutes at 37 ºC, followed by 2.1 µl ammonium acetate ‘stop solution’ and 52.5 
µl ethanol. The solution was then placed at -80 ºC for 2 hours to enhance precipitation, 
followed by centrifugation for 1 hour at 14,000 rpm, 4 ºC. The supernatant was drawn 
off in a laminar flow hood, and the dsRNA pellet allowed to air dry before resuspension 
in 100 µl PCR-grade water (Sigma, W4502). The efficiency of the reaction and fidelity 
of the dsRNA probes were assessed by NanoDrop spectrophotometry and gel 
electrophoresis. 
 
2.6.2  HUMAN siRNA ACQUISITION 
 
Human siRNAs used throughout this study were acquired from Dharmacon (Thermo 
Scientific) as siGENOME SMARTpools. For low-throughput analysis, frequently used 
siRNA probes include control, PINK1, parkin, SREBF1 and FBXW7. Below are the four 
siRNA sequences making up the SMARTpool for each gene target.  
 
 
  
Product code Gene Symbol Gene ID Gene Accession GI Number Sequence
GAAAUCCGACAACAUCCUU
GAGCAUCGGCCUGCAGUUG
GGAGCCAUCGCCUAUGAAA
GCAAAUGUGCUUCAUCUAA
GGAGUGCAGUGCCGUAUUU
UCAAGGAGGUGGUUGCUAA
UUAAAGAGCUCCAUCACUU
GUAAAGAAGCGUACCAUGA
UGACUUCCCUGGCCUAUUU
ACAUUGAGCUCCUCUCUUG
GCGCACUGCUGUCCACAAA
ACACAGACGUGCUCAUGGA
GAAAUUGCUUGCUUUAGAU
GAACUCAAAUCUCCUAAGG
CAACAACGACGCCGAAUUA
GGAGUUGUGUGGCGGAUCA
M-004264-02 FBXW7 55294 NM_001013415 61743925
M-003603-00 parkin 5071 NM_004562 4758883
M-006891-01 SREBF1 6720 NM_004176 52630417
M-004030-02 PINK1 65018 NM_032409 112382374
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2.6.3  QUANTITATIVE REAL-TIME PCR (qRT-PCR) 
 
2.6.3.1  RNA isolation from cells 
 
Extraction of total RNA from Drosophila and mammalian cells involved washing cell 
cultures briefly in cold PBS, before lysing cells and extracting total RNA using an 
RNeasy RNA purification kit, (Qiagen, 74104). This protocol was performed to 
manufacturers instructions.  
 
2.6.3.2  Reverse transcription for cDNA synthesis 
 
cDNA was synthesised from total RNA using ‘ProtoScript® II first strand cDNA 
Synthesis Kit (New England BioLabs, E6560S) according to manufacturers instructions. 
Here, total RNA concentration was ascertained using spectrophotometry, and 
equivalent amounts (typically 1 µg) of total RNA underwent reverse transcription for 
each sample. Following reverse transcription, cDNA synthesis efficiency was tested 
using spectrophotometry, and samples were adjusted accordingly to ensure equal 
sample concentrations.  
 
2.6.3.3  qRT-PCR 
 
Quantitative real-time PCR (qRT-PCR) was ultilised to measure relative expression 
levels of mRNA within cells. Here, mRNA extracted from cultured cells (2.6.3.1) was 
assessed by cDNA (2.6.3.2) quantification. Each sample was normalised to a 
‘reference gene,’ which maintains a steady expression in all samples under the 
experimental conditions. Here, the Drosophila ribosomal gene, RpL32, and the human 
ribosomal gene, RNA18S5, were chosen due to their reproducibility. 
 
The qRT-PCR assay was performed in 96-well PCR plates (Bio Rad, 223-9441) with a 
reaction volume of 25 µl. The reaction mixture consisted of 1 µl cDNA, 12.5 µl iQ™ 
SYBR® Green Supermix (Bio Rad, 170-8880), 1.5 µl forward and reverse primers (final 
concentration, 300 nM) and 8.5 µl PCR-grade water. Plates were sealed (Bio Rad, 
MSB1001) and briefly centrifuged before being loaded into the MyiQTM real-time PCR 
system (Bio Rad, 170-9770). For each condition, samples were assayed in triplicate, 
and an average value taken. 
 
For gene expression quantification, ‘SYBR Green’ binds to double-stranded DNA and 
emits fluorescence. As the qRT-PCR progresses, the intensity of the dye increases 
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proportionally as the cDNA of interest undergoes multiplication. In the exponential 
phase, the amount of cDNA should double for each cycle. As the fluorescence reaches 
a pre-set threshold level, the number of PCR cycles required to reach this point is 
recorded as the ‘threshold cycle’ or ‘CT’ value for that sample. Using these CT values, 
the relative expression ratio between samples can be ascertained. 
 
To achieve a set of CT values, the qRT-PCR system runs a standard qPCR program: 
  
 
 
The ‘melt curve’ performed at the end of the qRT-PCR amplification allows analysis of 
the specificity of the amplification. Here, for each sample, the melt curve should 
possess just one ‘peak’ indicating the amplification of just one product. In the case of 
more than one peak, this may indicate non-specificity, contamination, or primer dimers 
in the reaction mixture. In this situation, assay optimisation or primer redesign would be 
the appropriate action. 
 
2.6.3.4  Relative fold-change calculation 
 
To calculate the relative fold change of expression between cDNA samples, the 2–∆∆CT 
or ‘Livak’ method is used (Livak & Schmittgen, 2001). Here, for each sample, the 
average ‘threshold cycle’ (CT) value of the ‘gene of interest’ (GOI) is normalised to the 
average CT value of the ‘reference gene’. This produces a value known as ∆CT: 
 
∆CT = CT (GOI) - CT (Reference gene) 
 
Once each sample is normalised to the reference gene, the experimental samples (e.g. 
PINK1 siRNA-treated cells) must be normalised to the control sample (e.g. control 
siRNA-treated cells). This produces a value known as ∆∆CT: 
 
∆∆CT = ∆CT (Experimental sample) - ∆CT (Control sample) 
Step Name Temperature Seconds
1 Initialisation 95 ºC 180
2 Denaturation 95 ºC 30
3 Annealing 60 ºC 30
4 Extention 72 ºC 30  Real time measurement
5
6 95 ºC 30
7 60 ºC 30
8 55 ºC 10  Melt curve measurement
9
Repeat steps 2 - 4 (40x)
Increase step 8 by 1 ºC until 95 ºC is reached
Melt curve analysis
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Finally, to produce a normalised expression ratio between experimental and control 
samples, 2-∆∆CT is calculated for each value. Here, the control sample is equal to 1, with 
experimental samples representing relative expression levels. 
 
2.6.3.5  qRT-PCR primers 
 
Below is a table of all qRT-PCR primers utilised in this project. 
 
 
 
2.7  WESTERN BLOT 
 
2.7.1  REAGENTS 
 
All reagents are purchased from Sigma-Aldrich, unless otherwise stated. 
 
RIPA Buffer (filtered) 
- 50 mM Tris-HCL 
- 150 mM sodium chloride (NaCl) 
 
Lysis buffer (7 ml) 
- RIPA buffer - 6188 µl 
- 1% Triton X 
- 10% Glycerol 
- 2 mM ethylene glycol tetraacetic acid (EGTA) 
- 1 mM magnesium chloride (MgCl2) 
- 50 µM MG-132 
- 1x Protease inhibitor cocktail (Roche, 11836170001) 
- 10 mM N-Ethylmaleimide (NEM) 
 
4x SDS Sample Buffer 
- 240 mM Tris-HCl pH 6.8 
Gene Species Forward primer Reverse primer Amplicon size
RpL32 Drosophila  GCCGCTTCAAGGGACAGTATCTG  AAACGCGGTTCTGCATGAG 144 bp
PINK1 Drosophila  CAACATCCTCAATCCCAACC  TCTTAGTGGTCAGCGAAAGG 158 bp
RNA18S5 Human  CAGCCACCCGAGATTGAGCA  TAGTAGCGACGGGCGGTGTG 252 bp
PINK1 Human  GCCGGACGCTGTTCCTCGTT  TGGACACCTCTGGGGCCATC 327 bp
parkin Human  CACACTGACAGCAGGAAGGA  AGGGGCCTTTGCAATACA 91 bp
FBXW7 Human  GGGCACCAGTCGTTAACAAG  GTCACAGCACTCTGATGCTTG 149 bp
SREBF1 Human  CGTGCTGGGCACCGAGAGC  GGCCGTGTGACTGGCTCACC 138 bp
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- 8% Sodium dodecyl sulphate (SDS) 
- 40% Glycerol 
- 1% β-mercaptoethanol 
- 0.008% Bromophenol Blue 
 
2.7.2  CELL LYSIS 
 
Cells cultured in a 12-well plate were placed on an ice-block, washed briefly in cold 
PBS and lysed in 200 µl fresh lysis buffer (see 2.7.1). The cell monolayer was 
dislodged with a pipette tip and resuspended in the lysis buffer by repeat pipetting, 
before transfer to a microcentrifuge tube.  
 
2.7.3  PROTEIN QUANTIFICATION 
 
To quantify the amount of protein in each cell lysate, Bradford reagent (Sigma, B6916) 
was mixed with double distilled water (ddH2O) at a ratio of 1:1. 1 µl of lysis buffer alone 
(control) or cell lysate was mixed with 1 ml Bradford solution, and incubated at room 
temperature for between 5 – 60 minutes. Samples were transferred to cuvettes 
(Sarstedt, 67.742) and analysed by spectrophotometry (Eppendorf BioPhotometer) at 
595 nm. 
 
2.7.4  SDS PAGE 
 
Cell lysates were heated with 1x sodium dodecyl sulphate (SDS) sample buffer (see 
section 2.7.1) at 94 ºC for 10 minutes to remove secondary and tertiary structures. 
Samples were centrifuged briefly and placed on ice.  
 
Polyacrylamide gels were hand-cast to the appropriate concentration using a Bio-Rad 
Mini-PROTEAN® Tetra Handcast System, to manufacturers instructions. Gels were 
mounted in electrophoresis chambers, and 1x Tris/Glycine/SDS (TGS) running buffer 
(Bio-Rad, 161-0772) added. Protein samples were loaded at quantities ranging 
between 30 - 100 µg / lane, plus one lane of protein standard (5 µl) for monitoring 
protein molecular weight (Bio-Rad, 161-0373). Gels were run at 60 V through the 
stacking gel, and 190 V through the resolving gel until the protein of interest lay roughly 
halfway down the gel. 
 
Upon completion of gel electrophoresis, gels were removed from the running chamber 
and placed in 1x Tris/Glycine (TG) transfer buffer (Bio-Rad, 161-0771) containing 20% 
methanol. Simultaneously, membranes were activated in methanol (PVDF only) and 
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placed in transfer buffer (PVDF and nitrocellulose). Gels and membranes remained in 
transfer buffer for 5 - 10 minutes, allowing equilibration. To transfer proteins from the 
polyacrylamide gel to the membrane (PVDF - Bio-Rad 162-0177, nitrocellulose – 
Amersham RPN3032D), a transfer cassette ‘sandwich’ was constructed, consisting of 
two outer fibre pads, flanking two pieces of filter paper. This construction ensured that 
the gel and membrane were in close contact at the centre of the sandwich allowing 
efficient transfer. The transfer cassette was loaded into the transfer chamber together 
with an ice block and sufficient transfer buffer. The transfer was performed at 300 mA 
for 2 hours. 
 
Upon completion of protein transfer, the membrane was removed from the cassette 
and assessed for efficient transfer through analysis of the protein standard or Ponceau 
S staining (Sigma, P7170) for 5 minutes. The membrane was then placed on an orbital 
shaker, and blocked at room temperature or 4 ºC for 2 – 24 hours in 5% milk powder in 
PBST or TBST, depending on the assay. Following blocking, the membrane was 
sealed into a polythene bag together with the primary antibody, at room temperature or 
4 ºC for 1 – 24 hours on a rotating platform. Membranes were washed thoroughly in 
PBST or TBST for 1 - 2 hours before exposure to the secondary horseradish 
peroxidase (HRP)-conjugated antibody, for 0.5 – 2 hours. Following a further washing 
step, membranes were exposed using an enhanced chemiluminescence (ECL) system 
(Amersham, RPN2232). Here, membranes were incubated with ECL for 10 – 120 
seconds, before exposure to a light-sensitive photographic sheet (Amersham, 28-9068-
44) for 1 second to 10 minutes depending on the intensity of the chemiluminescence 
signal. Here, chemiluminescence arises when the enzyme, HRP and hydrogen 
peroxide oxidise the chemiluminescent substrate, luminol, causing it to emit light 
proportional to the amount of HRP present. Photographic films were developed using 
an automatic film developer. 
 
2.7.5  DATA ANALYSES 
 
Western blot films are quantified using the ImageJ plugin ‘Gels.’ Here, films are 
scanned, straightened, and opened in ImageJ. Using the rectangular selection tool, 
protein bands are selected, and the relative density of each protein lane is given. This 
is normalised to the relative density of the corresponding loading control, producing 
values of the relative protein amounts in each lane. These data are then plotted in a 
column graph, producing a graphical quantification of the qualitative western blot image. 
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2.7.6  ANTIBODIES  
 
All antibodies were diluted in blocking buffer prior to incubation. Detailed are the 
antibodies used during western blotting in this study, together with the favoured dilution 
buffer. 
 
 
 
2.7.7  ASSESSING GENERAL AUTOPHAGY VIA LC3 LIPIDATION 
 
General autophagy was assessed by the analysis of endogenous LC3 lipidation 
following starvation. HeLa cells were exposed to 25 nM siRNA as indicated, and 
incubated for 4 days. Media was replaced with either fresh media (U – untreated), 
HBSS (Invitrogen, 24020) (S – starvation), 20 nM bafilomycin A1-containing media 
(Sigma, B1793) (B – Bafilomycin A1) or 20 nM bafilomycin A1-containing HBSS (S&B – 
starvation and Bafilomycin A1) for 2 hours. Protein samples were collected and 
endogenous LC3 analysed using SDS-PAGE. Immunoblots were quantified using 
ImageJ. Assays were performed in triplicate, and the mean ‘LC3-II / total LC3’ ratio 
was calculated per sample. 
 
 
2.8  FLUORESCENCE MICROSCOPY 
 
2.8.1  SAMPLE PREPARATION 
 
For immunofluorescence techniques, cells were cultured on circular coverslips in 12-
well plates or 8-well chamber slides (BD Bioscience, 354118). Upon assay completion, 
media was aspirated, cells were washed briefly in cold PBS, and fixed / permeabilised 
in ice-cold methanol for 10 minutes. Cells were placed on an orbital shaker, and 
blocked for 30 minutes in a solution of 1% bovine serum albumin (BSA) in PBS. 
Following this, primary antibodies in blocking buffer were applied for 1-2 hours at room 
temperature. Cells were washed 3 x 10 minutes in PBST, before the addition of the 
secondary antibody in blocking buffer for 1 - 2 hours at room temperature. Cells 
underwent 3 further PBS-washing steps for 10 minutes each, before the addition of the 
Antibody type Name Source Product code Dilution Buffer Host animal
Primary DYKDDDDK-Tag (FLAG) Cell Signaling Technologies 2368 1 in 1,000 PBST Rabbit
Primary ATP5A Mitosciences MS507 1 in 10,000 PBST Mouse
Primary LC3 Sigma-Aldrich L8918 1 in 1,000 TBST Rabbit
Primary SREBP1 (2A4) Santa Cruz sc-13551 1 in 200 TBST Mouse
Primary SREBP1 (2A4) BD Biosciences 557036 1 in 1,000 TBST Mouse
Primary Actin Millipore MAB1501 1 in 5,000 PBST Mouse
Primary Tubulin Sigma T 9026 1 in 10,000 PBST Mouse
Secondary HRP-conjugate Anti-Mouse Abcam ab6789 1 in 5,000 PBST Goat
Secondary HRP-conjugate Anti-Rabbit Molecular probes G21234 1 in 5,000 PBST Goat
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nuclear stain, Hoechst, for 10 minutes. Following a final wash step, samples were 
mounted for imaging using MOWIOL mounting media.  
 
For live cell imaging, cells were cultured on 8-well live imaging trays (Ibidi, 80826). 
Cells were treated with fluorescent dyes in situ, allowing direct imaging with an inverted 
microscope. 
 
2.8.2  MICROSCOPES 
 
In this study, three microscopes have been utilised, with a variety of objectives as 
detailed in figure legends.  
 
2.8.2.1  Deltavision RT Deconvolution widefield microscope 
 
The Deltavision widefield microscope (Applied Precision, Inc. Washington) was used 
for early low-throughput assay development work. The two objectives used were a 60x 
Plan Apo NA 1.42 objective (Olympus) and a 100x U Plan S Apo NA 1.40 objective 
(Olympus). The following filter blocks were employed to visualise fluorescence: 
360/457 (DAPI), 490/528 (GFP), 500/535 (YFP), and 555/617 (Alexa Fluor 594).  
 
2.8.2.2  Olympus FV1000 Fluoview confocal microscope  
 
The Olympus FV1000 Fluoview confocal system (Olympus corporation) was used for 
the majority of the low-throughput data analysis. In all assays, the objective of choice 
was a 60x Plan Apo NA 1.42 (Nikon) with 2x digital zoom as indicated. Here, 405, 488, 
514 and 534 laser lines were used to visualise DAPI, GFP, YFP and Alexa Fluor 594 
respectively. 
 
2.8.2.3  ImageXpress Micro high content widefield microscope 
 
For all high-throughput work, an ImageXpress Micro widefield high content screening 
microscope (Molecular Devices) was employed. For Drosophila whole genome 
screening and the majority of Drosophila follow-up screens, a 40x S Plan Fluor NA 
0.60 ELWD objective (Nikon) was utilised. In addition, a small number of Drosophila 
follow-up screens and all human screening protocols required the use of a 10x Plan 
Fluor NA 0.30 objective (Nikon). A range of fluorescence filter cubes was used over the 
screening process including DAPI (1-6300-0442, Molecular Devices), GFP (1-6300
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0450, Molecular Devices), YFP (1-6300-0448, Molecular devices) and Texas Red® (1-
6300-0449, Molecular Devices). 
 
2.8.3  ANTIBODIES AND DYES 
 
The following antibodies and cellular dyes were used in fluorescence microscopy 
assays throughout this study as indicated. 
 
 
 
 
2.9  FLUORESCENCE ASSAYS 
 
2.9.1  PARKIN TRANSLOCATION RESCUE WITH LIPIDS 
 
In chapter 6, fluorescence microscopy is used to assess YFP-Parkin translocation in 
YFP-Parkin.HeLa cells. Here, control, PINK1 and SREBF1 siRNA was applied for 3 
days, before priming cells with various concentrations of lipids for 24 hours. Following 
lipid priming, cells were treated with 10 µM CCCP for 4 hours, fixed and processed for 
imaging as in 2.8.1. 
 
Lipids used in these assays are detailed below. 
 
  
Antibody / Dye Name Source Product code Dilution Host animal
Primary ATP5A Mitosciences MS507 1 in 5,000 Mouse
Primary c-Myc (9E10) Santa Cruz sc-40 1 in 50 Mouse
Primary GFP Abcam ab6556 1 in 1,000 Rabbit
Secondary Alexa Fluor® 594 Anti-Mouse Molecular probes A-11005 1 in 400 Goat
Secondary Alexa Fluor® 488 Anti-Rabbit Molecular probes A-11008 1 in 400 Goat
Dye Hoechst 33342 Molecular probes H3570 2 µg/ml -
Dye MitoTracker® Red CMXRos Molecular probes M7512 50 - 150 nM -
Dye TMRM Molecular probes T-668 50 nM -
Lipid Source Product code Dilution factor
Fatty Acid Supplement (aqueous mixture) Sigma F7050 1 in 2,000 ('High')1 in 4,000 ('Low')
SyntheChol™ Supplement (synthetic cholesterol) Sigma S5442
1 in 100 ('Very High')
1 in 250 ('High')
1 in 500 ('Low')
Cardiolipin Solution (bovine heart) Sigma C1649 1 in 1,000
Phosphatidylethanolamine Solution (soybean) Sigma 60660 1 in 1,000
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2.9.2  ASSESSING ∆Ψm WITH TMRM 
 
2.9.2.1  Reagents 
 
Tetramethylrhodamine, Methyl Ester (TMRM) – Molecular Probes, T668 
Stock solution - 100 µM (in DMSO) 
 
Assay Buffer (pH 7.8) 
 
- 80 mM sodium chloride (NaCl) 
- 75 mM potassium chloride (KCl) 
- 25 mM D-Glucose 
- 25 mM HEPES 
 
2.9.2.2  ∆Ψm analysis 
To analyse the integrity of the ∆Ψm in HeLa cells following siRNA silencing of PINK1, 
SREBF1 and FBXW7, the cationic dye Tetramethylrhodamine methyl ester (TMRM) 
was utilised. Assays were carried out in opaque 96-well plates (Corning, CLS3362) 
containing siRNA at a final concentration of 25 nM. Each siRNA was assessed in the 
presence of vehicle or CCCP, with 5 wells of each condition per plate. Additionally, 
plate controls comprised siRNA- and cell-free wells in the presence of vehicle or CCCP. 
 
The siRNA-silencing protocol was comparable to that detailed in section 2.4.2. Briefly, 
probes were complexed to the siRNA-delivery reagent, DF1 for 30 minutes at room 
temperature. Each well received 6,000 HeLa cells, before an incubation period of 24 
hours at 37 ºC. Media was replaced to reduce the risk of transfection-reagent toxicity, 
followed by a further incubation of 24 hours. Media was aspirated and replaced with 
either vehicle or CCCP-containing media (10 µM) for 1 hour. Media was aspirated, and 
cells washed with pre-warmed ‘assay buffer.’ Cells were then incubated with assay 
buffer containing 50 nM TMRM for 30 minutes at 37 ºC. Plates were washed 3x in 
vehicle- or CCCP-containing assay buffer, before fluorescence quantification using a 
Mithras LB940 plate reader. Here, TMRM fluorescence was detected at 580 nm, 
quantifying the output as relative fluorescence units (RFU).  
 
To determine the final data, average RFU data from ‘cell-free’ wells for vehicle- and 
CCCP-treated portions of the plate were subtracted from equivalent experimental data 
points to account for background. Additionally, each well was normalised according to 
! 76 
cell number, determined by the addition of the DNA-binding dye, CyQuant (Molecular 
Devices, C35007). Here, CCCP-containing assay buffer was applied across the entire 
plate to allow all remaining TMRM to diffuse away. Then, per well, 30 µl 1x CyQuant 
was incubated for a period of 1 hour at 37 ºC. CyQuant fluorescence was detected at 
530 nm by a Varioskan Flash plate reader (Thermo Scientific), quantifying the output 
as relative fluorescence units (RFU). Following cell number normalisation, average 
RFU values across 5 repeat wells were calculated for each condition. The dataset 
underwent a final normalisation step, to ‘control siRNA, vehicle.’ Four assays were 
performed and an overall average for each condition produced. 
 
2.9.3  PINK1 STABILISATION FOLLOWING CCCP-TREATMENT 
 
HeLa cells were treated with control, PINK1, FBXW7 or SREBF1 siRNA (25 nM) as in 
2.4.2. After 2 days, PINK1-GFP was transfected as in section 2.3, and cells were 
incubated for a further 16 hours before being treated with vehicle- or CCCP-containing 
media for 1 hour. Samples were fixed with ice-cold methanol and processed for 
imaging. Here, anti-ATP5A and anti-GFP primary antibodies were applied for the 
visualisation of mitochondria and enhanced detection of native PINK1-GFP. Secondary 
antibodies were anti-AlexaFluor 594 (mouse) and anti-AlexaFluor 488 (rabbit). 
 
2.9.4  CHEMICAL INHIBITION OF THE SREBP-PATHWAY 
 
The SREBP-pathway was chemically blocked by the addition of genistein (Sigma, 
G6649), prepared in DMSO and used over a range of concentrations from 10 – 100 µM. 
Here, YFP-Parkin.HeLa cells were exposed to varying concentrations of genistein-
containing NCM for 24 hours prior to toxification with 10 µM CCCP for 4 hours. Cells 
were fixed and processed for imaging.  
 
 
2.10 DROSOPHILA GENETICS 
 
2.10.1  DROSOPHILA HUSBANDRY 
 
All Drosophila stocks were maintained in cotton wool-stoppered plastic vials containing 
cornmeal agar media and bakers yeast. When placed at 18 ºC, the Drosophila life 
cycle persists for approximately 40 days. Each stock had at least three copies, which 
were flipped cyclically into fresh tubes every 2 weeks. To select flies of the correct 
genotype for crosses, stocks were tipped out onto CO2 anaesthesia stations. Crosses 
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generally consisted of 8 males and 10 - 12 virgin females, which were incubated at 25 
ºC allowing the appearance of larvae after ~3 days. Under most conditions, adults 
began to eclose from pupal cases 10 days after placing the cross in the incubator. 
Parental flies were flipped into fresh vials every three days, to increase longevity and 
egg-laying potential. 
 
2.10.2.  DROSOPHILA LINES 
 
Below are the fly stocks used to create the Drosophila genotypes utilised in this study. 
 
 
 
2.10.3  CLIMBING ASSAY 
 
Adult flies aged between 0 - 3 days were sorted according to their genotype and 
transferred to empty plastic tubes at a maximum density of 25 flies per tube. Tubes 
were placed with the climbing apparatus for 1 - 2 hours prior to assay commencement, 
to allow acclimatisation. Following acclimatisation, a single fly-containing tube was 
inserted into position 1 of the climbing apparatus, consisting of six lower tubes and six 
upper tubes in a counter-current arrangement. For each tube set, flies were given 10 
seconds to climb upwards from the lower tube to the upper tube. After 10 seconds, flies 
that reached the upper tube were transferred into the adjacent tube set. This process 
was repeated five times, giving flies the chance to arrive at the final tube set. Upon 
assay completion, the number of flies residing in each of the tubes were counted, and 
scored relative to their position within the climbing apparatus. From this, a ‘climbing 
index’ was calculated for the cohort, and normalised to the control group. 
  
Stock name Genotype Stock ID Source
Control RNAi w;P(UAS-RH4-RNAi) v46919 VDRC
HLH106 RNAI (1) w[1118]; P{GD4360}v37641 v37641 VDRC
HLH106 RNAi (2) w[1118]; P{GD4360}v37640 v37640 VDRC
ago RNAi yv; agoTRiP(4005) 31501 TRiP
sgg RNAi P{KK108994}VIE-260B v101538 VDRC
park25 w;park25/TM6B - Greene et al., 2003
UAS-ago UAS-ago/TM3 - Mortimer and Moberg 2007
UAS-ago∆F UAS-ago∆F/TM6B - Mortimer and Moberg 2007
ago1 ago1FRT80/TM6B - Moberg et al., 2001
ago3 ago3FRT80/TM6B - Moberg et al., 2001
UAS-HLH106 w[*]; P{w[+mC]=UAS-HLH106.K}2/CyO; HLH106[189]/TM6B, Tb[1) 38396 Bloomington
UAS-HLH106∆C y[1] w[*]; P{w[+mC]=UAS-HLH106.1-452}2/CyO; HLH106[189]/TM6B, Tb[1] 41018 Bloomington
Act5C-GAL4 w;P(Act5C-GAL4)/CyO 25374 Bloomington
da-GAL4 w;P(da-GAL4) 8641 Bloomington
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2.10.4  FLIGHT ASSAY 
 
Flies tested for climbing in 2.10.3 were transferred to food-containing tubes and left to 
acclimatise with the flight apparatus for ~ 1 hour. Following acclimatisation, flight ability 
was tested using a 1 litre-measuring cylinder, lined with a sticky grease-coated acetate 
sheet. Flies were gently but firmly dropped through a plastic funnel into the cylinder. 
Those able to initiate flight would fly out and up, becoming stuck to the acetate sheet. 
The position with which flies would become stuck depended on the speed with which 
the flight reflex was initiated. To quantify this, the acetate sheet was carefully removed 
from the cylinder, and sandwiched to an additional acetate ‘score sheet’ divided into 4 
portions. The number of flies residing in each portion of the scoring sheet were counted, 
and given a score relative to their position. From this, a ‘flight index’ was calculated for 
the cohort, and normalised to the control group. 
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3. WHOLE GENOME RNAi SCREEN 
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3.1 BACKGROUND 
 
3.1.1  PINK1/PARKIN-PATHWAY 
 
Following the discovery that the PD-related genes PINK1 and parkin were acting in a 
common pathway (Clark et al, 2006; Park et al, 2006; Yang et al, 2006), research has 
focused on ascertaining the role of the pathway in a cellular context. A large body of 
evidence built up over the last few years indicates a central importance in the 
maintenance of mitochondrial homeostasis, encompassing aspects of mitochondrial 
morphology, transport and clearance.  
 
Of particular interest to this project is the selective elimination of dysfunctional 
mitochondria from the cell via mitophagy. The current model involves the PINK1-
dependent translocation of Parkin from the cytoplasm to a subset of failing 
mitochondria, followed by their selective removal via the autophagy-lysosomal pathway 
(Narendra et al, 2008). To date, a number of additional genes have been shown to play 
a role in the PINK1/Parkin-pathway, including mitofusin, encoding a MOM GTPase 
involved in mitochondrial fusion (Gegg et al, 2010; Poole et al, 2010; Tanaka et al, 
2010; Ziviani et al, 2010), and miro, encoding a MOM GTPase involved in 
mitochondrial trafficking (Liu et al, 2012; Wang et al, 2011). However, there are many 
unanswered questions regarding the mechanism by which dysfunctional mitochondria 
are identified and flagged up for degradation by the PINK1/Parkin-pathway (Figure 
1.10). 
 
 
3.2 HYPOTHESES AND AIMS 
 
The initial aim of this project was to perform a cell-based whole genome RNAi screen 
in order to identify novel promoters of PINK1/Parkin-mediated mitophagy. Specifically, 
the screening assay was developed in Drosophila S2R+ cells, and focused on the 
identification of genes acting upstream of Parkin translocation following mitochondrial 
depolarisation with the protonophore carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP). The intended outcome of this screen was to produce a list of robust hit genes 
causing a decrease in Parkin translocation following silencing. Hence, these genes are 
potentially involved in the translocation event itself, or signaling events upstream, such 
as damage recognition and pathway initiation 
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3.2.1.  DROSOPHILA AS A SCREENING MODEL 
 
There are a number of advantages of using Drosophila cells as a model for high-
throughput screening assays. First, the Drosophila genome has a very low level of 
redundancy compared to mammalian genomes (Beckingham et al, 2005). This feature 
is likely to reduce the number of false negative events and decrease the complexity of 
data analyses following screening. Second, Drosophila cells readily take up dsRNA 
when applied in serum-free media, eliminating the need for transfection. This greatly 
reduces costs and eliminates the toxic side effects of transfection reagents, which 
would otherwise require consideration during assay optimisation. Finally, with the 
‘Sheffield RNAi Screening Facility’ (SRSF) on our doorstep, the reagents, equipment 
and support necessary for carrying out a screen in Drosophila cells are readily 
available. Importantly, the Drosophila RNAi library held in the SRSF contains identical 
dsRNA sequences to those used to make an in vivo Drosophila RNAi library (VDRC 
KK library), allowing easy transition from a cellular to a whole-organism system. 
 
3.2.1.1  Drosophila dsRNA library 
 
The available Drosophila dsRNA library is the Heidelberg 2 (HD2.0), second-
generation library developed by the Boutros laboratory using NEXT-RNAi software. 
This software is designed to avoid areas of low-complexity and reduce the number of 
potential off-target effects (Boutros et al, 2004; Horn et al, 2010).  
 
The mechanism by which dsRNA transiently silences genes in a post-transcriptional 
manner is well defined in Drosophila. Briefly, cells are bathed in FBS-free media 
containing the gene-specific dsRNA probe. This probe is taken up by the cell and 
broken into a number of 22mer, double-stranded siRNA fragments by the RNase 
enzyme Dicer. These siRNAs are unwound into single-stranded fragments following 
ATP-hydrolysis, and integrated into the RNA-induced silencing complex (RISC), where 
target mRNA recognition and Argonaute-dependent degradation takes (reviewed in 
Hannon & Rossi, 2004). 
 
The HD2.0 library itself contains dsRNA probes ranging in size from 81 – 800 bp, 
covering ~98.8% of the Drosophila transcriptome. Within the library, there are 18,434 
dsRNA probes targeting 15,177 coding and non-coding genes, thus in some cases 
there are two or more dsRNAs targeting the same gene. Additionally, dsRNA design is 
such that every known isoform of a gene is silenced by a single dsRNA, ensuring full 
knockdown of target gene expression. 
 83 
3.2.2  SCREENING OVERVIEW 
 
In order to successfully perform a whole genome screen, a clear screening strategy 
must be in place. In our case, a screening workflow guided the project from the initial 
biological question of ‘Which genes act upstream of Parkin translocation?; through to 
hit selection and low-throughput analysis (Figure 3.1). 
 
To ensure success, significant effort was committed to developing a robust and 
reproducible assay. Following assay development, the quality of the assay was 
assessed through a series of ‘pilot’ screens using small sub-set libraries, before 
undertaking the whole genome screen itself. Following completion of the whole 
genome screen, hits were confirmed in several rounds of re-screening. This acted to 
remove false positives from the dataset, and produced a final primary hit list of genes. 
Taking these hit genes, a number of secondary screening assays were performed 
looking at different of aspects of mitochondrial homeostasis. Collating these data 
produced an overall list of genes able to influence a range of mitochondria-related 
processes. To validate these genes in a system with greater genetic complexity, 
corresponding human orthologs of hits were assessed in the context of Parkin 
translocation and mitophagy using a HeLa cell line. This culminated in a final list of 
genes showing strong cross-species effects. With the help of bioinformatics, a small 
number of interesting hits were selected for low-throughput analysis.  
 
 
3.3 ASSAY DEVELOPMENT 
 
3.3.1  VALIDATING THE DROSOPHILA S2R+ CELL MODEL 
 
The majority of recent work on PINK1/Parkin-mediated mitophagy has been carried out 
in mammalian cell systems. The initial challenge of this project was to recapitulate the 
well-defined steps of the PINK1/Parkin-pathway in a Drosophila cell system, thus 
validating S2R+ cells as a viable model. These steps included the dissipation of the 
mitochondrial membrane potential (∆Ψm) following toxification with CCCP, the 
stabilisation of PINK1 on the MOM, the translocation of Parkin to mitochondria and the 
clearance of damaged mitochondria via mitophagy. 
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Figure 3.1. Screening Overview. Schematic representation of the screening process from the initial biological question 
through to the low-throughput analysis of the top screening hits. The biological assay involved the analysis of CCCP-
induced Parkin translocation following gene silencing, with a focus on dsRNA amplicons causing a significant reduction 
in Parkin-GFP puncta number. The reagents used included the HD2.0 dsRNA library developed by Michael Boutros and 
colleagues (Boutros et al, 2004; Horn et al, 2010), a stable S2R+ cell line overexpressing Parkin-GFP, and CCCP to 
induce the translocation event. Following thorough assay optimisation, a number of subset screens were performed 
(test plates & kinome / phosphatome) prior to the whole genome screen. Screen hits were confirmed in several rounds 
of re-screening, before being scrutinised for their ability to influence other aspects of mitochondrial homeostasis in 
secondary screening assays. Next, overall Drosophila hits were converted to their human orthologs, and HeLa-cell 
screening was undertaken, for validation in a mammalian system. From the point of Drosophila gene confirmation 
screening, hit lists were analysed for an involvement in common pathways using bio-informatics, as well as being 
compared to other published screening data. This assisted in the selection of a small number of genes for low-
throughput analysis following screening completion. 
 
3.3.1.1  Dissipation of the mitochondrial membrane potential 
 
CCCP is a diffusible protonophore, able to induce rapid dissipation of the ∆Ψm. As an 
amphipathic, weak acid, protonated CCCP+ freely diffuses across the mitochondrial 
membrane. Here, it rapidly dissociates from H+, and exits the mitochondria as an anion. 
As a consequence, this increase in H+ ions in the mitochondrial matrix causes the ∆Ψm 
to discharge, hence uncoupling the mitochondrial ETC. Whilst CCCP is present in 
culture media, this process will cycle continuously, maintaining mitochondrial 
uncoupling and blocking the production of ATP.  
Biological question: Which genes act 
upstream of Parkin translocation? 
Biological assay:  
Parkin translocation 
Reagents:  
HD2.0 dsRNA library, S2R+ cells, CCCP 
Test plate 
Confirmation screens 
Secondary screening 
Low throughput analysis of top hits  
Whole Genome Screen 
Kinome / Phosphatome screen 
Validation of hits in Human cells 
Assay optimisation 
Investigation of pathways, literature mining Comparison of hits with other screens 
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To demonstrate the effect of CCCP in S2R+ cells, cells were subjected to CCCP 
treatment and imaged live over a period of 60 minutes. The status of the ∆Ψm was 
measured using the potentiometric mitochondrial dye, MitoTracker Red (MTR). Prior to 
toxification, MTR co-localises with Mito-GFP, signifying a mitochondrial network with an 
intact ∆Ψm (Figure 3.2 A). This co-localisation is reduced after 5 minutes of CCCP 
toxification (Figure 3.2 B) and lost after 15 minutes of CCCP toxification (Figure 3.2 C). 
After 30 & 60 minutes of CCCP toxification, the MTR signal is lost entirely (Figure 3.2 D 
& E). These data demonstrate the rapid and successful collapse of the ∆Ψm following 
CCCP treatment in S2R+ cells. Importantly, the induction of mitochondrial 
fragmentation following CCCP toxification is also observed (Figure 3.2 B - E), as 
reported previously (Ishihara et al, 2003; Legros et al, 2002), further strengthening the 
similarities between Drosophila and mammalian cell systems. 
 
3.3.1.2  PINK1 stabilisation 
 
Under basal conditions, mammalian PINK1 is cleaved by the mitochondrial proteases 
MPP and PARL (Deas et al, 2011; Greene et al, 2012; Jin et al, 2010; Meissner et al, 
2011; Whitworth et al, 2008), before rapid proteasomal degradation via the N-end rule 
pathway (Yamano & Youle, 2013). When overexpressed, a very low level of diffusely 
localised PINK1 is observed in the cytoplasm. However, after a short CCCP 
toxification, PINK1 levels increase, and it becomes stabilised on the MOM (Matsuda et 
al, 2010; Narendra et al, 2010b). To assess this phenomenon in S2R+ cells, PINK1-
myc was overexpressed in the absence or presence of CCCP. In contrast to human 
cells, under basal conditions, PINK1-myc colocalises with the mitochondrial marker 
Mito-GFP, rather than adopting a diffuse cytoplasmic localisation (Figure 3.3 A & A’). 
However, upon CCCP treatment PINK1-myc no longer fully co-localises with Mito-GFP; 
now decorating an area around the periphery of the marker (Figure 3.3 B & B’). This 
observation is in agreement with mammalian data whereby CCCP causes PINK1 to 
become stabilised on the MOM. However, the disparity observed prior to toxification 
indicates a difference in the dynamic turnover of Drosophila PINK1 (dPINK1). Perhaps 
in S2R+ cells, dPINK1 is not degraded as rapidly as in mammalian cells, allowing the 
existence of a stable fraction in the inner compartments of mitochondria. In support of 
this suggestion, both full-length and processed dPINK1 isoforms are readily detectable 
in whole Drosophila lysates (Whitworth et al, 2008). 
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Figure 3.3. dPINK1 stabilisation following CCCP toxification. S2R+ cells were transiently transfected with PINK1-
myc. Following the addition of vehicle (A & A’) or CCCP (B & B’) for 4 hours, cells were fixed and processed for imaging. 
Mitochondria (Mito-GFP – green) and PINK1-myc (red) are represented. Images were acquired using a Deltavision RT 
system with a 100x objective. Boxed areas represent images in A’ & B’. Scale bar: 5 µm. 
 
3.3.1.3  Parkin translocation and mitophagy 
 
In mammalian cells, following CCCP-induced PINK1 stabilisation on the MOM, Parkin 
is recruited to those mitochondria in a PINK1-dependent fashion. To demonstrate this 
translocation event, S2R+ cells were transiently transfected with Parkin-GFP and 
subjected to either vehicle- or CCCP-toxification for a period of 2 hours. In vehicle-
treated cells, Drosophila Parkin (dParkin) distribution is largely cytoplasmic, with only 
~30% of cells exhibiting any degree of Parkin-GFP puncta (Figure 3.4 A & B). This 
observation is in agreement with published mammalian data whereby endogenous 
Parkin was shown to colocalise with a subset of mitochondria in the absence of 
toxification, albeit infrequently (Narendra et al, 2008). However, in CCCP-treated S2R+ 
cells, Parkin-GFP formed numerous punctate structures; which colocalise with the 
mitochondrial marker ATP5A; in ~80% of the population (Figure 3.4 A & B). Like in 
mammalian cells, these data confirm the occurrence of dParkin translocation in S2R+ 
cells following CCCP toxification. However, whilst dParkin clearly co-localises with a 
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Figure 3.4. dParkin translocation and mitophagy following CCCP toxification. Parkin-GFP.S2R+ cells were toxified 
for 2 hours (A & B) or 24 hours (C & D) with 10 µM CCCP. (A) Following a 2-hour CCCP toxification, Parkin-GFP 
(green) translocates from the cytoplasm to mitochondria (ATP5A – red). This effect has been analysed by eye and 
quantified in (B) as the percentage of cells with Parkin-GFP +ve puncta. Data from three biological repeats, with at least 
6 FOV per condition, per assay. Error bars represent standard deviation, ***P<0.001 (Student’s T-test). (C) Following a 
24-hour CCCP toxification, a marked decrease in the mitochondrial marker, ATP5A can be observed. Cells were 
counterstained with Hoechst nucleic acid dye. The decrease in ATP5A signal was quantified in (D) as the ‘average 
ATP5A signal’ in mean grey levels (ImageJ). Data from two biological repeats with at least 3 FOV per condition, per 
assay. Error bars represent standard deviation. No significance (ns) was found between toxified and non-toxified 
conditions (Student’s T-test). Images were acquired using an Olympus FV1000 confocal system with a 60x objective (A) 
or a Deltavision RT system with a 10x objective (C). Scale bars as indicated. 
 
 89 
subset of mitochondria here, a proportion of the mitochondrial network remains 
dParkin-free following toxification (Figure 3.4 A). The reason for this is unclear, but may 
be due to a heterogeneous response of the mitochondrial network to the CCCP 
challenge. For example, mitochondria exhibiting prior damage are likely to suffer a 
large drop in ∆Ψm following CCCP toxification, resulting in significant activation of the 
PINK1/parkin-pathway. In contrast, healthy mitochondria with a full complement of 
intact components may more easily maintain their ∆Ψm, hence avoiding dParkin 
translocation and the activation of mitophagy. In the mammalian field, whilst many 
studies show complete colocalisation between Parkin and mitochondria following 
CCCP application (Geisler et al, 2010; Narendra et al, 2010a; Okatsu et al, 2010; 
Rakovic et al, 2011; Tanaka et al, 2010; Vives-Bauza et al, 2010), others have a 
phenotype similar to that observed here (Narendra et al, 2008; Narendra et al, 2010b; 
Van Laar et al, 2011). Importantly, there is good correlation between Parkin-GFP 
translocation in S2R+ cells, and endogenous Parkin translocation in HEK293 cells and 
cultured rat neurons (Narendra et al, 2008; Van Laar et al, 2011), perhaps highlighting 
the physiological relevance of the observed distribution. 
 
Sustained CCCP toxification for 24 hours has been shown to lead to the loss of 
mitochondria from the cell via mitophagy (Narendra et al, 2008). The severity of the 
phenotype is very much cell-type specific, and has been shown to vary greatly in 
mammalian-derived cell lines. For example, primary neurons, which rely heavily upon 
oxidative phosphorylation for their energy production undergo mitophagy much less 
readily than glycolytic, cancer-derived HeLa cells (Gusdon & Chu, 2011). This 
suggests that cells with a greater reliance upon the mitochondrial network for ATP 
synthesis are less likely to permit mitophagy than those whose energy may be sourced 
by alternative routes. In S2R+ cells, persistent CCCP toxification for 24 hours does not 
appear to cause a complete loss of mitochondrial markers as shown in HeLa cells, but 
can lead to a marked reduction in the ATP5A signal (Figure 3.4 C & D). This 
demonstrates the ability of S2R+ cells to alter their mitochondrial proteome following 
toxification. However, this reduction in ATP5A signal has proved variable between 
experiments, and is therefore not a reliable occurrence in this cell-type under the tested 
conditions. Because of this variability, combined treatments of CCCP with autophagy 
inhibitors such as Bafilomycin A1 were unable to show definitively that the reduction in 
ATP5A signal was due to mitophagy. Despite this, published data in S2R+ cells have 
shown that CCCP-induced ATP5A signal reduction is dependent upon autophagy- but 
not proteasomal-related genes (Ziviani et al, 2010).  
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3.3.2  SCALING-UP FOR HIGH-THROUGHPUT SCREENING 
 
Having validated Drosophila S2R+ cells as a suitable model for the assessment of 
PINK1/Parkin-related processes, the next challenge was to scale-up the dParkin 
translocation assay into the 384-well plate format used for whole-genome primary 
screening. 
 
3.3.2.1  dParkin translocation 
 
For the primary screen, the chosen image-based assay assesses the translocation of 
Parkin-GFP to the MOM following CCCP toxification. The output of the screen is the 
quantification of the number of Parkin-GFP positive ‘dots’ or ‘puncta’ that are formed as 
a consequence of this toxification. This feature of the PINK1/Parkin-pathway was 
selected for screening due to the simple nature of the assay, making it amenable to 
high-throughput usage, and the reproducibility of the observed effect. The advantage of 
assessing dParkin itself is the increased likelihood of capturing PINK1/Parkin-specific 
hits, perhaps compared with a broader, mitochondrial degradation assay. In contrast, 
the disadvantage of focusing on an early pathway step is the limited number of positive 
screen controls. For example, the only known gene required for Parkin translocation in 
a mammalian setting is PINK1. However, when considering these points, the 
advantages offered by this screening scenario were perceived to outweigh the negative 
aspects, deeming it a viable assay for primary screening. 
 
3.3.2.2  Genes of interest 
 
The primary screening assay has the potential to identify genes causing both a 
decrease and an increase in dParkin translocation following CCCP toxification. For the 
scope of this project, data analyses focuses on genes causing a decrease in dParkin 
translocation when silenced. One motive for concentrating on this group is to identify 
genes phenocopying the loss of dPINK1. Such genes are potentially pathway agonists, 
acting upstream or downstream of dPINK1. In contrast, hits increasing translocation 
would represent pathway antagonists. Both gene groups are equally interesting, 
however, an increase in dParkin translocation may potentially arise from non-specific 
cellular toxicity as well as PINK1/Parkin-related processes. As a consequence, it will be 
difficult to uncouple these two root causes, in order to determine pathway-specific 
genes. 
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3.3.2.3  Reagents 
 
To simplify the screening protocol and maximise data capture, it was considered 
advantageous to produce an S2R+ cell line, stably overexpressing pMK33.Parkin-GFP 
(Parkin-GFP.S2R+). For this, a copper-inducible plasmid containing Drosophila Parkin-
GFP and a Hygromycin B resistant cassette was transiently transfected into S2R+ 
cells. Following selection with 300 µg/ml Hygromycin B for three weeks, virtually the 
entire population of cells expressed GFP at variable levels (Figure 3.5) Unlike 
mammalian cell lines which will grow readily at very low cell densities, Drosophila cell 
cultures often undergo widespread cell death if the population drops below optimum 
density. Because of this, producing clonal S2R+ cell lines is near impossible. However, 
despite our Parkin-GFP.S2R+ line being of a non-clonal origin, visual assessment 
found the vast majority of cells to stably express Parkin-GFP at largely comparable 
levels, circumventing this issue. 
 
3.3.2.4  Screening protocol 
 
The basic screening protocol entailed seeding 6,000 Parkin-GFP.S2R+ cells 
suspended in 30 µl serum-free Schneider’s medium (SFSM), in 384-well plates arrayed 
with pre-printed dsRNA probes. Whilst in SFSM, the cells readily take up the dsRNA, 
and gene silencing begins. After 1 hour, equal volumes (30 µl) of 2x FBS-containing 
Schneider’s media are added to screening plates, and cells are incubated at 25 ºC for 
72 hours. Parkin-GFP expression is induced by the addition of copper sulphate to a 
final concentration of 500 µM, and cells are incubated for a further 16 hours. Media is 
aspirated and replaced with vehicle- or CCCP-containing media at a final concentration 
of 10 µM for 2 hours. Cells are fixed for 10 minutes in Hoechst-containing 
formaldehyde, washed once in PBS, and stacked for automated imaging using an 
‘Automate.it Scara’ robotic loader (PAA) and ‘ImageXpress Micro’ high content 
microscope (Molecular Devices). Per well, 9 fields of view (FOV) and 2 fluorescent 
channels (GFP and DAPI) are captured using a 40x objective. Here, the chosen 
number of images per well provided enough cell-data to build a detailed overview of 
the entire population, and the degree of magnification allowed for the resolution of 
Parkin-GFP puncta. 
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Figure 3.5. Time course of Parkin-GFP expression induction with copper sulphate. Cells were imaged live at 
various time points following the addition of copper sulphate solution (500 µM). (A) At 0 hours very little GFP expression 
was observed. (B) By 7 hours and (C) 24 hours of copper sulphate induction, virtually the entire population expressed 
Parkin-GFP at high levels. Images captured on a Deltavision RT system with a 40x objective. Scale bar: 20 µm. 
 
3.3.3  ASSAY OPTIMISATION 
 
3.3.3.1  Automating data analyses 
 
The Drosophila whole genome screen library comprises 53x 384-well plates, totalling 
20,352 individual wells for data collection. Due to the scale of the screen, it was 
necessary to automate image analysis using a pre-programmed application called 
‘Transfluor’ (Molecular Devices). Transfluor works by quantifying the number of user-
defined objects within specified parameters in a FOV. For example, in the context of 
the primary screen, the chosen output was the ‘total number of GFP puncta’ in an 
image, normalised to cell (nuclei) number, and averaged across the 9 FOV. This gave 
a measure of the ‘average number of GFP puncta per cell’ for a given condition. To 
produce this quantification, the ‘Transfluor’ algorithm took the original micrograph 
image (Figure 3.6 A) and created a ‘mask’ (Figure 3.6 A’ & A’’) whereby objects such 
as nuclei (grey) and puncta (white) were identified. Together with the mask image, 
quantification data for each FOV was logged in a data file accessible via Microsoft 
Excel.   
 
Transfluor allows the user to specify object parameters within a FOV including 
minimum and maximum object size (µm), and the minimum intensity above local 
background (grey levels). Due to the influence of background fluorescence, such 
parameters required careful adjustment in order to produce optimum settings for the 
assay. The objectives for optimising these parameters were first, to achieve the 
greatest separation between vehicle- and CCCP-treated cells and second, to produce 
the most accurate ‘mask’ representation of the original image. Having tested a range of 
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object sizes and intensities, all parameters analysed were able to distinguish between 
the two conditions (Figure 3.6 B). In order to select the most appropriate parameters, 
both the degree of significance (Figure 3.6 C), and the fold change in puncta number 
(Figure 3.6 D) between the two conditions were analysed. Using this analysis, an 
object size between 0.6 – 1 µm was found to produce the greatest significant difference 
and greatest fold change between vehicle- and CCCP-treated cells. However, the 
optimum ‘minimum intensity’ was less easily identified using this method. Having 
analysed the mask outputs for a range of intensities (Figure 3.6 A’ and A’’), ‘60 grey 
levels above background’ most faithfully reproduced the micrograph data, as well as 
performing well in the aforementioned tests. Therefore the chosen screening 
parameters for automated data analyses were objects with a diameter between 0.6 µm 
– 1 µm, and a minimum intensity of 60 grey levels above background. 
 
3.3.3.2  Cellular parameters 
 
Prior to screening, a number of assay parameters required optimisation in order to 
achieve the greatest separation between vehicle- and CCCP-treated samples. These 
included the optimum number of cells per well (Figure 3.7 A, 6,000), copper induction 
concentration (Figure 3.7 B, 500 µM), toxin type (Figure 3.7 C, CCCP (Sigma)), and 
toxification duration (Figure 3.7 D, 2 hours). All chosen conditions provided a significant 
difference between vehicle- and CCCP-treated conditions. Additionally, the selected 
cell density of 6,000 cells per well produced a confluent cell population for maximum 
data capture. The chosen copper sulphate concentration of 500 µM lead to the most 
robust induction of Parkin-GFP expression, as well as producing a substantial increase 
in puncta number compared to lower concentrations. There were no obvious benefits 
to altering the CCCP manufacturer, or switching to the CCCP-analog FCCP. Therefore 
as in low-throughput assays, CCCP from Sigma Aldrich was used throughout 
screening. Finally, in mammalian cells, Parkin translocation is typically studied after a 
toxification of 1 - 4 hours (Geisler et al, 2010; Matsuda et al, 2010; Narendra et al, 
2008; Okatsu et al, 2010; Vives-Bauza et al, 2010). In S2R+ cells, at 2 & 4 hours 
toxification, Parkin-GFP translocation profiles were comparable; but by 6 hours the 
results became highly variable. Therefore, the earliest time point of 2 hours was 
chosen to increase the reproducibility of the observed effect, and decrease the assay 
duration. 
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Figure 3.7. Optimisation of cellular parameters. Graphical representation of (A) cell number optimisation, (B) copper 
sulphate concentration titration, (C) alternate toxin source / type and (D) toxification duration time-course, in vehicle or 
CCCP-treated cells. All other parameters remained constant between conditions and data were analysed using the 
Transfluor parameters described in Figure 3.6. Error bars represent standard deviation, ***P<0.001 (Student’s T-test 
compared to the equivalent ‘No CCCP’ control). 
 
3.4  dPINK1 SILENCING 
 
In mammalian cells, a fundamental aspect of the PINK1/Parkin-pathway is the absolute 
requirement of PINK1 for both Parkin translocation and mitophagy. In contrast, 
knockdown of Drosophila PINK1 (dPINK1) in S2R+ cells failed to prevent CCCP-
induced dParkin translocation (Figure 3.8 A), despite the employment of three dPINK1 
dsRNA probes, each targeting different regions of the gene (Figure 3.8 B). Closer 
scrutiny revealed that each of the dPINK1 dsRNA probes robustly reduced mRNA 
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Figure 3.8. The effect of dPINK1 knockdown on dParkin translocation and dMitofusin ubiquitination.  (A) The 
effect of dPINK1 or control dsRNA on dParkin translocation in S2R+ cells. At least 2 wells examined, each with 9 FOV. 
Error bars represent standard deviation; ***P<0.001, **P<0.01, *P<0.05 (Student’s T-test). One-way ANOVA with 
Bonferroni’s correction found no significant differences (ns) between dPINK1 dsRNA samples and the equivalent control 
dsRNA samples. (B) Schematic of dPINK1 with positions of three dsRNA probes (1-3) highlighted. (C) qRT-PCR data 
quantifying relative expression of dPINK1 in control and dPINK1 dsRNA samples following 4 days of knockdown. Data 
normalised to Rpl32; one biological repeat, 3 replicate samples per condition. Error bars represent standard deviation. 
(D) Western blot analysis of Mfn-FLAG following the application of control or dPINK1 dsRNA. Lane 1 contains cell lysate 
with no Mfn-FLAG transfection. Lanes 2-5 contain cell lysates expressing Mfn-FLAG plus knockdown with the 
corresponding dsRNA. Arrow indicates unmodified steady-state Mfn-FLAG, asterisks indicates high molecular weight 
species. Loading control - ATP5A 
 
levels when assessed by qRT-PCR (Figure 3.8 C), demonstrating the efficacy of gene 
silencing.  
 
In the absence of a suitable dPINK1 antibody, dPINK1 activity was assessed via the 
analysis of steady-state levels of Drosophila Mitofusin (dMfn), a target of the 
PINK1/Parkin-pathway (Figure 3.8 D). Published data show that in S2R+ cells, dMfn is 
ubiquitinated in a dParkin- and dPINK1-dependent manner, producing one or more 
high molecular weight dMfn species. However, following dParkin- or dPINK1- 
knockdown, an accumulation of unmodified, steady state dMfn is observed, together 
with an absence of ubiquitinated forms (Ziviani et al, 2010). In agreement with 
published data, all three dPINK1 dsRNAs cause an increase in steady-state dMfn-
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FLAG (Figure 3.8 D, arrow), and a loss of high molecular weight isoforms (Figure 3.8 
D, asterisks), compared to control dsRNA-treated S2R+ samples. These data indicate 
that dPINK1 dsRNA silences dPINK1 activity, and is effective in reducing dMfn 
ubiquitination. Together with the qRT-PCR data (Figure 3.8 C), this suggests that all 
dPINK1 dsRNA probes tested produce a significant reduction in both dPINK1 mRNA, 
and ostensibly dPINK1 protein levels, yet fail to prevent dParkin translocation upon 
CCCP-toxification. 
 
One conceivable explanation for a lack dPINK1 dsRNA effect is an adaptation of S2R+ 
cells to no longer require dPINK1 for dParkin translocation, perhaps via an additional 
protein with redundant function. Alternatively, a fraction of long-lived dPINK1 protein 
may persist even in the event of efficient dPINK1 mRNA knockdown, consequently 
maintaining the ability to promote dParkin translocation. This idea is supported by the 
observation that dPINK1 in S2R+ cells (Figure 3.3) and in vivo (Whitworth et al, 2008) 
exhibits differential dynamic turnover properties compared to that of mammalian PINK1 
(Narendra et al, 2010b). However, the fact that dPINK1 knockdown increases steady-
state levels of dMfn, purportedly by preventing dParkin-dependent ubiquitination and 
degradation (a step downstream of dParkin translocation), would suggest that dPINK1 
silencing blocks dParkin activity in spite of its sustained relocalisation. Therefore I 
postulate that this stable fraction of dPINK1 promotes dParkin-translocation following 
mitochondrial damage, but is unable to activate its ubiquitin ligase domain. This idea is 
supported by recent evidence suggesting that the activity of Parkin depends upon its 
tertiary structure. Here, Parkin was found to exist in an auto-inhibitory conformation, 
which can be altered by a number of site-specific phosphorylation events 
(Trempe & Fon, 2013; Trempe et al, 2013). Importantly, PINK1-dependent 
phosphorylation of Parkin’s ubiquitin-like (UBL) domain is suggested to relieve the 
auto-inhibitory effect of the UBL domain, hence leading to latent E3 ligase activation 
(Chaugule et al, 2011; Kondapalli et al, 2012; Shiba-Fukushima et al, 2012; Trempe et 
al, 2013). In the case of dParkin, it is conceivable that this dPINK1-dependent, ligase-
activating phosphorylation event is absent following dPINK1 silencing.  
 
With the PINK1/Parkin-pathway initially being described using genetic interaction 
studies in Drosophila (Clark et al, 2006; Park et al, 2006; Yang et al, 2006), it is well 
defined that dPINK1 acts upstream of dParkin in the same linear pathway in vivo. 
Therefore the inability of dPINK1 dsRNA to prevent dParkin translocation specifically, 
is likely due to an evolutionary divergence event between invertebrates and mammals, 
which seemingly converges again at later points in the pathway. 
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3.5  TEST PLATE ANALYSIS 
 
As part of the ‘assay development’ phase of screening, the SRSF offer a number of 
small ‘subset’ libraries alongside the whole genome library, including single, 384-well 
‘test plates’. The purpose of a ‘test plate’ is to assess the viability of screening assays 
in a high-throughput context, as well as allowing screeners to become familiar with the 
practicalities involved. Additionally in the context of this screen, the test plate served as 
an exercise for screen control discovery, in the hope of identifying a novel ‘positive’ 
control gene to take the place of dPINK1. 
 
The test plate consists of 275 dsRNAs arrayed across one 384-well plate. Among 
these are 60 random kinases arrayed in triplicate, a number of C. elegans negative 
controls, 16 empty wells for user-specific controls and a DIAP1 plate identifier 
containing dsRNA against the ‘Drosophila Inhibitor of Apoptosis 1.’ Every plate in the 
whole genome library carries its own unique ‘design’ of DIAP1-containing wells, 
producing a visible cell-death phenotype, and acting as a safeguard against plate 
barcode loss. (Figure 3.9 A).  
 
Following data analyses using Transfluor, a significant increase in puncta number 
between vehicle- (Figure 3.9 B, black) and CCCP-treated (Figure 3.9 B, grey) samples 
is observed. DIAP1-induced cell death (or the loss of GFP signal) is perceived by 
‘Transfluor’ as a ‘low puncta’ phenotype (Figure 3.9 B, yellow). Chosen user-specific 
controls included the three dPINK1 dsRNA probes (Figure 3.8 A), all of which failed to 
influence CCCP-induced dParkin translocation, as discussed. Additionally, dparkin 
dsRNA was included as a measure of knockdown efficiency, where silencing largely 
eliminated the GFP signal, and therefore puncta number (Figure 3.9 B). This confirmed 
efficient dsRNA silencing of dparkin; an effect that can be cautiously extrapolated to all 
dsRNAs. Finally, rhomboid-7 dsRNA (a Drosophila homolog of the intramembrane 
protease PARL, responsible for cleaving dPINK1 in the MIM) was included as a 
potential ‘increaser’ of puncta number. Here, it was hypothesised that the persistence 
of a full-length dPINK1 pool in the MIM may lead to a greater degree of dParkin 
translocation. Yet, despite a slight increase in dParkin translocation, this was minimal 
and non-significant (Figure 3.9 B, purple). However, as we now know, PINK1 
stabilisation on the MOM, rather than the MIM, is crucial for dParkin translocation.  
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Figure 3.9. Test plate analysis and identification of putative controls. (A) Test plate layout comprising a DIAP1 
plate identifier (yellow), 60 random kinases arrayed in triplicate (blue), a selection of negative controls designed against 
C.elegans targets (orange) and two columns of 8 empty wells for the addition of user-specific controls (red). (B) 
Graphical representation of control data, showing a clear increase in the average number of puncta between vehicle- 
and CCCP-treated wells. In addition, data from the user-specific controls rhomboid-7 and dparkin dsRNA are 
represented, together with the DIAP1 plate identifier (lethal). Data represent at least 2 wells per condition, each 
comprising 9 FOV. Error bars represent standard deviation, **P<0.01 (Student’s T-test, compared to ‘Control dsRNA, 2h 
CCCP.’). (C) Graphical representation of potential screen controls, chosen following test plate analysis. Group 1 (green) 
represents dsRNA that decreased dParkin translocation compared to the control. Group 2 (pink) represents dsRNA that 
increased dParkin translocation compared to the control. Data represent at least 8 wells per condition, comprising 9 
FOV per well. Error bars represent standard deviation, *P<0.05, ***P<0.001. (Student’s T-test, compared to ‘Control 
dsRNA’).  
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3.5.1  POTENTIAL SCREEN CONTROLS 
 
Having analysed data from the test plate, three groups of dsRNAs were identified as 
potential novel screen controls. First, dsRNAs targeting Abl, fwd, LIMK1, DASK1 and 
VPS34 were found to moderately reduce dParkin translocation. Second, dsRNAs 
targeting eas, kek2 and Src42a were found to moderately increase dParkin 
translocation. Finally, an inbuilt test-plate control, GFP dsRNA eliminated the GFP 
signal giving a comparable output to that of dparkin dsRNA. To check the 
reproducibility of these observed effects, genes were systematically silenced in a 
number of follow-up assays (Figure 3.9 C). However, the majority of dsRNAs failed to 
deviate significantly from CCCP-treated control samples, rendering them unsuitable as 
screen controls. Despite this, GFP and Src42A dsRNA consistently produced a 
significant loss of-, or increase in translocation respectively, allowing them to be carried 
forward as controls for the whole genome screen. 
 
As seen previously, dPINK1 dsRNA continued to lack any influence on dParkin 
translocation (Figure 3.9 C). 
 
3.5.2  FINALISING SCREEN CONTROLS 
 
Together with dparkin, GFP dsRNA was chosen as a ‘knockdown validation’ control. 
Src42a dsRNA was selected as an ‘increaser’ of puncta number. dsRNA targeting the 
C.elegans gene ‘Y39E4B.10’ was added as a negative control, chosen for its 
comparable phenotype to ‘no dsRNA.’ Finally, two copies of ‘dPINK1 (2)’ dsRNA were 
included in order to monitor the lack of effect observed during the development phase 
of the screen (Figure 3.10). 
 
In the absence of a suitable dsRNA ‘decreaser’ of dParkin translocation, it was 
necessary to artificially create this phenotype by including a non-toxified (‘No CCCP’) 
area in the plate design. Fortuitously, whole genome library plates contain a quadrant 
of wells devoid of dsRNA (Figure 3.10, blue), originally intended as a ‘no dsRNA’ 
control. However, this provided the ideal location for the inclusion of 4 non-toxified 
control wells, allowing for the measurement of basal dParkin translocation. Through 
this, screen amplicons were assessed for their ability to reproduce this phenotype. 
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Figure 3.10. Whole genome library plate layout with controls.  Schematic of the finalised plate layout for whole 
genome screening including positive, negative and ‘knockdown validation’ controls (see key). 
 
 
3.6  KINOME AND PHOSPHATOME SCREEN 
 
The kinome / phosphatome subset library comprises 1455 dsRNA arrayed over 5 
plates, targeting each kinase and phosphatase in the Drosophila genome. The purpose 
of performing this subset library was to become accustomed to handling multiple 
plates, as well as developing a program of assay logistics in preparation for whole 
genome screening. This proved to be a very useful exercise as it allowed estimation of 
how long each assay step took to implement, and therefore how many of the 53 
screening plates could be handled at once. With this, the whole genome library was 
split into 3 batches (18 plates, 18 plates & 17 plates), each being handled and 
processed at pre-defined points throughout the day. 
 
 
3.7 WHOLE GENOME SCREEN 
 
A single-assay format was adopted for whole genome screening, rather than the 
commonly used triplicate-assay method. The advantages of this approach are both 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Pre-printed contents Negative control Positive controls Knockdown Validation
Genome dsRNAs Control dsRNA (1) Src42a dsRNA (high) GFP dsRNA
DIAP1 plate identifier dPINK1 dsRNA (low?) dparkin dsRNA
No CCCP (low)
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financial and temporal, but with the disadvantage of relying upon the success of one 
assay for the entirety of data capture. Because of this, the primary dataset will almost 
certainly contain a number of false positives and false negatives. False positives are 
easily identified in follow-up confirmation assays; however false negatives will be 
forever lost from the dataset highlighting the limits of this approach.  
 
3.7.1  DATA ANALYSES 
 
The whole genome screen was performed as described in section 3.3.2.4. Following 
completion, plates were stacked onto an ‘Automate.it Scara’, robotic loading system, 
and systematically imaged over the course of 10 days. 9 FOV per well were captured 
on a 40x objective, taking approximately 4 hours per plate. Once imaging was 
complete, automated image analysis using the optimised ‘Transfluor’ algorithm could 
proceed, averaging a further 3 hours per plate. Once all 53 plates were analysed, 
scrutiny of the Transfluor spreadsheet output could commence. For this, raw well data 
from the 9 FOV were averaged to produce one value per well, and then normalised 
using the median absolute deviation (see section 3.7.1.1) to produce the final dataset. 
 
3.7.1.1  Data normalisation 
 
In order to compare data between individual screening plates, it was necessary to 
‘standardise’ or ‘normalise’ the values, converting raw puncta scores into a ‘robust z-
score’ (Figure 3.11). Through this, each plate adopted the same central point, and 
comparable data spread  
 
Data standardisation required two steps; first, normalisation on a plate-by-plate basis 
(Figure 3.11, steps 3 - 6); and second, normalisation across the entire genome (Figure 
3.11, step 7). In this instance, the ‘z-score’ is calculated using the median absolute 
deviation (MAD); the number of absolute deviations (AD) that a value (!) is from the 
population median (); where AD is the absolute difference between ! and . 
 
Absolute deviation (AD) =    !! !– !!! 
Median absolute deviation (MAD) =   !! !(!! − !!!) or !! !(!") 
z-score (z) =      
!!!! !!!!(!!!! !) or !"!"# 
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Figure 3.11. Schematic of data normalisation process. Raw values for each FOV were averaged to produce one 
mean value per well. Each plate was normalised individually using the MAD, before normalisation across the entire 
dataset.  
 
 
Typically a ‘z-score’ represents the number of standard deviations (σ)  the 
population mean (!).  
Deviation (d) =    (!!! − !) 
Standard deviation () =   ∑ !!! !!!!  
z-score (z) =     (!!!!)!   or !! 
              
However there are a number of reasons why the median absolute deviation is favoured 
for this type of analysis. First, the standard deviation is simply the square root of the 
variance; the sum of the squared deviation from the mean. The act of squaring the 
deviations ensures that all values of variance are positive, with the square root of the 
standard deviation merely reverting units back to the original. However, by squaring the
1.  Apply Transfluor algorithm:  
Puncta size: 0.6 - 1µm 
Minimum intensity: 60 grey levels 
2.  Find the mean ‘Average number 
of puncta per cell’ for each well 
3.  Find the median value for the plate 
4.  Find the absolute deviation for 
each value (x-median) 
6.  Give each value a z-score: 
(x-median)/MAD 
(9 fields of view per well) 
(1 value for each well in the plate)  
5.  Find the median absolute 
deviation (MAD) of the plate 
 
 
Raw values  
(per well) 
Normalised values 
(per plate) 
7.  Repeat steps 3-6 for the whole 
genome dataset  
Normalised values 
(per genome) 
(1 value for each well in the genome)  
Repeat for 
each plate 
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deviation, outliers are emphasised and smaller deviations from the mean can become 
hidden. By taking the absolute deviation, the numerical difference is returned 
irrespective of sign, therefore eliminating the need to square the values. In the absence 
of squaring, equal weight is given to every datum point, affording a greater significance 
to lesser changes. Second, by taking the median rather than the mean absolute 
deviation, the middle value is used, rather than the average. This is advantageous in a 
skewed dataset, as outliers with very high or very low values will have less influence on 
the central data point. This aspect was particularly relevant to our dataset, which 
exhibited a moderate skew to the right (Figure 3.14 C). 
 
Following data normalisation, the process was validated by the observation that the 
negative screen control carried an average z-score of 0.2, very close to the 50th 
percentile (z-score = 0) (Figure 3.14 A).  
 
3.7.1.2  Heat maps and box plots 
 
With the final dataset complete, initial data analyses focused on the success of the 
assay itself, and how normalisation had affected the data as a whole. For this, both the 
generation of heat maps (Figure 3.12) and box-plot analysis (Figure 3.13) were found 
to be of use. Heat map representation for each well of every plate provides a quick 
visual overview of the spread of values within the dataset, particularly for those at the 
extremes such as controls (Figure 3.12). For example, the ‘No CCCP’ positive control 
quadrant and four ‘knockdown validation’ control wells (2x dparkin dsRNA & 2x GFP 
dsRNA) are clearly visible in all plates apart from plate 23, giving a crude indication 
that both gene silencing and dParkin translocation occurred successfully across the 
entire assay.  
 
Additionally, heat maps (Figure 3.12) and box-plots (Figure 3.13) are invaluable for 
highlighting issues that have arisen during the screening process such as edge effects 
and/or equipment failure. For example, the second batch of plates has an overall lower 
number of puncta compared to the general plate population, likely caused by an 
equipment malfunction between plates 22 and 23 (Figure 3.12 A & 3.13 A i). Here the 
liquid handling robot crashed whilst adding the CCCP, delaying toxin application to the 
following plates and reducing the overall toxification duration. Additionally, the crash 
damaged a number of wells in plate 23, represented in the heat map by the brightest 
green squares. Plate 32 was dropped prior to imaging (Figure 3.12 A & 3.13 A ii) and 
plate 51 received a double dose of copper sulphate due to multidropper issues (Figure 
3.12 A & 3.13 A iii); two events which appear to have caused a general increase in 
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Figure 3.12. Heat map representation of the whole genome screen. 53 plates representing raw, non-normalised 
data (A - average number of puncta per cell) and normalised data  (B - z-scores). At the extremes of the scale, green 
represents the lowest value, and red represents the highest value, with white being the 50th percentile or median (see 
scale). Numbers on the left hand side represent plate number. Black lines represent batch boundaries and bold 
numbers (right hand side) represent batch number.  
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Figure 3.13. Box and whisker plots of raw and normalised plate data. Box-plot representation of raw, non-
normalised screening data (A – average number of puncta per cell) and data normalised across the whole genome (B – 
z-score (normalised to genome)). Each box plot represents one screening plate, excluding controls (x-axis), where the 
box marks the 25th and 75th percentile; the central line indicates the plate median; and the whiskers represent the 5th 
and 95th percentile. Red labels signify events of interest during the screening process, and the grey lines and numbers 
demarcate the three plate batches. 
  
5 10 15 20 25 30 35 40 45 50
-10
-5
0
5
10
5 10 15 20 25 30 35 40 45 50
-2
-1
0
1
2
3
4
5
6
7
Plate number 
z-
sc
or
e 
(n
or
m
al
is
ed
 to
 g
en
om
e)
 
Av
er
ag
e 
nu
m
be
r o
f p
un
ct
a 
pe
r c
el
l 
A 
B 
vi vi 
ii 
iii 
i 
vi vi i 
iii ii 
1 2 3 
1 2 3 
 107 
puncta number. Plates 3 & 50 also have clear ‘low puncta’ phenotypes compared to 
the overall plate population, due to unknown errors during screening (Figure 3.12 A & 
3.13 A iv). 
 
3.7.1.3.  Analyses of normalised data 
 
Following data normalisation, inter-plate differences are greatly reduced, with each 
plate sharing a common median of 0 and a comparable data spread (Figure 3.12 B & 
3.13 B). Next, screen controls were assessed in comparison to the overall performance 
of the genome dsRNA amplicons (Figure 3.14 A). The complete genome dataset 
exhibits a median of zero as a consequence of the normalisation process (Figure 3.14 
A, grey). As expected, the two ‘knockdown validation’ controls (dparkin and GFP) and 
‘No CCCP’ positive control had negative z-scores; representing values lower than the 
data median (Figure 3.14 A, purple, green and blue respectively). The dPINK1 dsRNA 
controls (Figure 3.14 A, pink) mirrored the C.elegans dsRNA negative control (Figure 
3.14 A, orange), with a median close to zero. This is in agreement with previous results 
(Figure 3.8 A). Finally, Src42A dsRNA (Figure 3.14 A, red) led to a positive z-score, 
representing values higher than the data median. Taken together, all controls behaved 
as expected, validating the screening assay.  
 
Looking at the dataset in its entirety, arrayed either as a scatter plot (Figure 3.14 B) or 
a frequency distribution histogram (Figure 3.14 C), there is a clear skew to the right. In 
order to test for normality, the D'Agostino and Pearson omnibus normality test was 
employed, taking into account the degree of asymmetry (skewness) and the shape 
(kurtosis) of the frequency distribution curve. The output of such a test is a P-value of 
the likely deviation from normality. For an entirely symmetrical dataset, the measure of 
skewness is 0, with a left skew having a negative value and a right skew having a 
positive value. Here our dataset has a skewness value of 2.353 pulling to the right. 
 
Additionally, when measuring the kurtosis or ‘peakedness’ of the data, a normal 
distribution will have a score of 0; with a positive score (leptokurtic) implying a curve 
with a sharp peak and long tails, and a negative score (platykurtic) denoting a curve 
with a rounded peak and short tails. Here, our dataset is leptokurtic, with a value of 
33.06.  
 
This skewness, together with the kurtosis of the data makes it a non-Gaussian dataset 
(P>0.001). The observed right skew in the dataset may be due to the limited potential 
for decreases in puncta number, compared to increases. For example, with a mean of 
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Figure 3.14. Whole genome screen data. (A) Box plot of average control z-scores (y-axis) across the genome. Box 
plot features as in Figure 3.13. One-way ANOVA with Bonferroni correction where ***P>0.0001 compared to ‘Neg. ctrl 
dsRNA.’ (B) Whole genome scatter graph (excluding screen controls) arranged ascending according to z-score. Red 
lines represent the boundary of amplicons with a z-score of ±3. The left hand tail is populated by dsRNA amplicons 
producing low numbers of puncta, and the right hand tail, with those producing high numbers of puncta. (C) Frequency 
distribution graph (histogram) of all data excluding controls. Dataset is non-normal, as surmised from D' Agostino and 
Pearson omnibus normality test, skewness and kurtosis (indicated). (D) Magnification of the first 3000 dsRNA 
amplicons, showing the left hand tail. The boundaries of -2, -3 & -4 z-scores are highlighted in red.  
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~2.5 puncta per cell, a complete block of translocation can take the data -2.5 to the left. 
However, an increase in translocation could potentially produce a limitless number of 
puncta - the highest being 19.9 puncta per cell in this case. This potential for large 
increases causes the data to have a long tail, or skew to the right. 
 
Despite the data not being perfectly ‘normal’ there are very few cases in reality that fit 
the Gaussian ideal. The data do have some Gaussian-like properties, for example the 
median (2.32) and the mean (2.35) ‘puncta number per cell’ are very close. 
Additionally, the dataset has a single peak at the centre of the distribution, with tails 
falling away either side. For this reason, the data can be deemed ‘normal’ enough to 
prevent concern. 
 
3.7.1.4  Defining hits 
 
For the scope of this project, the data of interest are those dsRNA amplicons causing a 
decrease in toxin-induced Parkin translocation, as these are fewer in number and 
potentially more pathway-specific. Defining the cut-off for primary screen hits is largely 
an arbitrary task, however two factors influenced the decision; z-score values and the 
number of hits. Z-scores are a measure of the likelihood that the decreased dParkin 
translocation occurred by chance. For example, a z-score of -2 equates to a chance of 
5%, where -3 equates to 0.3%. In many examples, an accepted level of significance is 
deemed to be a cut-off of ± 2 z-scores (Chia et al, 2010; Fisher et al, 2012; Orvedahl et 
al, 2011). However, this decision is also influenced by the quantity of hits falling into 
each of the cut-off groups. For example, if ± 2 z-scores produces an extensive hit list 
comprising thousands of genes, a more stringent cut-off of may be employed, and vice 
versa. Here, -2 z-scores provided a vast group of >2000 hit amplicons. Because of this, 
the stringency of the primary screen cut-off was increased to -3 z-scores, reducing the 
hit amplicon group to a more manageable number (Figure 3.14 D & 3.15 A). 
 
3.7.1.5  Visual analysis of hits 
 
Before finalising the primary genome hit list, it was apparent that a number of ‘empty’ 
wells were present within the 1004 amplicons of the -3 z-score group. These were 
undoubtedly false positives, and removed from the dataset.  
 
Furthermore, dsRNA amplicons causing cell death or low levels of GFP would likely 
translate as a ‘low puncta’ phenotype, due to the absence of a signal in the green 
channel. In order to reduce false positives via this avenue, every FOV within the
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Figure 3.15. Defining primary screen hits for confirmation screens. (A) Numbers of hits depending on the chosen 
z-score cut-off before and after visual analysis of images. Highlighted in red is the chosen cut-off of -3 z-scores, giving a 
final primary screen hit list of 625 amplicons. (B) Schematic of final hit-list workflow, detailing the points of amplicon 
elimination and addition. (C) & (D) Graphical representation of average values (C - average raw data, D - average 
normalised data), of hit groups, compared to average screen controls. ***P<0.001 (one-way ANOVA with Bonferroni’s 
correction, compared to ‘Neg. ctrl dsRNA’). 
 
‘-3 z-score’ cut-off group underwent manual ‘visual analysis,’ where the viability of the 
phenotype was assessed. Here, wells containing ‘dead,’ or ‘sick’ looking cells were 
eliminated, as well as those with very low levels of GFP expression. Additionally, wells 
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due to the lack of puncta definition. From this, the finalised number of hit amplicons 
decreased from 1004 to 625 (Figure 3.15 A & B). 
 
Prior to amplicon elimination, the average raw values and z-scores of the complete hit 
group (1004) were close in magnitude to the average ‘No CCCP’ control values (Figure 
3.15 C & D). This was encouraging as it confirmed that the hit gene group mirrored the 
positive screen control, hence blocking dParkin translocation to basal levels. To 
ascertain whether amplicon elimination following visual analysis would dilute the 
strength of this block, data from the finalised hit group (625 genes) and the eliminated 
group (379) were compared (Figure 3.15 C & D). Here, slight increases in the average 
raw value and z-score were observed in the finalised hit group. However, this is not 
unexpected as many amplicons within the eliminated group caused severe phenotypes 
such as a complete loss of the GFP signal, and therefore a dramatic decrease in 
puncta number. However, despite the observed increase, the hit group continues to 
exhibit a clear effect on dParkin translocation compared to the negative control dsRNA. 
 
 
3.8  CONFIRMING PRIMARY SCREEN HITS 
 
In order to confirm the phenotypes observed in the primary genome screen, the 625 
primary hits went through multiple rounds of re-screening. For this, a custom validation 
library of 3x 384-well plates was designed and printed, consisting of all 625 hits, 
negative and positive controls, and any additional non-hit amplicons targeting hit genes 
within the genome and kinome/phosphatome libraries (Figure 3.15 B). Unlike the whole 
genome screen, the re-screen plates were custom-designed, allowing for a larger 
number of inbuilt controls. Therefore, 16 wells per plate were dedicated to ‘No CCCP’ 
positive controls, and 60 wells comprised negative control dsRNA against two 
C.elegans genes. Additionally, to reduce the risk of edge effects, all outer wells 
remained devoid of dsRNA (Figure 3.16 A). 
 
3.8.1  HIT PICKING AND PLATE PRINTING 
 
Generation of the custom re-screen library involved identifying and ‘picking’ stock PCR 
templates corresponding to hit dsRNA amplicons. Due to the vast number of hit 
amplicons, the most efficient method was to automate the process using a liquid 
handling robot. Once complete, additional templates from the kinome / phosphatome 
subset library were hand picked and spiked into position manually. Control dsRNA 
templates were synthesised de novo, validated by gel electrophoresis, and added to 
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Figure 3.16 Confirmation library layout and data analyses. (A) Assay plate layout with positive and negative 
controls, and knockdown validation controls indicated (see key) (B) Box-plot representation of control raw data from one 
round of confirmation screening. Box plot features as in Figure 3.13. 
 
the library by hand. Next, the ‘in vitro transcription’ reaction mixture was added, and 
dsRNA synthesis could proceed. Upon completion, newly synthesised dsRNA 
amplicons were diluted to achieve a working concentration of 5 ng/µl, and printed at 5 
µl/well (250 ng dsRNA), producing multiple copies of the re-screen library. 
 
3.8.2  CONFIRMING PRIMARY HIT AMPLICONS 
 
To confirm primary screen hits, four rounds of re-screening were performed using the 
same assay implemented in whole genome screening (section 3.3.2.4). Controls 
behaved as expected in each round, with ‘No CCCP’ positive controls producing low 
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numbers of puncta (Figure 3.16 B, navy), and CCCP-treated negative controls 
producing high numbers of puncta (Figure 3.16 B, orange). Knockdown validation 
controls (dparkin and GFP dsRNA) largely eliminated puncta, and Src42a dsRNA 
moderately increased puncta number (Figure 3.16 B, red) as anticipated. The complete 
dataset (Figure 3.16 B, light blue) exhibits a lower median value compared to negative 
control samples (Figure 3.16 B, orange) as expected, and this reduction is further 
accentuated by removing screen controls (Figure 3.16 B, grey).  
 
3.8.2.1 Defining final screen hits 
 
Unlike the whole genome screen, it was deemed unnecessary to normalise 
confirmation screen data, as the median and variance of the raw values were 
comparable between the three library plates. Per re-screen round, a hit amplicon was 
any dsRNA with a raw puncta score within two standard deviations (SD) of the mean of 
the ‘No CCCP’ control. Over four rounds of screening, each time a dsRNA amplicon 
appeared in the hit list, it achieved a score of 1, enabling an overall score (out of 4) to 
be calculated (Table 3.1). Additionally, if a gene had more than one dsRNA amplicon in 
any of the four hit lists, that gene gained an extra ‘multiples score’ of 0.5, enabling 
extra weight to be given to genes with reproducible effects. With this, the maximum 
screen score became 4.5.  
 
An arbitrary confirmation hit cut-off of 2.5 was defined. Here, an amplicon would either 
be a hit in at least 3 out of 4 repeat screens, or 2 out of 4 screens with multiple hit 
amplicons. This produced a final confirmed hit list of 115 dsRNA amplicons, targeting 
96 unique Drosophila genes (Table 3.1). 
 
 
3.9  DISCUSSION 
 
The initial aim of this chapter was to validate a Drosophila S2R+ cell model as an 
appropriate system to study the PINK1/Parkin-pathway. For this, four major pathway 
features, previously defined in mammalian cell systems, were assessed. These were 
CCCP-based dissipation of the ∆Ψm, dPINK1 MOM stabilisation, dParkin translocation 
and mitophagy. In the majority of cases, Drosophila S2R+ cells faithfully recapitulate 
events observed in mammalian cells. However, a small number of deviations were 
observed. First, dPINK1 overexpression highlighted the existence of a stable dPINK1 
fraction, co-localising with the mitochondrial marker Mito-GFP, under basal conditions. 
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On the contrary, in mammalian cells, basal PINK1 is cytoplasmic in distribution and 
expressed at very low levels owing to its rapid turnover. This suggests a deviation in 
the rate of protein turnover between Drosophila and mammalian systems in the 
absence of mitochondrial stress.  
 
Additionally, despite an observed decrease in the mitochondrial marker ATP5A 
following chronic exposure to CCCP, the severity of this effect in S2R+ cells proved 
highly variable compared to reports in HeLa cells (Narendra et al, 2008). In S2R+ cells, 
high levels of cell death were frequently observed at CCCP time-points in excess of 16 
hours, suggesting that these cells favour apoptosis over mitophagy. In a bid to optimise 
the assay, many parameters were assessed including a wide range of CCCP time 
points and concentrations, but to no avail. Perhaps much like mammalian systems, 
Drosophila mitophagy occurs in a cell-type specific manner, whereby nutrient source 
and the favoured mode of energy production dictate mitochondrial degradation under 
toxic conditions. Like mammalian primary neurons, S2R+ cells favour mitochondrial 
oxidative phosphorylation over glycolysis (Freije et al, 2012; Gusdon & Chu, 2011) 
suggesting that they are less likely to permit mitophagy even following widespread 
mitochondrial damage. In contrast, transformed HeLa cancer cells favour glycolytic, 
mitochondria-independent modes of energy production, perhaps explaining why they 
readily ‘give-up’ their mitochondria following damage.  
 
Despite these deviations, S2R+ cells appear to exhibit the majority of PINK1/Parkin-
pathway characteristics compared with mammalian systems, therefore providing a 
reliable model for pathway analysis. The next challenge was to design and optimise an 
assay capable of successful high-throughput application, with the objective of 
improving our understanding of the PINK1/Parkin-pathway in the context of mitophagy. 
In the absence of a robust ‘mitophagy’ assay (perhaps the most obvious choice for 
maximum data capture) our attention turned to processes upstream of mitophagy, 
specifically Parkin translocation. Here, Parkin translocation proved to be efficiently 
induced with a short, 2-hour exposure to CCCP, and easily quantified through the 
appearance of Parkin-GFP dots or ‘puncta.’ With the addition of an S2R+ cell line 
stably expressing Parkin-GFP, an image-based screening assay was designed looking 
at CCCP-induced Parkin translocation. 
 
The assay proved to be very robust and extremely reproducible between experiments; 
essential attributes for high-throughput screening. However, a significant obstacle 
appeared in the form of our positive screen control. One of the fundamental principles 
of the PINK1/Parkin-pathway, at least in mammalian cell systems, is the requirement of 
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PINK1 for Parkin translocation and subsequent mitophagy. However, in our S2R+ 
system, dPINK1 silencing had no effect on the ability of dParkin to translocate. Having 
verified the reduction of both dPINK1 mRNA, and protein activity (using indirect 
means), the most obvious conclusion is that these cells don’t rely upon dPINK1 for 
dParkin translocation. This is most likely due to a divergence in pathway function at the 
level of Parkin translocation, as downstream processes such as dMfn modification and 
mitochondrial perinuclear aggregation (Chapter 4) are blocked by dPINK1 silencing. 
Additionally, in the whole organism, dPINK1 is known to act upstream of dParkin, with 
mutants sharing comparable phenotypes. I would speculate that in S2R+ cells, dParkin 
continues to translocate to damaged mitochondria following dPINK1 silencing, perhaps 
via a long-lived MIM dPINK1 pool. However, once at the mitochondrial surface, this 
pool of dPINK1 is incapable of activating dParkin’s latent E3-ubiquitn ligase activity (for 
reasons currently unknown), hence blocking pathway activation. Therefore, like 
mammalian systems, dPINK1 loss in S2R+ cells appears to block the PINK1/Parkin-
pathway, albeit downstream of dParkin translocation. 
 
Rather than abandoning the entire assay based on the failings of dPINK1-silencing to 
confer the ‘expected’ result, an alternative means of creating a ‘positive control effect’ 
came in the form of a ‘No CCCP’ region within the screening plates. This acted to 
create an ‘artificial’ positive phenotype, essentially providing a measure of basal 
dParkin translocation levels. With the assay fully optimised, the aim of the whole 
genome screen was to discover novel genes acting upstream of dParkin translocation 
in the PINK1/Parkin-pathway. By performing the assay as a single pass, it was 
accepted that a number hits were likely to be missed through false negative events. 
These false negatives could occur for a number of reasons including experimental 
error with regards to equipment, and user and reagent malfunctions. Additionally, 
differential protein dynamics could play a role in this process, with some proteins out-
living the knockdown duration, even after 72 hours of silencing. However, it is generally 
agreed that no whole genome RNAi screen is perfect, and despite these drawbacks, 
we expected to identify at least a proportion of dParkin translocation-dependent genes.  
 
Following data analyses, a cut-off of -3 z-scores provided a substantial primary hit list 
of 1004 dsRNA amplicons. However, due to the nature of the ‘Transfluor’ algorithm, 
any dsRNA reducing the expression of GFP or causing cell death would be 
indistinguishable from genuine hits. Such genes were likely to be performing a vital 
housekeeping function rather than exhibiting PINK1/Parkin-pathway specificity, and 
were therefore considered ‘false positives.’ In order to deal with these ‘hits,’ visual 
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analysis of raw microscopy images was undertaken, leading to the removal of over 
35% of the original primary hit group. This reduced the hit list to 625 dsRNA amplicons.  
 
Following completion of the primary screen, rigorous hit ‘confirmation screens’ aimed to 
further eliminate false positives in the dataset. After four rounds of repeat screening, 
over 80% of the original 625 primary screen hits fell outside the hit criteria, producing a 
final validation hit list of 115 dsRNA amplicons, corresponding to 96 unique genes. 
 
From the initial ~20,000 dsRNA targets, repeat rounds of screening have led to the 
identification of 96 Drosophila genes able to robustly and reproducibly decrease 
dParkin translocation following CCCP toxification. The next challenge was to take 
these genes, and assess their ability to influence other aspects of mitochondrial 
homeostasis using a range of secondary screening assays. Specifically, these assays 
aim to assess dParkin translocation using an alternative mode of mitochondrial 
damage, mitochondrial morphology alterations and toxin-induced mitochondrial 
perinuclear aggregation. Collating data from these secondary screens should help to 
build a clearer picture of the way in which hit genes influence PINK1/Parkin-mediated 
processes, and crucially whether this effect is specific to mitochondria and their toxin-
induced degradation. 
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4. SECONDARY SCREENING – 
DROSOPHILA CELLS 
  
 120 
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4.1 BACKGROUND 
 
Following completion of the primary screen, the next challenge was to assess the 
primary hit genes in a series of secondary assays, examining several aspects of 
mitochondrial homeostasis. These included analysis of mitochondrial morphology, and 
mitochondrial perinuclear aggregation following toxification. Collating data from these 
secondary screens allowed the production of a final Drosophila hit list, within which a 
number of distinct, pre-defined pathways emerged. The presence of such pathways 
assisted in the construction of the final hit list, allowing genes of particular interest to be 
included where they would have otherwise been omitted. 
 
4.2 HYPOTHESES AND AIMS 
 
The purpose of applying a range of secondary screens to the primary hit amplicons is 
to test their ability to alter processes that are distinct, but related in nature to the 
original screen. This is particularly useful when dealing with large datasets, where 
specific genes or pathways must be selected for in-depth analysis. For example, in the 
case of this project, the 115 confirmed hit amplicons were too great in number to take 
directly into an in vivo model, and required narrowing down further. 
 
An additional aim of secondary screen analysis is to learn more about how these 
genes could play a role in the pathway of interest. For example, the three assays 
implemented here assess multiple points of the PINK1/Parkin-pathway including 
dParkin translocation, alterations in mitochondrial morphology and toxin-induced 
perinuclear aggregation of mitochondria prior to mitophagy (Figure 1.10).  
 
After collating data from each of the secondary screens, and cross-referencing back to 
the primary screening data, final Drosophila screen hits were determined based on 
their ability to influence a range of mitochondrial homeostatic processes. 
 
4.2.1  PARAQUAT-INDUCED PARKIN TRANSLOCATION 
 
With respect to the primary screen, one important question to answer was whether the 
dParkin translocation observed was a CCCP-specific effect, or whether alternative 
mitochondrial insults could produce the same effect. To tackle this question, the 
herbicide paraquat was employed. The nature of paraquat is to increase the production 
of reactive oxygen species (ROS), causing oxidative damage to various cellular 
components. Where CCCP is able to dissipate any compartment with a differential pH 
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gradient, including lysosomes & peroxisomes, paraquat is suggested to act at the level 
of complex I of the mitochondrial ETC (Cocheme & Murphy, 2008), perhaps making 
this toxin more ‘mitochondria-specific’.  
 
4.2.2  MITOCHONDRIAL MORPHOLOGY ANALYSIS 
 
A crucial mechanism for maintaining the health of the mitochondrial network is the 
ability of individual organelles to undergo fission and fusion. This dynamism allows 
damaged mitochondrial components to become segregated from the network, and 
removed via the mitophagy route, whilst facilitating their replacement through content 
mixing (Twig et al, 2008). The importance of this process is highlighted in Mitofusin 
(Mfn)-null MEFs, where in the absence of fusion, the fragmented network comprises a 
heterogeneous population of mitochondria with varying degrees of health (Narendra et 
al, 2010). Additionally, in conditional double knockout mice, lacking both MFN1 and 
MFN2 in muscle cells, mitochondria display a marked reduction in mtDNA content 
coupled with an increase in mtDNA mutation (Chen et al, 2010). 
 
In Drosophila cells, the loss of dPINK1 or dparkin produces a hyper-fused 
mitochondrial network, indicating a pro-fission or anti-fusion role for these proteins 
under physiological conditions. This involvement of the PINK1/Parkin-pathway in 
mitochondrial morphology is likely linked to the need to segregate damaged 
mitochondrial compartments for removal via mitophagy. Recent reports show that Mfn 
is ubiquitinated and degraded via the proteasome in a PINK1- and Parkin-dependent 
manner, preventing isolated mitochondria from re-fusing with the network (Gegg et al, 
2010; Glauser et al, 2011; Poole et al, 2010; Rakovic et al, 2011; Ziviani et al, 2010). 
Also, PINK1 and Parkin may reduce the fusion-potential of damaged mitochondria by 
causing the degradation of the mitochondrial transport protein, Miro, leading to spatial 
isolation (Wang et al, 2011).  
 
This secondary assay aimed to assess whether primary screen hits were able to effect 
mitochondrial morphology, and if so, by what means. Particular interest focused on 
those amplicons able to phenocopy the dPINK1 and dparkin dsRNA effect; but any 
deviation from the wild-type scenario was deemed noteworthy. 
 
4.2.3  MITOCHONDRIAL PERINUCLEAR AGGREGATION 
 
One of the last stages of PINK1/Parkin-mediated mitophagy prior to degradation is the 
aggregation of dysfunctional mitochondria in the perinuclear region (Figure 1.10). This 
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organellar re-distribution is considered to increase the efficiency of the autophagy 
machinery, allowing degradation to progress rapidly (Okatsu et al, 2010; Vives-Bauza 
et al, 2010). Essentially, the manifestation of aggregated mitochondria in the 
perinuclear region is tantamount to the induction of mitochondrial degradation.  
 
Using this phenomenon as a screen read-out, the aim was to ascertain which of the 
primary ‘dParkin translocation’ hits also influence the redistribution of mitochondria 
prior to degradation. Through this, it can be determined whether the observed dParkin 
translocation block was due to mitophagy-pathway inhibition, or a non-specific effect.  
 
4.2.4  SECONDARY SCREENING LIBRARY 
 
For secondary screening, the confirmation screen library from section 3.8 was 
deployed rather than generating a further custom library of confirmed screen hits. This 
was for a number of reasons. First, as experienced in previous rounds of hit picking, 
the process is both time-consuming and costly due to the vast number of dsRNA 
probes required. Second, confirmation dsRNA stock volumes were greatly in excess of 
that required for re-screening purposes, and therefore able to provide multiple surplus 
copies of the library. Finally, it was deemed an interesting exercise to assess if 
amplicons falling outside of the final hit list could influence other aspects of 
mitochondrial homeostasis despite a weak or inconsistent influence on dParkin 
translocation.  
 
The confirmation library was made up of 3x 384 plates, comprising all 625 primary 
screen hits, plus user controls and an empty outside edge of wells (Figure 3.16 A). 
These empty wells were built into the plate design to reduce the risk of edge effects. 
However, here they offered the additional advantage of allowing extra screen controls 
to be added to the plates depending upon the assay. 
 
 
4.3 PARAQUAT-INDUCED PARKIN TRANSLOCATION 
 
Paraquat is a herbicide and oxidant known to increase the production of cellular ROS 
via redox cycling (Berry et al, 2010; Bonneh-Barkay et al, 2005). Due to the similarities 
in structure between paraquat and the parkinsonian toxin, MPP+ it is suggested that 
these toxins act in an analogous fashion, via the inhibition of complex I of the electron 
transport chain (ETC). Whilst the exact mechanism of paraquat-related toxicity remains 
unclear (reviewed in Berry et al, 2010; Blesa et al, 2012; Miller, 2007), the 
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mitochondrial matrix, and complex I of the ETC have been identified as the principle 
site of paraquat action, and reduction respectively (Castello et al, 2007; Cocheme & 
Murphy, 2008). However, paraquat-dependent complex I inhibition is weak compared 
to MPP+, and requires millimolar concentrations (Richardson et al, 2005). These data 
suggest that paraquat may exert its oxidative damage on targets other than 
mitochondrial complex I. Yet, mitochondria appear to be the principle site of paraquat 
action, and are therefore likely to be particularly vulnerable to the ensuing oxidative 
damage. 
 
The aim of this secondary screen was to assess the effect of paraquat toxification on 
dParkin translocation. The reason for examining a different toxin with the same read-
out as the primary screen was to verify that the observed translocation was due to 
mitochondrial damage caused by CCCP, and not the CCCP itself. Paraquat exposure 
was chosen over other cellular toxins because of its distinct mode of action compared 
to CCCP, as well as the suggestion that it acts directly at the level of the mitochondria. 
Chronic exposure to paraquat and the subsequent build-up of cellular ROS are 
anticipated to have analogous effects on PINK1/Parkin-pathway activation as CCCP 
toxification. This is due to increased mitochondrial molecular damage caused by ROS 
production. From a temporal point of view however, the paraquat-toxification 
phenotype is likely to be less severe than that observed with CCCP, due to the time 
taken for ROS to build up and mediate its deleterious effect. In agreement with this 
suggestion, Parkin translocation in HeLa cells is observed after 24 hours of paraquat 
toxification, compared to 1 hour of CCCP treatment (Narendra et al, 2008).  
 
4.3.1  ASSAY DEVELOPMENT 
 
In line with other studies, the concentration of paraquat required to produce a Parkin 
translocation event is in the millimolar region (Narendra et al, 2008; Narendra et al, 
2010; Ziviani et al, 2010). For this reason, assay development involved the analysis of 
cells after the application of 10 mM paraquat. Following a toxification time-course, 
increasing levels of dParkin translocation were observed at 12 and 24 hours of 
paraquat treatment (Figure 4.1 A - C). In agreement with mammalian data, 24 hours of 
toxification was selected as the optimum duration (Narendra et al, 2008) as here, 
widespread dParkin translocation is observed compared to the non-toxified control. 
This time point also enabled the assay to run in parallel with mitochondrial perinuclear 
aggregation analysis (section 4.5), reducing the secondary screen workload.  
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Figure 4.1 Parkin translocation following paraquat toxification. Parkin-GFP.S2R+ cells were subjected to 10 mM 
paraquat toxification for 0 hours (A), 12 hours (B) and 24 hours (C), after which an increase in GFP puncta formation 
could be observed. Scale bar: 5 µm (D) Diagram of assay plate design where colours represent different conditions (see 
key). Here columns 1 & 24 remain non-toxified, providing the ‘no paraquat’ control. Within these columns there are both 
‘Neg ctrl dsRNA’ (indigo) and ‘no dsRNA’ (blue) controls. (E) Protocol workflow for paraquat-induced Parkin 
translocation. (F) Graphical representation of controls, normalised to ‘Neg. ctrl. dsRNA’ (vehicle) and averaged across 
the three repeat screens, Error bars represent standard deviation, ***P<0.001 (One-way ANOVA with Bonferroni’s 
correction, compared to the vehicle-treated ‘Neg. ctrl dsRNA’ unless otherwise indicated).  
 
4.3.2  PLATE LAYOUT 
 
As previously mentioned, copies of the confirmation library (section 3.8) were ultilised 
for all secondary screening purposes. The similarity of this particular assay to that of 
the primary screen meant the availability of empty wells for extra screen controls were 
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largely unnecessary. However, four dPINK1 dsRNA-containing wells were included, to 
test whether dPINK1-silencing could prevent dParkin translocation under an alternative 
toxification regime (Figure 4.1 D, pink). Also, like the primary screen, a ‘no paraquat’ or 
‘vehicle-treated’ control was employed, providing the base level of Parkin-GFP puncta. 
Rather than integrate these controls into the four quadrants as in previous assays, here 
they populate columns 1 & 24 of the plate (Figure 4.1 D, blue), eliminating the 
requirement of the liquid handling robot. Where this equipment is a great time-saver 
when dealing with large numbers of plates, it becomes inefficient on a smaller scale 
due to lengthy set-up procedures. 
 
As before, pre-printed dsRNA controls included two C. elegans dsRNA negative 
controls, two knockdown validation controls (dparkin & GFP dsRNA), and Src42A 
dsRNA (Figure 4.1 D). 
 
4.3.3  PROTOCOL 
 
The assay protocol for this screen followed largely the same steps as outlined for the 
primary screen. However, there were some deviations, mostly due to the fact that both 
this assay, and the perinuclear aggregation of mitochondria were assessed in the 
same plate. Because of the differing requirements of the perinuclear aggregation 
assay, the cells were exposed to a lower concentration of copper sulphate, for a longer 
duration; specifically 200 µM for 40 hours. Additionally, samples were fixed using ice-
cold methanol rather than formaldehyde, allowing cellular permeabilisation for antibody 
application (Figure 4.1 E). 
 
4.3.4  DATA ANALYSES 
 
Parkin translocation assays were performed in triplicate to ensure reproducibility of the 
observed effect. Using the high content screening microscope, 9 FOV were captured 
per well using a 40x objective. As in the primary screen, data analyses were automated 
with the ‘Transfluor’ application, where objects with a size between 0.6 – 1 µm, and 
intensity above 60 grey levels, were counted as ‘puncta’. The numerical output from 
this analysis was averaged over the 9 FOV, giving one value of ‘average number of 
puncta per cell’ for each dsRNA amplicon. 
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4.3.4.1  Controls 
 
Having analysed the data from all three screens, average values for each of the 
controls could be calculated (Figure 4.1 F). This analysis showed a clear paraquat-
induced increase in puncta number in both empty & negative control dsRNA-containing 
wells compared to vehicle-treated samples. Additionally as before, both dparkin & GFP 
dsRNA reduced the number of puncta to very low levels, confirming the silencing 
process. dPINK1 dsRNA shows a slight reduction in the number of puncta per cell; and 
Src42A dsRNA shows a slight increase in the number of puncta per cell, but neither 
reach significance. Looking at the hit dsRNA dataset as a whole, this trends towards 
reducing the number of puncta per cell, as expected. 
 
4.3.5  DEFINING HITS 
 
Per screening round, a hit amplicon was any dsRNA with a raw puncta score within two 
standard deviations (SD) of the mean of the vehicle-treated negative control dsRNA 
(background puncta levels). Over three rounds of screening, each time an amplicon 
appeared in the hit list it was given a score of 1. Upon completion of the three screens, 
the score from each round was totaled, producing an overall ‘score’ for each dsRNA. 
For an amplicon to be deemed an overall ‘hit’, a minimum score of 2 was required 
 
4.3.6  FINALISED HIT LIST 
 
Having applied the above parameters to the screen data, a final list of 99 dsRNA hits 
were defined (Table 4.1). 56% of these hits were confirmed primary screen hits from 
section 3.8, with the remaining 44% of genes failing to qualify for this group. One such 
gene was archipelago, which achieved an overall score of 2 in the confirmation 
screens, hence missing out on the confirmed primary hit list. The significance of this 
gene will become apparent in later chapters.  
 
Of note, this secondary screen hit list also contains two genes denoted ‘withdrawn.’ 
This has arisen due to the Drosophila gene database, FlyBase continuously reviewing 
the status of Drosophila genes, removing or ‘withdrawing’ suspected pseudogenes 
from the database. Whilst these dsRNA amplicons produce an observable effect in our 
assays, it is unknown whether this is due to genuine gene silencing, or an off-target 
effect. These ‘genes’ possess no gene name, and have no obvious mammalian 
homolog, making further investigation challenging. Because of this, all ‘withdrawn’ 
genes achieving ‘hit’ status in this chapter are disregarded in subsequent analyses. 
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Table 4.1 Paraquat-induced translocation of Parkin - hit table. Each row gives details of the official Drosophila gene 
name, library probe identifier (BKN), and overall secondary screen score. The list has been arranged by the ‘score’ 
(high to low), and then alphabetically according to ‘Name.’ Genes highlighted in grey have more than one amplicon in 
the hit list. 
 
4.4. MITOCHONDRIAL MORPHOLOGY ANALYSIS 
 
A well-documented feature of mitochondria in both mammalian and Drosophila 
systems is the highly dynamic nature of the mitochondrial network. Individual 
mitochondria are able to undergo rounds of fusion and fission, whereby content mixing 
and quality control is regulated. Under basal conditions, the mitochondrial network 
consists of a mixture of ‘tubular’ or ‘fused’ mitochondria, and ‘dot-like’ or ‘fragmented’ 
mitochondria; the make-up of which is constantly changing depending on cellular 
requirements. A number of core fusion and fission genes are known to be involved in 
this process, with Drp1 and Fis1 regulating fission, and Opa1 and Mfn1 & 2 regulating 
fusion.  
 
Key studies in Drosophila have identified a genetic interaction between the core 
morphology machinery proteins, dPINK1 and dparkin, suggesting a role for the 
PINK1/Parkin-pathway in the promotion of fission and/or inhibition of fusion (Deng et al, 
2008; Poole et al, 2008; Yang et al, 2008). In support of these data, dPINK1 or dparkin 
Name Probe ID Score Name Probe ID Score Name Probe ID Score
1 ago BKN27400 3 34 CG14215 BKN21028 2 67 l(2)01810 BKN23239 2
2 atms BKN20176 3 35 CG14239 BKN30730 2 68 l(2)37Cb BKN20322 2
3 Bap55 BKN20365 3 36 CG16922 BKN30892 2 69 MED14 BKN22798 2
4 CG14023 BKN30204 3 37 CG17209 BKN20183 2 70 MED19 BKN22921 2
5 CG1677 BKN23607 3 38 CG2469 BKN21463 2 71 MED7 BKN27339 2
6 CG17912 BKN29387 3 39 CG2685 BKN20517 2 72 MRG15 BKN27689 2
7 CG3078 BKN41059 3 40 CG34137 BKN40629 2 73 msi BKN22154 2
8 CG40228 BKN41643 3 41 CG34420 BKN29967 2 74 Npc2f BKN31008 2
9 CG5591 BKN27099 3 42 CG34449 BKN40585 2 75 Peritrophin-A BKN29878 2
10 Cp1 BKN27765 3 43 CG3975 BKN30497 2 76 Pk17E BKN31019 2
11 Ctr1A BKN27755 3 44 CG4294 BKN23609 2 77 Pka-R1 BKN22753 2
12 Dis3 BKN21524 3 45 CG5118 BKN25778 2 78 Pros25 BKN29089 2
13 lilli BKN23012 3 46 CG6220 BKN25940 2 79 ptip BKN22515 2
14 MED24 BKN20580 3 47 CG7886 BKN21063 2 80 Rpb10 BKN29118 2
15 Pcaf BKN22042 3 48 CG8369 BKN31376 2 81 Rpb5 BKN20359 2
16 Pp1-87B BKN31383 3 49 CG8378 BKN20173 2 82 Rpb8 BKN29127 2
17 Pros26.4 BKN21532 3 50 CG9866 BKN30634 2 83 RpL28 BKN45643 2
18 Pros29 BKN28002 3 51 CG9883 BKN30450 2 84 sec23 BKN20755 2
19 pUf68 BKN27426 3 52 CkIIalpha BKN50525 2 85 Sec61alpha BKN45120 2
20 Rrp6 BKN20686 3 53 CkIIalpha BKN28436 2 86 sgg BKN50830 2
21 scny BKN22179 3 54 CkIIalpha BKN50398 2 87 SMC2 BKN20562 2
22 sgg BKN50521 3 55 CkIIbeta BKN50911 2 88 snRNP-U1-70K BKN45552 2
23 Srp54 BKN22462 3 56 CkIIbeta BKN29263 2 89 srp BKN32327 2
24 ana1 BKN29607 2 57 CkIIbeta BKN51125 2 90 ssh BKN20682 2
25 Arc2 BKN29801 2 58 clumsy BKN25605 2 91 Sym BKN21288 2
26 Arf84F BKN28053 2 59 cn BKN22004 2 92 TfIIFalpha BKN45044 2
27 Ars2 BKN29705 2 60 comm3 BKN27166 2 93 TfIIFbeta BKN45759 2
28 BG4 BKN25956 2 61 e(y)3 BKN32108 2 94 tlk BKN28036 2
29 Brd8 BKN27830 2 62 Eaf BKN46090 2 95 tlk BKN50352 2
30 Cdk9 BKN50890 2 63 Eaf BKN27861 2 96 U2af38 BKN28210 2
31 CG10267 BKN25765 2 64 Gclc BKN45924 2 97 U2af50 BKN22886 2
32 CG1109 BKN20307 2 65 Gclm BKN27668 2 98 Withdrawn BKN40739 2
33 CG12050 BKN22946 2 66 l(1)G0007 BKN22970 2 99 Withdrawn BKN41635 2
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silencing in Drosophila S2R+ cells causes a hyperfused mitochondrial network, likely 
due to the absence of dParkin-dependent dMfn ubiquitination (Ziviani et al, 2010). Data 
from mammalian studies have shown that this Mfn ubiquitination leads to its removal 
from the MOM, and subsequent proteasomal degradation (Glauser et al, 2011; Sarraf 
et al, 2013; Tanaka et al, 2010); a process believed to be important for the segregation 
of failing mitochondria from the network (Ziviani & Whitworth, 2010). Without this 
ubiquitination event, Mfn will persist on the MOM, promoting incongruous organelle 
fusion.  
 
The aim of this secondary screen was to assess the effect of hit gene silencing on the 
morphology of the mitochondrial network. The working hypothesis was that genes 
causing a comparable ‘fused’ morphology to that of dPINK1 and dparkin dsRNA, may 
act in the same linear pathway. Additionally, dsRNA amplicons causing a severe fusion 
or fragmentation phenotype were regarded as interesting, due to their ability to impact 
upon mitochondrial morphology as a whole. 
 
4.4.1  ASSAY DEVELOPMENT 
 
Before assessing mitochondrial morphology in a high-throughput setting, a number of 
low-throughput assays were performed to ascertain the optimal method of 
quantification, as well as validating potential screen controls. 
 
4.4.1.1  Scoring system 
 
To give a numerical value to the qualitative morphological phenotypes observed, a 
scoring system previously developed in the laboratory was implemented (Pogson et al., 
manuscript in preparation). This involved the identification of four distinct phenotypes 
using a scale ranging from 1 - 4 (Figure 4.2 A). Here, a score of 1 represents a 
‘fragmented’ mitochondrial network; a score of 2 represents a ‘wild-type’ network; 3 
represents a ‘fused’ network, and 4 represents a ‘clumped’ network.  
 
For a network to be deemed ‘fragmented,’ small discrete mitochondria are present, 
with scant areas of fusion. In the ‘wild-type’ situation, a mixture of both fused and 
fragmented mitochondria are present. In the ‘fused’ state, the majority of the network 
comprises long, interconnected ‘strings’, and a ‘clumped’ phenotype is regarded as a 
severe form of fusion, with mitochondria forming a large, aggregated mass, often in 
perinuclear regions (Figure 4.2 A). 
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4.4.1.2  Low-throughput analysis 
 
Low-throughput analysis first focused on the involvement of the PINK1/Parkin-pathway 
in mitochondrial morphology. Previous data have shown that in the absence of dPINK1 
or dparkin, mitochondria adopt a hyperfused network, exhibiting an increase in the 
tubular appearance of the mitochondria (Ziviani et al, 2010). To quantify this effect 
following pathway silencing in S2R+ cells, mitochondria were imaged live using the 
mitochondrial dye, MitoTracker Red (MTR). This negated the need for cellular fixation; 
a process documented to alter mitochondrial morphology (Ziviani et al, 2010). For each 
condition, cells were scored manually, as in 4.4.1.1, depending on their mitochondrial 
network morphology.  
 
dPINK1 and dparkin dsRNA have a significant and comparable influence on the 
mitochondrial phenotype, producing network fusion compared to the negative control 
dsRNA (Figure 4.2 B). Additionally, the loss of the core morphology machinery 
components dDrp1, dOpa1 and dmfn also produced the expected phenotypes in S2R+ 
cells, with dDrp1 dsRNA causing a severe ‘clumped’ phenotype; and dOpa1 & dmfn 
dsRNA causing a fragmented phenotype (Figure 4.2 C). These data confirm that 
silencing the core morphology genes, as well as dPINK1 and dparkin produces the 
expected mitochondrial morphology phenotypes in S2R+ cells. Having effectively 
developed the mitochondrial morphology assay in a low-throughput setting, this could 
then be applied to a high-throughput screening scenario. 
 
4.4.2 PLATE LAYOUT 
 
As with paraquat-induced dParkin translocation, plates originally designed for 
confirmation screening were re-used for mitochondrial morphology analysis. Here, a 
number of additional positive screen controls were added to the outer edge of the plate 
(Figure 4.3 A), including dPINK1, dmfn, dOpa1 & dDrp1 dsRNA, plus additional copies 
of dparkin dsRNA. These additional controls provided morphologies spanning the 
entire scoring range, allowing easy identification of comparable phenotypes within the 
dataset. Additionally, they also acted to verify the knockdown efficacy of the assay. 
 
4.4.3  PROTOCOL 
 
The protocol deviated substantially from previous screening assays in that wild-type 
S2R+ cells were used, rather than the stable Parkin-GFP.S2R+ cell line. This was due 
to reports that dParkin overexpression causes a significant shift in mitochondrial 
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Figure 4.3 High-throughput analysis of mitochondrial morphology. (A) Diagram of assay plate design where 
colours represent different conditions (see key). Here, extra assay-specific controls were added to the outside edge of 
the plate. These comprised dOpa1 - O, dDrp1 – D, dmfn – M, dPINK1 – Pi and dparkin – Pa. (B) Protocol workflow for 
mitochondrial morphology analysis. (C) Graphical representation of the ‘average morphology score’ of screen controls. 
Data comprises a minimum of 12 wells/condition, with 9 FOV per well. Error bars represent standard deviation, 
***P<0.001 (One-way ANOVA with Bonferroni’s correction, compared to the ‘Neg. ctrl dsRNA’).  
 
morphology towards fission (Ziviani et al, 2010), distorting the basal morphology 
phenotype. Additionally, mitochondrial morphology was analysed in the absence of 
toxification, as CCCP has been shown to cause a mitochondrial fragmentation 
response, perhaps due to widespread network damage (Legros et al, 2002).  
 
Briefly, the protocol involved plating 4,000 S2R+ cells per well in SFSM. After 1 hour, 
2x FBS-containing media was added, and cells were incubated for 96 hours at 25ºC. 
Media was aspirated and replaced with normal culture media containing MitoTracker 
(150 nM) and Hoechst (2 mg/ml). After an incubation period of 15 minutes, media was 
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replaced, and live cells imaged immediately using the high content screening 
microscope (Figure 4.3 B). 
 
4.4.4  DATA ANALYSES 
 
Because of the complexity of the mitochondrial morphology phenotypes, it was not 
possible to automate data analyses of this secondary screen. Instead of automation, 
each image was scored manually, using the scoring system outlined in 4.4.4.1. Due to 
the sheer volume of data per plate, this screen was carried out as a single assay rather 
than in triplicate, with scoring performed per FOV, rather than on a cell-by-cell basis. 
The numerical values from this analysis were averaged over the 9 FOV, giving one 
‘average morphology score’ for each dsRNA amplicon (Figure 4.3 C). 
 
4.4.4.1  Controls 
 
All negative controls behaved as expected, with a mean score close to the ‘wild-type’ 
value of 2 (Figure 4.3 C, Figure 4.4 C). With regards to the positive controls, dmfn & 
dOpa1 caused a fragmented phenotype, each achieving a score of ~1 (Figure 4.3 C, 
Figure 4.4 A & B), and dDrp1 dsRNA caused a clumped phenotype, achieving a score 
of 4 (Figure 4.3 C, Figure 4.4 F). These values are in line with data from earlier, low-
throughput analyses (Figure 4.2 C). Importantly, both dPINK1 and dparkin dsRNA 
caused a hyperfused phenotype as seen previously (Figure 4.3 C, Figure 4.4 D & E), 
and the dataset as a whole trended towards a more fused network, suggesting an 
enrichment of PINK1/Parkin-phenocopiers (Figure 4.3 C). These morphology scores 
closely reflect the qualitative data in example high-throughput microscopy images of 
control conditions (Figure 4.4 A-F). 
 
4.4.5 DEFINING HITS 
 
For the purposes of mitochondrial morphology screening, a hit amplicon was any 
dsRNA with an average morphology score outside two SD of the mean of the negative 
control dsRNA. Therefore any amplicon deviating from the ‘wild-type’ scenario, hence 
causing fragmentation, fusion or clumping would be deemed a hit in this screen. 
Despite being particularly interested in those amplicons phenocopying dPINK1 and 
dparkin silencing, interest also lies with those producing extreme morphology changes 
such as fragmentation & clumping. For example, there may be some benefit in 
assessing which gene-types fall into each group, and whether there are common
 134 
 
 
Figure 4.4 High-throughput images of screen controls. (A-F) Original micrograph images (acquired on a 
ImageXpress Micro widefield high content screening microscope, 40x objective), and corresponding ‘inverted’ images 
(Adobe Photoshop) of screen controls. Mitochondria are visualised using MTR, scale bar: 10 µm. Conditions 
represented comprise (A) dmfn and (B) dOpa1 dsRNA - both of which cause a ‘fragmented’ phenotype; (C) negative 
control dsRNA, producing a ‘wild-type’ phenotype; (D) dPINK1 and (E) dparkin dsRNA – causing a ‘fused’ phenotype; 
and (F) dDrp1 dsRNA, producing a ‘clumped’ phenotype. 
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pathways involved. For example, in the ‘fragmented’ group, 5 genes are found to be 
involved in fatty acid biosynthesis, a topic that will be discussed in greater detail in later 
chapters. 
 
4.4.7. FINALISED HIT LIST 
 
Having applied the above parameters to the screening data, a final list of 161 dsRNA 
hits were defined (Table 4.2). This table contains hits from the confirmed primary hit 
group (43%), as well as dsRNAs that did not qualify for this list (57%). The majority of 
hits favour increases in fusion (Table 4.2, below the bold line) rather than 
fragmentation (Table 4.2, above the bold line), which is in agreement with them being 
‘phenocopiers’ of dPINK1 and dparkin. Compared to paraquat-induced translocation, 
there are substantially more hit amplicons in this list. This may be down to non-
pathway related changes in morphology, such as general cellular toxicity; or because 
this assay was performed as one single experiment rather than in triplicate. Due to this, 
the potential for retaining false positives here is greater. 
 
 
4.5 MITOCHONDRIAL PERINUCLEAR AGGREGATION 
 
A phenomenon believed to occur prior to the removal of damaged mitochondria from 
the cell is the relocation of these mitochondria to the juxtanuclear region (Okatsu et al, 
2010; Vives-Bauza et al, 2010). It is proposed that this enables efficient activation of 
the mitophagy process, by concentrating both substrates and autophagic machinery in 
the same location. For this process to occur, damaged mitochondria must be 
segregated from the mitochondrial network, and prevented from re-fusing (Twig et al, 
2008). This is believed to occur with the help of PINK1- and Parkin-dependent 
ubiquitination and degradation of the pro-fusion protein, Mitofusin, and the transport 
protein, Miro. Here, the arrest of anterograde movement and inhibition of mitochondrial 
fusion is proposed to quarantine dysfunctional mitochondria, allowing them to begin 
retrograde movement back to the nucleus.  
 
In the absence of a robust and reproducible mitophagy assay in Drosophila cells, the 
closest read-out for the end point of the pathway was deemed to be this perinuclear 
aggregation event. Despite this phenomenon being qualitatively distinct from 
mitophagy itself, it provided a mechanism with which to analyse processes further 
downstream of both Parkin translocation and mitochondrial morphology. The aims of 
this secondary screen were to identify dsRNA amplicons able to block the transport 
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and aggregation of mitochondria in the perinuclear region following paraquat 
toxification. This blockage reflects the phenotype observed in the positive control 
situation, whereby dPINK1 and dparkin dsRNA are able to significantly reduce 
perinuclear aggregation (Figure 4.6 B). Therefore, we can hypothesise that these 
phenocopiers are potentially acting in a common pathway with dPINK1 and dParkin. 
 
4.5.1  ASSAY DEVELOPMENT 
 
The ability of Parkin-GFP.S2R+ cells to undergo perinuclear aggregation following 
toxification was first observed when attempting to induce mitophagy. Efforts to optimise 
the induction of mitophagy for these cells involved testing a range of toxins, including 
CCCP & paraquat. Where CCCP was unable to cause perinuclear aggregation of 
mitochondria under the conditions tested, the application of 10 mM paraquat for 24 
hours produced a clear phenotype (Figure 4.5 A). Here, under basal conditions 
mitochondria occupied sites throughout the cytoplasm, producing a ‘diffuse’ 
localisation. However, following paraquat toxification, mitochondria largely relocated to 
the perinucleus of the cell, forming an aggregated mass. Importantly, this aggregation 
phenotype was blocked by dPINK1 or dparkin silencing (Figure 4.6 B), indicating that 
this phenomenon was pathway-specific. 
 
4.5.1.1  Scoring system 
 
To evaluate the degree of mitochondrial perinuclear aggregation, images were 
assessed manually using a three-point scale (Figure 4.5 B - D). Here, a score of 1 
reflected a ‘diffuse’ mitochondrial network, and was attributed to ‘vehicle’-treated 
samples, and paraquat-treated positive controls (Figure 4.5 B). A score of 2 reflected 
cellular populations with a mixture of both diffuse and aggregated mitochondria (Figure 
4.5 C); and a score of 3 reflected cells where perinuclear aggregations of mitochondria 
were in the majority, such as with paraquat-treated negative controls (Figure 4.5 D). 
 
4.5.2 PLATE LAYOUT 
 
As with the previous secondary screens, plates designed for confirmation screening 
were re-used for mitochondrial perinuclear aggregation assessment. Because of the 
complementary cell-type and toxification duration, it was possible to combine 
mitochondrial aggregation analysis with the first secondary screen, assessing dParkin 
translocation. This feature provided a substantial temporal benefit, whilst still producing 
satisfactory screening results. 
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Figure 4.5 Paraquat-induced mitochondrial perinuclear aggregation. (A) Parkin-GFP.S2R+ cells were treated with 
vehicle or 10 mM paraquat for 24 hours. Mitochondrial localisation was assessed using a using a 20x objective, scale 
bar: 20 µm. Nuclei (blue – Hoechst), mitochondria  (Red – ATP5A). (B - D) Example images reflecting the 3-point 
manual scoring system where 1 = majority diffuse mitochondria (B), 2 = a mixture of aggregated & diffuse (C), and 3 = 
majority aggregated mitochondria (D). Original images were acquired using a 60x objective, scale bar: 5 µm, Nuclei 
(Hoechst) and mitochondria  (ATP5A). Corresponding inverted images were produced using Adobe Photoshop. Boxed 
areas represent magnification (‘Zoom’). All images were acquired on a Deltavision RT system.  
 139 
Together with the pre-printed controls, this secondary screen also analysed a number 
of additional controls, added to the outer edge of the plate (Figure 4.6 A). These 
included dPINK1, Atg5, Atg8a and Atg8b dsRNA, plus additional copies of dparkin 
dsRNA. Here, dPINK1 and dparkin silencing was expected to prevent toxin-induced 
perinuclear aggregation through the persistence of dMfn and dMiro on the MOM, 
promoting network fusion and anterograde transport respectively. Additionally, 
autophagy genes, Atg5, Atg8a and Atg8b, involved in the synthesis of the 
autophagosome membrane, were predicted to cause a deviation from the control, 
perhaps also preventing perinuclear aggregation.  
 
As before, a ‘no paraquat’ or ‘vehicle-treated’ control was employed, populating 
columns 1 & 24. Not only was this control required for assay 4.3, but also served an 
important purpose here, providing the base-line wild-type mitochondrial distribution 
phenotype. This extra control safeguarded against the risk of ineffective positive 
dsRNA controls. 
 
4.5.3  PROTOCOL 
 
The perinuclear aggregation protocol, was identical to that followed for paraquat-
induced dParkin translocation (Figure 4.1 E). Here, Parkin-GFP.S2R+ cells were 
induced with copper sulphate for considerably longer than the primary screen, due to 
the prolonged toxification duration required. As a consequence, the copper sulphate 
concentration was lowered accordingly, to reduce the potential for toxic side-effects. 
Despite this, Parkin-GFP expression remained sufficient for effective data analyses. 
 
An additional deviation from the primary screening protocol was the need to visualise 
mitochondria. Because of this, samples were fixed using ice-cold methanol rather than 
formaldehyde, allowing concurrent cellular permeabilisation (Figure 4.1 E). Application 
of an anti-ATP5A primary antibody and an Alexa-594 secondary antibody produced a 
strong MIM signal in the red channel. 
 
4.5.4  DATA ANALYSES 
 
Perinuclear aggregation assays were performed in triplicate to ensure reproducibility of 
the observed effect. Using the high content screening microscope, 4 FOV were 
captured per well with a 10x objective. This acquisition regime deviated from the 
previous screens in that fewer FOV were acquired, but at a much lower magnification. 
This was permissible due to the fact that the mitochondrial aggregates quantified here 
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Figure 4.6 High-throughout analysis of mitochondrial perinuclear aggregation.  (A) Diagram of assay plate design 
where colours represent different conditions (see key). Here, extra assay-specific controls were added to the outside 
edge of the plate. These comprised dPINK1 – Pi, dparkin – Pa, Atg5 – A5, Atg8a – A8a and Atg8b – A8b. (B) Graphical 
representation of the ‘average perinuclear aggregation phenotype’ of screen controls. Data represents average control 
data from three rounds of screening, with a minimum of 8 wells/condition, per screening round. Error bars represent 
standard deviation, ***P < 0.001, **P < 0.01, (One-way ANOVA with Bonferroni’s correction, compared to the ‘Neg. ctrl 
dsRNA’, unless otherwise indicated). 
 
could be resolved much easier than the tiny puncta and faint tubules of previous 
assays. Additionally with the lower magnification, a greater proportion of the cellular 
population was captured per FOV, compared to the 40x objective. This allowed the 
number of images acquired per condition to be reduced, whilst still capturing enough 
data to build a detailed overview. 
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As in the mitochondrial morphology screen, each image was scored manually using the 
scheme outline in section 4.5.1.1, rather than via automation (Figure 4.5 C). Original 
efforts concentrated on attempting to automate analysis, however, after lengthy 
parameter optimisation, it was deemed too unreliable. Nevertheless, due to the clear 
nature of the phenotype and smaller number of images per well, manual analysis was 
time consuming, but feasible. 
 
4.5.4.1  Controls 
 
Plate controls included those pre-printed within the plates, as well as additional 
controls spiked in around the outer edge. With regards to the dsRNAs already present 
in the screening plates, Src42A was expected to have a negligible effect on perinuclear 
aggregation. This was indeed the case, with an average phenotype score of 2.58 (data 
not shown). dparkin dsRNA showed a strong block of perinuclear aggregation, bringing 
the phenotype almost back to a wild-type, non-toxified level (Figure 4.6 B, purple). In 
agreement with this phenotype, GFP dsRNA also had the same affect, presumably due 
to the silencing of the Parkin-GFP fusion construct (Figure 4.6 B, green). This result is 
interesting as it suggests that dParkin overexpression is necessary for the observed 
perinuclear aggregation phenotype. Crucially, dPINK1 dsRNA was able to partially 
block the perinuclear aggregation of mitochondria, giving a phenotype score close to 2 
(Figure 4.6 B, pink). This was reassuring as it provided further evidence that dPINK1 
silencing could impact upon the mitophagy pathway in Drosophila S2R+ cells, as 
discussed in section 3.4. Finally, several dsRNAs targeting the core autophagy 
machinery (Atg5, 8a and 8b) were added as potential controls. It was hypothesised that 
by playing an essential role in the formation of the autophagosome, these genes may 
have an influence on the aggregation phenotype. However, this was not formally tested 
prior to screening, and transpired to have no influence on mitochondrial aggregation 
(Figure 4.6 B, aqua). In retrospect, this was not unexpected, as Atg5 (involved in 
autophagosome elongation) and Atg8a/b, (key in the formation of autophagosome 
membranes) are involved in degrading mitochondria, whilst this assay focuses on 
events just upstream of this. Perhaps a more appropriate control may have been the 
knockdown of the dynein motor responsible for transporting mitochondria to the 
perinucleus, or perhaps the application of microtubule polymerisation inhibitors such as 
nocodazole or colchicine (Okatsu et al, 2010)  
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4.5.5 DEFINING HITS 
 
Per screening round, a hit amplicon was any dsRNA with a perinuclear aggregation 
score outside two SD of the mean of the paraquat-treated negative control dsRNA. 
Over three rounds of screening, each time an amplicon appeared in the hit list it was 
given a score of 1. Upon screen completion, the overall ‘score’ for each dsRNA was 
calculated. For an amplicon to be deemed an overall ‘hit’ in this secondary screen, a 
minimum score of 2 was required. 
 
4.5.6 FINALISED HIT LIST 
 
Having applied the above parameters to the screening data, a final list of 65 dsRNA 
hits were defined (Table 4.3). This list contains dsRNA from the confirmed primary hit 
group (52%) as well as a proportion that did not qualify for this list (48%). The number 
of hits in this final secondary screen is lower than that of the previous two, perhaps 
because the phenotype here was much easier to judge compared to the more variable 
nature of the morphology screen for example. Additionally, performing the assay in 
triplicate and screening each image by eye meant less potential for false-positive hits. 
 
 
4.6 COLLATING DATA 
 
The next challenge following secondary screening was to collate data from the three 
screens in order to arrive at a final Drosophila hit list. For this, a number of aspects had 
to be considered such as whether to treat each secondary screen equally or attribute 
greater weight to one screen over another. In addition, how to deal with secondary 
screen hits falling outside of the confirmed primary hit group required deliberation. 
 
4.6.1 DEFINING HITS 
 
To define an overall group of secondary screen hits, I decided that the mitochondrial 
perinuclear aggregation assay should hold greater weight over the other two secondary 
screens for the following reasons. First, paraquat-induced dParkin translocation was 
very similar in nature to the primary screen; hence, despite providing important 
information about the specificity of the toxification, it did not provide further insight into 
other aspects of mitochondrial homeostasis. Second, mitochondrial morphology; whilst 
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Table 4.3 Paraquat-induced mitochondrial perinuclear aggregation - hit table. Each row gives details of the official 
Drosophila gene name, library probe identifier (BKN), and overall secondary screen score following three rounds of 
screening. The list has been arranged by the ‘score’ (high to low), and then alphabetically according to ‘Name.’ Genes 
highlighted in grey have more than one amplicon in the hit list. 
 
probing a distinct aspect of mitochondrial homeostasis, had the potential of providing 
fewer mitophagy-specific hits compared to the perinuclear aggregation of mitochondria. 
Therefore, for a gene to be defined as a hit, it had to fall into one of the following 
categories (A or B): 
 
A) A confirmed primary screen hit, AND a hit in: 
I. ≥ 2 secondary screens or 
II. mitochondrial perinuclear aggregation screen only 
 
Name Probe ID Score Name Probe ID Score
1 atms BKN20176 3 33 CG33051 BKN32889 2
2 CG10418 BKN27632 3 34 CG5591 BKN27099 2
3 CG17912 BKN29387 3 35 CG7886 BKN21063 2
4 CG2469 BKN21463 3 36 comm3 BKN25753 2
5 CG30359 BKN22317 3 37 Dp1 BKN20845 2
6 CG32685 BKN23988 3 38 faf BKN20871 2
7 CG4294 BKN23609 3 39 fz3 BKN25989 2
8 CG7065 BKN24944 3 40 GATAe BKN32653 2
9 Cp1 BKN27765 3 41 HLH106 BKN22813 2
10 Ctr1A BKN27755 3 42 lilli BKN23012 2
11 Dis3 BKN21524 3 43 MED14 BKN22798 2
12 l(1)G0007 BKN22970 3 44 MED19 BKN22921 2
13 lid BKN22841 3 45 MED24 BKN20580 2
14 pic BKN20655 3 46 MED28 BKN27691 2
15 Prp31 BKN22756 3 47 MED7 BKN27339 2
16 pUf68 BKN27426 3 48 msl-2 BKN30252 2
17 rept BKN20068 3 49 Pcaf BKN22042 2
18 Rpb5 BKN20359 3 50 PCID2 BKN21400 2
19 Rrp6 BKN20686 3 51 pont BKN21199 2
20 sec10 BKN20533 3 52 ptip BKN22515 2
21 sgg BKN50521 3 53 Rpb10 BKN29118 2
22 Srp54 BKN22462 3 54 Rpb8 BKN29127 2
23 tlk BKN28036 3 55 Saf-B BKN20574 2
24 ago BKN27400 2 56 Sec61alpha BKN22564 2
25 Art3 BKN28748 2 57 sgg BKN28994 2
26 Atu BKN24095 2 58 Tango6 BKN26681 2
27 CG11092 BKN25863 2 59 TfIIFalpha BKN45044 2
28 CG14683 BKN20003 2 60 tkv BKN50543 2
29 CG15459 BKN32433 2 61 tlk BKN50260 2
30 CG2685 BKN20517 2 62 tlk BKN50352 2
31 CG30007 BKN24788 2 63 transfer RNA BKN40552 2
32 CG30127 BKN33676 2 64 U2af50 BKN22886 2
65 Withdrawn BKN33475 2
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B) A non-confirmed primary screen hit, but an ‘interesting’ secondary screen 
hit (see below). 
 
4.6.2.  DEFINING ‘INTERESTING' SECONDARY SCREEN HITS 
 
Genes falling into category (A) were automatically considered as Drosophila screening 
hits. However, those genes falling outside of this group were able to qualify for the final 
screen hit group based on other ‘interesting’ or ‘unique’ attributes. These genes 
(category B) were not ‘confirmed’ primary screen hits, meaning they were selected as 
hits in the whole genome screen, but fell out of this group following confirmation 
screening. However, each of these genes featured in the hit groups of at least 2 
secondary screens, or the perinuclear aggregation screen alone.  
 
As well as satisfying the parameters defined above, these genes required additional 
‘interesting’ attributes, ascertained through bioinformatic analysis. These included: 
 
1) Protein-protein interactions (BioGRID/IntAct/HPRD) 
2) Gene function – both Drosophila & human orthologs (UniProt / GO / PANTHER) 
3) Protein interaction pathways (STRING) 
 
4.6.2.1  Protein-protein interactions 
 
Using the ‘Interactions’ facility in NCBI ‘Gene’, it was possible to establish protein-
protein interactions from a number of different resources. These included the 
‘Biological Repository for Interaction Datasets’ (BioGRID) (Stark et al, 2006), the 
‘Human Protein Reference Database’ (HPRD) (Prasad et al, 2009) and IntAct (Kerrien 
et al, 2012). Each of these databases curates published and user-submitted data from 
both high- and low-throughput datasets, in order to build their interaction datasets. 
Using this facility, a number of interesting protein interactions were identified. These 
were based either on interactions with other genes in the hit list, as well as interactions 
with genes of interest outside of the list, such as those linked to Parkinson’s disease. 
For example, some of the secondary screen genes (detailed in Table 4.4) were found 
to interact with the putative, PD-linked genes LINGO1 and GIGYF2, as well as parkin 
itself. Additionally, links to selective autophagy via the adaptor protein SQSTM1/p62 
were discovered, together with a number of inter-hit interactions (CSNK2B and 
GSK3B). Finally, KAT2B was found to interact with RAB11A. This is of particular 
interest to our lab, as Rab11-interacting proteins were found to be enriched in a 
previous screen looking at modifiers of dPINK1-related mitochondrial fusion. 
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Table 4.4 Protein-protein interactions. Analysis of equivalent human protein interactions between hits and relevant or 
interesting proteins. Brackets represent the method of analysis. 
 
4.6.2.2  Gene function 
 
To assess the function of the hit genes, a number of different strategies were employed 
including the use of Swiss-Prot; a manually annotated protein database providing 
functional and molecular information (UniProt, 2013); Gene Ontology (GO) which looks 
at cellular components, molecular functions and biological processes (Ashburner et al, 
2000); and PANTHER pathways (an integral part of the GO project), which looks at the 
relationship between interacting molecules (Mi et al, 2013). Using the aforementioned 
databases, key areas of interest included stress pathways, degradation pathways (both 
autophagy and proteasomal), the nervous system, Parkinson’s disease and 
mitochondria. From this, a handful of additional genes were added to the final hit list 
(Table 4.5). 
 
 
 
Table 4.5 Examining gene function. Analysis of Drosophila and orthologous human gene function. Key details appear 
in a bold typeface. 
 
4.6.2.3  Protein interaction pathways 
 
In attempting to glean clues about how PINK1/Parkin-mediated mitophagy occurs, a 
useful exercise was to analyse the hit list for an enrichment of pre-defined pathways.  
An excellent tool for visualising protein interactions between large groups of genes is 
Drosophila gene Gene ID Human Gene Interaction 1 Interaction 2
ago CG15010 FBXW7 LINGO1 (Two-hybrid) Parkin (Affinity Capture-Western)
BAP55 CG6546 ACTL6B CSNK2B (Two-hybrid) GSK3B (Two-hybrid )
CG7886 CG7886 CEP78 SQSTM1 (Affinity Capture-MS) -
Pcaf CG4107 KAT2B RAB11A (Two-hybrid) -
U2af38 CG3582 U2AF1L4 GIGYF2 (Affinity Capture-MS ) -
U2af50 CG9998 U2AF2 GIGYF2 (Affinity Capture-MS ) -
Drosophila Gene Gene ID Human Gene Gene Information
CG15459 CG15459 USMG5 Mitochondrial inner membrane
fz3 CG16785 FZD5
Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-
catenin canonical signaling pathway, which leads to the activation of disheveled 
proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and 
activation of Wnt target genes. 
l(1)G0007 CG32604 DHX38
DEAD box proteins are putative RNA helicases. They are implicated in a 
number of cellular processes involving alteration of RNA secondary structure 
such as translation initiation, nuclear and mitochondrial splicing, and 
ribosome and spliceosome assembly
Pros25 CG5266 PSMA2 Proteosome subunit that may have a regulatory effect on another component(s) of the proteasome complex through tyrosine phosphorylation
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the program ‘STRING’ (‘Search Tool for the Retrieval of Interacting Genes/Proteins’) 
(Jensen et al, 2009). This database collates data from known and predicted 
interactions, of physical (direct) and functional (indirect) associations, drawing on many 
of the resources mentioned in previous sections. The advantage of using STRING as 
an additional resource is the facility to easily visualise known protein networks, allowing 
the grouping of genes into individual processes or pathways.  
 
Among the hit genes from primary and secondary screens, there is a clear enrichment 
of three large pathways; the Mediator Complex, the RNA polymerase II/III network and 
the PAF1 complex (Figure 4.7); all of which are involved in ‘housekeeping’ 
transcriptional processes. Here, due to the housekeeping nature of these gene groups, 
the PINK1/Parkin-pathway specificity of observed phenotypes may  be questioned. 
This suggestion is strongly reinforced by the possibility that Parkin expression; 
essential for both Parkin translocation and perinuclear aggregation assays, may be 
reduced or lost as a result of impaired protein synthesis. Such events would therefore 
categorise these hits as ‘false positives.’ One way of dealing with these potential false 
positives would be to eliminate them from analysis based on their known function. 
However, although this is one quick method for reducing the number of hit genes, it 
also carries the risk of excluding genes of real interest. For example, despite their well-
defined housekeeping roles, these genes may perform an alternative dual function in 
other processes. Additionally, genes causing a significant decrease in Parkin-GFP 
transcription should have been identified and removed via visual analysis in the first 
stages of primary screen analysis, therefore presumably safeguarding against this type 
of false positive. Finally, MED13, a member of the mediator complex, has been 
recently implicated as a risk-loci in the development of sporadic Parkinson’s disease 
(Lill et al, 2012), demonstrating tangible links to Parkinson’s disease pathways. 
Therefore, to prevent the risk of losing genuine pathway members, all hit genes linked 
to these large transcription networks were included in the final hit list.  
 
4.6.3 FINAL DROSOPHILA HIT LIST 
 
Having collated the above data, a final Drosophila screening hit list was compiled. This 
list contained 42 amplicons targeting 39 Drosophila genes from category A.I, 2 genes 
from A.II and a further 21 ‘interesting’ genes from category B. Together, the final hit list 
contains 65 dsRNA amplicons targeting 62 individual Drosophila genes (Table 4.6) 
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Table 4.6 Collating data to produce a final Drosophila hit list. Numbers of dsRNA amplicons and equivalent genes 
falling into each hit category.  
 
After multiple rounds of primary and secondary screening, these final Drosophila 
screening hits have been found to reproducibly and robustly reduce toxin-induced 
dParkin translocation, as well influencing a wide range of additional mitochondria-
linked processes (Table 4.7).  
 
 
4.7 DISCUSSION 
 
The aim of this part of the project was to use secondary screening methods in order to 
assess primary screen hits in a wider, mitochondrial context. For this, amplicons were 
tested for 1) an ability to influence dParkin translocation following an alternative mode 
of cellular toxification, 2) their effect on mitochondrial morphology and 3) their ability to 
prevent mitochondrial perinuclear aggregation. The reasons for looking at additional 
aspects of mitochondrial biology were to ascertain whether the block on dParkin 
translocation observed during primary screening was a stand-alone effect, or intimately 
linked to mitochondrial homeostasis as a whole. This was expected to go someway 
towards eliminating remaining false positives within the dataset. Furthermore, this 
process was hoped to strengthen the position of robust pathway hits, whilst reducing 
the overall number of Drosophila hits genes. 
 
The primary screen had identified 625 dsRNA amplicons able to reduce dParkin 
translocation following CCCP toxification; and repeat rounds of confirmation screening 
brought that number down to 115 dsRNA amplicons. With secondary screening, the 
number of confirmed primary hits able to significantly influence paraquat-induced 
translocation, mitochondrial morphology and/or perinuclear aggregation fell to 44 
dsRNA amplicons, more than halving the original list of confirmed hits. This list was 
increased to 65 hit amplicons with the inclusion of interesting, non-confirmed primary 
hits (Figure 4.8). 
 
A) I. A) II. B) Total
Drosophila amplicons 42 2 21 65
Drosophila genes 39 2 21 62
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Table 4.7 Final Drosophila hit list. Each row gives details of the official Drosophila gene name, library probe identifier 
(BKN), and overall secondary screen score following the collation of data from all three secondary screens. A score of 3 
means that the amplicon was a hit in all three screens, a score of 2 = two screens and a score of 1 = one screen. Those 
amplicons shaded blue are category A) I. hits, orange are category A) II. hits and green are category B) hits. The list 
has been arranged by category, and then by the ‘score’ (high to low), and ‘Name’ (A to Z). The asterisks represent 
genes with more than one amplicon in the hit list. 
 
Having finalised a robust list of Drosophila genes involved in mitochondrial 
homeostasis, the next logical step was to identify human orthologs of each of these 
hits, and re-screen them using a mammalian cell line. This provided two advantages. 
First, it was expected to further decrease the number of genes with a weaker influence 
on PINK1/Parkin-pathway processes, whilst reinforcing confidence in the stronger hits. 
Second, the efficacy of screen hits could be tested across species, further validating 
their effect in a higher organism. Given the issues that this project faced with respect to 
the lack of a dPINK1-silencing effect on dParkin translocation, it was vital to 
Name Probe ID Score Name Probe ID Score
1 atms BKN20176 3 33 ptip BKN22515 2
2 CG2469 BKN21463 3 34 RpL28 BKN45643 2
3 Ctr1A BKN27755 3 35 Rrp6 BKN20686 2
4 Lilli BKN23012 3 36 scny BKN22179 2
5 MED14 BKN22798 3 37 sgg * BKN50521 2
6 MED19 BKN22921 3 38 sgg * BKN28994 2
7 MED24 BKN20580 3 39 Srp54 BKN22462 2
8 MED7 BKN27339 3 40 TfIIFα BKN45044 2
9 pUf68 BKN27426 3 41 tlk * BKN50260 2
10 Rpb10 BKN29118 3 42 Withdrawn BKN41059 2
11 Rpb5 BKN20359 3 43 Tango6 BKN26681 1
12 Rpb8 BKN29127 3 44 Withdrawn BKN33475 1
13 tlk * BKN28036 3 45 ago BKN27400 3
14 tlk * BKN50352 3 46 Pcaf BKN22042 3
15 Cdk9 BKN50890 2 47 U2af50 BKN22886 3
16 CG12050 BKN22946 2 48 ab BKN30195 2
17 CG14023 BKN30204 2 49 Atu BKN24095 2
18 CG14239 BKN30730 2 50 BAP55 BKN20365 2
19 CG2685 BKN20517 2 51 CG17209 BKN20183 2
20 CG34449 BKN40585 2 52 CG33051 BKN32889 2
21 CG5591 BKN27099 2 53 CG6220 BKN25940 2
22 CG9883 BKN30450 2 54 CG7886 BKN21063 2
23 CkIIα BKN50525 2 55 l(1)G0007 BKN22970 2
24 cn BKN22004 2 56 Pros25 BKN29089 2
25 Cp1 BKN27765 2 57 U2af38 BKN28210 2
26 Dis3 BKN21524 2 58 CG15459 BKN32433 1
27 Gclm BKN27668 2 59 faf BKN20871 1
28 HLH106 BKN22813 2 60 fz3 BKN25989 1
29 l(2)01810 BKN23239 2 61 GATAe BKN32653 1
30 Maltase A5 BKN22317 2 62 MED28 BKN27691 1
31 pic BKN20655 2 63 pont BKN21199 1
32 Prp31 BKN22756 2 64 rept BKN20068 1
65 sec10 BKN20533 1
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Figure 4.8 Overall Drosophila screening diagram. Workflow diagram representing each step of Drosophila cell 
screening. Briefly, the whole genome library was comprised of ~ 15,000 Drosophila genes. Following primary screening, 
625 dsRNAs were found to reduce Parkin-GFP translocation following CCCP treatment. Of these, 115 dsRNAs were 
confirmed in 4 repeat screens. Primary hit amplicons then underwent multiple secondary screening rounds, looking at 
paraquat-induced dParkin translocation, mitochondrial morphology and mitochondrial perinuclear aggregation. The final 
Drosophila dsRNA hit list comprises 65 confirmed and ‘interesting’ non-confirmed primary amplicons with an influence 
on secondary screens. 
 
demonstrate that the hits identified in our Drosophila system could have a comparable 
influence on the mammalian PINK1/Parkin-pathway. In the following chapter, two 
aspects of the mammalian PINK1/Parkin-pathway will be assessed, focusing on 
CCCP-induced Parkin translocation and mitophagy. 
 
  
Drosophila genome: ~15,000 genes 
Whole genome screen: 625 amplicons Confirmation screen: 115 amplicons 
Paraquat toxification Mitochondrial morphology Perinuclear aggregation 
Secondary screening 
65 Drosophila dsRNA hits 
ab CG14239 CG6220 faf Maltase A5 pont Rpb8 Tango6
ago CG15459 CG7886 fz3 MED14 Pros25 RpL28 TfIIFα
atms CG17209 CG9883 GATAe MED19 Prp31 Rrp6 tlk
Atu CG2469 CkIIα Gclm MED24 ptip scny tlk
BAP55 CG2685 cn HLH106 MED28 pUf68 sec10 tlk
Cdk9 CG33051 Cp1 l(1)G0007 MED7 rept sgg U2af38
CG12050 CG34449 Ctr1A l(2)01810 Pcaf Rpb10 sgg U2af50
CG14023 CG5591 Dis3 Lilli pic Rpb5 Srp54 Withdrawn
Withdrawn
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5. TERTIARY SCREENING –  
HUMAN CELLS 
  
 152 
 
  
 153 
5.1 BACKGROUND 
 
Following the conclusion of Drosophila screening, hit genes were converted into their 
human orthologs and re-tested in a mammalian HeLa cell system. This enabled hit 
validation in a more complex model, and demonstrated the relative importance of final 
hit genes in mammalian PINK1/Parkin-pathway processes. 
 
The majority of the cellular work studying PINK1/Parkin-function has been performed in 
mammalian systems, with much of the earlier studies focusing on HeLa cells (Geisler 
et al, 2010a; Matsuda et al, 2010; Narendra et al, 2008; Vives-Bauza et al, 2010). 
HeLa cells are particularly useful for cellular studies due to their readiness for 
transfection, efficient gene silencing, large size facilitating imaging approaches, and 
ease of culturing. However, these cells also lack endogenous Parkin expression 
(Denison et al, 2003). Ordinarily, the expression of a major component of the studied 
pathway would seem like a critical requirement for a cellular model. However, in HeLa 
cells expressing exogenous Parkin, it has been well demonstrated that Parkin 
translocates to mitochondria and induces mitophagy following toxification with CCCP, 
analogous to that observed with endogenous Parkin in HEK293 and SH-SY5Y cells 
(Geisler et al, 2010a; Narendra et al, 2008). Together with the aforementioned 
advantages of this system, these observations make HeLa cells an attractive model for 
studying PINK1/Parkin-processes.  
 
In this chapter, HeLa cells stably expressing YFP-Parkin are utilised to assess the 
ability of Drosophila hit genes to influence Parkin translocation and mitophagy. Vitally, 
in contrast to Drosophila S2R+ cells, it is well documented that HeLa cells undergo 
robust levels of mitophagy (Geisler et al, 2010b; Narendra et al, 2008; Tanaka et al, 
2010), allowing the end point of the pathway to be assessed in this system. This 
feature, together with the fact that HeLa cells are derived from a human source make 
them a favourable candidate for use in the next stage of the screening process.  
 
 
5.2 HYPOTHESES AND AIMS 
 
The aim of this portion of the screening process was to determine which Drosophila hit 
genes have an equivalent effect on PINK1/Parkin-processes in a human cell system. 
Here, the use of a more complex system was hoped to demonstrate the conserved 
function of these genes across species, as well as reaffirming the most robust hits. For 
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this, two tertiary screening assays were developed looking at CCCP-induced Parkin 
translocation, and mitophagy,  
 
As detailed in previous sections, Parkin translocates from a cytoplasmic location to the 
mitochondrial network following CCCP toxification, representing an early step in the 
initiation of mitophagy. At the mitochondria, a number of MOM proteins become 
ubiquitinated in a Parkin- and PINK1-dependent manner, preceding the degradation of 
those mitochondria. In this chapter, hit amplicons are assessed for their ability to 
phenocopy the Parkin translocation block observed following PINK1 siRNA application, 
hence placing them upstream of mammalian Parkin. With this assay evaluating the 
same process as the primary Drosophila screen, the expected outcome would be an 
enrichment of genes causing a reduction in CCCP-induced Parkin translocation. 
However, one caveat with regards to mammalian genetics is the presence of greater 
functional redundancy of genes compared to the Drosophila genome, perhaps resulting 
in a weaker translocation block than expected in some cases.  
 
Unlike the Drosophila S2R+ cell system, a wide variety of mammalian cells have been 
shown to undergo complete mitophagy following lengthy CCCP application, in a robust 
and reproducible manner (Kawajiri et al, 2010; Narendra et al, 2008; Vives-Bauza et al, 
2010). This phenomenon is well documented in HeLa cells, where ~40% of cells have 
a reduced or eliminated mitochondrial network after 24 hours of toxification (Narendra 
et al, 2008). As with Parkin translocation, PINK1 silencing leads to a block of CCCP-
induced mitophagy. Utilising these observations, this aspect of tertiary screening aims 
to assess the ability of hits to influence the end-point of the mitophagy pathway, with 
screen hits expected to phenocopy the effect of PINK1 silencing. 
 
 
5.3  DESIGNING A CUSTOM siRNA LIBRARY  
 
In order to produce a human screening library of Drosophila hits, orthologous human 
genes had to be determined, and custom library plates designed. Library synthesis was 
conducted by Dharmacon (Thermo Scientific Molecular Biology), who produced 
SMARTpool siRNA stock plates incorporating appropriate user controls. 
 
5.3.1  FINALISING THE DROSOPHILA HIT LIST 
 
Despite having finalised the Drosophila hit group following the conclusion of secondary 
screening, several additional genes were added prior to mammalian screening. These 
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genes originated from an earlier screening project undertaken by Joe Pogson, a 
postgraduate student in the Whitworth laboratory. This screen assessed the ability of 
genes in the Drosophila kinome and phosphatome to modify mitochondrial 
morphology, with hits being defined as those that phenocopied dPINK1 silencing. 
Using a manual scoring system, hit dsRNAs had an average morphology score within 1 
standard deviation of the mean of the dPINK1 dsRNA control, therefore producing a 
hyper-fused network of mitochondria. Here, human orthologs of these genes were 
added to the human library due to their ability to mimic a major component of the 
PINK1/Parkin-pathway. When comparing these additional genes to the finalised 
Drosophila hit group, just one common gene was identified (Tousled-like kinase) out of 
the eleven dPINK1 morphology phenocopiers. This perhaps reflects a propensity for 
non-PINK1/Parkin-pathway specific modifiers of mitochondrial morphology, such as 
genes affecting membrane fluidity or causing general cellular toxicity. However, with 
space in the tertiary human screening library, the potential for a pathway-specific effect 
made their inclusion worthwhile. Therefore, the Drosophila genes taken forward for 
human screening purposes encompassed the groups defined in chapter 4 (category A 
& B), as well as additional Drosophila mitochondrial morphology genes (category C):   
 
A) A confirmed primary screen hit, AND a hit in: 
I. ≥ 2 secondary screens or 
II. perinuclear aggregation screen only 
 
B) Non-confirmed primary screen hit, but an ‘interesting’ secondary screen hit. 
 
C) dPINK1 phenocopier hit in the mitochondrial morphology screen 
 
These parameters produced a group of 75 hit dsRNA amplicons equating to 72 
Drosophila genes. Of these, 10 Drosophila genes were added from category C (Table 
5.1 and Figure 5.1, grey). 
 
 
Table 5.1 Converting Drosophila hit genes into their putative human orthologs. Final quantification of Drosophila 
dsRNA amplicons and equivalent genes falling into each hit category (blue), with corresponding human genes (orange). 
A) I. A) II. B) C) Total
Drosophila amplicons 42 2 21 10 75
Drosophila genes 39 2 21 10 72
No human ortholog 3 1 0 0 4
Putative human orthologs 50 1 25 14 90
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5.3.2  CONVERTING DROSOPHILA HITS INTO PUTATIVE HUMAN GENES 
 
In order to convert Drosophila screen hits into their putative corresponding human 
orthologs, an online ortholog prediction tool from the Drosophila RNAi Screening 
Center (DRSC) was implemented. The ‘DRSC Interactive Ortholog Prediction Tool or 
‘DIOPT’, collates data from existing ortholog prediction programs (Ensembl Compara, 
HomoloGene, Inparanoid, Isobase, OMA, OrthoDB, orthoMCL, Phylome, RoundUp, 
and TreeFam), thereby producing a comprehensive list of putative orthologs for each 
gene (Hu et al, 2011). By inputting the 72 unique Drosophila hit genes, a list of 90 
putative human orthologs was produced (Table 5.1 & Figure 5.1), where 4 Drosophila 
genes had no known human ortholog, and 18 Drosophila genes had two or more 
putative human orthologs. 
 
5.3.3  HUMAN TERTIARY SCREENING LIBRARY 
 
Having produced a list of human orthologs, the next step was to design the custom 
siRNA library plate layout. Here, there were a number of aspects to consider, including 
the most appropriate plate format and assay controls. Due to the relatively small 
number of human genes and the larger cell size, a 96-well plate format was chosen 
over the 384-well format of primary and secondary screens (Figure 5.2). This format 
allowed for a larger population of cells per condition, plus greater ease of manipulation 
with the high-throughput equipment. 
 
PINK1 and parkin siRNA were included as positive screen controls, both of which were 
expected to produce a strong Parkin translocation and mitophagy phenotype. 
Additionally, two distinct ‘non-targeting’ siRNAs (NT1 and NT2) were included as 
negative controls (Figure 5.2). The plate was designed with the outer edge devoid of 
siRNA, to avoid edge effects. Further to this, 11 additional empty wells were integrated 
into the interior of the plate, acting as ‘no siRNA’ controls, as well as providing the 
facility for extra controls at a later date. With this design, the library consisted of two 
plates, with human gene siRNAs arranged according to their ‘Ensembl gene ID.’ 
 
The silencing reagent chosen for screening was the ‘siGENOME siRNA’ system, in a 
‘SMARTpool’ format (Dharmacon, Thermo Scientific Molecular Biology). siGENOME 
siRNA guarantees a high-efficiency reduction in gene expression of 75% or more, 
whilst maintaining target specificity. Each well contains a ‘SMARTpool’ of four 
siGENOME siRNA 19mers, targeting distinct regions of the mRNA - intended to 
increase reagent potency compared to individual siRNAs alone.  
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Figure 5.1 Converting Drosophila hit genes into their putative human orthologs. Schematic of 72 final Drosophila 
(Dmel) hit genes (white) and morphology screen hits from category C (grey), with their equivalent 90 human orthologs. 
Gene lists are arranged alphabetically according to the official Drosophila gene name. Asterisks denote genes with 
multiple amplicons in the hit group. 
 
The amount of stock siRNA purchased had to provide sufficient copies of the library for 
completion of the tertiary screen, whilst preventing wastage and unnecessary expense. 
Taking this into consideration, 0.1 nmol of each SMARTpool was acquired, allowing for 
~30 library copies at a concentration of 25 nM. 
 
 
5.4  LOW-THROUGHPUT ASSAY DEVELOPMENT 
 
Low-throughput assay development initially focused on selecting the most appropriate 
cell system for screening purposes. As previously mentioned, many of the early 
mammalian PINK1/Parkin studies utilised a HeLa cell system for study of the pathway, 
and this continues to be favoured by some groups. However, given that HeLa cells are 
a cancer cell line with abnormal genetic make-up, they are perhaps less favorable to 
study than a more ‘normal’ cell type. This point is strongly reinforced by the fact that 
HeLa cells do not express the major pathway component, Parkin. Despite this, HeLa 
Dmel gene Putative Human ortholog(s) Dmel gene Putative Human ortholog(s)
1 ab ZBTB22,!ZNF295,!ZBTB37,!ZBTB17,!ZBTB39 37 MED28 MED28
2 ago FBXW7 38 MED7 MED7
3 atms PAF1 39 Pcaf KAT2A, KAT2B
4 Atu LEO1 40 pic DDB1
5 BAP55 ACTL6A, ACTL6B 41 pont RUVBL1
6 Cdk9 CDK9 42 Pros25 PSMA2
7 CG12050 WDR75 43 Prp31 PRPF31
8 CG14023 NCOA6 44 ptip PAXIP1
9 CG14239 - 45 pUf68 PUF60
10 CG15459 USMG5 46 rept RUVBL2
11 CG17209 POLR3A 47 Rpb10 POLR2L
12 CG2469 CTR9 48 Rpb5 POLR2E
13 CG2685 WBP11 49 Rpb8 POLR2H
14 CG33051 POLR3G,!POLR3GL 50 RpL28 RPL28
15 CG34449 ZDHHC8, ZDHHC5 51 Rrp6 EXOSC10
16 CG5591 MLL3 52 scny USP36, USP42
17 CG6220 CDC73 53 sec10 EXOC5
18 CG7886 CEP78 54 sgg * GSK3B, GSK3A
19 CG9883 - 55 Srp54 SREK1, SRSF11
20 CkIIα CSNK2A1, CSNK2A2 56 Tango6 TMCO7
21 cn KMO 57 TfIIFα GTF2F1
22 Cp1 CTSL2, CTSL1, CTSS, CTSK 58 tlk * TLK2, TLK1
23 Ctr1A SLC31A1 59 U2af38 U2AF1,!U2AF1L4
24 Dis3 DIS3 60 U2af50 U2AF2
25 faf USP9X,!USP9Y 61 Withdrawn -
26 fz3 FZD5 62 Withdrawn -
27 GATAe GATA4 63 Ac78C ADCY8
28 Gclm GCLM 64 aPKC PRKCI, PRKCZ
29 HLH106 SREBF1, SREBF2 65 CG11870 NUAK1, NUAK2
30 l(1)G0007 DHX38 66 CG2277 NT5DC1
31 l(2)01810 SLC17A3, SLC17A9 67 Csk CSK
32 Lilli AFF4, AFF1, AFF3, AFF2 68 fwd PI4KB
33 Maltase A5 SLC3A1 69 Pka-R1 PRKAR1A, PRKAR1B
34 MED14 MED14 70 ND42 NDUFA10
35 MED19 MED19 71 Pp4-19C PPP4C
36 MED24 MED24 72 Sk1 SPHK2, SPHK1
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Figure 5.2 Custom siRNA library - plate layout. 96-well plates were arrayed with human siRNA SMARTpools against 
equivalent Drosophila hits (white), screen controls (coloured wells) and a quantity of empty wells (grey). Positive 
controls were PINK1 siRNA (pink) and parkin  siRNA (green), plus two negative controls (orange): non-targeting siRNA 
1 (NT1) and non-targeting siRNA 2 (NT2). 
 
 
cells offer many advantages over other cells lines, including a readiness for 
transfection and ease of culturing; attributes which are vital for high-throughput work. 
However, in order to diminish potential criticisms arising through the use of HeLa cells, 
screening of two mammalian cell types in parallel was proposed. These were HeLa 
cells, and human retinal pigment epithelial cells (RPE1) cells. RPE1 cells are epithelial-
like adherent cells with a largely ‘normal’ genetic profile. In addition, like HeLa cells, 
their size makes them amenable to microscopy analyses, and they grow with relative 
ease in culture.  
 
Prior to human screening, we were fortunate to be provided with HeLa- and RPE1- cell 
lines, stably expressing N-terminal YFP-tagged Parkin (a kind gift from the Lane lab, 
University of Bristol). Here, exogenous Parkin expression provided clear benefits for 
both screening assays, permitting easy visualisation of Parkin translocation as well as 
allowing mitophagy to proceed in the absence of endogenous Parkin. 
  
EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY
EMPTY EMPTY HIT EMPTY HIT HIT EMPTY HIT EMPTY HIT EMPTY EMPTY
EMPTY HIT HIT PINK1 HIT HIT HIT HIT NT2 HIT HIT EMPTY
EMPTY HIT HIT HIT HIT HIT HIT HIT HIT HIT EMPTY EMPTY
EMPTY EMPTY HIT HIT HIT HIT HIT HIT HIT HIT HIT EMPTY
EMPTY HIT HIT NT1 HIT HIT HIT HIT parkin HIT HIT EMPTY
EMPTY EMPTY HIT HIT EMPTY HIT HIT EMPTY HIT HIT EMPTY EMPTY
EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY EMPTY
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5.4.1  CCCP-INDUCED PARKIN TRANSLOCATION 
 
The first assay to establish was Parkin translocation following CCCP application. In the 
mammalian field, this type of analysis is typically performed between 1 and 4 hours of 
CCCP toxification (Geisler et al, 2010a; Matsuda et al, 2010; Narendra et al, 2008; 
Okatsu et al, 2010; Vives-Bauza et al, 2010). To assess the dynamics of YFP-Parkin 
translocation in the two stable lines, a CCCP time-course was performed over 0 - 4 
hours of toxification (Figures 5.3). YFP-Parkin.HeLa cells, in the presence of the 
negative control siRNA show a clear increase in Parkin translocation over the time-
course, with 4 hours showing almost complete mitochondrial coverage (Figure 5.3 A). 
In agreement, YFP-Parkin.RPE1 cells also show increased translocation, with 
complete mitochondrial coverage occurring a little earlier, at 3 hours of CCCP 
toxification (Figure 5.3 B). 
 
Following the application of PINK1 siRNA in YFP-Parkin.HeLa cells, Parkin 
translocation is almost completely absent at early CCCP time-points, and only mildly 
initiated after 3 and 4 hours of toxification (Figure 5.3 A). Therefore without PINK1, 
these cells no longer translocate Parkin to the MOM, making them an appropriate 
model for PINK1/Parkin-pathway screening. In contrast, PINK1 silencing in YFP-
Parkin.RPE1 cells failed to prevent Parkin translocation at later time-points, and 
caused only a mild blocking effect after 1 hour of toxification (Figure 5.3 B), This 
observation may indicate that RPE1 cells are inappropriate for screening purposes in 
the context of the PINK1/Parkin-pathway, or that gene silencing and/or toxification 
methodologies require further optimisation. 
 
The second assay to establish was CCCP-induced mitophagy. This was a crucial 
assay to optimise, as up to this point screening has focused on upstream stages of the 
pathway, rather than the end-point proper. Therefore, this assay provided the 
opportunity to observe a complete blockage of the entire mitophagy process. Typically, 
mitophagy is analysed after 24 or 48 hours of CCCP treatment (Geisler et al, 2010a; 
Matsuda et al, 2010; Narendra et al, 2008; Tanaka et al, 2010). However, as there is 
currently no published data with regards to RPE1 mitophagy dynamics, a time-course 
of 0, 16, 24 and 48 hours of CCCP toxification was implemented. The incidence of 
mitophagy was observed by monitoring the loss of the mitochondrial inner membrane 
(MIM) protein ATP5A, both through qualitative and quantitative means. To quantify the 
amount of mitophagy observed in qualitative images, cells were put into three distinct 
categories according to their mitochondrial content - ‘full mitochondria,’ ‘reduced 
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Figure 5.3 CCCP-induced Parkin translocation. YFP-Parkin.HeLa (A) and YFP-Parkin.RPE1 (B) cells were treated 
with 100 nM negative control or PINK1 siRNA and toxified with 10 µM CCCP for a time-course of 0 - 4 hours as 
indicated. Parkin translocation was assessed by the re-distribution of YFP-Parkin (green) from the cytosol to the 
mitochondrial network (ATP5A – red). Scale bar: 20 µm. 
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mitochondria,’ or ‘no mitochondria’ (Figure 5.4). For each condition, the percentage of 
cells falling into each of these categories was calculated.  
 
5.4.2  CCCP-INDUCED MITOPHAGY 
 
YFP-Parkin.HeLa cells, in the presence of the negative control siRNA showed a clear 
decrease in the number of cells with a full complement of mitochondria, and an 
increase in cells with ‘reduced’ or ‘no’ mitochondria after 16 and 24 hours of 
toxification. However, by 48 hours of toxification, much of the cell population appeared 
either sick or dead (Figure 5.5 A). Following quantification, a steady decrease in the 
number of cells with a ‘full’ mitochondrial network, and an increase in those with 
‘reduced’ or ‘no’ mitochondria was observed over the CCCP time-course (Figure 5.5 
B). Upon PINK1 silencing, after 16 & 24 hours of CCCP treatment, many more cells 
retained a full complement of mitochondria compared to the negative control (Figure 
5.5 C). After 48 hours of toxification, some reduction in the ATP5A signal was 
observed, however in contrast to the negative control, the cells look far healthier at this 
time-point. These data indicate that PINK1 loss is able to block mitophagy between 
16–24 hours of CCCP treatment as previously reported (Matsuda et al, 2010; Narendra 
et al, 2010), and reduce mitophagy after longer toxification durations. Quantification of 
data from microscopy images confirmed the observed maintenance of a ‘full’ 
mitochondrial network after 16 and 24 hours of CCCP treatment (Figure 5.5 D). This 
effect is weaker but still evident at 48 hours, in agreement with the qualitative 
assessment. Taken together, this confirms that the loss of PINK1 in YFP-Parkin.HeLa 
cells is able to prevent mitophagy as well as Parkin translocation, supporting their use 
for PINK1/Parkin-pathway screening in our hands. 
 
The observed levels of mitophagy in YFP-Parkin.RPE1 cells show a dramatic deviation 
from that of YFP-Parkin.HeLa cells. Here mitochondria are readily lost from almost the 
entire cell population by 24 hours of CCCP treatment (Figure 5.6 A & B). Even after a 
shorter CCCP treatment of 16 hours, cells have either a greatly reduced or absent 
mitochondrial network. Therefore, these cells appear to respond to CCCP toxification 
with a more widespread, severe induction of mitophagy. Upon PINK1 silencing, both 
the qualitative and quantitative data indicate very little influence of PINK1 loss on the 
amounts of mitophagy after 24 and 48 hours of CCCP treatment (Figure 5.6 C & D). 
However, as with Parkin translocation, PINK1 siRNA appears to cause a modest block 
on mitophagy at the earliest CCCP time-point of 16 hours in these cells, showing a 
greater proportion of ‘reduced mitochondria’ phenotypes compared to ‘no 
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Figure 5.4 Low-throughput mitophagy quantification. To quantify mitophagy, cells are assessed on a cell-by-cell 
basis according to their mitochondrial content. Cells with an extensive mitochondrial network fall into the ‘full 
mitochondria’ category (A) whilst those with a reduced network fall into the ‘reduced mitochondria’ category. (B), 
asterisks). Cells that have undergone complete mitophagy, fall into the ‘no mitochondria’ category (C, asterisks). 
Mitochondrial content is assessed according to the MIM marker, ATP5A. White outlines denote YFP-Parkin-expressing 
cell boundaries, scale bar - 20 µm. 
 
mitochondria.’ (Figure 5.6 D). Here, the ‘reduced mitochondria’ appear qualitatively 
different in their distribution compared to the negative control, with a less aggregated, 
perinuclear position. However, the nature of the manual scoring system implemented 
does not allow distinctions to be made between these phenotypes, perhaps lessening 
the quantified effect at this point.  
 
Taken together, these data again indicate that either YFP-Parkin.RPE1 cells are less 
sensitive to PINK1/Parkin-pathway manipulations, or that assay parameters require 
optimisation before the full effect of PINK1 silencing can be observed. It may be that 
earlier time-points need to be assessed in order to observe a significant mitophagy 
block’ caused by PINK1 silencing. Alternatively, the lack of effect may be due to 
ineffective gene knockdown, as gene-silencing techniques often produce differential 
results depending on the cell type. If this is the case, poor PINK1 siRNA silencing may 
explain the weak blocking effect observed. To address this issue, siRNA concentration 
and delivery method underwent full optimisation using qRT-PCR analysis.  
 
 
5.5  DEVELOPMENT OF siRNA GENE SILENCING TECHNIQUES 
 
In order to optimise gene silencing, quantitative real-time reverse transcription PCR 
(qRT-PCR) analysis of PINK1 mRNA was undertaken. For this, a range of transfection 
reagents, siRNA concentrations and delivery techniques were analysed.  
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Figure 5.5 CCCP-induced mitophagy in YFP-Parkin.HeLa cells. (A & C) CCCP (10 µM) time-course over 0 - 48 
hours following the application of 100 nM negative control siRNA (A) or PINK1 siRNA (B). Mitochondria are represented 
by the MIM marker ATP5A (red), YFP-Parkin (green), scale bar: 20 µm. (B & D) Manual quantification of mitophagy 
induction in cell samples from (A) and (C) respectively. One biological repeat with at least 5 FOV per condition. 
Quantification based on three distinct categories; ‘full mitochondria,’ ‘reduced mitochondria’ and ‘no mitochondria.’ (D) 
*P<0.05, ***P<0.001 (Student’s T-test compared to equivalent conditions in (B) 
 164 
 
 
Figure 5.6 CCCP-induced mitophagy in YFP-Parkin.RPE1 cells. (A & C) CCCP (10 µM) time-course over 0 - 48 
hours following the application of 100 nM negative control siRNA (A) or PINK1 siRNA (B). Mitochondria are represented 
by the MIM marker ATP5A (red), YFP-Parkin (green), scale bar: 20 µm. (B & D) Manual quantification of mitophagy 
induction in cell samples from (A) and (C) respectively. One biological repeat with at least 5 FOV per condition. 
Quantification based on three distinct categories; ‘full mitochondria,’ ‘reduced mitochondria’ and ‘no mitochondria.’ 
Student’s T-test comparing equivalent conditions in (B) and (D) found no significance. 
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5.5.1  qRT-PCR ANALYSIS OF PINK1 SILENCING 
 
A common issue with siRNA delivery is the cell-specific toxicity of transfection reagents 
used. To optimise siRNA delivery in YFP-Parkin.HeLa and YFP-Parkin.RPE1 cells, a 
range of reagents were tested, comprising Dharmafect 1 (Dharmacon), Effectene 
(Qiagen) and Lipofectamine 2000 (Invitrogen). In addition, most low-throughput 
silencing assays make use of a ‘forward transfection’ technique of siRNA delivery. This 
involves allowing the cells to adhere to the assay vestibule before delivering the siRNA. 
In contrast, high-throughput techniques tend to use a ‘reverse transfection’ 
methodology, plating cells and delivering siRNA simultaneously. This method allows 
siRNAs to be arrayed across the multi-well screening plates prior to assay 
commencement, saving a great deal of time. However, it also has the potential to 
reduce cell viability by increasing toxicity at the time of adherence. Under most 
circumstances, this reduction in cell viability and therefore cell number can be tolerated 
and simply overcome by increasing the starter population density.  
 
A final aspect of siRNA delivery to consider is the optimum SMARTpool concentration 
for efficient gene silencing. Recommended siRNA concentrations are between 5 - 100 
nM. Here, the chosen concentration should be high enough to allow efficient and long-
lasting gene silencing, yet low enough to minimise siRNA-induced toxicity. The ideal 
siRNA concentration is largely gene-specific. However when screening large numbers 
of genes, optimisation of each individual siRNA would be time-consuming and costly. 
Therefore, the knockdown technique was optimised for the most crucial control, PINK1. 
 
Initial qRT-PCR analysis used the protocol implemented in low-throughput assay 
development (section 5.4). This methodology involved the forward transfection of 100 
nM of siRNA, delivered using Effectene transfection reagent (Figure 5.7 A). This 
method produced efficient PINK1 silencing in YFP-Parkin.HeLa cells, but a poor 
reduction of gene expression in YFP-Parkin.RPE1 cells, perhaps explaining the lack of 
PINK1 siRNA effect observed in these cells. Additionally, as the siRNA concentration 
used was at the high extreme of the range recommended by Dharmacon, subsequent 
assay optimisation focused on reducing this concentration, as well all ascertaining the 
optimum siRNA delivery method for both cell types. By reducing the siRNA 
concentration, the risk of siRNA-associated toxicity and the cost of the screen itself 
would be diminished. 
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Figure 5.7 qPCR analysis of PINK1 silencing. Analysis of optimal gene silencing conditions in YFP-Parkin.HeLa & 
YFP-Parkin.RPE1 cells. Cells were treated with negative control or PINK1 siRNA at 100 nM (A), 50 nM (B & C) or 25 
nM (D) concentrations for 4 days before qRT-PCR analysis of gene expression. siRNA SMARTpools were delivered 
using forward (A) or reverse (B-D) transfection methods, by Effectene (A), Lipofectamine 2000 (B) or Dharmafect 1 (C & 
D) reagents. Data averaged over three samples within one biological repeat; normalised to the housekeeping gene 18S. 
 
The first optimisation step involved altering the method of siRNA delivery to incorporate 
the ‘reverse transfection’ of PINK1 siRNA at the same time as cell plating (Figure 5.7 B 
– D). Second, two additional transfection reagents were assessed; Lipofectamine 2000 
(Figure 5.7 B), and Dharmafect 1 (Figure 5.7 C & D). Third, the concentration of siRNA 
was reduced to 50 nM (Figure 5.7 B & C) and 25 nM (Figure 5.7 D).  
 
Altering the delivery protocol to a ‘reverse’ transfection method had no obvious 
negative effects on gene silencing (Figure 5.7 B – D) or survival of the cell population 
(data not shown). Additionally, both Lipofectamine 2000 and Dharmafect 1 produced 
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robust gene silencing in both cell-types (Figure 5.7 B – D). However, upon cellular 
inspection, Lipofectamine 2000 caused an increase in cell death in the HeLa 
population, whereas Dharmafect 1 appeared to cause RPE1-cell toxicity (data not 
shown). This result indicated that optimal siRNA delivery in these two cell-types 
required distinct transfection reagents. Finally, the efficiency of gene silencing 
remained comparable following the reduction of siRNA concentration from 100 nM to 
50 nM and 25 nM. Therefore, no advantage was gained by increasing the siRNA 
concentration beyond 25 nM for tertiary screening purposes.  
 
Taken together, optimised conditions for gene silencing involved the reverse 
transfection of 25 nM siRNA, using Dharmafect 1 (YFP-Parkin.HeLa cells) or 
Lipofectamine 2000 (YFP-Parkin.RPE1 cells).  
 
 
5.6 CCCP-INDUCED PARKIN TRANSLOCATION 
 
Having optimised conditions for gene silencing, the next stage was to scale-up the 
Parkin translocation assay for use in a high-throughput format. As shown previously, 
YFP-Parkin.HeLa cells readily translocate YFP-Parkin to the mitochondrial network 
following short CCCP application. Importantly, the loss of PINK1 is able to produce a 
strong translocation block, providing a valuable positive siRNA control for the assay. In 
contrast, whereas YFP-Parkin.RPE1 cells demonstrated efficient translocation over 
equivalent toxification durations, the potency of the PINK1 siRNA translocation block 
was much weaker than in the HeLa cell line. As mentioned, this may have been due to 
suboptimal silencing methodologies. Having optimised the RPE1 silencing protocol, 
PINK1 siRNA was found to substantially reduce Parkin translocation, but continued to 
produce a weak mitophagy block. Therefore, for the scope of this project it was 
decided to concentrate on screening with the YFP-Parkin.HeLa cells alone. 
 
The aim of this assay was to identify human orthologs of Drosophila hit genes able to 
block Parkin translocation in a way analogous to PINK1 siRNA. Within this group of 
genes, an overall trend towards reduced Parkin translocation was expected because of 
the enrichment of genes having an equivalent effect in the Drosophila system. 
However, due to a greater redundancy within the human genome, the expected effect 
is potentially less than that seen in S2R+ cells. 
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5.6.1  ASSAY DEVELOPMENT 
 
In order to scale up the assay into 96-well plates, a number of parameters required 
optimisation. These included the optimum cell-density, toxification duration and data 
analysis method. The doubling time of a cellular population is influenced by a number 
of factors including the cell type, transfection reagents applied and toxification method. 
Having tested a range of seed densities in the 96-well plate format, an optimal density 
of 4,000 cells per well was established, providing a confluent population for assay 
analysis (data not shown). Previous, low-throughput analysis established that YFP-
Parkin underwent CCCP-induced translocation between 1 and 4 hours of toxification in 
the stable HeLa cell-line (Figure 5.3 A). Over this time-course, translocation peaked at 
4 hours of CCCP treatment; with earlier time-points maintaining clusters of partially- or 
non-translocated cells. Therefore, high-throughput assay development focused on 
Parkin translocation after 4 and 6 hours of CCCP toxification (Figure 5.8). Here, the 
aim was to ascertain if even greater amounts of translocation could be achieved by 
CCCP-applications longer than 4 hours. In the vehicle-treated negative control, no 
Parkin translocation is observed (Figure 5.8 A), however after 4 and 6 hours of CCCP 
treatment, almost the entire cell population displays a strong translocation phenotype 
(Figure 5.8 B & C). Following PINK1 silencing, CCCP toxification for 4 and 6 hours 
failed to induce Parkin translocation, producing a phenotype comparable to that of the 
‘0 hour’ controls (Figure 5.8 D - F). This demonstrated that the silencing procedure had 
transferred well from the low-throughput scenario to the 96-well screening plates. 
 
One concern with regards to the 6-hour time-point was an observed decrease in YFP-
intensity compared to 4 hours of CCCP treatment in the negative control (Figure 5.8 
C). This decrease may have been an issue with YFP-stability following persistent 
exposure to CCCP, although there is no precedent for this in the literature. 
Alternatively, by 6 hours of toxification, YFP-Parkin may be undergoing degradation; 
having already ubiquitinated targets at the MOM. Because of this, and the strength of 
the phenotype at earlier time-points, a 4-hour toxification period was favoured. 
 
To quantify the observed translocation, automation using the ‘Transfluor’ application 
was attempted. Initial efforts utilised a ‘puncta number’ measurement, as applied in the 
Drosophila primary screen. However, the Parkin translocation phenotype observed in 
HeLa cells differs to that of S2R+ cells in that there are fewer discrete ‘puncta’ 
observed at this magnification and resolution, and more of a continuous ‘ring’ in the 
juxtanuclear region of the cell. This perhaps reflects the differential dynamics of these 
two cell types, where S2R+ cells maintain a cytoplasm-wide distribution of damaged 
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Figure 5.8 High-throughput Parkin translocation optimisation. YFP-Parkin.HeLa cells were subjected to negative 
control siRNA (A-C) or PINK1 siRNA (D-F), and toxified for 0 hours (A & D), 4 hours (B & E) or 6 hours (C & F) with 10 
µM CCCP. YFP-Parkin (green) translocation was assessed via qualitative data (A-F), acquired on a high content 
screening microscope using a 10x objective, scale bar: 20 µm. Automated quantitative data (G) was produced by the 
‘Transfluor’ application, with a read-out of ‘average area of YFP-Parkin puncta per cell (µm2). Data acquired from one 
biological repeat, with a minimum of 4 wells, each with 9 FOV per condition. 
 
mitochondria for a greater duration before transporting them to the perinucleus for 
degradation. In light of this observation, quantification of ‘puncta number’ proved 
difficult as the algorithm could pick up just one or two individual puncta per cell (data 
not shown). As an alternative, ‘puncta area’ was employed, quantifying the area of  
YFP-Parkin puncta with an intensity above the non-toxified background (Figure 5.8 G). 
However, where this algorithm was able to quantify a clear increase in Parkin puncta 
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area between vehicle-treated negative controls and those exposed to 4 hours of 
CCCP, this distinction was lesser after 6 hours. This assessment was not in agreement 
with visual image analysis, and may reflect the inability of the algorithm to detect areas 
of lower YFP intensity as discussed previously.  
 
In the absence of PINK1, vehicle-treated conditions had a slightly higher puncta area 
than that of the negative control (Figure 5.8 G). However, this was not a substantial 
increase, and may be diminished following further biological repeats. After 4 hours of 
CCCP treatment, there was a slight increase in the area of YFP-Parkin puncta 
compared to the non-toxified control, perhaps representing low levels of Parkin 
translocation persisting under these conditions. Despite this, in comparison to the 
negative control at the equivalent time-point, a substantial block in translocation is 
observed. However, by 6 hours of CCCP toxification, this block is lesser, with the 
puncta area becoming closer in magnitude to the negative control sample. This 
automated assessment is in stark contrast to the qualitative data of the microscopy 
images (Figure 5.8 C & F), indicating failings of the algorithm to distinguish between 
these phenotypes. In light of these issues, manual quantification of the phenotypic data 
was chosen over automation. 
 
5.6.2  PLATE LAYOUT 
 
The human screening library consists of two 96-well plates, containing 90 siRNA 
SMARTpools against human orthologs of the final Drosophila hits (Figure 5.9 A). In 
addition, each plate contains positive controls against PINK1 and parkin, plus two 
negative controls, NT1 and NT2. The outer edge of each plate is devoid of siRNA, in 
order to reduce the negative impact of edge effects on hit siRNA-containing wells. 
Additionally, this allowed for two rows of ‘no CCCP’ controls to be introduced, both in 
the absence of siRNA (empty), or in concert with the negative control, NT1 (Figure 5.9 
A). This provides an additional ‘positive’ phenotype with which to compare screen hits. 
Finally, 11 ‘inner edge’ wells were left devoid of siRNA at the time of plate design, in 
order to provide the facility for extra siRNA addition. Here, additional PINK1, parkin and 
NT1 siRNA SMARTpools were added, with two wells remaining siRNA-free (Figure 5.9 
A).  
 
5.6.3  PROTOCOL 
 
Both of the tertiary screen assays were performed in triplicate in order to ensure the 
robust and reproducible nature of the overall screening hits. Before screening could 
take place, the custom siRNA library, supplied as dried pellets in two 96-well ‘mother 
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plates,’ required resuspension in RNase-free water to a stock concentration of 2 µM. 
Once fully resuspended, stock siRNAs were printed into assay plates to give a final 
working concentration of 25 nM, and stored at -20 ºC. 
 
For Parkin translocation analysis, plates were defrosted, and centrifuged briefly. 
Dharmafect 1 (DF1) diluted in serum and antibiotic-free media (SAbFM) was arrayed 
across the plates, and left to complex with the siRNA for 30 minutes at room 
temperature. Following this, 4,000 YFP-Parkin.HeLa cells in antibiotic-free media 
(AbFM) were added to each well, and plates incubated for 24 hours at 37ºC. To reduce 
transfection-reagent toxicity, media was replaced with normal culture media (NCM), 
and plates were incubated for a further 72 hours. Next, media was replaced with 
vehicle- or CCCP-containing media for 4 hours, before cellular fixation with ice-cold 
methanol for 10 minutes. Samples were then processed for imaging by the addition of 
anti-ATP5A & anti-AlexaFluor 594 (mitochondria), and Hoechst (nucleus) (Figure 5.9 
B). 
 
5.6.4  SCORING SYSTEM 
 
Following sample processing, plates were imaged with a 10x objective at a frequency 
of 9 FOV per well. As automated data analysis proved both difficult and unreliable, this 
was performed manually using a 5-point scoring system (Figure 5.9 C). For each FOV, 
a score of 0, 1, 2, 3 or 4 was awarded, where 0 = extensive cell death or low YFP 
expression, 1= <10% of cells with Parkin translocation, 2 = between 10 - 50% of cells 
with Parkin translocation, 3 = between 50 - 90% of cells with Parkin translocation, and 
4 = >90% of the cells with Parkin translocation (Figure 5.9 C). For each condition, the 
‘average Parkin translocation score’ was calculated, producing one value per well. 
 
5.6.5  CONTROLS 
 
After visual analysis of images, vehicle-treated negative control samples consistently 
exhibited a diffuse, non-translocated distribution of Parkin (Figure 5.10 A). This lack of 
Parkin translocation is faithfully reflected in the quantification, where the ‘average 
translocation score’ is exactly ‘1’ across all three replicate screens (Figure 5.10 B). 
After 4 hours of CCCP toxification, the negative control adopts a strong translocation 
phenotype in the majority of the cell population (Figure 5.10 A), achieving a score close 
to the maximum of ‘4’ (Figure 5.10 B). In agreement, the average ‘no siRNA’ score also 
came close to ‘4’, confirming the absence of negative effects from siRNA delivery. In 
contrast, PINK1 siRNA prevented CCCP-induced translocation (Figure 5.10 A), 
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Figure 5.10 Parkin translocation screen analysis. (A) Example high-throughput images of negative control, PINK1 
and parkin siRNA treated cells, following the application of vehicle or CCCP for 4 hours (indicated). (B) Graphical 
representation of control ‘average Parkin translocation scores’ over three assays. Data comprises a minimum of 24 
wells/condition, with 9 FOV per well. Error bars represent standard deviation, ***P<0.001 (One-way ANOVA with 
Bonferroni’s correction, compared to the vehicle-treated ‘Neg. ctrl siRNA’ unless indicated). (C) Example high-
throughput images of selected hit siRNAs following CCCP treatment. YFP-Parkin (green), ATP5A (red), acquired on a 
high content screening microscope using a 10x objective, scale bar: 40 µm. 
 
returning the phenotype back to vehicle-treated levels (Figure 5.10 B), and parkin 
siRNA efficiently eliminated the YFP-Parkin signal confirming the success of the 
silencing process, and achieving a score of ‘0’ (Figure 5.10 A & B). 
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5.6.6  DATA ANALYSES 
 
Visual analysis of screening images revealed a number of siRNAs producing a 
phenotype comparable to that of PINK1 siRNA. Among these were siRNAs against 
SREBF1, FBXW7, GSK3A and SLC17A9 (Figure 5.10 C and Figure 5.11, ‘area of 
interest’), all of which produced a strong Parkin translocation block. This result was 
encouraging as it demonstrated the ability of Drosophila screen hits to influence Parkin 
translocation across species, hence validating S2R+ cells for use in PINK1/Parkin-
pathway analysis. Despite this however, the majority of siRNAs tested had little effect 
on the translocation process, accumulating an ‘average translocation score’ of 4 or 
close to this (Figure 5.11). A possible reason for the widespread lack of effect is due to 
the presence of high levels of redundancy in the human genome, masking the outcome 
of gene silencing. Additionally, evolutionary divergence may have rendered some of 
these human orthologs obsolete in the processes studied here. Nevertheless, a small 
proportion of siRNAs successfully recapitulated the PINK1 phenotype, achieving the 
aim of this first tertiary screen. 
 
5.6.7  DEFINING HITS 
 
Per screen, hits were defined as siRNAs with a Parkin translocation score outside 3 
standard deviations (SD) of the mean of the CCCP-treated negative control dsRNA. 
For a gene to feature in the final hit group, it must have been a hit in at least 2 out of 3 
screens.  
 
5.6.8  FINALISED HIT LIST 
 
Having applied the above parameters to the screening data, a final list of 28 siRNA hits 
were defined (Table 5.2); 20 of which were hits in all three screens, and 8 of which 
were hits in two out of three screens. Of the 14 genes added from the mitochondrial 
morphology screen (category C), 4 genes feature in the final mitophagy hit list (Table 
5.2, grey). 
 
 
5.7  CCCP-INDUCED MITOPHAGY 
 
The second tertiary screen involved the analysis of mitophagy, through the loss of the 
MIM marker ATP5A. This was a key experiment as it tied together the inhibition of 
Parkin translocation with a block of mitochondrial degradation. By collating the 
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Table 5.2 CCCP-induced Parkin translocation - hit table. Columns contain the official human gene symbol, average 
Parkin translocation score & standard deviation over the 3 replicate screens, and the ‘hit frequency indicating the 
number of screens with which the siRNA was deemed a hit. Data were arranged according to the ‘Hit frequency’ score 
and then ‘average translocation score’ (low to high). Heat-map representation of the ‘average translocation score’ is 
included, with green representing low scores, red representing high scores and yellow representing the 50th percentile 
or median. Genes highlighted in grey were derived from category C hits. 
 
mitophagy data with that from the Parkin translocation screen, a greater confidence in 
the PINK1/Parkin-pathway specificity of overall hits could be gained. 
 
5.7.1  ASSAY DEVELOPMENT 
 
Following development of the mitophagy assay in a low-throughput environment 
(section 5.4), the next step was to scale-up the assay into the 96-well screening format. 
As with Parkin translocation, the cell number, toxification duration and data analysis 
method required optimisation before tertiary screening was undertaken. After titrating a 
range of cell densities from 4,000 – 12,000 cells, a seed population of 10,000 cells per 
well was chosen. At this relatively high cell density, the confluency of the population 
Gene Symbol Average Parkin Translocation score Standard deviation
Hit frequency 
(out of 3 rounds)
1 SREBF1 1.00 0.00 3
2 FBXW7 1.11 0.19 3
3 SLC17A9 1.78 0.68 3
4 USP36 1.96 0.61 3
5 U2AF1 2.00 0.00 3
6 RPL28 2.11 0.11 3
7 PRKAR1B 2.15 0.26 3
8 ZBTB17 2.22 0.19 3
9 WBP11 2.30 0.26 3
10 ACTL6A 2.30 0.23 3
11 RUVBL1 2.44 0.00 3
12 DHX38 2.52 0.17 3
13 POLR3A 2.56 0.11 3
14 GSK3A 2.59 0.55 3
15 SREBF2 2.63 0.23 3
16 EXOSC10 2.63 0.34 3
17 CSK 2.74 0.23 3
18 NDUFA10 2.81 0.55 3
19 ZDHHC8 3.11 0.73 3
20 U2AF2 3.22 0.33 3
21 POLR2L 2.50 0.55 2
22 FZD5 2.85 0.50 2
23 CTSK 2.93 0.79 2
24 NCOA6 3.22 0.22 2
25 PRKAR1A 3.30 0.67 2
26 CSNK2A2 3.37 0.55 2
27 WDR75 3.50 0.39 2
28 KAT2A 3.67 0.29 2
 177 
after a prolonged CCCP application was great enough to overcome increased cell 
death, whilst providing sufficient data for mitophagy analysis (data not shown).  
 
Next, the optimum duration of CCCP toxification was ascertained. Here, it was 
important to identify the time-point causing the highest levels of mitophagy, together 
with the lowest levels of cell death. Following a CCCP time course of 0 – 48 hours, it 
was clear that after 16 and 24 hours, the ATP5A signal had greatly decreased 
compared to the ‘0 hour’ control (Figure 5.12 A). However, by 48 hours, the cell density 
had fallen dramatically, making it difficult to judge the overall mitochondrial content of 
the population. Because of this, the extended toxification time of 48 hours was deemed 
inappropriate for screening purposes.  
 
In an attempt to automatically quantify the observed mitophagy effect, ‘Transfluor’ was 
programmed to count the number of ATP5A-positive puncta per cell. This algorithm 
was able to detect a difference between toxified and non-toxified conditions, showing a 
steady decrease in puncta number over the CCCP time course (Figure 5.12 B). 
However, the detected decrease in puncta number was relatively modest, perhaps 
reflecting the complexity of the mitophagy phenotype. Nevertheless, taking the 
qualitative and quantitative data together, an optimal CCCP time-point of 24 hours was 
agreed. 
 
To assess the effect of positive control siRNAs after CCCP treatment, the same 
algorithm was applied to samples from negative control, PINK1 and parkin siRNA-
treated cells (Figure 5.12 C). Again, the negative control showed a moderate decrease 
in ATP5A-puncta over the CCCP time-course. However, where PINK1 and parkin 
siRNA-treated samples maintained a steady number of ATP5A-puncta throughout, 
overall counts are considerably lower than that of the non-toxified negative control. 
Because of this, the puncta quantification after 24 hours of CCCP treatment is 
comparable between PINK1, parkin and negative control siRNA conditions. One 
feasible reason for this may be due to the influence of PINK1 and parkin on 
mitochondrial morphology, causing the algorithm to pick up fewer individual organelles. 
However, where the ‘fused’ phenotype following Drosophila dPINK1 and dparkin 
silencing is very well defined (Ziviani et al, 2010), much controversy over their influence 
on mammalian mitochondrial morphology remains, with some groups even reporting 
fragmentation (Exner et al, 2007; Mortiboys et al, 2008; Wood-Kaczmar et al, 2008; 
Yang et al, 2008). Still, as the nature of the automated algorithm means that any 
change in mitochondrial morphology is likely to influence the output, mitophagy data 
were scored manually to avoid spurious results. 
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5.7.2  PLATE LAYOUT 
 
Screening plates for mitophagy analysis carried the same design as those used for 
Parkin translocation analysis (Figure 5.9 A). These included two rows of ‘no CCCP’ 
control-wells, producing a ‘basal’ mitochondrial phenotype; plus a number of extra 
CCCP-treated controls including PINK1-, parkin-,  and negative-control siRNA. 
 
5.7.3  PROTOCOL 
 
Like the plate design, the protocol for mitophagy analysis was similar to that used for 
Parkin translocation (Figure 5.9 B), with the exception of a higher cell number (10,000 
cells per well), and longer toxification duration (24 hours).  
 
5.7.4  SCORING SYSTEM 
 
Following sample processing, 9 FOV per condition were imaged on a high content 
screening microscope using a 10x objective. As automated analysis produced 
disparate results from the qualitative data, images were analysed manually, using a 5-
point scoring system (Figure 5.13). For each FOV, a score of 0, 1, 2, 3 or 4 was 
awarded, where 0 = extensive cell death or low YFP expression, 1 = a full complement 
of mitochondria, 2 = an overall reduced mitochondrial signal, 3 = a reduced 
mitochondrial signal, plus ~10% of cells with no mitochondria, and 4 = a reduced 
mitochondrial signal plus >20% of cells with no mitochondria (Figure 5.13). For each 
condition, the ‘average mitophagy score’ was calculated, producing one value per well. 
 
5.7.5  CONTROLS 
 
Following visual analysis of control images, under non-toxified conditions the negative 
control siRNA exhibited a full complement of mitochondria across the population, 
achieving an average mitophagy score of ‘1’ (Figure 5.14 A & B). However, after 24 
hours of CCCP toxification, a strong mitophagy induction is observed (Figure 5.14 A), 
producing an average score close to the maximum of ‘4’ (Figure 5.14 B). In agreement 
with the negative control, the average ‘no siRNA’ score also came close to ‘4’, although 
greater variation was observed here, indicating the possibility of edge effects. In 
contrast, PINK1 siRNA prevented CCCP-induced mitophagy (Figure 5.14 A), reverting 
the phenotype back to non-toxified levels (Figure 5.14 B). parkin siRNA also produced 
an almost complete block of mitophagy, but achieved a score of ‘0’ due to the lack of
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Figure 5.14 Mitophagy screen analysis. (A) Example high-throughput images of negative control, PINK1 and parkin 
siRNA treated cells, following the application of vehicle or CCCP for 24 hours (indicated). (B) Graphical representation 
of control ‘average mitophagy scores’ over three assays. Data comprises a minimum of 24 wells/condition, with 9 FOV 
per well. Error bars represent standard deviation, ***P<0.001 (One-way ANOVA with Bonferroni’s correction, compared 
to the vehicle-treated ‘Neg. ctrl siRNA’ unless indicated). (C) Example high-throughput images of selected hit siRNAs 
following CCCP treatment. YFP-Parkin (green), ATP5A (red), acquired on a high content screening microscope using a 
10x objective, scale bar: 40 µm. 
 
YFP-Parkin signal. Once again, the parkin control phenotype confirmed the efficacy of 
the silencing process (Figure 5.14 A & B). 
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5.7.6  DATA ANALYSES 
 
Visual analysis of screening images revealed a number of siRNAs producing a 
phenotype comparable to that of PINK1 siRNA. Among these were siRNAs against 
SREBF1, FBXW7, SLC17A9 and WBP11 (Figure 5.14 C and Figure 5.15, ‘area of 
interest’), all of which produced a strong mitophagy block. This result was encouraging 
as it demonstrated the ability of these genes to block the end-point of the pathway for 
the first time, hence strengthening the possibility of pathway specificity. Unlike Parkin 
translocation, many more siRNAs had some influence on the mitophagy process 
(Figure 5.15), perhaps due to the complexity of the phenotype making analysis more 
challenging. In addition, a greater number of siRNAs achieved a score of 0 (Figure 
5.15, asterisks), probably due to increased levels of CCCP-induced cell death 
compared with Parkin translocation assays. 
 
5.7.7  DEFINING HITS 
 
Per screen, hits were defined as siRNAs with a mitophagy score outside 3 SD of the 
mean of the CCCP-treated negative control dsRNA. For a gene to feature in the final 
hit group, it must have been a hit in at least 2 out of 3 screens.  
 
5.7.8  FINALISED HIT LIST 
 
Having applied the above parameters to the screening data, a final list of 47 siRNA hits 
were defined (Table 5.3), with 23 being hits in all three screens, and 24 being hits in 
two out of three screens. Of the 14 genes added from the aforementioned 
mitochondrial morphology screen (category C), 6 feature in the final mitophagy hit list 
(Table 5.3, grey). 
 
 
5.8 COLLATING DATA 
 
Having completed both Parkin translocation and mitophagy screens, the final task was 
to collate the data to produce an overall list of hits for future study. Once complete, the 
list could be assessed for the presence of interesting bioinformatic features including 
pathway enrichments. Through this, the selection of a small number of genes for 
further scrutiny in a low-throughput setting could be made. 
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Table 5.3 CCCP-induced mitophagy - hit table. Columns contain the official human gene symbol, average mitophagy 
score & standard deviation over the 3 replicate screens, and the ‘hit frequency indicating the number of screens with 
which the siRNA was deemed a hit. Data are arranged according to the ‘Hit frequency’ score and then ‘average 
mitophagy score’ (low to high). Heat-map representation of the ‘average translocation score’ is included, with green 
representing low scores, red representing high scores and yellow representing the 50th percentile or median. Genes 
highlighted in grey were derived from category C hits. 
  
Gene Symbol Average Mitophagy score Standard deviation
Hit frequency 
(out of 3 rounds)
1 SLC17A9 1.00 0.00 3
2 WBP11 1.00 0.00 3
3 SREBF1 1.11 0.11 3
4 USP36 1.19 0.17 3
5 FBXW7 1.22 0.22 3
6 MED28 1.22 0.00 3
7 RUVBL2 1.44 0.44 3
8 EXOC5 1.63 0.57 3
9 ZBTB17 1.63 0.57 3
10 ZDHHC8 2.04 0.71 3
11 PRKCZ 2.04 0.17 3
12 RPL28 2.19 0.97 3
13 KAT2B 2.33 0.22 3
14 USP42 2.33 0.40 3
15 GSK3A 2.41 0.06 3
16 CSNK2A2 2.56 1.26 3
17 WDR75 2.56 0.78 3
18 ACTL6B 2.56 0.40 3
19 MED24 2.63 1.03 3
20 NDUFA10 2.63 0.34 3
21 SPHK2 2.81 0.63 3
22 CSNK2A1 2.93 0.61 3
23 KAT2A 3.07 0.46 3
24 POLR2H 1.56 0.79 2
25 U2AF1L4 1.78 0.38 2
26 RUVBL1 1.81 0.23 2
27 U2AF2 1.94 0.08 2
28 GATA4 2.00 0.38 2
29 SREBF2 2.04 0.32 2
30 KMO 2.11 0.16 2
31 SLC31A1 2.11 0.69 2
32 ACTL6A 2.26 0.39 2
33 PUF60 2.26 0.80 2
34 U2AF1 2.30 0.06 2
35 PPP4C 2.44 0.40 2
36 SPHK1 2.56 0.59 2
37 USMG5 2.63 0.93 2
38 POLR3A 2.67 0.89 2
39 FZD5 2.78 1.25 2
40 USP9X 2.83 0.08 2
41 CDK9 2.89 0.33 2
42 CTSK 3.06 0.71 2
43 SLC3A1 3.11 0.29 2
44 TMCO7 3.11 0.97 2
45 SLC17A3 3.17 0.24 2
46 CSK 3.19 0.06 2
47 SRSF11 3.26 0.57 2
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5.8.1  FINAL HUMAN HIT LIST 
 
For a gene to be defined as a final human screen hit, it needed to appear in the hit 
tables of both Parkin translocation and mitophagy screens. Having collated these 
datasets, a final hit group of 22 human genes was determined (Table 5.4). To give the 
genes an order of strength, average scores from the Parkin translocation and 
mitophagy screens were combined, with the lowest scores towards the top, and the 
highest scores towards the bottom. With this, SREBF1 became the top screening hit, 
followed by FBXW7 and SLC17A9. 
 
To assess whether siRNA amplicons had equivalent effects on Parkin translocation 
and mitophagy, datasets from all 90 human siRNAs (Figure 5.16 A) and the hit group 
alone (Figure 5.16 B) were plotted. To determine the strength of the association 
between the two variables of a linear regression, the square of Pearson’s correlation 
coefficient (also called the ‘coefficient of determination’ or ‘R2’) is useful. Here, an R2 of 
1 signifies perfect correlation, and an R2 of 0 indicates no correlation. In the case of all 
90 screen siRNAs (Figure 5.16 A), an R2 of 0.275 signifies that 27.5% of mitophagy 
scores can be directly accounted for by the Parkin translocation score, and vice versa. 
This shows a significant positive relationship between Parkin translocation and 
mitophagy within this group of genes, albeit a relatively modest one. However, if the hit 
group is taken alone, the coefficient of determination increases dramatically to 0.742, 
meaning that 74.2% of mitophagy scores can now be directly accounted for by Parkin 
translocation scores, and vice versa (Figure 5.16 B). The hit group therefore contains a 
strong enrichment of genes having equivalent effects on both Parkin translocation and 
mitophagy. With regards to the linearity of the PINK1/Parkin-pathway, genes with a 
direct role upstream of Parkin translocation would be anticipated to affect both 
processes equally, confirming that the hit group follows the expected trend.  
 
5.8.2.  BIOINFORMATIC ANALYSIS 
 
Having produced a final list of 22 hit genes, known pathway interactions and gene 
functions were explored. For this, the hit group together with PINK1 and parkin 
(PARK2) were passed through the STRING algorithm, allowing visualisation of 
previously defined interactions (Figure 5.17). From this analysis, three clear groups of 
genes emerged, the largest of which included experimental data of a parkin interaction 
with the hit gene, FBXW7. Importantly, this large interaction group included the two top 
human hits, SREBF1 and FBXW7, prompting further investigation into the functions of 
these proteins. 
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Table 5.4 Final human screening hit table. Columns contain the official human gene symbol, average translocation 
and mitophagy score with corresponding standard deviations over 3 replicate screens, and the ‘combined average 
score’ of collated data out of a maximum score of 8. Data are arranged according to the ‘combined average score’ (low 
to high). Genes highlighted in grey were derived from category C hits. 
 
 
Having drawn information from a number of sources including Uniprot and NCBI gene, 
the function and interacting partners of each of the hit genes were investigated (Table 
5.5). Many of the hits have major roles in housekeeping processes such as 
transcription, DNA splicing and translation. In addition, a number of genes are also 
involved in metabolic processes such a lipid and glucose homeostasis; as well as links 
to the mitochondrial respiratory complexes. Importantly, many hit genes have been 
shown to physically interact with each other (Table 5.5, Interactors – black) or other 
genes related to the hit group (Table 5.5, Interactors – green), as well as with 
‘interesting’ genes (Table 5.5, Interactors – orange) such as previously reported 
Parkinson’s disease genes, parkin (PARK2) and DJ-1 (PARK7). 
 
Collated
Average score StDev Average score StDev Combined average score
1 SREBF1 1.000 0.00 1.111 0.11 2.111
2 FBXW7 1.111 0.19 1.222 0.22 2.333
3 SLC17A9 1.778 0.68 1.000 0.00 2.778
4 USP36 1.963 0.61 1.185 0.17 3.148
5 WBP11 2.296 0.26 1.000 0.00 3.296
6 ZBTB17 2.222 0.19 1.630 0.57 3.852
7 RUVBL1 2.444 0.00 1.815 0.23 4.259
8 RPL28 2.111 0.11 2.185 0.97 4.296
9 U2AF1 2.000 0.00 2.296 0.06 4.296
10 ACTL6A 2.296 0.23 2.259 0.39 4.556
11 SREBF2 2.630 0.23 2.037 0.32 4.667
12 GSK3A 2.592 0.55 2.407 0.06 5.000
13 ZDHHC8 3.111 0.73 2.037 0.71 5.148
14 U2AF2 3.222 0.33 1.944 0.08 5.167
15 POLR3A 2.556 0.11 2.667 0.89 5.222
16 NDUFA10 2.815 0.55 2.630 0.34 5.444
17 FZD5 2.852 0.50 2.778 1.25 5.630
18 CSNK2A2 3.370 0.55 2.555 1.26 5.926
19 CSK 2.741 0.23 3.185 0.06 5.926
20 CTSK 2.926 0.79 3.056 0.71 5.981
21 WDR75 3.500 0.39 2.555 0.78 6.056
22 KAT2A 3.667 0.29 3.074 0.46 6.740
 Parkin translocation Mitophagy
Gene Symbol
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Figure 5.17 Protein interaction analysis of final human genes. Schematic representation of known and predicted 
protein interactions between the 22 final human hits (STRING 9.0). Nodes are joined together with coloured lines 
representing the type of interaction evidence used (see key). 
 
5.8.3  GENE SELECTION FOR LOW-THROUGHPUT ANALYSIS 
 
Following screening, the desired outcome was to identify a small number of hits for in-
depth, low throughput analysis. For this, both screening data and bioinformatic 
information played a big part in deciding which genes to select. Taking these two data 
sources into account, ‘sterol regulatory element binding transcription factor 1’ 
(SREBF1) and ‘F-box and WD repeat domain containing E3 ubiquitin ligase’ (FBXW7) 
were selected for closer scrutiny. The reasons for selecting these two genes were due 
to the fact that they occupy first and second positions in the overall screening hit table, 
as well as forming part of a large, PINK1/Parkin-related interaction network (Figure 
5.17). Additionally, SREBF2, a gene closely related to SREBF1 is also found in the hit 
list, helping to strengthen the confidence in SREBF1-related pathway specificity. 
Finally, FBXW7 has been shown to physically interact with Parkin in an SCF-like 
complex (Staropoli et al, 2003), and Parkin is reported to be responsible for the 
proteasomal degradation of FBXW7, promoting neuronal protection (Ekholm-Reed et 
al, 2013). 
 
 
Line Key!
!
Co-expression!
Experiments!
Databases!
Text mining!
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Following extensive literature searches, SREBP1, the transcription factor 
corresponding to the gene SREBF1, is known to be required for the transcription of 
enzymes for de novo lipid synthesis; predominantly of fatty acids, but also cholesterol 
(Brown & Goldstein, 1997). Importantly, SREBP1 levels are tightly regulated by the E3-
ubiquitin ligase FBXW7, via the proteasomal degradation pathway (Sundqvist et al, 
2005). For FBXW7-dependent ubiquitination and degradation of SREBP1 to take 
place, a prior phosphorylation event must occur. This phosphorylation event is 
performed by the serine/threonine kinase GSK3β (Kim et al, 2004; Sundqvist et al, 
2005). Despite GSK3B itself not appearing in the hit list, the closely-related gene, 
GSK3A does feature, both of which are orthologous to Drosophila shaggy (sgg); a high 
performing gene in the Drosophila screen. Due to the two genes, GSK3A and GSK3B, 
having high amino acid homology (98% within the kinase domain) (Doble & Woodgett, 
2003), and proven functional redundancy (Doble et al, 2007), GSK3A was also 
considered for low throughput analysis (Figure 5.18). 
 
 
5.9 DISCUSSION 
 
Having started the screening process with ~15,000 Drosophila genes, a final group of 
22 human genes with a robust and reproducible effect on mammalian Parkin 
translocation and mitophagy have been defined. During this process, the primary 
Drosophila hits have been assessed for their ability to influence Parkin translocation 
under different toxification scenarios, as well as mitochondrial morphology and 
mitochondrial perinuclear aggregation. Taken together, this project has overseen a 
comprehensive screen for genes with the ability to affect PINK1/Parkin-related 
processes, conserved across species (Figure 5.18). 
 
In order to select a small group of genes for further analysis, a great help came in the 
form of pre-defined interaction pathways, facilitated by the online interaction program, 
STRING. Interaction maps produced by STRING highlighted a cluster of hit genes 
acting in a common pathway. This pathway transpires to hold a central role in lipid 
homeostasis, through the maintenance of fatty acid and cholesterol levels. 
 
One confusing aspect of this pathway is that FBXW7, the second hit in the final list, 
acts by degrading SREBP1 in the nucleus following DNA binding. This would therefore 
be expected to produce the opposite phenotype to that of SREBF1 siRNA, if the 
observed effect is SREBP-pathway-specific. One possible explanation is that a fine 
balance of SREBP-pathway activation is required for efficient Parkin translocation and 
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Figure 5.18 Overall screening workflow diagram. Workflow diagram representing each step of Drosophila and 
human cell screening. Briefly, the whole genome library was comprised of ~15,000 Drosophila genes. Following primary 
screening, 625 dsRNAs were found to reduce Parkin-GFP translocation after CCCP treatment. Of these, 115 dsRNAs 
were confirmed in 4 repeat screens. Primary hit amplicons then underwent multiple secondary screen assays looking at 
paraquat-induced Parkin translocation, mitochondrial morphology and perinuclear aggregation. Collating these data, the 
final Drosophila dsRNA hit list comprises 75 amplicons, including 10 from an earlier screen performed by Joe Pogson 
(grey). These Drosophila dsRNA amplicons equated to 90 unique human orthologs, which were tested for an ability to 
influence Parkin translocation and mitophagy in a human cell system, Of these 90 genes, 22 were found to robustly 
influence both assays, and three lipolysis-related genes were selected for closer scrutiny. 
 
mitophagy, therefore too little or too much causes the same phenotype. This is an 
issue that will need addressing experimentally before we fully understand the 
relationship, if any, between SREBF1, FBXW7 and the PINK1/Parkin-pathway. 
 
The next stage of the project involved analysing the three ‘favourite’ hit genes, 
SREBF1, FBXW7 and GSK3A, in a low-throughput setting. In the following chapter, the 
influence of these genes on several aspects of mitochondrial biology, as well as their 
interaction with PINK1 and parkin, was assessed using cell-based and in vivo models.  
Here, the aim was to understand how these genes interact in the context of 
mitochondrial homeostasis.  
ab CG15459 CG9883 Gclm MED28 rept sgg Withdrawn Pka-R1
ago CG17209 CkIIα HLH106 MED7 Rpb10 Srp54 Withdrawn Pp4-19C
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Drosophila genome: ~15,000 genes 
Whole genome screen: 625 amplicons Confirmation screen: 115 amplicons 
Paraquat toxification Mitochondrial morphology Perinuclear aggregation 
Secondary screening 
65 Drosophila dsRNA hits + 10 prior screen hits 
90 human orthologs 
22 human hit genes 
3 human genes for low-throughput analysis 
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6. LOW-THROUGHPUT ANALYSIS  
OF SCREEN HITS
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6.1  BACKGROUND 
 
Following screening completion, the next challenge was to select a small number of 
genes for follow-up analysis. The purpose of this was to ascertain whether the 
influence on PINK1/Parkin-related processes such as Parkin translocation and 
mitophagy, were pathway-specific or an artifact of a non-specific gene function e.g. 
general autophagy. As detailed in chapter 5, a number of top screening hits have been 
shown to act in a pre-defined pathway, with de novo lipid synthesis at its centre. These 
genes are SREBF1, FBXW7 and GSK3. In this final results chapter, these genes will 
be tested for an ability to biochemically and genetically interact with the PINK1/Parkin-
pathway using a range of different techniques. Analysis of these data will allow 
hypotheses to be offered as to how these genes may act together to promote the 
degradation of dysfunctional mitochondria. 
 
6.2  THE SREBP-PATHWAY IN LIPID HOMEOSTASIS 
 
‘Sterol Regulatory Element Binding Proteins’ (SREBPs) were first identified as nuclear 
transcription factors able to activate low density lipoprotein receptor (LDLR) 
transcription, required for cholesterol uptake from the bloodstream (Briggs et al, 1993; 
Wang et al, 1993). In mammals, the SREBF-family of genes confers three distinct 
basic helix-loop-helix (bHLH) transcription factors; SREBP1a, SREBP1c and SREBP2; 
all of which bind both E-box and sterol regulatory element (SRE) motifs in the promoter 
of target genes. The key role of these genes is in the regulation of global lipid synthesis 
by the transcription of key enzymes of fatty acid, triglyceride and cholesterol production 
(Brown & Goldstein, 1997). In general, SREBP1a is a potent activator of genes 
required for fatty acid, triglyceride and cholesterol production, whereas SREBP1c is 
responsible for fatty acid and triglyceride synthesis alone and SREBP2 for cholesterol 
synthesis. These three SREBP proteins are encoded for by two SREBF genes, with 
SREBF1 responsible for SREBP1a and 1c, and SREBF2 responsible for SREBP2.  
 
SREBP family members are multidomain proteins comprising an N-terminal 
transactivation domain, a transcription-activating basic helix-loop-helix leucine zipper 
(bHLH-Zip) domain, two transmembrane domains flanking a small loop domain, and a 
large C-terminal regulatory domain (Figure 6.1 A, Osborne & Espenshade, 2009; 
Shimano, 2001). For the synthesis of SREBP1a and 1c, differential promoters within 
SREBF1 are utilised, producing either a long (SREBP1a) or short (SREBP1c) 
transactivation sequence in the C-terminus of the protein (Hua et al, 1995) 
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Figure 6.1 SREBP-pathway members and their regulation by sterols (A) Schematic of the functional domains, 
protein conformation and basal cellular localisation of the three SREBP proteins, SREBP1a, SREBP1c, and SREBP2. 
Pathway targets for each of the SREBP proteins are indicated. Figure adapted from Shimano (2001). (B) Schematic 
representation of SREBP-pathway regulation and activation by sterols. Under conditions of saturating sterols, flSREBP 
is retained in the ER membrane, in a hairpin conformation, with its regulatory and transcriptional domains facing the 
cytoplasm. Here it is in complex with the escort protein SCAP, through an interaction between the C-terminal regulatory 
domain of SREBP, and the N-terminal protein interacting domain (WD-40) of SCAP. To retain the SREBP-SCAP 
complex in the ER, the SSD domain of SCAP senses high sterol levels and allows an interaction with the retention 
factor INSIG. However, when sterol levels fall below the optimum, this is sensed by SCAPs SSD domain, promoting a 
conformational change. This leads to the dissociation of INSIG from the SREBP-SCAP complex, and allows an 
interaction between SCAP and the COPII coat protein Sec24. In combination with Sec23 and Sar-1, the SREBP-SCAP 
complex undergoes ER-to-Golgi transport via the COPII vesicular trafficking pathway. At the Golgi, two proteolytic 
cleavage events via the membrane-linked proteases S1P and S2P, lead to the release of the N-terminal transcriptional 
domain or ‘mSREBP’ into the cytoplasm. mSREBP1 undergoes homodimerisation before translocation to the nucleus 
via Importin-β. Here, it promotes target gene transcription, leading to the synthesis of fatty acids, triglycerides and 
cholesterol. Figure adapted from Horton et al., (2002). 
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thesis. Like SREBP-1a, SREBP-2 has a long transcrip-
tional activation domain, but it preferentially activates
cholesterol synthesis (1). SREBP-1a and SREBP-2 are the
predominant isoforms of SREBP in most cultured cell
lines, whereas SREBP-1c and SREBP-2 predominate in
the liver and most other intact tissues (6).
When expressed at higher than physiologic levels,
each of the three SREBP isoforms can activate all
enzymes indicated in Figure 2, which shows the
biosynthetic pathways used to generate cholesterol
and fatty acids. However, at normal levels of expres-
sion, SREBP-1c favors the fatty acid biosynthetic path-
way and SREBP-2 favors cholesterologenesis. SREBP-
2–responsive genes in the cholesterol biosynthetic
pathway include those for the enzymes HMG-CoA
synthase, HMG-CoA reductase, farnesyl diphosphate
synthase, and squalene synthase. SREBP-1c–respon-
sive genes include those for ATP citrate lyase (which
produces acetyl-CoA) and acetyl-CoA carboxylase and
fatty acid synthase (which together produce palmitate
[C16:0]). Other SREBP-1c target genes encode a rate-
limiting enzyme of the fatty acid elongase complex,
which converts palmitate to stearate (C18:0) (ref. 7);
stearoyl-CoA desaturase, which converts stearate to
oleate (C18:1); and glycerol-3-phosphate acyltrans-
ferase, the first committed enzyme in triglyceride and
phospholipid synthesis (3). Finally, SREBP-1c and
SREBP-2 activate three genes required to generate
NADPH, which is consumed at multiple stages in
these lipid biosynthetic pathways (8) (Figure 2).
Knockout and transgenic mice
Ten different genetically manipulated mouse models
that either lack or overexpress a single component of the
SREBP pathway have been generated in the last 6 years
(9–16). The key molecular and metabolic alterations
observed in these mice are summarized in Table 1.
Knockout mice that lack all nSREBPs die early in
embryonic development. For instance, a germline dele-
tion of S1p, which prevents the processing of all SREBP
isoforms, results in death before day 4 of development
(15, 17). Germline deletion of Srebp2 leads to 100%
lethality at a later stage of embryonic development
than does deletion of S1p (embryonic day 7–8). In con-
trast, germline deletion of Srebp1, which eliminates
both the 1a and the 1c transcripts, leads to partial
lethality, in that about 15–45% of Srebp1–/– mice survive
(13). The surviving homozygotes manifest elevated lev-
els of SREBP-2 mRNA and protein (Table 1), which pre-
sumably compensates for the loss of SREBP-1a and -1c.
When the SREBP-1c transcript is selectively eliminat-
ed, no embryonic lethality is observed, suggesting that
the partial embryonic lethality in the Srebp1–/– mice is
due to the loss of the SREBP-1a transcript (16).
To bypass embryonic lethality, we have produced
mice in which all SREBP function can be disrupted in
adulthood through induction of Cre recombinase. For
this purpose, loxP recombination sites were inserted
into genomic regions that flank crucial exons in the
Scap or S1p genes (so-called floxed alleles) (14, 15).
Mice homozygous for the floxed gene and heterozy-
gous for a Cre recombinase transgene, which is under
control of an IFN-inducible promoter (MX1-Cre), can
be induced to delete Scap or S1p by stimulating IFN
expression. Thus, following injection with polyi-
nosinic acid–polycytidylic acid, a double-stranded
RNA that provokes antiviral responses, the Cre recom-
binase is produced in liver and disrupts the floxed gene
by recombination between the loxP sites.
Cre-mediated disruption of Scap or S1p dramatically
reduces nSREBP-1 and nSREBP-2 levels in liver and
diminishes expression of all SREBP target genes in
both the cholesterol and the fatty acid synthetic path-
ways (Table 1). As a result, the rates of synthesis of cho-
lesterol and fatty acids fall by 70–80% in Scap- and
S1p-deficient livers.
In cultured cells, the processing of SREBP is inhibit-
ed by sterols, and the sensor for this inhibition is SCAP
(5). To learn whether SCAP performs the same function
in liver, we have produced transgenic mice that express
a mutant SCAP with a single amino acid substitution
in the sterol-sensing domain (D443N) (12). Studies in
tissue culture show that SCAP(D443N) is resistant to
inhibition by sterols. Cells that express a single copy of
this mutant gene overproduce cholesterol (18). Trans-
genic mice that express this mutant version of SCAP in
the liver exhibit a similar phenotype (12). These livers
manifest elevated levels of nSREBP-1 and nSREBP-2,
owing to constitutive SREBP processing, which is not
suppressed when the animals are fed a cholesterol-rich
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Figure 1
Model for the sterol-mediated proteolytic release of SREBPs from mem-
branes. SCAP is a sensor of sterols and an escort of SREBPs. When cells
are depleted of sterols, SCAP transports SREBPs from the ER to the Golgi
apparatus, where two proteases, Site-1 protease (S1P) and Site-2 protease
(S2P), act sequentially to release the NH2-terminal bHLH-Zip domain
from the membrane. The bHLH-Zip domain enters the nucleus and binds
to a sterol response element (SRE) in the enhancer/promoter region of tar-
get genes, activating their transcription. When cellular cholesterol rises,
the SCAP/SREBP complex is no longer incorporated into ER transport
vesicles, SREBPs no longer reach the Golgi apparatus, and the bHLH-Zip
domain cannot be released from the membrane. As a result, transcription
of all t rget genes declines. Reprinted from r f. 5 with permission.
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cholesterol synthesis (1). SREBP-1a and SREBP-2 are the
predominant isoforms of SREBP in most cultured cell
lines, whereas SREBP-1c and SREBP-2 predominate in
the liver and most other intact tissues (6).
When expressed at higher than physiologic levels,
each of the three SREBP isoforms can activate all
enzymes indicated in Figure 2, which shows the
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and fatty acids. However, at normal levels of expres-
sion, SREBP-1c favors the fatty acid biosyntheti  path-
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synthase, and squalene synthase. SREBP-1c–resp n-
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fatty acid synthase (which together produce palmitate
[C16:0]). Other SREBP-1c target genes encode a rate-
limiting enzyme of the fatty acid elongase complex,
which converts palmitate to stearate (C18:0) (ref. 7);
stearoyl-CoA desaturase, which converts stearate to
oleate (C18:1); and glycerol-3-phosphate acyltrans-
ferase, the first committed enzyme in triglyceride and
phospholipid synthesis (3). Finally, SREBP-1c and
SREBP-2 activate three genes required to generate
NADPH, which is consumed at multiple stages in
these lipid biosynthetic pathw ys (8) (Figure 2).
Knockout and transgenic mice
Ten different genetically manipulated mouse models
that either lack or overexpress a single component of the
SREBP pathway have been generated in the last 6 years
(9–16). The key molecular and metabolic alterations
observed in these mice are summarized in Table 1.
Knockout mice that lack all nSREBPs die early in
embryonic development. For instance, a germline dele-
tion of S1p, which prevents the processing of all SREBP
isoforms, results in death before day 4 of development
(15, 17). Germline deletion of Srebp2 leads to 100%
lethality at a later st ge of embryonic development
than does deletion of S1p (embryonic day 7–8). In con-
trast, germline deletion of Srebp1, which eliminates
both the 1a and the 1c transcripts, leads to partial
lethality, in that about 15–45% of Srebp1–/–mice survive
(13). The survivi g homozygotes manifest elevated lev-
els of SREBP-2 mRNA and protein (Table 1), which pre-
sumably com ensates for the loss of SREBP-1a and -1c.
When the SREBP-1c transcript is selectively eliminat-
ed, no embry nic lethality is observed, suggesting that
the p r ial embryonic lethality in the Srebp1–/– mice is
due to the loss of the SREBP-1a transcript (16).
To bypass embryonic lethality, we have produced
mice in which all SREBP fu ction can be disrupted in
adulthood through induction of Cre recombinase. For
t is purpos , loxP recombination sites were inserted
into genomic regions that flank crucial exons in the
Scap or S1p genes (so-called floxed alleles) (14, 15).
Mice homozygous for the floxed gene and heterozy-
gous for a Cre r combinase transgene, which is under
control of an IFN-inducible promoter (MX1-Cre), can
be induced to delete Scap or S1p by stimulating IFN
expression. Thus, following injection with polyi-
nosinic acid–polycytidylic acid, a double-stranded
RNA that provokes antiviral responses, the Cre recom-
bi ase is produced in liver and disrupts the floxed gene
by recombination between the loxP sites.
Cre-mediated disruption of Scap or S1p dramatically
reduces nSREBP 1 and nSREBP-2 levels in liver and
dimi ishes expression of all SREBP target genes in
both the cholesterol and the fatty acid synth tic path-
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lesterol and fatty acids fall by 70–80% in Scap- and
S1p-deficient livers.In cultured cells, t e processing of SREBP is inhibit-
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manifest elevated levels of nSREBP-1 and nSREBP-2,
owing to constitutive SREBP processing, which is not
suppressed when the animals are fed a cholesterol-rich
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genic mice that express this mutant version of SCAP in
the liver exhibit a similar phenotype (12). These livers
manifest elevated levels of nSREBP-1 and nSREBP-2,
owing to constitutive SREBP processing, which is not
suppressed when the animals are fed a cholesterol-rich
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Figure 1
Model for the sterol-mediated proteolytic release of SREBPs from mem-
branes. SCAP is a sensor of stero s and an escort of SREBPs. Whe  cells
are deple ed f s rols, SCAP transpo s REBPs from the ER to the Golgi
apparatus, where two proteases, Site-1 protease (S1P) and Site-2 protease
(S2P), act sequentially to release the NH2-terminal bHLH-Zip domain
from the membrane. The bHLH-Zip doma  enters t e nucleus and binds
to a sterol response ele ent (SRE) in the enhancer/promoter regio  of tar-
get genes, activating their transcri tion. When cellular cholesterol ris ,
the SCAP/SREBP co plex is no longer incorporated into ER transport
vesicles, SREBPs no longer reach the G lgi apparatus, and the bHLH-Zip
domain cannot be released from the membrane. As a result, transcription
of all target gen s declines. Reprinted from ref. 5 with permission.
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structurally composed of four domains with two membrane-spanning regions. Both amino- and
carboxyl-terminal portions of the proteins project into the cytoplasm. The N-terminal domain of
approximately 480 amino acids is a basic-helix-loop-helix leucine zipper (bHLHZip) protein and
a functionally active portion as a transcription factor. This segment begins with an acidic trans-
activation domain that clusters acidic residues. When this segment is deleted in transfection
studies, the proteins retain the ability to bind to the relevant DNA sequence, but they lose their
ability to activate transcription [7]. The acidic NH2-terminal sequence is followed by a glycine,
serine, proline, and glutamine rich region whose function is unknown. These sequences are fol-
lowed by the bHLH-Zip domain. SREBPs are believed to form a homodimer to bind to an SRE.
What makes SREBPs a unique membrane-bound transcription factor is the subsequent sequence
consisting of a hydrophobic membrane-spanning sequence, a hydrophilic loop region, a second
membrane-spanning sequence, and a long carboxyl-terminal region. SREBP forms a complex
with WD domain of SREBP cleavage activating protein (SCAP) through this carboxyl-terminal
region (Fig. 2). Therefore, this region of SREBP should be involved in sterol-regulation, and thus
is named a carboxyl regulatory domain [8,9].
2.2. Cleavage of SREBPs for activation (Fig. 2)
Unlike other members of this class, SREBPs are produced as membrane-bound precursors that
require cleavage by a two-step proteolytic process in order to release their amino-terminal bHLH-
Zip-containing domain (nuclear SREBP) into the nucleus to activate their target genes [10,11].
Molecular mechanisms for cleavage of SREBPs in sterol regulation have been elegantly and
extensively analyzed by Goldstein and Brown [3,12–14]. Upon sterol deprivation, the membrane-
bound SREBP precursor protein undergoes a sequential two-step cleavage process to release the
amino-terminal portion SREBP [10,11]. This nuclear SREBP, then enters the nucleus and acti-
vates the transcription of genes involved in cholesterol and fatty acid synthesis by binding to
sterol regulatory elements (SREs) or to palindromic sequences called E-boxes within their pro-
moter regions. SREBP precursor and SCAP form a complex on the rough endoplasmic reticulum
(ER) membrane [9]. SCAP is a multiple membrane-spanning protein containing a consensus
sequence for a sterol-sensing domain which is shared by HMG CoA reductase, Niemann-Pick C1
disease gene product (NPC1), and Patched [8,15]. Therefore, SCAP has been suggested to func-
tion as a cholesterol sensor. SCAP is prerequisite for cleavage of SREBPs [16,17]. When sterol is
depleted, the SREBP-SCAP complex targets to golgi where site-1 and site-2 proteases await. Site-1
Fig. 1. Domain structure of SREBP family.
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6.2.1  SREBP-PATHWAY ACTIVATION 
 
Activation of SREBP-target genes is tightly regulated according to the metabolic status 
of the cell. For example, under conditions of high intracellular cholesterol or fatty acid 
concentration, low metabolite availability or a lack of growth factor signaling, SREBP is 
inactive. However, in the event of decreased cellular cholesterol or fatty acid content, 
increased carbohydrate availability or signaling via the insulin pathway, SREBP 
becomes activated, allowing target gene transcription to commence. 
 
Most data regarding the regulation of the SREBP-pathway have come from studies in 
cholesterol-dependent SREBP activation. However, although less well studied, an 
increasing amount of data suggest that SREBP activation is also governed by 
intracellular fatty acid concentration and extracellular insulin signaling. Here, whilst the 
mode of activation may be different, the overall activation process appears to be 
similar. Initially, de novo SREBP is transcribed and embedded in the endoplasmic 
reticulum (ER) membrane as an inactive full-length precursor (Figure 6.1 A and B). 
However, upon the receipt of activating stimuli, SREBP undergoes ER-to-Golgi 
transport, followed by two activating proteolytic cleavage events and subsequent 
release from the membrane. Activated SREBP is then able to translocate to the 
nucleus where transcription may begin (Figure 6.1 B). The following sections outline 
some of the stimulus-specific details that govern the regulation of this activation 
process. 
 
6.2.1.1  SREBP-pathway activation by sterols 
 
Sterols are part of the lipid family, and incorporate a wide range of molecules including 
steroid hormones and cholesterol. Of note, cholesterol is an essential component of 
membranes, with roles in membrane fluidity and permeability, as well as secondary 
messenger signaling. Sterols such as cholesterol have a well-defined role in the 
regulation of the SREBP pathway. Here, prior to activation by membrane-incorporated 
sterols, full-length SREBP (flSREBP) is embedded in the ER membrane as an inactive 
precursor protein (Figure 6.1 A & B). In this location, the C-terminal regulatory domain 
of SREBP interacts with the N-terminal WD-40 repeat domain of ‘SREBP Cleavage 
Activating Protein’ (SCAP) (Sakai et al, 1997), a SREBP escort protein required for 
sterol sensing via a 5-transmembrane ‘sterol sensing domain’ (SSD) (Hua et al, 1996). 
Under conditions of saturating intracellular sterol levels, the SREBP-SCAP complex is 
retained in the ER by an interaction between the SCAP SSD-domain and the 6-
transmembrane retention factor ‘Insulin Induced Gene 1/2’ (INSIG-1/2) (Yabe et al, 
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2002; Yang et al, 2002). However, as sterol levels fall, SCAP undergoes a SSD-
dependent conformational change (Brown et al, 2002; Feramisco et al, 2005), leading 
to the dissociation of INSIG from SCAP. Unbound INSIG-1 is unstable and undergoes 
rapid proteasomal degradation, coordinated by the membrane-bound ER-ubiquitin 
ligase Gp78, the AAA ATPase p97, and the complex-forming protein, Ubxd8 (Figure 
6.2, Gong et al, 2006; Lee et al, 2006; Lee et al, 2008). The dissociation of SCAP from 
INSIG permits the free, cytosolic-loop 6 of SCAP to interact with the COPII vesicle coat 
proteins Sec23, Sec24 and Sar1 (Espenshade et al, 2002; Nohturfft et al, 2000; Sun et 
al, 2007). This interaction allows SCAP to mediate the translocation of SREBP from the 
ER to the Golgi via the COPII vesicular transport route (Sun et al, 2007). 
 
6.2.1.2  SREBP-pathway activation by insulin 
 
Historically, the circulating hormone insulin has been associated with the initiation of 
growth under nutrient rich conditions. Initial clues for an insulin involvement in the 
SREBP-pathway came following the observation that SREBP1c transcript levels were 
controlled by insulin in rat hepatocytes (Shimomura et al, 1999). Later, it was also 
shown that SREBP1c processing and nuclear relocation were elevated in the presence 
of insulin (Hegarty et al, 2005), and that insulin-dependent activation of the SREBP1c 
occurs via the growth-stimulating PI3K-Akt-mTOR pathway (Figure 6.3, Porstmann et 
al, 2009). Here, Akt phosphorylates the mTORC1-inhibitors TSC1/2, relieving the 
negative regulation on mTOR. This has two consequences; first it leads to the 
activation of mTOR-dependent protein synthesis; second it allows SREBP-pathway 
activation, probably via the initiation of ER-to-Golgi transport and SREBP-processing 
(see section 6.2.2) (Porstmann et al, 2008). Akt also regulates activated-SREBP-
stabilisation in a non-mTOR dependent manner, through the inhibitory phosphorylation 
of GSK3, a negative regulator of the SREBP pathway (Cross et al, 1995; Porstmann et 
al, 2008). Together, this activation and stabilisation of SREBP promotes the lipid 
synthesis required for membrane expansion. Therefore, between mTOR-dependent 
protein synthesis and SREBP-dependent lipid synthesis, the raw materials for cellular 
growth are provided (Figure 6.3). Such processes rely heavily on Akt, for increased 
nutrient uptake (Barthel et al, 1999; Edinger & Thompson, 2002; Porstmann et al, 
2008), and mitochondria, for the production of ATP and key metabolic substrates such 
as citrate. 
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Figure 6.2 Proteasomal degradation of INSIG. Schematic representation of INSIG regulation. Here, in the presence 
of high sterol concentrations, INSIG retains the SREBP-SCAP complex in the ER membrane. However, in the presence 
of low sterol concentrations, INSIG dissociates from the SREBP-SCAP complex, becomes poly-ubiquitinated in a Gp78-
dependent manner, and undergoes proteasomal degradation in a p97-dependent manner. This allows the translocation 
of SREBP to the nucleus and initiation of target-gene transcription. Figure adapted from Bengoechea and Ericsson 
(2007)  
 
6.2.1.3  SREBP-pathway activation by fatty acids 
 
In addition to sterol- and insulin-dependent ER-to-Golgi transport, SREBP is also 
regulated by fluctuations in intracellular fatty acid concentrations. Studies have shown 
that in the presence of elevated unsaturated fatty acids, INSIG-1 is stabilised, 
preventing the exit of SREBP1 from the ER (Lee et al, 2008). Interestingly, the 
mechanism for this stabilisation is not through the inhibition of INSIG-1 ubiquitination 
as with sterol sensing, but through the block of p97-dependent membrane extraction of 
ubiquitinated INSIG-1. Specifically, high intracellular fatty acid content prevents the 
interaction between INSIG-1 and the complex forming protein Ubxd8, allowing INSIG-
dependent retention of SREBP-SCAP to persist in the ER membrane. 
 
6.2.1.4  SREBP-pathway activation by ER stress 
 
flSREBP is also activated under conditions of ER stress, arising from the build-up of 
unfolded proteins in the ER lumen (Osborne & Espenshade, 2009). Here flSREBP 
becomes activated through the depletion of INSIG-1 in thapsigargin-induced ER–stress 
models (Lee & Ye, 2004). Thapsigargin causes ER-stress by blocking ER-dependent 
calcium buffering (Lee & Ye, 2004; Lytton et al, 1991), leading to the depletion of ER 
calcium stores, the disruption of intra-ER protein folding, and an increase in cytosolic 
calcium concentration (Lee & Ye, 2004). This build-up of unfolded proteins triggers the 
‘unfolded protein response’ (UPR), which coordinates the return of protein homeostasis 
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Figure 6.3 SREBP-pathway regulation by the PI3K-Akt-mTOR pathway. Schematic representation of the interplay 
between cellular growth and the PI3K-Akt-mTOR signaling pathway. Here, growth factors including insulin activate the 
PI3K-Akt pathway, which in turn relieves the negative inhibition of TSC1/2 on mTORC1. SREBP1 activation and 
stabilisation is coordinated by the serine/threonine kinase, Akt. Here, via the activation of mTOR, Akt stimulates 
SREBP-activation, and by the inhibition of the SREBP negative-regulator, GSK3, Akt promotes stabilisation. 
Additionally, Akt stimulates amino acid and glucose uptake, as well as stabilising HK2 for efficient glycolysis. The 
glycolysis pathway feeds into the mitochondrial TCA cycle, leading to ATP production and the anabolic synthesis of 
citrate. The availability of both energy and citrate from mitochondria is essential for SREBP-related lipid synthesis. 
Together, the PI3K-Akt-mTOR- and SREBP-pathways coordinate the synthesis of the building blocks required for 
cellular growth. Lipid synthesis abbreviations: ACLY, ATP-citrate lyase; ACC, acetyl-CoA carboxylase (also called 
ACAC); FASN, fatty acid synthase; SCD, stearoyl-CoA desaturase; MDH1, malate dehydrogenase 1; ME1, malic 
enzyme 1. Figure adapted from Porstmann et al., (2009). 
 
by activating protein-folding chaperones and increasing protein degradation. The 
protein responsible for stress mediated INSIG-depletion is the stress-transducer kinase 
PERK, a master regulator of the UPR response. Here PERK inhibits de novo protein 
translation via the inactivating phosphorylation of ‘eukaryotic translation initiation factor-
2’ (eIF2α) (Bobrovnikova-Marjon et al, 2008; Ron & Walter, 2007). These data show 
that ER-stress can promote the activation of SREBP, and hence its target genes, 
purportedly by reducing the inhibitory effects of INSIG-1. However, whether stress-
related activation of SREBP is an accidental byproduct of a general translation block, 
or a functionally relevant process, (e.g. via a direct interaction between mediators of 
the UPR and SREBP-SCAP), is as yet unknown (Osborne & Espenshade, 2009).  
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6.2.2 SREBP PROCESSING AND NUCLEAR TRANSLOCATION 
 
Regardless of the pathway stimulus, once integrated into the Golgi membrane, SREBP 
undergoes two proteolytic cleavage events via the membrane-integrated proteases, 
Site-1 Protease (S1P) and Site-2 Protease (S2P) (Figure 6.1 B, Brown & Goldstein, 
1999). Here, the serine protease, S1P cleaves the intraluminal hydrophilic loop of 
SREBP, separating the N-terminal transcriptional domain from its C-terminal regulatory 
domain and associated SCAP escort (Duncan et al, 1997; Sakai et al, 1998). This is 
closely followed by an intramembrane cleavage within the hydrophobic transmembrane 
domain by the zinc metalloprotease, S2P, releasing the N-terminus of SREBP from the 
Golgi membrane (Rawson et al, 1997; Sakai et al, 1996). Now, the mature form of 
SREBP (mSREBP) is free to undergo homodimerisation, translocation to the nucleus 
via Importin-β, and activation of its target genes (Figure 6.1 B, Nagoshi & Yoneda, 
2001). This process is dependent on SREBPs bHLH-Zip domain, and initiates the 
transcription of lipid-synthesis enzymes including 3-hydroxy-3-methylglutaryl-CoA 
synthase (HMGCS), Fatty Acid Synthase (FASN) and Acetyl CoA Carboxylase (ACAC) 
(Brown & Goldstein, 1997). Interestingly, another transcriptional target is LDLR, 
involved in the uptake of cholesterol from the bloodstream. Therefore the SREBP 
pathway can regulate cholesterol levels through both de novo synthesis and dietary 
uptake.  
 
In the nucleus, SREBP interacts with a number of cofactors, resulting in an increase in 
its transcriptional activity. These include P300-CBP (Ericsson & Edwards, 1998), 
MED15 (Yang et al, 2006a) and PGC1-β (Lin et al, 2005). Strikingly, PGC1-β is 
responsible for promoting the transcription of mitochondrial biogenesis genes, as well 
as SREBP-dependent lipid-synthesis genes, offering a link between SREBP1 and 
mitochondria. Thus, under nutrient-rich conditions, PGC1-β and SREBP may 
coordinate the synthesis of materials for membrane expansion, as well as the 
increased energy required for growth. 
 
6.2.3 REGULATION OF SREBP EXPRESSION AND TURNOVER 
 
Once in the nucleus, SREBP activity is tightly regulated on a number of levels. First, 
SREBP is its own transcriptional target, replenishing flSREBP levels in the ER 
membrane (Amemiya-Kudo et al, 2000; Sato et al, 1996). Second, INSIG-1 is also a 
target for SREBP-mediated transcription (Janowski, 2002), resulting in a concomitant 
inhibition of SREBP activation as sterol and/or fatty acid levels increase. Additionally, 
SREBP stability is regulated by the proteasome, via Skp1-Cullin-F-box (SCF)-mediated 
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proteolysis. The SCF is a multi-protein ubiquitin ligase complex, which leads to 
proteasomal degradation of target proteins often in a phosphorylation-dependent 
fashion. In the case of SREBP, a double-phosphorylation event, instigated by 
‘Glycogen Synthase Kinase 3 β’ (GSK3β) (Kim et al, 2004; Sundqvist et al, 2005), acts 
as a scaffold for the interaction of the SCF-related E3 ubiquitin ligase, ‘F-box and WD 
repeat domain containing 7’ (FBXW7) with SREBP (Sundqvist et al, 2005). Here, 
FBXW7 ubiquitinates SREBP, initiating its rapid degradation via the ubiquitin-
proteasomal system (UPS) (Figure 6.4). Importantly, DNA-binding of SREBP to target 
gene promoters stimulates its association with both GSK3β and FBXW7, hence 
upregulating SREBP turnover (Punga et al, 2006). Taken together, these data highlight 
the tight regulation of SREBP expression, stability and function at multiple points of the 
pathway. Importantly, it also highlights the need for continuous replacement of nuclear 
mSREBP in order to maintain persistent transcription of SREBP-target genes. 
 
6.2.4  SREBP-PATHWAY IN DROSOPHILA 
 
The Drosophila genome encodes orthologs of the core SREBF-pathway genes 
including one SREBF ortholog (also known as HLH106) with high homology to human 
SREBF (Seegmiller et al, 2002), SCAP, S1P and S2P (Dobrosotskaya et al, 2002). In 
contrast to mammalian SREBP, which is sensitive to both fatty acids and cholesterol, 
Drosophila SREBP is regulated by the sphingolipid pathway product, 
phosphatidylethanolamine (PE) (Dobrosotskaya et al, 2002). This is in part due to 
Drosophila lacking many of the enzymes required for cholesterol synthesis, making 
them cholesterol auxotrophs (Clark & Bloch, 1959). PE is the major phospholipid 
component of Drosophila membranes, accounting for 55% of the total composition 
(Jones et al, 1992), indicating that in Drosophila, SREBP is likely to be involved in the 
monitoring and maintenance of membrane phospholipid composition (Seegmiller et al, 
2002). The lack of cholesterol synthesis in Drosophila may explain why they possess a 
single SREBF gene rather than two SREBF genes with distinct lipid-specific targets, as 
in mammals. This additional role of SREBP-dependent cholesterol homeostasis in 
mammalian systems is suggested to be due to a genome replication event, producing 
divergent pathway functions (Seegmiller et al, 2002). The absence of sterol 
homeostatic control in Drosophila may also explain the apparent lack of an obvious 
ortholog to mammalian INSIG, as INSIG-dependent SCAP inhibition relies largely upon 
sterol sensing in the ER membrane (Rawson, 2003). However, the presence of the 
core escort factor SCAP suggests that an unidentified Drosophila-specific retention 
factor with analogous roles to INSIG may be awaiting discovery in Drosophila. It is 
currently unknown whether Drosophila SCAP is responsible for the assessment of PE 
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Figure 6.4 Proteasomal degradation of SREBP. Schematic representation of SREBP regulation. Here, following 
homodimerisation and translocation to the nucleus, mSREBP binds to target gene promoters and initiates transcription. 
Concomitantly, the protein kinase GSK3 phosphorylates SREBP in two locations, acting as a scaffold for the binding of 
the SCF-E3-ligase, FBXW7. FBXW7 promotes the polyubiquitination of SREBP, leading to its rapid turnover via the 
UPS. (Figure adapted from Bengoechea-Alonso and Ericsson, 2007).  
 
membrane composition, although here, it is likely that the SSD-domain is not restricted 
to monitoring sterol levels, but also characteristics such as lipid composition and fluidity 
(Seegmiller et al, 2002). 
 
Clues as to the global impact of SREBF in Drosophila came following analysis of null 
mutants and siRNA-treated animals. SREBF-null flies die during larval-stages 
indicating a crucial role in developmental processes. Mutant larval analysis showed a 
significant reduction in fatty acid content, with a concomitant decrease in the enzymes 
required for fatty acid synthesis. Additionally, mutant animals were much smaller than 
their heterozygous counterparts, indicating a critical role in growth (Kunte et al, 2006). 
In agreement, dSREBP siRNA-treated flies persisted to adulthood, probably due to 
residual SREBP expression, but exhibited much smaller body mass and size compared 
with control flies (Porstmann et al, 2008).  
 
6.2.5  LIPIDS AND MITOCHONDRIA 
 
Mitochondria play an important role in the anabolic synthesis of de novo fatty acids and 
cholesterol, as well as the release of energy from lipids via β-oxidation. Under 
conditions of high metabolite concentration, rather than utilising the Krebs’ cycle to 
produce units of ATP, mitochondria release citrate into the cytoplasm for conversion 
into fatty acids, triglycerides and cholesterol (Figure 6.3). At the same time, malate is 
shuttled into mitochondria, in order to shut off the enzymes involved in fatty acid 
catabolism. This process provides the building blocks required for biological membrane 
synthesis, and allows the storage of excess energy for later use. Conversely, in the 
case of reduced metabolite concentration, the energy stored in fatty acids is released 
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in the mitochondrial matrix via fatty acid β-oxidation. This process leads to the 
production of NADH and H+, which feed into the ETC, producing ATP units for the cell. 
Therefore, mitochondria are not only involved in the anabolic synthesis of lipids, but 
also fatty acid catabolism, allowing both the storage and release of energy depending 
upon cellular demands (Vamecq et al, 2012). 
 
The composition of the mitochondrial membrane is unique in that it is enriched in the 
non-bilayer forming fatty acids, cardiolipin (CL) and phosphatidylethanolamine (PE). CL 
is synthesised solely in the mitochondria, whereas approximately 50% of cellular PE 
synthesis occurs in mitochondria (van Meer & de Kroon, 2011). Importantly, the 
synthesis of CL and PE relies upon SREBP-dependent transcription of lipid-
synthesising enzymes including Fatty Acid Synthase (FASN) and Glycerol-3-phosphate 
Acyltransferase, Mitochondrial (GPAM) (Black et al, 2010; Dobrosotskaya et al, 2002), 
outlining the importance of SREBP in mitochondrial biosynthesis.  
 
6.2.6  SREBP-PATHWAY COMPONANTS IN SCREEN HIT LISTS 
 
As SREBF1 and 2, FBXW7 and GSK3A were strong hits in the final human hit group, it 
seemed appropriate to assess the performance of other SREBF-pathway genes during 
the screening process (Table 6.1). Encouragingly, a large proportion of SREBF-related 
genes produced a significant effect in the primary screen. These included the 
chaperone SCAP, two members of the COPII coat complex Sec23/24, SREBP-target 
genes FASN, ACAC and SCD; and transcriptional cofactors P300 and MED15. Whilst 
some of these genes failed to progress past the confirmation screen stage due to 
inconsistent effects, or aberrant cellular phenotypes (e.g. cell death), a small number 
proceeded to secondary screening. At this stage, many pathway genes failed to meet 
the criteria for advancement through to human cell screening, aside from SREBF1 and 
2, GSK3A and B and FBXW7, most of which went on to populate the final human hit 
table. Nevertheless, these data highlight a clear enrichment for genes involved in the 
regulation and output of the SREBP-pathway, suggesting the involvement of lipid 
homeostasis in mitochondrial quality control. 
 
 
6.3  ANALYSIS OF SREBP-PATHWAY COMPONENTS 
 
Through extensive screening, key members of the SREBP-pathway have been 
identified as altering PINK1/Parkin-mediated mitochondrial quality control. In order to 
scrutinise this cross-pathway interaction, a number of approaches have been taken, 
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Table 6.1 Screen analysis of SREBP-pathway members. Table showing the effect of SREBP-pathway genes (left) on 
mitochondrial homeostasis. Genes in bold typeface indicate final screening hits. Their performance in Drosophila and 
mammalian screens are indicated. Green cells represent screen hits, red cells represent non-hits, and grey cells 
represent situations where a protein was not tested. In the primary screen, z-sores are indicated. In the re-screen, the 
hit frequency (out of 4) is shown. In secondary screening the mitochondrial morphology phenotype is indicated. Proteins 
are grouped according to their function as indicated in the key (A-E). 
 
both biochemically and genetically. The key aims of the following experiments are to 
ascertain whether SREBP-related proteins play a direct role in the PINK1/Parkin-
pathway, perhaps aiding in the understanding of Parkinson’s disease etiology. 
 
6.3.1  PARKIN TRANSLOCATION AND MITOPHAGY 
 
Prior to low-throughput analysis, gene silencing efficiencies were confirmed for all 
siRNAs utilised in this chapter, using a qRT-PCR approach in HeLa and YFP-
Parkin.HeLa cells (Appendix, Figure 9.1).  
 
As identified in mammalian screening assays, SREBF1 and FBXW7 strongly influence 
Parkin translocation and mitophagy following CCCP toxification. In order to confirm this 
effect in a low-throughput setting, YFP-Parkin.HeLa cells were treated with control, 
PINK1, SREBF1 or FBXW7 siRNA before exposure to CCCP for 4 hours (Figure 6.5 A) 
or 24 hours (Figure 6.5 B). Without CCCP, Parkin translocation and mitophagy were 
absent in all conditions analysed. However, following 4 hours of CCCP treatment 
(Figure 6.5 A), control cells experienced almost complete translocation of YFP-Parkin 
to mitochondria. In contrast, upon PINK1 and SREBF1 silencing, translocation was 
Primary screen Re-screen
Z-score Hit score Paraquat translocation Morphology Perinuclear Aggregation Parkin translocation Mitophagy
SREBF1 -5.60 3 of 4 Fragmented
SREBF2 -5.60 3 of 4 Fragmented
SCAP -4.06 2 of 4 Fragmented
INSIG
GP78
S1P 1.10
S2P -0.92
Sec23 -5.16 4 of 4
Sec24 -4.13 1 of 4 Fused
Sar1
FBXW7 -3.98 2 of 4 Fused
GSK3A -3.77 4 of 4 Fragmented
GSK3B -3.77 4 of 4 Fragmented
FASN -4.09
ACAC -4.37 3 of 4 Fragmented
SCD -4.28 3 of 4 Fragmented
ACS 0.40
P300 -4.81
MED15 -3.38 2 of 4
PGC-1B 0.40
Eliminated: sick looking cells
Drosophila Screening Mammalian Screening
No known Drosophila ortholog
Plate 23 - equipment crash (re-screened but not a hit)
Secondary screen HeLa cells
Eliminated: odd looking cells
No known Drosophila ortholog
A 
B 
C 
D 
E 
A.  Main pathway components 
B.  COPII vesicle adaptors (interact with SCAP) 
C.  SREBP degradation pathway 
D.  SREBP target genes 
E.  SREBP co-activators (important for SREBP-dependent transcription) 
Not tested 
Non-hit 
Hit 
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Figure 6.6 High throughput quantification of Parkin translocation and mitophagy following CCCP toxification. 
Graphical representation of average Parkin translocation (A) and mitophagy (B) scores following 10 µM CCCP 
treatment for 4 hours (A) or 24 hours (B). Data represent control, PINK1, SREBF1, FBXW7 and GSK3A siRNA-treated 
YFP-Parkin.HeLa cells from three rounds of screening. Error bars denote the standard deviation. *** P<0.001 (One-way 
ANOVA with Bonferroni’s correction, compared to control siRNA unless otherwise indicated). 
 
largely absent, and upon FBXW7 silencing, translocation was greatly reduced, with 
some cells displaying partial Parkin translocation phenotypes. 
 
When CCCP-treatment was extended to 24 hours (Figure 6.5 B), a substantial 
proportion of control cells experienced a significant reduction or complete loss of the 
mitochondrial marker, ATP5A. This loss was attributed to the degradation of 
mitochondria via the mitophagy pathway, in agreement with published data (Narendra 
et al, 2008). However, upon the silencing of PINK1, SREBF1 and FBXW7, the 
observed reduction in ATP5A signal was blocked. 
 
Both Parkin translocation (Figure 6.5 A) and mitophagy (Figure 6.5 B) qualitative data 
are in agreement with the average quantitative high-throughput results obtained during 
Parkin translocation (Figure 6.6 A) and mitophagy (Figure 6.6 B) mammalian 
screening. Together, these data confirm that SREBF1 and FBXW7 are able to 
phenocopy PINK1 with regards to Parkin translocation and mitophagy in cell culture. 
 
6.3.2  ASSESSING PINK1 TRANSCRIPT LEVELS 
 
As CCCP-induced Parkin translocation and mitophagy require PINK1 stabilisation on 
the MOM, any alteration in PINK1 expression levels may potentially alter the efficiency 
of both events. In an attempt to understand the mechanism with which SREBF1 and 
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FBXW7 influence Parkin translocation and mitophagy, the effect of SREBF1 and 
FBXW7 siRNA on PINK1 transcript levels was assessed (Figure 6.7). Here, if SREBF1 
and FBXW7 silencing cause a concomitant downregulation of PINK1 expression, the 
likely explanation for the observed block on PINK1/Parkin-pathway processes would be 
due to a lack of PINK1. However upon quantification of PINK1 mRNA levels using a 
qRT-PCR approach, no significant differences between PINK1 expression in control, 
SREBF1 or FBXW7 siRNA samples were found. However, PINK1 siRNA-treated 
samples produced a significant decrease in transcript levels, validating the assay. 
These data confirm that SREBF1 and FBXW7 have no discernable effects on PINK1 
expression under basal conditions. 
 
6.3.3  CHEMICAL INHIBITION OF THE SREBP-PATHWAY 
 
In order to assess the specificity of SREBF1 siRNA, a chemical inhibitor of the SREBP-
pathway was employed. Genistein, a soy isoflavone, inhibits SREBP1 cleavage by 
causing the down-regulation of the activating protease, S1P. The resulting inhibition of 
SREBP1 activation leads to a significant decrease in the expression of SREBP1-target 
genes including FASN and ACAC (Shin et al, 2007). Using this approach, Parkin 
translocation was assessed following the application of vehicle or a range of genistein 
concentrations, from 10 – 100 µM (Figure 6.8). In the absence of toxification, genistein-
treated cells exhibit comparable Parkin phenotypes to vehicle treated samples, 
maintaining a diffuse, cytoplasmic distribution (Figure 6.8 A - D). Following toxification 
with CCCP for 4 hours, vehicle-treated cells saw a robust initiation of Parkin 
translocation (Figure 6.8 E). However, in combination with genistein treatment, the 
observed Parkin translocation is reduced, seemingly in a dose-dependent manner 
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Figure 6.7 qRT-PCR analysis of PINK1 gene 
expression following siRNA treatment. HeLa 
cells were exposed to 25 nM of control, SREBF1, 
FBXW7 or PINK1 siRNA for 4 days. PINK1 
expression levels were analysed using qRT-PCR 
against the housekeeping gene RNA18S5. Graph 
represents the mean of 3 biological repeats. Error 
bars represent the standard error. ***P<0.0001 
(Student’s T-test, compared to control siRNA-
treated samples). 
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Figure 6.8 Chemical inhibition of the SREBP-pathway following Genistein treatment. YFP-Parkin.HeLa cells 
treated with either vehicle (A & E) or genistein (B – D, F - H) over a range of concentrations - 10 µM (B & F), 50 µM (C & 
G) and 100 µM (D & H), for 24 hours prior to the application of vehicle (A - D) or 10 µM CCCP (E – H) for 4 hours. 
Parkin translocation (YFP-Parkin – green) was assessed qualitatively by fluorescence confocal microscopy (60x 
objective, 2x digital zoom, scale bar: 10 µm). 
 
(Figure 6.8 F - H). These data demonstrate a similar Parkin translocation blockage 
phenotype as observed with SREBF1 silencing, hence demonstrating the specificity of 
the SREBF1 siRNA effect. 
 
6.3.4  ASSESSING STARVATION-INDUCED BULK AUTOPHAGY 
 
Autophagy is the bulk degradation of large cellular components including mitochondria 
and ER, via the lysosomal pathway. Here, cargo becomes engulfed in a double 
membrane autophagic vesicle, known as the autophagosome, before fusing with the 
lysosomal compartment for hydrolytic degradation. There are a number of well-defined 
steps involved this process, comprising the initiation, elongation and maturation of the 
autophagosome; autophagosome-lysosome fusion; and content degradation (Tanida, 
2011).  
 
In an attempt to understand the interaction between PINK1/Parkin-mediated mitophagy 
and members of the SREBP-pathway, SREBF1 and FBXW7 were assessed for their 
influence on general autophagy (Figure 6.9). This approach aimed to ascertain whether 
the loss of these proteins via siRNA-gene silencing caused a general block of 
autophagy downstream of mitophagy initiation.  
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Figure 6.9 Starvation-induced autophagy. (A & B) Following control, SREBF1 (A) or FBXW7 (B) silencing, HeLa cells 
were subjected to 2 hours of control (U – untreated), starvation (S), 20 nM bafilomycin (B) or starvation with 20 nM 
bafilomycin (S&B) treatment. LC3 lipidation (shift from LC3-I to LC3-II) was assessed by western blot, Actin is used as a 
loading control. (C & D) Quantification of LC3 lipidation performed following control and SREBF1 (C) or FBXW7 (D) 
silencing. LC3 lipidation is assessed as LC3-II / total LC3 levels. Graphs represent the average of 3 assays, error bars 
represent standard error. Quantification was achieved using the ImageJ ‘Gel’ plugin. Student’s T-test analysis of 
equivalent conditions found no significance (ns). 
 
The SREBP-pathway has known links to autophagy, with SREBF2 being involved in 
starvation-induced lipid autophagy (termed lipophagy) (Seo et al, 2011), and Gp78 
being involved in Parkin-independent mitophagy (Fu et al, 2013). In addition, the 
central role of the SREBP-pathway is to produce lipids required for membrane 
synthesis. In relation to autophagy, autophagosomes are double-membrane vesicular 
compartments, whose membrane is suggested to issue from organelle donors such as 
the ER and mitochondria (Tooze & Yoshimori, 2010). Therefore, it is conceivable that 
the absence of SREBF1-dependent membrane synthesis may cause a parallel 
reduction in autophagosome synthesis. The putative knock-on effect in the context of 
PINK1/Parkin-mediated mitophagy is a simultaneous block on mitochondrial 
degradation via this route. As CCCP-induced mitophagy is blocked following the loss of 
SREBF1 and FBXW7, this may explain the observed effects. 
 
To test the involvement of the SREBP-pathway in general autophagy, HeLa cells were 
subjected to starvation conditions for 2 hours (Figure 6.9 A & B). Here, nutrient 
depletion stimulates the cell to release stored energy and amino acids through the non-
specific autophagic degradation of the cytoplasm and its contents (Mizushima, 2007). 
To assess the degree of starvation-induced autophagy, ‘starved’ samples were 
compared to non-starved or ‘untreated’ samples. Additionally, the degree of 
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‘autophagic flux’ within the system was analysed through the addition of the autophagy 
inhibitor, bafilomycin A1. Here, bafilomycin A1; a lysosomal proton pump inhibitor, 
causes an increase in lysosomal pH, hence preventing autophagosomal fusion with- 
and proteolytic degradation by the lysosome.  
 
In order to monitor the amount of autophagy, the ubiquitin-like protein and 
autophagosomal marker, LC3 was examined by western blot. In the absence of 
autophagy, LC3-I is inactive, soluble and cytoplasmic. However, following autophagy 
initiation, LC3-I undergoes PE-dependent lipidation, by the E1- and E2-like enzymes 
ATG7 and ATG3 respectively. This lipidation event produces an active, insoluble, 
membrane-associated form of LC3, known as LC3-II (Tanida et al, 2004). LC3-II is a 
major component of the autophagosome membrane, typically used as readout for the 
amount of autophagy occurring within a system (Klionsky et al, 2012). Interestingly PE 
levels are influenced by SREBP-dependent fatty acid synthesis (Dobrosotskaya et al, 
2002), further implicating the SREBP-pathway in this process. 
 
Biochemical analysis of LC3 reveals one protein band of ~16 kDa, representing LC3-I, 
and an additional protein band of ~14 kDa, representing LC3-II (Figure 6.9 A & B). 
Following the application of control siRNA, untreated samples (U) exhibit a greater 
proportion of LC3-I compared to LC3-II (Figure 6.9 A & B). However, following 
starvation (S), the ratio shifts in favour of LC3-II, signifying the initiation of autophagy.  
 
Of note, under starvation conditions, the total levels of LC3 are diminished compared to 
untreated samples. This is likely due to the autophagic degradation of LC3-II on the 
intra-autophagosomal surface by lysosomal cathepsins (Tanida, 2011); an occurrence 
that represents ‘autophagic flux’. To assess the degree of autophagic flux, bafilomycin 
A1 can be employed. In this situation, the autophagy pathway continues to produce 
autophagosomes, but their lysosomal degradation is inhibited, leading to an 
autophagosomal build-up. Under basal conditions in control siRNA-treated cells, the 
application of bafilomycin A1 alone (B) leads to a significant increase in the amount of 
LC3-II, but has little effect on the amount of LC3-I (Figure 6.9 A & B). However, under 
starvation conditions, the simultaneous application of bafilomycin A1 (S&B) causes the 
ratio of LC3-I to LC3-II to shift dramatically in favour of autophagosome-associated 
LC3-II.  
 
Together, these data demonstrate first that starvation stimulates autophagy (U:S and 
B:S&B), and second, that there is a small amount of flux in the system (U:B and 
S:S&B). In order to quantify this effect, the amount of LC3-II was compared to the total 
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LC3 levels (LC3-I + LC3-II) (Figure 6.9 C & D, Klionsky et al, 2012). This calculation 
reflected the biochemical data whereby an increase in the proportion of LC3-II (and 
therefore autophagy) was observed following starvation, and low levels of autophagic 
flux were detected with the addition of bafilomycin A1.  
 
When comparing control siRNA-treated samples (Figure 6.9 A - D), with SREBF1 
siRNA (Figure 6.9 A & C), and FBXW7 siRNA (Figure 6.9 B & D) treated samples, no 
significant difference is observed under any conditions. These data indicate that the 
silencing of SREBF1 and FBXW7 has no detectable influence of the initiation of 
general autophagy after 2 hours of starvation. This result would suggest that SREBF1 
and FBXW7 are acting in a CCCP-induced mitophagy-specific fashion. 
 
6.3.5 MITOCHONDRIAL MEMBRANE POTENTIAL ANALYSIS 
 
Another possible explanation for the observed Parkin translocation and subsequent 
mitophagy block following SREBF1 and FBXW7 silencing is via the reversal of the 
mitochondrial transmembrane complex, ATP-synthase. ATP-synthase utilises the MIM 
proton gradient to drive the production of ATP, as H+ ions flow from the IMS to the 
matrix though its Fo proton pore. This proton flow catalyses the phosphorylation of ADP 
to ATP in an ATP-synthase dependent manner. However, ATP-synthase can also 
function in reverse, by hydrolysing ATP in order to pump H+ ions out of the matrix and 
into the IMS. Through this, ATP-synthase has the ability to repolarise the ∆Ψm when 
the proton-motive force is reduced. Whether ATP-synthase acts to synthesise or 
hydrolyse ATP depends on the energy requirements of the cell and steepness of the 
proton gradient across the MIM (Alberts et al, 1994). 
 
In the case of SREBF1 and FBXW7, if their silencing leads to a reversal of ATP-
synthase, PINK1 is unlikely to become stabilised on the MOM even in the presence of 
CCCP, leading to a loss of Parkin translocation and mitophagy. In support of this event, 
a recent genome-wide RNAi screen reported that the loss of ATPase inhibitory factor 1 
(ATPIF1) blocked Parkin translocation following CCCP-treatment due to ATP-Synthase 
reversal and subsequent maintenance of ∆Ψm (Lefebvre et al, 2013). In order to 
assess whether ATP-synthase reversal is occurring under these conditions, the ∆Ψm 
was assessed using the mitochondrial membrane potential indicator dye, 
tetramethylrhodamine methyl ester (TMRM). TMRM is a lipophilic, cationic dye that 
easily traverses biological membranes, and accumulates in the most negatively 
charged compartments within the cell - primarily mitochondria (Scaduto & Grotyohann, 
1999). Hyperpolarised mitochondria with a negatively charged matrix accumulate more 
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Figure 6.10 Mitochondrial membrane potential analysis. HeLa cells were treated with control or PINK1 siRNA (A & 
B), SREBF1 siRNA (A), FBXW7 siRNA (B) or a combination of PINK1 & SREBF1 siRNA (A) or PINK1 & FBXW7 siRNA 
(B) for 2 days before the addition of either vehicle or 10 µM CCCP for 1 hour as indicated. ∆Ψm was assessed by the 
application of the potentiometric dye, TMRM (50 nM) for 30 minutes. Cells were washed with either vehicle or 10 µM 
CCCP-containing assay buffer before fluorescence quantification by a microplate reader, providing the output as relative 
fluorescence units (RFU). TMRM fluorescence was normalised to cell number through the application of the DNA-
binding dye, CyQuant for 1 hour. Nuclear count was assessed using a microplate reader. Data represent four biological 
repeats; error bars denote the standard error. Student’s t-test was performed between vehicle and CCCP-treated pairs, 
***P<0.001. One-way ANOVA with Bonferroni’s correction was applied across vehicle-treated and CCCP-treated 
groups, and compared to control siRNA-treated samples. No significance (ns) was found within any of the groups. 
 
TMRM dye than hypopolarised mitochondria, producing bright red/orange 
fluorescence. 
 
To test whether SREBF1 and FBXW7 loss leads to the maintenance of the ∆Ψm, HeLa 
cells were exposed to SREBF1 and FBXW7 siRNA, before the application of either 
vehicle or CCCP for 1 hour. Following this, cells were bathed in TMRM-containing 
buffer before further washes in either vehicle or CCCP-containing buffer. TMRM 
fluorescence was determined using a microplate reader, and normalised to cell number 
(Figure 6.10).  
 
SREBF1 and FBXW7 siRNA-treated samples were compared to control and PINK1 
siRNA-treated samples, as well as a double knockdown situation, where PINK1 was 
silenced in combination with ether SREBF1 or FBXW7. As expected, control siRNA-
treated samples showed intense TMRM fluorescence following vehicle treatment, with 
a robust fall in fluorescence after the application of the ∆Ψm uncoupler, CCCP (Figure 
6.10 A & B). When comparing control siRNA treated cells to those treated with PINK1 
(Figure 6.10 A & B), SREBF1 (Figure 6.10 A), FBXW7 (Figure 6.10 B) or a combination 
1.00 
0.90 
0.96 
0.94 
0.20 
0.16 0.18 0.15 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Control PINK1 SREBP1 PINK1 & 
SREBP1 
R
FU
 (n
or
m
al
is
ed
 to
 c
el
l n
um
be
r) 
Vehicle 
CCCP 
siRNA 
1.00 
0.90 
0.96 
0.94 
0.20 
0.16 0.18 0.15 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Control PINK1 SREBP1 PINK1 & 
SREBP1 
R
FU
 (n
or
m
al
is
ed
 to
 c
el
l n
um
be
r) 
Vehicle 
CCCP 
1.00 
0.90 
0.96 
0.94 
0.20 
0.16 0.18 0.15 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Control PINK1 SREBP1 PINK1 & 
SREBP1 
R
FU
 (n
or
m
al
is
ed
 to
 c
el
l n
um
be
r) 
Vehicle 
CCCP 
1.00 
1.06 
1.00 
1.06 
0.23 0.23 0.22 0.22 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Control PINK1 FBXW7 PINK1 & 
FBXW7 
R
FU
 (n
or
m
al
is
ed
 to
 c
el
l n
um
be
r)
 
Vehicle 
CCCP 
1.00 
0.90 
0.96 
0.94 
0.20 
0.16 0.18 0.15 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Control PINK1 SREBP1 PINK1 & 
SREBP1 
R
FU
 (n
or
m
al
is
ed
 to
 c
el
l n
um
be
r) 
Vehicle 
CCCP 
*** 
*** *** *** 
ns 
ontrol PI  S F1 PI 1 & 
SREBF1 
1.00 
1.06 
1.00 
1.06 
0.23 0.23 0.22 0.22 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Control PINK1 FBXW7 PINK1 & 
FBXW7 
R
FU
 (n
or
m
al
is
ed
 to
 c
el
l n
um
be
r) 
Vehicle 
CCCP 
siRNA 
*** *** *** *** 
ns 
trol PI  FB 7 PI  & 
FBXW7 
A B 
 214 
(Figure 6.10 A & B) of siRNAs, no significant difference was observed. These data 
indicate that SREBF1 and FBXW7 silencing does not block Parkin translocation and 
mitophagy through the maintenance of the ∆Ψm. 
 
Of note, in contrast to the residual TMRM staining observed here after CCCP treatment 
(~20%), preparation of isolated rat heart mitochondria treated with CCCP results in the 
complete loss of TMRM staining (Scaduto & Grotyohann, 1999). One possible reason 
for the observed ‘background’ TMRM fluorescence is the ∆Ψm-independent binding of 
TMRM to mitochondria in this assay, albeit at low levels (Perry et al, 2011). 
Alternatively, despite CCCP-induced loss of TMRM from the mitochondrial matrix, the 
dye may still remain trapped in the cytosol, perhaps accounting for some low 
background fluorescence. Despite this residual staining, the outcome of the assay 
remains clear, and the overall conclusions unaffected. 
 
6.3.6  PARKIN TRANSLOCATION RESCUE WITH LIPIDS 
 
To assess whether the block on Parkin translocation following SREBF1 siRNA is a 
consequence of a decrease in SREBP-induced lipid synthesis, Parkin translocation 
was assessed following the application of cholesterol, fatty acids or a combination of 
the two (Figure 6.11). Here, YFP-Parkin.HeLa cells were exposed to control or 
SREBF1 siRNA before being ‘primed’ for 24 hours with vehicle- (Figure 6.11 A - D), 
cholesterol- (Figure 6.11 E, I & J - high concentrations, Figure 6.11 F, K & L, low 
concentrations) or fatty acid- (Figure 6.11 F, K & L - high concentration, Figure 6.12 G, 
J & L - low concentration) containing media. In the absence of fatty acids and 
cholesterol, control siRNA-treated cells exhibited a lack of Parkin translocation in the 
absence of CCCP (Figure 6.11 A), and a robust translocation phenotype following 4 
hours of CCCP treatment (Figure 6.11 B). As previously demonstrated, SREBF1 
siRNA results in a lack of Parkin translocation in the absence of CCCP (Figure 6.11 C), 
and a substantial reduction following 4 hours of CCCP (Figure 6.11 D). However, 
following the addition of fatty acids and/or cholesterol, a partial restoration of Parkin 
translocation was observed in most cases (Figure 6.11 E - L). This effect was 
quantified manually, demonstrating a general trend in all conditions towards increased 
Parkin translocation, with four of these conditions reaching significance (Figure 6.11 
M). Importantly, the application of exogenous fatty acids and cholesterol had no effect 
on Parkin translocation in non-toxified control and SREBF1 siRNA samples (Appendix, 
Figure 9.2 A), consistent with the absence of general toxicity. Additionally, no effect of 
fatty acid and cholesterol application was observed in CCCP-treated control siRNA 
samples, demonstrating the specificity of the rescue (Appendix, Figure 9.2 B). 
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Figure 6.11 Rescuing SREBP1-dependent Parkin translocation with fatty acids and cholesterol. YFP-
Parkin.HeLa cells were treated with control or SREBF1 siRNA for 4 days before the addition of either vehicle (A - D), 
cholesterol (E & F), fatty acids (G & H) or a combination of cholesterol and fatty acids (I-L) for 24 hours. Samples were 
then treated with either vehicle (A & C) or 10 µM CCCP (B, D, E - L) for 4 hours. Parkin translocation (YFP-Parkin – 
green) was assessed qualitatively (A - L) by fluorescence confocal microscopy (60x objective, 2x digital zoom, scale 
bar: 10 µm) and quantitatively as the percentage of cells with Parkin translocation (M). (M) Graphical representation of 
Parkin translocation quantification following the application of conditions A - L. Data represent 3 biological repeats, each 
with 5 FOV per condition, per assay. Error bars represent standard error. **P<0.01, *P<0.05 (one-way ANOVA with 
Bonferroni’s correction, compared to SREBF1 siRNA, 4h CCCP). FA - fatty acids; Chol – cholesterol. High – high 
concentration; Low – low concentration. 
 
Interestingly, both cholesterol and fatty acids were able to overcome the SREBF1-
dependent block on Parkin translocation, indicating a potential role for both lipid groups 
in mitophagy initiation. Seemingly higher concentrations of cholesterol and lower 
concentrations of fatty acids were required for a significant rescue of Parkin 
translocation. Additionally, some combinations of fatty acids and cholesterol together 
produced a significant translocation recue, which relied upon the presence of high 
cholesterol levels. Taken together, these data suggest that SREBP-dependent lipid 
synthesis is key to Parkin translocation, rather than an alternative pathway output.  
  
The next step was to assess whether the application of fatty acids and/or cholesterol 
was able to overcome PINK1 siRNA-dependent inhibition of Parkin translocation. For 
this, three of the strongest translocation rescue conditions from the previous assay 
were employed, together with an additional condition, combining low fatty acid 
concentrations with ‘very high’ cholesterol concentrations. Here, control siRNA 
samples behaved as in Figure 6.11 (Figure 6.12 A, E & I). Following PINK1 siRNA 
treatment, almost a complete lack of Parkin translocation was observed in vehicle- 
(Figure 6.12 C & I) and CCCP-treated (Figure 6.12 D & I) conditions. However, under 
these conditions, the application of cholesterol and/or fatty acids prior to toxification 
produced no rescue of the Parkin translocation block (Figure 6.12 E - I). These data 
show that PINK1 siRNA phenotypes are not rescued by the application of SREBP-
related lipids, at least at the concentrations tested. Hence this suggests that SREBP1-
dependent lipid production acts upstream of PINK1 in the PINK1/Parkin-pathway.  
 
As discussed, mitochondria exhibit a distinct lipid profile, with the majority of the 
membrane comprising the non-bilayer forming lipids cardiolipin (CL) and 
phosphatidylethanolamine (PE). As SREBF1 siRNA leads to a block of mitophagy, the 
next logical step was to test whether exogenous application of these mitochondrial 
lipids could rescue Parkin translocation (Figure 6.13). Here, following control (Figure 
6.13 A – E) or SREBF1 (Figure 6.13 F – J) siRNA application, YFP-Parkin.HeLa cells
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Figure 6.12 Rescuing PINK1-dependent Parkin translocation with fatty acids and cholesterol. YFP-Parkin.HeLa 
cells were treated with control or PINK1 siRNA for 4 days before the addition of either vehicle (A - D), cholesterol (E), 
fatty acids (F) or a combination of cholesterol and fatty acids (G & H) for 24 hours. Samples were then treated with 
either vehicle (A & C) or 10 µM CCCP (B, D, E - H) for 4 hours. Parkin translocation (YFP-Parkin – green) was 
assessed qualitatively (A - H) by fluorescence confocal microscopy (60x objective, 2x digital zoom, scale bar: 10 µm) 
and quantitatively as the percentage of cells with Parkin translocation (I). (I) Graphical representation of Parkin 
translocation quantification following the application of conditions A - H. Data represent 1 biological repeat with 5 FOV 
per condition. FA - fatty acids; Chol – cholesterol. High – high concentration; Low – low concentration; V.High – very 
high concentration. 
 
were primed with vehicle (Figure 6.13 A, C, F & H), cardiolipin (Figure 6.13 B & G), PE 
(Figure 6.13 D & I) or a combination of cardiolipin and PE (Figure 6.13 E & J) for 24 
hours. Following this, cells were treated with either vehicle or CCCP for 4 hours, as
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Figure 6.13 Rescuing SREBP1-dependent Parkin translocation with cardiolipin and PE. YFP-Parkin.HeLa cells 
were treated with control or SREBF1 siRNA for 4 days before the addition of either vehicle (A, F, C & H), cardiolipin (B 
& G), PE (D & I) or a combination of cardiolipin and PE (E & J) for 24 hours. Samples were then treated with either 
vehicle or 10 µM CCCP for 4 hours as indicated. Parkin translocation (YFP-Parkin – green) was assessed qualitatively 
by fluorescence confocal microscopy (60x objective, 2x digital zoom, scale bar: 10 µm). 
 
indicated. As shown previously, control siRNA-treated cells primed with ‘vehicle’ 
displayed no Parkin translocation in the absence of toxification, and a strong Parkin 
translocation phenotype upon CCCP application (Figure 6.13 A & C); as seen upon the 
application of cardiolipin (Figure 6.13 B) or PE (Figure 6.13 D).  
 
As before, SREBF1 siRNA showed a lack of Parkin translocation both in the absence 
and presence of CCCP toxification (Figure 6.13 F & H). However, following the 
exogenous application of cardiolipin (Figure 6.13 G), PE (Figure 6.13 I), or cardiolipin 
and PE (Figure 6.13 J), the inhibition of Parkin translocation persisted both with and 
without CCCP. These data indicate that at these concentrations, Parkin translocation is 
not rescued by exogenous application of cardiolipin or PE.  
 
Interestingly in control samples, following the application of cardiolipin and PE together, 
non-toxified cells exhibited a partial translocation phenotype (Figure 6.13 E ‘0h 
CCCP’). In contrast, the same condition failed to induce translocation after SREBF1 
siRNA treatment (Figure 6.13 J, ‘0h CCCP’). The reason for this is currently unknown. 
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However, perhaps under control conditions, the observed Parkin translocation is 
triggered by increased toxicity caused by the combined presence of both lipids - an 
event that requires SREBF1. Alternatively, the combined treatment of CL and PE may 
alter the composition and behaviour of the mitochondrial membrane, perhaps 
preventing the mitochondrial import of PINK1. Here, full-length PINK1 stabilisation on 
the MOM would prompt Parkin to translocate even in the absence of CCCP. However, 
due to time constraints, this hypothesis remains to be tested. 
 
In addition, following SREBF1 silencing, PE, or the combined treatment of cardiolipin 
and PE caused a redistribution of Parkin to the nucleus after CCCP treatment (Figure 
6.13 I & J, ‘4h CCCP’). This observation suggests that excess PE results in a CCCP-
dependent redistribution of Parkin to the nucleus only in the absence of SREBP1. 
Currently, this observation cannot be adequately explained. However, it may be that in 
the absence of SREBP1, the combination of PE and CCCP stimulates the 
redistribution of Parkin to the nucleus for the degradation of Parkin target proteins. 
Indeed, following DNA damage, Parkin has previously been shown to translocate to the 
nucleus and promote DNA repair (Kao, 2009), setting a precedence for nuclear 
localisation under certain stress conditions. 
 
6.3.7 PINK1 STABILISATION FOLLOWING CCCP 
 
As mentioned, recent studies have shown that PINK1 is stabilised on the outer 
membrane of damaged mitochondria in a ∆Ψm-dependent manner, leading to the 
translocation of Parkin from the cytoplasm (Matsuda et al, 2010; Narendra et al, 2010). 
Under basal conditions, healthy mitochondria exert a hyperpolarised membrane, 
leading to the import of full-length PINK1 through the translocase complexes TOM and 
TIM23. At the MIM, PINK1 undergoes rapid cleavage by MPP (Greene et al, 2012; Jin 
et al, 2010) and PARL (Deas et al, 2011; Jin et al, 2010) and subsequent release into 
the cytosol for proteasomal degradation by the N-end rule pathway (Yamano & Youle, 
2013). However, in the event of reduced ∆Ψm, such as following CCCP treatment, full-
length PINK1 is no longer imported into the mitochondria. Instead, it decorates the 
MOM, promoting the relocation of Parkin to the mitochondria, activation of latent Parkin 
E3-ligase activity, ubiquitination of mitochondrial Parkin substrates, and the removal of 
damaged mitochondria via mitophagy (Matsuda et al, 2010; Narendra et al, 2008; 
Narendra et al, 2010). If PINK1 fails to stabilise on the MOM, even in the presence of 
CCCP Parkin no longer receives the signal to undergo translocation, hence blocking 
PINK1/Parkin-mediated mitophagy (Matsuda et al, 2010; Narendra et al, 2010).  
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To further our understanding of the influence of SREBF1 and FBXW7 on the 
PINK1/Parkin-pathway, PINK1 redistribution to mitochondria following CCCP was 
analysed (Figure 6.14). Here, HeLa cells were treated with control, FBXW7 or SREBF1 
siRNA, prior to transient transfection of PINK1-GFP. Following this, cells were 
subjected to vehicle- (Figure 6.14 A) or CCCP-treatment (Figure 6.14 B) for 1 hour. 
The co-localisation of PINK1-GFP with the mitochondrial marker, ATP5A was 
assessed via fluorescence microscopy (Figure 6.14 A & B), and manually quantified as 
the percentage of cells exhibiting no-, partial- or complete colocalisation of PINK1-GFP 
with ATP5A (Figure 6.14 C). 
 
In the absence of toxification, control siRNA-treated cells exhibited a diffuse, 
cytoplasmic PINK1-GFP distribution, with almost no mitochondrial colocalisation 
(Figure 6.14 A). However, following CCCP toxification, the majority of control cells 
displayed almost complete PINK1-GFP colocalisation with ATP5A (Figure 6.14 B). 
FBXW7 siRNA mirrored the data obtained with control siRNA application. However, 
where SREBF1 siRNA treatment produces a comparable PINK1-GFP distribution in 
the absence of CCCP (Figure 6.14 A), following CCCP treatment, a partial block on 
PINK1-GFP colocalisation with ATP5A is observed, with many more cells displaying 
either ‘no colocalisation’ or a ‘partial colocalisation’ phenotype (Figure 6.14 B). 
 
These data infer that whilst FBXW7 appears to have no influence upon the stabilisation 
of PINK1 following CCCP application, SREBF1 silencing causes a partial block of 
PINK1 stabilisation. This partial block may be due to changes in the lipid composition 
of the mitochondrial membrane, causing alterations in characteristics such as 
membrane fluidity and thickness. Such events may reduce the efficiency with which 
PINK1 associates with- and remains held upon- the MOM. In this respect, it may be 
interesting to assess if basal PINK1 is able to undergo mitochondrial import and 
cleavage following SREBF1 silencing, or whether this manipulation prevents a general 
association between PINK1 and mitochondria.  
  
Nevertheless, this assay suggests that SREBF1 is acting upstream, and FBXW7 is 
acting downstream, of PINK1 stabilisation in the PINK1/Parkin-pathway. However, 
whether the SREBF1-dependent partial block of PINK1 stabilisation is sufficient to 
cause the robust block on Parkin translocation, is yet to be determined. For example, it 
may be that SREBF1 plays a more complex, dual role in the PINK1/Parkin-pathway. 
This question could be tackled in part by overexpressing a non-cleavable form of full-
length PINK1 in combination with SREBF1 siRNA. Here, if Parkin translocation 
continues to be reduced, it would indicate that SREBF1 also has a part to play
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Figure 6.14 PINK1 redistribution following CCCP treatment. HeLa cells were treated with control, FBXW7 or 
SREBF1 siRNA for 3 days before the transient transfection of PINK1-GFP (green) for 16 hours. Cells were subjected to 
either vehicle (A) or 10 µM CCCP (B) for 1 hour, before being assessed for PINK1-GFP colocalisation with the 
mitochondrial network (ATP5A – red) by fluorescence confocal microscopy (60x objective, 2x digital zoom, scale bar: 10 
µm). Confocal microscopy data were analysed manually as the percentage of cells with no PINK1-GFP colocalisation, 
partial PINK1-GFP colocalisation or complete PINK1-GFP colocalisation with ATP5A (C). Graphical data represent 3 
biological repeats, each with 10 FOV per condition, per assay. Error bars represent standard deviation. * P<0.05, 
**P<0.01 (one-way ANOVA with Bonferroni’s correction, compared with the equivalent control siRNA conditions). 
 
downstream of PINK1 stabilisation. Additionally, it would be interesting to establish 
whether the SREBF1-dependent reduction in PINK1 stabilisation can be rescued by 
adding fatty acids and cholesterol back into the system as observed with Parkin 
translocation (section 6.3.6). 
 
 222 
6.3.8  ANALYSIS OF SREBP1 PROTEIN LEVELS 
 
In order to gain a more complete picture of the interaction between the PINK1/Parkin-
pathway and SREBP-pathway, SREBP1 protein levels were assessed using western 
blot, in the presence of control, PINK1 or parkin siRNA (Figure 6.15 A). In the control 
situation, a CCCP time-course between 0 – 6 hours resulted in the gradual decrease of 
flSREBP1 (Figure 6.15 A & B), suggesting the possibility of induced SREBP1 
activation. One explanation for this proposed activation is that CCCP is known to cause 
both mitochondrial and ER-related stress (Bouman et al, 2011). Under these 
conditions, the ER unfolded protein response (UPR) is triggered, an event known to 
cause PERK-activation and a consequent decrease in the translation of INSIG-1. In the 
absence of INSIG, the SREBP-SCAP complex is no longer retained in the ER, and 
may undergo ER-to-Golgi translocation and activation.  
 
Upon PINK1 silencing, the same gradual decrease in flSREBP1 protein levels was 
observed. However, in contrast, silencing of parkin prevented this CCCP-dependent 
decrease in flSREBP1 levels, leading to a slight, but variable increase in flSREBP1 
over time. Why parkin siRNA leads to a block of this process is currently unknown. It 
could be that in the event of ER-stress, Parkin is somehow required for flSREBP1 exit 
from the ER, or in mediating the branch of the UPR responsible for flSREBP1 
activation. This theory has some support from the recent observation that Parkin 
expression is upregulated by the UPR following ER stress. Here, Parkin expression is 
activated by ATF4, a transcription factor downstream of PERK, which leads to a 
reduction in ER-stress-induced apoptosis (Bouman et al, 2011). Perhaps interaction 
analyses using an immunoprecipitation approach between Parkin, SREBP and its 
pathway interactors would go some way to elucidate the relationship between these 
proteins following CCCP treatment.  
 
In order to understand fully the way with which CCCP and the PINK1/Parkin-pathway 
regulates SREBP1 protein levels, both isoforms of SREBP1 must be assessed. The 
SREBP1 antibody used in figure 6.15 is raised against an epitope able to detect both 
flSREBP1 (125 kDa) and mSREBP1 (68 kDa) (Appendix, Figure 9.3 A). However, 
despite this, the detection of mSREBP1 in this assay remained elusive (Appendix, 
Figure 9.3 B). These data indicate that either the antibody is unable to recognise 
mSREBP1, suggesting specificity issues, or that mSREBP1 was absent from the 
protein preparations. 
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Figure 6.15 SREBP1 protein analysis following CCCP treatment. YFP-Parkin.HeLa cells were treated with control, 
PINK1 or parkin siRNA for 4 days before being subjected to 0, 2, 4, or 6 hours of 10 µM CCCP. Full length SREBP1 
(flSREBP1) protein levels (125 kDa) were assessed via western blot using anti-SREBP1 (2A4) antibody (Santa Cruz) 
(A). Average protein levels from 4 biological repeats were analysed using the ImageJ plugin, ‘Gels,’ (B). In each case, 
the relative protein levels were normalised to the tubulin loading control, and then ‘0 hours CCCP’ for each siRNA 
condition. Error bars represent the standard deviation. *P<0.05 (one-way ANOVA with Bonferroni’s correction, 
compared to equivalent ‘Control siRNA’ conditions).  
 
To test the specificity of the antibody, YFP-Parkin.HeLa cells treated with either control 
or SREBF1 siRNA were assessed (Appendix, Figure 9.3 B). Compared to control 
siRNA samples, SREBF1 siRNA caused a robust reduction in the high molecular 
weight band, representing flSREBP1 (125 kDa). This established that the antibody was 
specific to SREBP1, as well as confirming the efficiency of SREBF1 silencing following 
siRNA treatment. Next, the stability of activated mSREBP1 was tested through the 
application of the proteasomal inhibitor MG-132 (Appendix, Figure 9.3 C). Under these 
conditions, a low molecular weight band of ~68 kDa appeared, representing 
mSREBP1. These data indicated that the absence of the processed form of SREBP1 
was due to its instability. As we know, mSREBP1 undergoes rapid proteasomal 
turnover in the nucleus (Wang et al, 1994), in a GSK3 and FBXW7-dependent manner 
(Kim et al, 2004; Punga et al, 2006; Sundqvist et al, 2005). To test whether the E3-
ubiquitin ligase, FBXW7 was responsible for the observed turnover of mSREBP1, 
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FBXW7 was silenced (Appendix, Figure 9.3 D). As with MG-132 application, under 
these conditions, mSREBP1 was once again detectable.  
 
Having established that the lack of mSREBP1 detection was due to its proteasomal 
turnover, analysis of the literature revealed that many groups working on the SREBP-
family apply ALLN, a cysteine protease and proteasome inhibitor, prior to mSREBP1 
analysis (Hegarty et al, 2005; Porstmann et al, 2008; Seegmiller et al, 2002; Sun et al, 
2007; Wang et al, 1994). Through this adaption to the protocol, together with 
alternative sourcing of the SREBP1 (2A4) antibody and the loading of more protein per 
lane, mSREBP1 could be easily detected as a band of the correct size (Figure 6.16 A). 
 
The effect of ALLN on YFP-Parkin.HeLa cells was tested in the presence or absence of 
CCCP treatment over a time-course of 6 hours (Figure 6.16). In the absence of CCCP, 
ALLN causes a gradual increase in the amount of both flSREBP1 (Figure 6.16 A & B) 
and mSREBP1 (Figure 6.16 A & C). This is likely due to mSREBP1 stabilisation, and a 
concomitant increase in flSREBP1 transcription, by persisting mSREBP1 activity. As 
observed in the absence of ALLN (Figure 6.15), flSREBP1 sees a gradual decrease 
over time in the presence of ALLN and CCCP (Figure 6.16 A & B). This is supposedly 
due to the activation of SREBP1 in the presence of CCCP-induced ER-stress. 
However, if CCCP is causing flSREBP1 activation, the expected outcome for 
mSREBP1, when comparing ‘ALLN’ to ‘ALLN and CCCP’ treated conditions would be a 
build-up of mSREBP1 levels in the nucleus. In contrast, CCCP induces a sharp 
decrease in mSREBP1 even when the proteasome is blocked by ALLN. These data 
would suggest that either in the presence of CCCP, the ALLN-dependent proteasome 
block is insufficient to prevent a proteasomal-dependent degradation, or that 
mSREBP1 is undergoing degradation via an alternative route such as autophagy. 
Alternatively, perhaps flSREBP1 itself may be being degraded rather than activated 
following CCCP treatment. In this circumstance, it is unlikely that degradation is 
occurring via the proteasomal route, as levels decrease robustly in the presence of 
ALLN. Therefore again, flSREBP1 may be being degraded via the autophagy route. 
 
To test whether autophagy is playing a role in SREBP1 degradation in the presence of 
CCCP, combinations of ALLN, the autophagy inhibitor bafilomycin A1 and CCCP were 
applied to YFP-Parkin.HeLa cells for 2 hours (Figure 6.17). As seen in Figure 6.16, 
large decreases in flSREBP1 (Figure 6.17 A & B, dark grey), and mSREBP1 (Figure 
6.17 A & C, dark grey) were observed between ‘ALLN’ and ‘ALLN and CCCP’ treated 
conditions. If autophagy is involved in causing the degradation of either flSREBP1 or 
mSREBP1 following CCCP toxification, we would expect to see the maintenance of
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Figure 6.16 SREBP1 protein analysis following ALLN and CCCP treatment. YFP-Parkin.HeLa cells were subjected 
to 0, 2, 4, or 6 hours of 10 µM CCCP, in the absence or presence of 25 µg/ml ALLN as indicated. (A) flSREBP1 (125 
kDa) and mSREBP1 (68 kDa) protein levels were assessed via western blot using anti-SREBP1 (2A4) antibody (BD 
Biosciences). Loading control – anti-tubulin. (B and C) Protein levels from 1 biological repeat were analysed using the 
ImageJ plugin, ‘Gels,’ In each case, the relative protein levels were normalised to the tubulin loading control, and then 
‘0h CCCP.’  
 
SREBP1 levels in ‘bafilomycin and CCCP’ treated conditions compared to ‘bafilomycin’ 
treated cells alone. However, there is a CCCP-dependent decrease in both flSREBP1 
(Figure 6.17 A & B, light grey) and mSREBP1 (Figure 6.17 A & C, light grey), indicating 
that SREBP1 is not degraded by the autophagy route under these conditions. 
Interestingly, bafilomycin treatment alone causes a general decrease in flSREBP1 
levels compared to untreated cells (Figure 6.17 A & B, black vs. light grey). This may 
be due to the fact that defective autophagy, as caused by bafilomycin treatment, 
causes increased ER-stress, therefore leading to the activation of flSREBP1 
(Schonthal, 2012; Yin et al, 2012). This suggestion is supported by the slight increase
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Figure 6.17 SREBP-1 protein analysis following ALLN, bafilomycin A1 and CCCP treatment. YFP-Parkin.HeLa 
cells were treated subjected to 2 hours (2h) of 10 µM CCCP, in the absence or presence of 25 µg/ml ALLN and/or 20 
nM bafilomycin as indicated. (A) flSREBP1 (125 kDa) and mSREBP1 (68 kDa) protein levels were assessed via 
western blot using anti-SREBP-1 (2A4) antibody (BD Biosciences). Loading control – anti-tubulin. (B and C) Protein 
levels from 1 biological repeat were analysed using the ImageJ plugin, ‘Gels,’ In each case, the relative protein levels 
were normalised to the tubulin loading control, and then to ‘untreated’ (-). 
 
in mSREBP1 levels observed under the same conditions (Figure 6.17 A & C, black vs. 
light grey).  
 
Finally, in order to determine whether SREBP1 protein levels are controlled by a 
combination of proteasomal and autophagic degradation, the combined inhibition of 
these routes by ‘ALLN and bafilomycin’ was analysed. Here, compared to ‘ALLN’ 
treatment alone, flSREBP1 is decreased in the absence of CCCP, indicating again that 
bafilomycin-induced ER-stress causes SREBP1 activation (Figure 6.17 A & B, dark 
grey vs. white). The levels of flSREBP1 are slightly higher than those seen with 
bafilomycin alone, suggesting that the additional proteasomal block leads to increased 
transcription of flSREBP1 (Figure 6.17 A & B, light grey vs. white). Following CCCP-
treatment, only a small decrease in flSREBP1 levels is observed (Figure 6.17 A & B, 
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white). This suggests either that only a small additional increase in SREBP1 activation 
occurs by the addition of CCCP in combination with bafilomycin, or that a combination 
of proteasomal and autophagic degradation is responsible for the observed flSREBP1 
decrease after ALLN or bafilomycin-treatment alone.  
 
With regards to mSREBP1 in the presence of ALLN and bafilomycin, there is an 
increase in levels compared to untreated cells before CCCP-treatment, likely reflecting 
the activation of flSREBP1 by bafilomycin treatment, together with the inhibition of the 
proteasome by ALLN (Figure 6.17 A & C, black vs. white). However, following CCCP 
treatment, the levels of mSREBP1 change very little compared to non-CCCP treated 
conditions (Figure 6.17 A & C, white). This may be again, because the additional 
CCCP insult causes only a minor additional activation of SREBP1. Alternatively, it 
could indicate that following CCCP treatment; mSREBP1 is degraded in a proteasomal 
and autophagic–dependent manner.  
 
In order to understand these data fully, first the observed effects would require 
confirmation via repeat analysis. However, overall, it may suggest that SREBP1 
undergoes both autophagic and proteasomal degradation. This is perhaps 
understandable, as ER-stress activates the autophagy pathway, causing the 
engulfment of parts of the ER-network by autophagosomes (Bernales et al, 2006; Ding 
et al, 2007; Ogata et al, 2006). This may lead to the autophagic degradation of at least 
flSREBP1, which would reduce the amount of activated mSREBP1 available for 
translocation to the nucleus. 
 
Despite failing to elucidate exactly what happens to SREBP1 isoforms following CCCP 
treatment, the application of ALLN, together with a new source of SREBP1 antibody 
and increased protein amounts has enabled the analysis of mSREBP1 levels. Hence, 
SREBP1 isoforms were again analysed following the application control, PINK1 or 
parkin siRNA, in the presence or absence of ALLN and/or CCCP (Figure 6.18). First 
looking at flSREBP1, there is a clear decrease in levels following the application of 
CCCP in both control and PINK1 siRNA-treated cells (Figure 6.18 A, B & D). However, 
as observed in figure 6.15, the dynamics of flSREBP1 following parkin siRNA 
application deviate from that seen with control siRNA (Figure 6.18 C & D). Here, 
despite an initial decrease in flSREBP1 after 2 hours of CCCP treatment, flSREBP1 
levels begin to increase after 4 and 6 hours of CCCP.  
 
Second, as shown in Figure 6.16, control conditions also produce a decrease in 
mSREBP1 levels over the CCCP time-course (Figure 6.18 A & E). This same pattern is 
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Figure 6.18 Analysis of SREBP1 isoforms following PINK1/Parkin-pathway silencing.  YFP-Parkin.HeLa cells 
were treated with control (A), PINK1 (B) or parkin (C) siRNA for 4 days before being subjected to 0, 2, 4, or 6 hours of 
ALLN (25 µg/ml) and/or CCCP (10 µM) as indicated. flSREBP1 (125 kDa) and mSREBP1 (68 kDa) protein levels were 
assessed via western blot using anti-SREBP1 (2A4) antibody (BD Bioscience) (A - C). Average flSREBP1 (D) and 
mSREBP1 (E) protein levels from 3 biological repeats were analysed using the ImageJ plugin, ‘Gels.’ In each case, the 
relative protein levels were normalised to the actin loading control, and then ‘0h CCCP’. Error bars represent the 
standard error. Equivalent conditions were analysed by one-way ANOVA with Bonferroni’s correction. *P<0.05.  
 
observed following the application of PINK1 and parkin siRNA (Figure 6.18 B, C & E), 
indicating that the loss of these genes has no effect on mSREBP1 levels. 
 
Taken together, these data suggest that CCCP promotes the gradual reduction of both 
flSREBP1 and mSREBP1 levels over a duration of 6 hours. This reduction in SREBP1 
protein levels may be due to ER-stress caused by CCCP application. One of the 
consequences of the UPR is a temporary block of de novo translation until cellular 
homeostasis is restored. Therefore, CCCP may promote the conversion of flSREBP1 
into mSREBP1, but block the translation of de novo protein for ER-replenishment. How 
these changes in SREBP1 protein levels are related to PINK1/Parkin-mediated 
mitophagy are currently unknown. However, interestingly, the loss of parkin alters the 
dynamics of flSREBP1, suggesting a feedback system between these two proteins. As 
ER-stress leads to increases in SREBP1-dependent lipid synthesis, and CCCP causes 
both mitochondrial and ER stress, it is conceivable that the PINK1/Parkin-pathway 
utilises SREBP-dependent lipids for the execution of mitophagy. In support of this, 
Parkin is a known lipid sensor (Kim et al, 2011), whose expression levels are enhanced 
upon CCCP treatment (Bouman et al, 2011). Following SREBF1 siRNA treatment, the 
reduction in free lipid concentration, and hence the ability to undergo mitophagy may 
be sensed by Parkin, blocking it from translocating to damaged mitochondria. Why free 
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lipids are required for mitophagy is not yet understood. However, as lipids are essential 
for mitochondrial biogenesis, it may be that the cost of losing mitochondria, coupled 
with the lack of resources required to replenish those lost, cause the cell to block 
mitophagy initiation.  
 
6.3.9  DROSOPHILA IN VIVO ANALYSIS 
 
Currently, in vivo genetic interaction analyses between the SREBP-pathway and 
PINK1/Parkin-pathway are in the preliminary stages. However, there are a plethora of 
tools available to allow for a future in-depth assessment. In Drosophila, there is one 
SREBF ortholog, known as helix loop helix protein 106 (HLH106) and one FBXW7 
ortholog known as archipelago (ago). Additionally, Drosophila also possess a single 
ortholog of GSK3, known as shaggy (sgg). Available stocks for each of these genes 
include overexpression, null-mutant and RNAi lines, allowing a wide scope for 
experimentation. The initial question to be addressed was whether the loss of SREBP-
pathway genes cause phenotypes similar to PINK1 (PINK1B9) and parkin  (park25) null-
mutants. Following this assessment, key experiments begun to address whether 
overexpression or loss of SREBP-pathway genes were able to modify the parkin or 
PINK1-null phenotypes. Importantly, as described in section 1.6, both parkin and 
PINK1 mutant flies exhibit almost identical phenotypes including male sterility, 
locomotor defects, mitochondrial swelling, DA neuron loss and muscle wasting. These 
phenotypes can be easily assessed in an experimental setting, with the simplest tests 
addressing locomotor defects by way of established climbing and flight assays. Here, 
parkin and PINK1-null mutants, and PINK1 RNAi lines exhibit drastically reduced 
climbing and flight abilities (Clark et al, 2006; Greene et al, 2003; Park et al, 2006; 
Yang et al, 2006b). These simple phenotypes were employed in preliminary analyses, 
to assess the presence of genetic interactions between PINK1/Parkin- and SREBP-
pathway members. Here, genetic combinations causing amelioration or exacerbation of 
the locomotor phenotypes were of interest. 
 
6.3.9.1  Gene silencing with RNAi 
 
Initial SREBP-pathway assessment involved climbing and flight analysis following the 
application of HLH106 RNAi (Figure 6.19 A & B), ago RNAi (Figure 6.19 C & D) and 
sgg RNAi (Figure 6.19 E & F). Following HLH106 silencing using two different RNAi 
lines, significant defects in both climbing and flight were observed, with HLH106 RNAi 
line 2 producing the strongest phenotype in both cases (Figure 6.19 A & B). This may 
be because of greater knockdown efficiency in this RNAi line, or perhaps a higher 
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Figure 6.19 Locomotor responses in SREBP-pathway RNAi-treated Drosophila. Drosophila expressing RNAi 
against HLH106 (A & B), ago (C & D) and sgg (E & F) via the GAL4-UAS system were assessed for their ability to climb 
(A, C & E) and fly (B, D & F). HLH106 and ago RNAi was driven with the strong ubiquitous driver, daughterless, 
whereas sgg RNAi was driven using the weaker ubiquitous driver, Act5C. Error bars represent standard error. Figures 
within columns represent the number of animals tested per condition. Data were tested using either one-way ANOVA 
with Bonferroni’s correction (A & B) or Student’s t-test (C - F). **P<0.01, ***P<0.001. 
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degree of toxicity. One way to address this would be via qRT-PCR analysis of 
transcript levels, enabling the quantification of gene expression in these flies. In the 
case of ago RNAi, both climbing and flight are significantly reduced following gene 
silencing, with a stronger decrease observed in the climbing assay compared to the 
flight assay (Figure 6.19 C & D). This may be to do with tissue- and system-specificity, 
as the climbing assay tests both coordination and muscle strength, whereas the flight 
assay tests the reflex action of the indirect flight muscles. Typically, the climbing assay 
is a more sensitive test of locomotion, and is often less variable than the flight assay. 
Therefore, subtle defects may be detected in the climbing assay, but missed in the 
flight assay. Finally, sgg RNAi causes a climbing defect but not a flight defect (Figure 
6.19 E & F). This again may be due to tissue- or system-specific effects of sgg 
silencing. Interestingly, sgg siRNA follows the same pattern as ago RNAi, which is in 
agreement with these two proteins having a shared function of HLH106 proteasomal 
degradation. Overall these data are encouraging, as all SREBP-pathway components 
analysed phenocopy the loss of PINK1 and parkin to some extent with regards to 
locomotor difficulties. 
 
6.3.9.2  Genetic interaction analysis 
 
Of particular interest is the possibility of a genetic interaction between the 
PINK1/Parkin-pathway and the SREBP-pathway. To test this possibility, initial efforts 
focused on the upregulation and/or downregulation of HLH106 and ago in a park25 
mutant background (Figures 6.20 and 6.21 respectively). Here, the upregulation of 
wild-type HLH106 in a park25 mutant background produced lethality (Figure 6.20 A & 
B). This observation is intriguing as upregulation of HLH106 in a wild-type background 
is viable (Figure 6.20 A & B). This could indicate a genetic interaction between parkin 
and HLH106, whereby increased HLH106-expression exacerbates parkin-null 
phenotypes.  
 
A constitutively active (CA) variant of HLH106, missing its regulatory C-terminus (∆C) 
was viable in both a wild-type and park25 background, but failed to significantly alter the 
reduced climbing and flight observed in park25 mutants (Figure 6.20 A & B). However, 
whilst this genetic combination produces live progeny, the flies are weak and 
completely unable to climb (Figure 6.20 A), despite performing moderately in the flight 
assay (Figure 6.20 B). These data suggest that again, overexpression of a CA form of 
HLH106 produces tissue and/or system-specific effects, affecting co-ordination and leg 
strength, rather than indirect flight muscle reflexes. Intriguingly, the CA form of HLH106 
appeared less noxious than the wild-type form in both wild-type and park25
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Figure 6.20 Locomotor responses in park25 Drosophila following upregulation of HLH106 levels. parkin-null 
Drosophila (park25) were assessed for their ability to climb (A) and fly (B) following the overexpression of wild-type 
HLH106 or constitutively active HLH106∆C (HLH106 without its regulatory C-terminus). HLH106 overexpression was 
driven by Act5C-GAL4. Assay controls were park25 heterozygotes (wild-type) or homozygotes (mutant) in the presence 
of either UAS-HLH106, UAS-HLH106∆C or the Act5C-GAL4 driver and UAS-HLH106 and UAS-HLH106∆C driven by 
.Act5C-GAL4. Error bars represent standard error. Figures above columns represent the number of animals tested per 
condition. Data were tested using one-way ANOVA with Bonferroni’s correction compared to Act5C-GAL4/+;park25/+, 
***P<0.001 
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backgrounds. The deleterious effect of wild type HLH106 may be due to off-target 
toxicity, or perhaps the fact that wild-type HLH106 is trapped in the ER, whilst CA 
HLH106 freely activates its target genes.   
 
The upregulation of wild-type ago, or a dominant negative ago transgene lacking its 
core F-box domain (ago∆F) (Mortimer & Moberg, 2007), failed to modify the reduced 
climbing and flight phenotypes of the park25 mutant (Figure 6.21 A & B). Additionally, a 
reduction in ago expression, with the employment of two mutant alleles, ago1 or ago3 
(Moberg et al, 2001), also failed to modify the park25 phenotypes (Figure 6.21 C & D). 
Here, flies were heterozygous for the ago mutant alleles, as complete deletion of ago is 
embryonic lethal (Data not shown, Mortimer & Moberg, 2007).  
 
Altogether, these data suggest that overexpression of HLH106 may exacerbate, but 
does not rescue locomotor phenotypes caused by the absence of parkin. However, 
alterations in ago expression levels have no obvious effect on the parkin-null 
phenotypes assessed. These data would therefore place HLH106 and ago upstream of 
parkin in the PINK1/Parkin pathway. Next, it will be interesting to assess whether the 
overexpression or loss of these genes in a PINK1-null background are able to modify 
PINK1-associated locomotor defects, perhaps giving a clearer idea of how these genes 
interact. However, in the context of SREBF1 at least, a rescue under these 
circumstances is perhaps unlikely, as data from cellular analyses suggest that SREBF1 
is upstream of PINK1. 
 
 
6.4  DISCUSSION 
 
In this chapter, I have outlined initial efforts made to understand the relationship 
between the SREBP-pathway and PINK1/Parkin-mediated mitophagy. Whilst the story 
is incomplete, these data have gone some way to suggest ways in which these 
pathways interact at a number of different levels, to coordinate mitochondrial quality 
control. Specifically, I have used genistein, the SREBP-pathway inhibitor, to show that 
the PINK1/Parkin-pathway effects observed following SREBP1 silencing are SREBP1-
specific. Additionally, I have eliminated the possibility that the observed decreases in 
Parkin translocation are due to reduced PINK1 expression levels, general autophagy 
blockage or the maintenance of the ∆Ψm under CCCP-treated conditions. Importantly, 
I have shown that fatty acids and cholesterol, the output of the SREBP-pathway, are 
able to rescue Parkin-translocation following SREBF1 silencing, highlighting the 
importance of the maintenance of intracellular lipid levels for mitophagy induction. 
Interestingly, the application of fatty acids and cholesterol were insufficient to rescue
 234 
 
 
Figure 6.21 Locomotor responses in park25 Drosophila following altered ago levels. (A & B) parkin-null Drosophila 
(park25) were assessed for their ability to climb (A) and fly (B) following the overexpression of wild-type ago or dominant 
negative ago∆F. (ago without its F-box domain). ago overexpression was driven by Act5C-GAL4. (C & D) park25 
Drosophila were assessed for their ability to climb (C) and fly (D) following reduced ago expression (the loss of one 
copy of ago - ago1 and ago3). In all cases, assay controls were park25 heterozygotes (wild-type) and homozygotes 
(mutant). Error bars represent standard error. Figures within columns represent the number of animals tested per 
condition. Data were tested using one-way ANOVA with Bonferroni’s correction, ***P<0.001. 
 
the block on Parkin translocation observed under PINK1 siRNA conditions, indicating 
that SREBP1 and lipid synthesis is upstream of PINK1 stabilisation. With regards to 
this, PINK1 stabilisation is partially compromised following SREBF1 silencing, 
suggesting that SREBP1 and/or SREBP-dependent lipid synthesis plays a role in 
stabilising PINK1 on the outer mitochondrial membrane. Again, this observation would 
suggest that SREBP1 acts upstream of PINK1.  
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SREBP1 protein analysis has revealed a dynamic change in protein levels in the 
presence of CCCP. This may be due to flSREBP1 activation and the increased 
transcription of lipid-related genes. This would tie in with the suggestion that mitophagy 
will proceed only in a lipid-rich environment where degraded mitochondria may be 
replaced by increased mitochondrial biogenesis. Interestingly, parkin siRNA produces 
a change in SREBP-dynamics following CCCP, leading to the maintenance of 
flSREBP1 protein levels rather than the observed decrease seen under control siRNA 
conditions. This may indicate a feedback mechanism between Parkin and SREBP1, 
whereby under CCCP toxification, Parkin assesses the lipid-content of the cell, and if 
appropriate, initiates mitophagy, and the activation of SREBP1. 
 
In vivo analysis of Drosophila SREBP, FBXW7 and GSK3 homologs showed that a 
reduction in gene expression by the application of RNAi caused a reduction in 
locomotor abilities, as is the case with PINK1 and Parkin loss. However, no clear 
genetic interaction between these genes could be observed in preliminary experiments. 
This may suggest that these genes do not interact with each other. However, in 
combination with cellular data, these observations are consistent with the SREBP-
pathway acting upstream of PINK1 and Parkin. An interesting avenue of exploration 
would be to assess the mitochondrial and dopaminergic neuron status of SREBP-
pathway mutants and siRNA-treated flies, in order to assess similarities between 
SREBP- and PINK1/Parkin-phenotypes. Of note, both dSREBP RNAi-treated flies and 
parkin-null flies show a reduced body size and weight (Pesah et al, 2004; Porstmann et 
al, 2008). Additionally, parkin- and PINK1-null flies exhibit an abnormal wing posture, 
with wings being ‘held up’ in some instances (Clark et al, 2006; Yang et al, 2006a). A 
similar phenotype has also been observed following a reduction in ago expression 
(data not shown), which will warrant future investigation and quantification. 
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7. DISCUSSION 
  
 238 
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7.1  SUMMARY 
 
Despite several years of intense study, a number of mechanistic questions remain 
regarding the process of PINK1/Parkin-mediated mitophagy. These include the manner 
in which mitochondria are damaged, and how these mitochondria are identified for 
degradation, the stimulus for PINK1 stabilisation on the MOM, and the mode of Parkin 
translocation. In a bid to resolve some of these remaining questions, the aim of this 
study was to perform a genome-wide RNAi screen in Drosophila S2R+ cells to identify 
novel promoters of PINK1/Parkin-mediated mitophagy. Here, Parkin redistribution from 
the cytoplasm to dysfunctional mitochondria was assessed, thereby providing the 
potential for gene discovery upstream of Parkin translocation. The desired outcome 
from this screen was to identify novel genes acting in the PINK1/Parkin-pathway, to 
promote mitochondrial degradation. 
 
 
7.2  RNAi SCREENING 
 
The initial stages of Drosophila S2R+ cell screening focused on assay development 
and optimisation, and included undertaking a number of small, subset screens. After 
finalising the best conditions for Parkin translocation assessment, a Drosophila whole 
genome primary screen was performed, where ~18,000 dsRNA amplicons were tested 
for their ability to alter the degree of Parkin translocation following CCCP toxification. 
Here ~1,000 dsRNA amplicons were found to produce an inhibitory effect on Parkin 
translocation. After visual analysis of images, this group was reduced to 625, through 
the removal of amplicons causing low levels of GFP, or cellular toxicity. Of these 625 
primary hits, 115 were found to have a robust and reproducible effect following four 
rounds of confirmation screening. To test the ability of these hits to influence other 
aspects of mitochondrial biology, a series of secondary screens analysed three 
aspects of PINK1/Parkin-mediated mitochondrial homeostasis. These included an 
alternative method of toxin-induced Parkin translocation, mitochondrial morphology 
changes and toxin-induced mitochondrial aggregation in the juxtanuclear region. 
Having collated data from these screens, 65 dsRNA amplicons equating to 62 unique 
Drosophila genes were found to influence a range of PINK1/Parkin-related 
mitochondrial processes. 
 
To assess the functional conservation of Drosophila hit genes across species, human 
orthologs corresponding to the final Drosophila hit list were identified, and re-tested for 
their ability to alter Parkin translocation and mitophagy in a human HeLa cell system. 
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Out of 90 human genes, 22 were found to reproducibility influence both processes, 
demonstrating cross-species conservation of gene function. Using bioinformatic 
analysis, a clear pathway emerged within this group, containing several members of a 
well-defined lipogenesis pathway. This group included the two strongest hit genes, 
together with a predefined functional link with Parkin. Because of this, the SREBP 
lipogenesis pathway was selected for follow-up study in a low-throughput setting. 
 
7.2.1  EVALUATION OF SCREENING 
 
Each step of the screening process presented challenges that had to be overcome. 
However the identification of a small group of genes with reproducible effects on 
PINK1/Parkin-pathway processes provides a marker for screen success. 
 
The first major challenge to overcome was that silencing dPINK1 in Drosophila S2R+ 
cells has little effect on CCCP-induced dParkin translocation. This was unexpected, as 
both dPINK1 mRNA levels, via qRT-PCR analysis, and dPINK1 activity, via the 
assessment of dMfn steady state levels, followed the expected trend. In order to 
rationalise this, the assessment of dPINK1 protein distribution in S2R+ cells under 
basal conditions revealed a deviation from the situation reported in mammalian 
systems. In mammalian cells, due to its rapid turnover by the N-end rule pathway 
(Yamano and Youle, 2013), PINK1 protein levels are very low, with diffuse cytoplasmic 
distribution under basal conditions (Narendra et al., 2010). However in S2R+ cells, a 
substantial proportion of dPINK1 was found to co-localise with the mitochondrial 
marker, Mito-GFP (Figure 3.3). This observation is consistent with Drosophila in vivo 
data, whereby a fraction of cleaved dPINK1 is readily detectable under control 
conditions (Whitworth et al., 2008). These data suggest the presence of a stable 
fraction of cleaved dPINK1, perhaps explaining how Parkin translocation persists 
following dPINK1 dsRNA application. Here, I posit that even following dPINK1 mRNA 
silencing, this stable fraction of dPINK1 continues to produce a translocation event. 
However, despite continued translocation of Parkin, intriguingly both dMfn 
ubiquitination and perinuclear aggregation of damaged mitochondria are reduced in 
PINK1 dsRNA-treated samples (Figures 3.8 D and 4.6 B). These data would suggest 
that cleaved dPINK1 can stimulate the redistribution of Parkin to the mitochondria, but 
is unable to activate latent Parkin E3-ligase activity, hence blocking the pathway at the 
level of Parkin target proteins. This is in agreement with recent published data that 
suggest that Parkin exists in an auto-inhibited state, where its tertiary structure 
occludes its E3-ligase domain (Trempe et al., 2013). However, following Parkin 
phosphorylation by PINK1 (Kondapalli et al., 2012), Parkin undergoes a conformational 
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change, activating its latent E3-ligase activity and allowing stable accumulation on the 
MOM (Lazarou et al., 2013), and interaction with target substrates. 
 
In the light of the proposed divergence of PINK1 function between Drosophila and 
mammalian systems, the choices for proceeding were either to re-think the primary 
assay in order to develop a screening scenario with a suitable positive control, or 
continue developing the Parkin translocation screen in the absence of a positive 
control. Because S2R+ cells faithfully recapitulate many of the well-defined stages of 
the mitophagy pathway, including robust Parkin translocation upon CCCP-toxification, 
our decision was to continue focusing on this step, employing a ‘no CCCP’ control in 
the place of dPINK1 dsRNA. Whilst this was a risk, the assay was still expected to 
identify genes involved in the translocation event and processes upstream of this, even 
in the absence of a dPINK1 dsRNA effect. 
 
Because of the issues with the dPINK1 in the primary screen, the secondary screens 
proved extremely valuable, as they provided clues as to the specificity of the observed 
effects with regards to PINK1/Parkin-mediated mitophagy. First, paraquat, the redox 
cycling oxidative stressor, was employed to induce Parkin translocation. This assay 
demonstrated that the observed Parkin distributions were likely caused by 
mitochondrial dysfunction rather than a CCCP-specific effect. Second, the effect of 
gene silencing on mitochondrial morphology was assessed. This assay was particularly 
relevant to the PINK1/Parkin-pathway, as PINK1 and parkin are known to promote 
fragmentation, with their RNAi producing a hyper-fused phenotype. Here, dsRNA 
amplicons causing a deviation from the wild-type morphology, particularly in the 
direction of PINK1 and parkin dsRNA, were of interest. Third, a later stage of the 
mitophagy pathway was assessed, looking at the perinuclear aggregation of 
mitochondria following prolonged toxification. This aspect of screening was particularly 
important as it tested the mitophagy-specific effects of hit genes downstream of Parkin 
translocation. Here, mitochondrial perinuclear aggregation occurs prior to mitophagy 
proper (Okatsu et al., 2010; Vives-Bauza et al., 2010). Conspicuously, the obvious 
assay to implement here would have been the analysis of mitophagy itself. However, 
where reductions in the MIM marker ATP5A, are observed following prolonged 
toxification, this effect proved variable (Figure 3.4 C & D). The reasons for this are 
unknown, but may be a cell-specific effect, due to the mode of energy production in 
S2R+ cells. For example, cells reliant on oxidative respiration such as neurons are less 
likely to undergo widespread mitophagy compared to cells favouring glycolytic ATP-
producing pathways such as HeLa cells (Gusdon and Chu, 2011). Therefore this would 
suggest that S2R+ cells favour oxidative phosphorylation, thus rely too heavily on their 
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mitochondrial population to degrade them. In agreement, Drosophila S2 cells have 
been reported to favour a predominantly mitochondria-dependent oxidative respiratory 
state (Freije et al., 2012). Crucially however, a recent in vivo study in Drosophila 
successfully demonstrated the occurrence of PINK1/Parkin-related mitophagy in a 
physiological setting, confirming the existence of this process in the whole Drosophila 
organism, and supporting the notion of cell-type specificity (Vincow et al., 2013). The 
study of mitophagy in Drosophila cell culture may be possible using alternative 
Drosophila-derived cell lines, although many of these are difficult to culture and small in 
size, making them less amenable to image-based experimentation. 
 
Switching to a human cell system following the conclusion of Drosophila screening 
provided a number of clear benefits. These included the opportunity to confirm hit gene 
involvement in PINK1/Parkin-related processes across species, demonstrating 
conserved pathway function. Additionally, the use of HeLa cells allowed the 
assessment of Parkin translocation and mitophagy in the presence of a strong PINK1 
siRNA-dependent pathway block. Here, PINK1 silencing virtually eliminated both 
processes. Notably, a small number of tested siRNAs were able to phenocopy the 
PINK1 siRNA effect (Figures 5.11 and 5.15), demonstrating that in spite of 
aforementioned disparities, clear functional conservation between Drosophila and 
human PINK1/Parkin-processes exist. Critically, when assessing mitophagy proper for 
the first time, the majority of siRNA probes causing a strong Parkin translocation block 
also produced a robust mitophagy block (Figure 5.16 B), highlighting the pathway 
specificity of the observed effects. 
 
Initial development of human screening techniques involved analysis of both HeLa and 
RPE1 cells. The aim was to screen both cell types in order to assess similarities and 
differences in pathway regulation between these two systems. Here, HeLa cells are a 
cancer cell line with abnormal genetic makeup, whereas RPE1 cells are an epithelial 
cell line with a relatively normal genetic profile. Comparisons in a low-throughput 
setting found that both cell lines undergo efficient Parkin translocation following short 
periods of CCCP toxification. However, where HeLa cells undergo moderate levels of 
mitophagy after 24 hours of CCCP treatment, RPE1 cells exhibit almost complete loss 
of their mitochondria by this time point (section 5.4). These data suggest differences in 
the readiness of these cells to lose their mitochondria, perhaps again due to the mode 
of energy synthesis favoured. However, another disparity was observed following 
PINK1 silencing. In HeLa cells, PINK1 loss completely blocks Parkin translocation and 
mitophagy (section 5.4). However, in RPE1 cells, whilst optimisation of PINK1 siRNA 
silencing (Figure 5.7) resulted in a moderate PINK1-dependent block on Parkin 
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translocation, mitophagy continued to occur at levels comparable to control siRNA-
treated samples (data not shown). The reasons for this lack of effect are currently 
unknown, but may be due to the expression of a functionally redundant mitophagy-
promoting pathway in RPE1 cells. In support of this, a recent study in COS-7 cells 
reported that the endoplasmic reticulum (ER) E3-ubiquitin ligase, Gp78 ubiquitinates 
the fusion protein Mitofusin at mitochondria-associated ER-membrane sites (MAMs) 
following CCCP, promoting mitophagy in a Parkin-independent manner (Fu et al., 
2013). Nevertheless, whilst the differences between HeLa and RPE1 cells raise many 
interesting questions that warrant further investigation, for the scope of this project 
HeLa cells alone were selected for screening, as here, PINK1/Parkin-processes are 
well defined in the literature. 
  
Post-screening, the identification of several components of the SREBP1 pathway 
within the 22 final human hits was an exciting occurrence, particularly as the pathway 
member, FBXW7 had previously been found to act in an SCF-like complex with Parkin 
(Staropoli et al., 2003), as well as undergoing Parkin-dependent degradation (Ekholm-
Reed et al., 2013). Importantly this pathway, with a central role in lipid homeostasis, 
contained the two strongest screen hits; therefore supporting its selection for further 
investigation. This decision was greatly influenced by the utilisation of the online 
protein interaction program, STRING (Jensen et al., 2009), which allowed easy 
visualisation of experimental and predicted interactions between hit genes (Figure 
5.17). However, a cautionary note is that where the ‘strongest’ interactions are 
documented here, independent investigation using BioGRID, IntAct and HPRD 
highlighted protein interactions between hit genes that were absent from the STRING 
output (Table 5.5). Such findings highlight the limits of using bioinformatic tools, and 
outline the benefits of manual bioinformatic investigation. 
 
Other pathway enrichments in the hit group included genes involved in histone 
acetyltransferase transcriptional activation and pre-mRNA splicing (Figure 5.17). 
However, these contained fewer pathway members, produced a weaker block on 
PINK1/Parkin-related processes compared to SREBF1 and FBXW7, and lacked 
previous links to parkin, PINK1 or associated pathway genes. On this basis, this group 
of genes was not considered for closer scrutiny in the context of this project. However, 
these, and other genes in the hit list still represent attractive candidates for 
PINK1/Parkin-mediated mitophagy regulation. Future work may therefore investigate 
pathway interactions between the remaining hits, PINK1 and parkin in a low-throughput 
setting. 
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Comparing our whole genome screen to recently published whole genome RNAi data, 
it is clear that whilst there are some common trends, the overall outcomes are quite 
different. For example, a screen originally looking at the autophagic degradation of viral 
proteins, and later at CCCP-induced Parkin-dependent mitophagy, identified SMURF1 
as a promoter of these processes (Orvedahl et al., 2011). In our screen, dSMURF1 has 
a z-score of -3.1, hence being included in the hit group. However, this gene failed to 
achieve hit status in confirmation and secondary screens. Additionally, two genome-
wide RNAi screens specifically looking at Parkin translocation identified Hexokinase 2 
(HK2) (McCoy et al., 2013) and ATPIF1 (Lefebvre et al., 2013) as promoters of Parkin 
translocation. Where dHK2 only achieved a z-score of -0.7 in our screen, two 
Drosophila orthologs of ATPIF1, CG13551 and CG34423 each achieved a z-score of -
2.6, trending in the right direction. It’s worth noting that whilst the top hits from these 
screens deviated somewhat from our final hit list, these screens were all carried out in 
human cells, with some looking at slightly different aspects of mitochondrial biology. 
Because of this, it is perhaps unsurprising that the outcomes are different. Additionally, 
in many cases, full screening datasets are not published, with most groups only 
reporting on ‘favourite’ genes. This therefore does not rule out the inclusion of SREBP-
pathway components within the hit lists of these screens. 
 
 
7.3  THE SREBP-PATHWAY 
 
The SREBP-pathway plays a central role in the regulation of cellular fatty acid, 
triglyceride and cholesterol synthesis and uptake. The core members of the pathway 
are the transcription factors, SREBP1 and 2, master regulators of the pathway, SCAP - 
a SREBP-escort, INSIG - a negative regulator of the pathway, S1P and S2P - 
proteases involved in SREBP activation, and GSK3 and FBXW7 – a serine threonine 
kinase and SCF-ubiquitin ligase complex member respectively, who coordinate SREBP 
turnover. Within the human hit list of 22 genes, SREBF1/2, as well as FBXW7 and 
GSK3A were present. This signifies a clear enrichment of genes involved in the 
SREBP pathway.  
 
The SREBP pathway can be activated by a number of stimuli including reductions in 
intracellular cholesterol and fatty acids, increases in carbohydrate availability and 
growth hormones, and ER stress. With this, inactive, full-length SREBP (flSREBP) 
undergoes ER-to-Golgi transport via the COPII-coated vesicular transport route, 
together with the escort protein, SCAP. Here, SREBP is proteolytically activated by 
S1P/S2P, releasing the active N-terminal bHLH domain into the cytoplasm. From here, 
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active or ‘mature’ SREBP (mSREBP) translocates to the nucleus, where transcription 
of target genes begins (Figure 6.1 B). 
 
Importantly, activation of mSREBP target genes is tightly regulated on a number of 
levels. First, coactivators such as P300, PGC-1β and MED15 associate with mSREBP 
to enhance its transcriptional activity. Second, both SREBP and INSIG are 
transcriptional targets of mSREBP, allowing replacement of ER-localised flSREBP, as 
well as its negative regulator. Finally, the binding of mSREBP to its target promoters 
stimulates its phosphorylation by GSK3, leading to FBXW7-dependent ubiquitination 
and proteasomal degradation (Figure 6.4). Through this, sustained activation of the 
SREBP-pathway requires a continuous supply of mSREBP in the nucleus.   
 
 
7.4  PINK1, PARKIN AND THE SREBP-PATHWAY 
 
7.4.1  SREBP-PATHWAY GENES AND PARKIN TRANSLOCATION 
 
Following the discovery of SREBP-pathway enrichment in the final human hit group, a 
germane question to pose was how other SREBP-related genes performed in whole 
genome screening. To answer this, Drosophila orthologs of the main pathway 
members were identified, and their behaviour over the screening process assessed. 
Encouragingly, many SREBP-pathway members produced a significant reduction in 
Parkin translocation in the primary screen (Table 6.1). These included the SREBP 
escort dSCAP, essential for SREBP activation (Rawson, 2003), the COPII coat 
elements, dSec23 and dSec24, required for ER-to-Golgi transport, and the 
transcriptional coactivators dP300 and dMED15. Importantly, the major SREBP 
transcriptional targets, acetyl CoA carboxylase (dACAC), fatty acid synthase (dFASN) 
and stearoyl-CoA desaturase (dSCD), also produced a reduction in Parkin 
translocation. This implied that the canonical lipid-synthesis role of the SREBP 
pathway was important for Parkin translocation. 
 
All of the aforementioned genes are positive regulators of the SREBP-pathway, 
therefore predicted to produce an equivalent phenotype to SREBF1 silencing, 
Intriguingly, two negative regulators of the pathway, dFBXW7 and dGSK3 also 
produced a robust decrease in Parkin translocation, whilst having the opposite effect 
on lipid synthesis. The reasons for this unexpected occurrence are unclear, but 
possible explanations are discussed in detail in later sections. 
 246 
SREBP-pathway genes failing to influence Parkin translocation included dS1P and 
dS2P proteases. This was a surprising result as the proteolytic activation of SREBP by 
S1P and S2P is essential for the transcription of SREBP-targets in mammals (Rawson, 
2003). However, it may be that under screening conditions (i.e. CCCP-treatment), or in 
a Drosophila system, SREBP is activated via an alternative proteolytic route. 
Alternatively, S1P and S2P cleavage may be unnecessary for Parkin translocation or 
exhibit functional redundancy with other genes. Finally, the stability of these proteins 
may exceed the knockdown period, preventing manifestation of a phenotype. 
 
The SREBP-coactivator dPGC-1B, involved in mitochondrial biogenesis, also failed to 
influence Parkin translocation. This may be because PGC-1β enhances the 
transcription of non-mitophagy-related SREBP genes, or that genes required for PGC-
1B-dependent mitochondrial biogenesis are activated downstream of PINK1/Parkin-
pathway activation.  
 
Finally, the SREBP-target gene, Acetyl CoA Synthetase (ACS) was unable to inhibit 
Parkin translocation, despite target genes ACAC, FASN and SCD producing a strong 
block. During lipogenesis, ACS catalyses the conversion of acetate to acetyl CoA - the 
major substrate of the lipid synthesis pathway. However, whilst acetyl CoA is essential 
for lipid synthesis, ACS-dependent acetyl CoA production is not the sole source. 
Rather, citrate from the Kreb’s cycle also supplies the lipid synthesis pathway with 
acetyl CoA via the action of ATP-citrate lyase (ACLY) (Hynes and Murray, 2010). With 
this, it is perhaps not surprising that the loss of ACS has a negligible effect on Parkin 
translocation. In contrast, ACAC, FASN and SCD are absolutely required for the 
conversion of acetyl CoA into lipids (Figure 6.3, Porstmann et al., 2009), explaining the 
robust block on translocation here.   
 
7.4.2  NOVEL EVIDENCE FOR SREBP-PATHWAY INVOLVEMENT IN PD 
 
The final results chapter in this study performed an in-depth analysis of SREBP1 and 
FBXW7 in the context of the PINK1/Parkin-pathway. Here the effects of SREBF1 and 
FBXW7 silencing on Parkin translocation and mitophagy were confirmed in a low-
throughput setting (Figure 6.5). In order to elucidate the mechanism behind this 
pathway block, a number of approaches were taken. First, PINK1 transcript levels were 
assessed, as any reduction in PINK1 mRNA expression levels would likely influence 
the degree with which pathway processes were initiated. However, qRT-PCR analysis 
confirmed the maintenance of PINK1 expression after downregulation of these genes 
(Figure 6.7). Next, the effect of reduced SREBF1 and FBXW7 expression on general 
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autophagy was analysed. Here the hypothesis proposed that a block in general 
autophagy might lead to the pathway phenotypes observed, due to saturation of the 
autophagy degradation route. In support of this hypothesis, evidence from the literature 
highlights a number of SREBP-pathway links with autophagy. First, 
phosphatidylethanolamine (PE) required for the lipidation of the autophagosome 
membrane component LC3, requires the SREBP-pathway for its synthesis 
(Dobrosotskaya et al., 2002). Second, SREBP2 has been linked to the regulation of 
starvation-induced autophagy, associating with promoters of autophagy-related genes 
including ATG8 and ATG4, both involved in autophagosome biogenesis (Seo et al., 
2011). Third, the E3-ligase Gp78, involved in SREBP-pathway activation, has been 
shown to induce mitophagy in a Parkin-independent manner (Fu et al., 2013). 
However, when general starvation-induced autophagy was assessed in the absence of 
SREBF1 and FBXW7, the pattern of LC3 isoforms recapitulated that seen in control 
siRNA-treated conditions (Figure 6.9). Therefore, under the conditions tested the 
SREBP-pathway does not cause a general autophagy block.  
 
Next, the effect of SREBP-pathway members on ∆Ψm was assessed. Here if gene 
silencing produced a reversal of ATP-synthase, the PINK1/Parkin-pathway would fail to 
be activated due to the maintenance of the ∆Ψm, and consequent absence of PINK1 
stabilisation on the MOM. In the literature, there are some grounds for this theory, as a 
recent whole genome RNAi screen identified ATPIF1 as producing this effect (Lefebvre 
et al., 2013). However, using the potentiometric dye, TMRM, no difference was 
observed between experimental and control siRNA-treated samples (Figure 6.10). 
 
Having disregarded the above hypotheses, the next question was whether the 
canonical, lipid synthesising function of the SREBP-pathway was important for 
PINK1/Parkin-processes. For this, fatty acids and cholesterol in varying concentrations 
and combinations were added to SREBF1 siRNA-treated cells prior to CCCP 
application (Figure 6.11). Indeed, certain combinations - specifically high 
concentrations of cholesterol and low concentrations of fatty acids, were able to 
partially rescue Parkin translocation. This result indicated that SREBP-pathway lipid 
synthesis was important for PINK1/Parkin-pathway activation. Interestingly, the 
addition of fatty acids and cholesterol in a PINK1 siRNA-background was unable to 
rescue Parkin translocation defects (Figure 6.12), suggesting that SREBP-pathway 
lipids act upstream of PINK1 in the pathway. In support of this, SREBF1 siRNA partially 
blocks PINK1 stabilisation on the MOM, suggesting a role for SREBP or SREBP-
dependent lipid synthesis in PINK1 activation (Figure 6.14). Here it will be important to 
ascertain whether the application of exogenous lipids is able to rescue the reduction in 
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PINK1-stabilisation, hence confirming a role for lipids in this process. In contrast, 
FBXW7 siRNA does not affect PINK1 stabilisation, suggesting that FBXW7 acts 
downstream of PINK1 in the PINK1/Parkin pathway.  
 
Biochemical analysis of SREBP following CCCP toxification revealed a reduction in 
inactive flSREBP1 in a time-dependent manner, suggesting a CCCP-dependent 
activation event (Figure 6.15). Intriguingly, this decrease in flSREBP1 was blocked by 
parkin siRNA treatment, indicating a feedback loop, whereby Parkin is involved in 
stimulating flSREBP1 activation and consequent lipid synthesis. However, whilst this is 
an attractive proposition, data from mSREBP1 analysis under the same conditions also 
produced a marked decrease over time even in the presence of a proteasome inhibitor. 
The reason for this is currently unknown, but may be due to insufficient proteasomal 
blockage or degradation via an alternative route.  
 
Finally, in vivo analysis of dSREBF, dFBXW7 and dGSK3 revealed climbing and flight 
defects in RNAi-treated animals comparable to those seen in dPINK1 and dparkin-
deficient animals (Figure 5.19). Whilst these data are encouraging and suggest defects 
in locomotion, without performing genetic interaction analyses it would be difficult to 
claim that these effects were PINK1/Parkin-pathway specific.  Preliminary efforts to 
assess genetic interactions between dSREBF, dFBXW7 and the PINK1/Parkin 
pathway focused on altering expression levels in a dparkin-null background. However, 
with the combinations tested, no obvious interactions were observed apart from 
increased lethality when overexpressing wild-type dSREBF in a dparkin-null 
background (Figure 6.20). This result ties in nicely with the suggestion that Parkin is 
involved in the activation of SREBP, as a constitutively active form of SREBP is viable 
in the absence of dparkin. Here, the next logical step is to test if dSREBF and dFBXW7 
overexpression are able to rescue dPINK1 mutant phenotypes. However, as cellular 
data indicate that dSREBF acts upstream of PINK1, the expected outcome here would 
be negative. However, the same may not be true for dFBXW7, as discussed below 
(Section 7.4.3.1). 
 
7.4.3  CLUES FROM THE LITERATURE 
 
Currently, there are no reports in the literature of a direct interaction between SREBP 
and PINK1 or Parkin. Despite this, a recent GWAS study has identified a SREBF1-
containing locus as a risk factor in the development of sporadic Parkinson’s disease 
(Do et al., 2011). This report is of great significance to this study as it provides a clear 
link between SREBF1, our top screening hit, and sporadic PD. Not only has this gone 
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some way towards validating the screening process, it has also highlighted the 
possibility of a link between sporadic risk variants and familial causes of PD, with 
mitochondrial turnover a central theme. 
 
Of the other SREBP-pathway genes included in the final hit group, FBXW7 has been 
found to physically and functionally interact with Parkin. First, FBXW7 was reported to 
act in a multi-protein, SCF-like complex with Parkin and Cullin-1, where the WD-repeat 
domain of FBXW7 interacts with the carboxy-terminus of Parkin in the region of the 
RING domains (Staropoli et al., 2003). This interaction mediates the proteasomal 
degradation of Cyclin E, a protein involved in apoptosis initiation following excitotoxicity 
in neurons, hence preventing cell death. Second, a recent study found that FBXW7 is 
degraded in a Parkin-dependent manner in primary neurons, allowing regulation of the 
SCF-complex (Ekholm-Reed et al., 2013). The outcome of this degradation event was 
the stabilisation of the MOM anti-apoptotic factor, Mcl-1. Together these data provide 
evidence that Parkin exerts cytoprotection by directly interacting with a SREBP-
pathway member, strengthening the suggestion that these two pathways are 
functionally related.  
 
More evidence for a common pathway function comes from the observation that both 
dSREBF RNAi expressing Drosophila and parkin-null Drosophila have a reduced body 
mass and wing size (Pesah et al., 2004; Porstmann et al., 2008) and parkin-null mice 
exhibit significantly lower weight-gain compared to control animals (Palacino et al, 
2004). These phenotypic similarities suggest a role for these two proteins in cellular 
growth. In agreement with this, the SREBP pathway is activated following elevated 
growth hormone signaling and consequent activation of the Akt/mTOR pathway 
(Porstmann et al., 2009). Additionally, Parkin regulates cellular uptake of fatty acids via 
the stabilisation of the fatty acid transporter CD36 (Kim et al., 2011). Together these 
data suggest that SREBP and Parkin promote cell growth via increases in intracellular 
lipids. 
 
7.4.3.1  Opposing actions of SREBP1, FBXW7 and GSK3A 
 
SREBP-pathway analysis reveals that SREBP promotes lipid synthesis and organism 
growth, whilst GSK3A and FBXW7 switch off the SREBP-pathway by promoting 
mSREBP proteasomal turnover. These opposing roles suggest that SREBF1 loss 
should produce opposite phenotypes to that of GSK3A and FBXW7. Indeed, 
mitochondrial morphology analysis revealed that dSREBF dsRNA causes a 
fragmented phenotype, whilst dFBXW7 causes a fused phenotype (Table 6.1). 
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Additionally, in contrast to the growth-promoting effects of SREBP, FBXW7 is a known 
tumour suppressor (Mao et al., 2004), which inhibits cell proliferation via the 
degradation of Cyclin E and Myc (Moberg et al., 2001; Mortimer and Moberg, 2007). 
However, in the context of the PINK1/Parkin-pathway, all three genes produce a 
pathway block, to varying degrees. Why this is the case is currently unknown, however 
it may be that a tightly controlled balance of lipid levels within the cell is required for 
PINK1/Parkin-pathway activation. In support of this, epidemiology studies in sporadic 
Parkinson’s disease have identified a correlation between decreased dietary fatty acids 
and cholesterol, and increased risk of developing PD (de Lau et al., 2005; de Lau et al., 
2006; Huang et al., 2008). Conversely, the accumulation of free lipids in cells can also 
produce lipotoxicity leading to ER and mitochondrial stress. Particularly relevant to 
mitochondria, elevated saturated fatty acids lead to increased ROS production and a 
fall in ∆Ψm, ultimately causing cell death (Rial et al., 2010). Additionally, in the brains 
of PD patients, elevated polyunsaturated fatty acids have been detected (Sharon et al., 
2003). These data highlight the importance of maintaining homeostatic lipid levels; 
where tipping the balance in either direction can have pathological consequences. 
 
Further to the above, reduced cellular cholesterol via the administration of Simvastatin 
in cardiomyocytes inhibited the Akt/mTOR pathway and evoked Parkin translocation, 
and mitophagy, providing cardioprotection (Andres et al., 2013). This result contrasts 
with our data, where SREBF1 silencing, and a presumed concomitant decrease in 
intracellular lipids leads to a block in Parkin translocation and mitophagy. However, 
while these results appear to contradict each other, they may help to explain why 
FBXW7, a negative regulator of the SREBP pathway produces the same phenotype as 
the loss of SREBF1 itself. Intriguingly, in our study the application of exogenous 
cardiolipin and phosphatidylethanolamine produced a Parkin translocation phenotype 
in control, but not SREBF1 siRNA-treated samples (Figure 6.13 E and J), suggesting 
that excess lipids can activate the PINK1/Parkin pathway. 
 
Another possible explanation for the equivalent effects of SREBF and FBXW7 siRNA 
could be that the persistence of mSREBP in the nucleus in the absence of proteasomal 
turnover leads to the hyper-activation of SREBP target genes, one of which is the 
negative pathway regulator INSIG. Here, over a silencing period of 4 days, INSIG 
levels may rise so high that SREBP becomes ‘locked’ in the ER despite the metabolic- 
or toxification- status of the cell. Under these circumstances, the loss of FBXW7 may 
produce phenotypes equal to the loss of SREBF itself. One way to test this hypothesis 
would be to analyse the cellular lipid profile after silencing these two genes. Here, the 
prediction would be a decrease in free lipids under both conditions.  
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However, a more attractive explanation for the corresponding phenotypes of SREBF1 
and FBXW7 is the occurrence of a non-SREBP related function of FBXW7. With 
regards to the degradation of FBXW7, Parkin was found to specifically target a 
cytosolic isoform of FBXW7, called FBXW7β, for proteasomal degradation (Ekholm-
Reed et al., 2013). Here, FBXW7β degradation was shown to be required for cell 
survival following the application of oxidative stressors such as CCCP and tertiary-butyl 
hydroperoxide (tBHP). The purpose of this degradation was the resulting stabilisation 
of the pro-survival, anti-apoptotic MOM protein, Mcl-1 (Ekholm-Reed et al., 2013). 
Interestingly, FBXW7-dependent degradation of Mcl-1 requires prior phosphorylation of 
Mcl-1 by GSK3. Taking these data together, I speculate that the trigger for Parkin 
translocation is the requirement for Mcl-1 stabilisation on the MOM. Therefore, in the 
absence of Mcl-1 degradation through FBXW7 and GSK3 silencing, a stable fraction of 
Mcl-1 persists, eliminating Parkin translocation and subsequent mitophagy. In support 
of this study, it has been shown that upregulation of Drosophila Bcl-2 (Buffy), an anti-
apoptotic MOM protein related to mammalian Mcl-1, can rescue PINK1B9 mitochondrial 
dysfunction in vivo (Park et al., 2006), highlighting a clear relationship between anti-
apoptotic mitochondrial proteins and the PINK1/Parkin-pathway.  
 
In contrast to the predicted lack of rescue of Drosophila dPINK1-null phenotypes 
following dSREBF overexpression (section 7.4.2), if FBXW7 is responsible for Parkin 
translocation downstream of PINK1, dFBXW7 overexpression may rescue the 
associated phenotypes. However, if Parkin translocation requires both PINK1 
stabilisation and FBXW7, dFBXW7 overexpression would have no effect on the PINK1-
null phenotypes. Alternatively, if dFBXW7 overexpression leads to potent Buffy 
degradation, the outcome may be widespread apoptosis and a resulting reduction in 
viability. Unfortunately this scenario was not tested due to time restrictions. 
  
GSK3A, a gene with very close homology and functional redundancy to the more 
widely studied GSK3B (Doble et al., 2007; Doble and Woodgett, 2003) was also 
present in the final human hit list. Interestingly, where GSK3β is known to co-ordinate 
the regulation of SREBP-stability together with FBXW7, it was found to have no effect 
on the PINK1/Parkin-processes tested. However, the loss of GSK3A produced a 
moderate Parkin translocation and mitophagy block. The reasons for this are unknown, 
however, it may be that like GSK3β, GSK3α can phosphorylate SREBP, leading to its 
degradation. This would make GSK3α a negative regulator of the SREBP-pathway. 
However, this is yet to be formally tested. To address this, the stability of mSREBP 
following GSK3A and GSK3B silencing could be analysed, as GSK3B loss causes an 
increase in mSREBP protein levels (Bengoechea-Alonso and Ericsson, 2009; 
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Sundqvist et al., 2005). An alternative explanation is that GSK3A is a known 
transcriptional target of SREBP (Reed et al., 2008). Therefore loss of SREBF and 
GSK3A could produce equivalent phenotypes. However, as mentioned above, together 
with FBXW7β, GSK3 is known to be involved in Mcl-1 degradation, highlighting yet 
another role for GSK3.  
 
Taken together, the preferred explanation for the equivalent pathway effects are as 
follows: 1) SREBP1 acts upstream of PINK1, where lipid synthesis is required for 
efficient stabilisation of PINK1 and translocation of Parkin to mitochondria. 2) FBXW7β 
and GSK3 act downstream of PINK1, with a role in degrading the anti-apoptotic 
mitochondrial factor, Mcl-1. Here, for mitophagy to proceed without the release of pro-
apoptotic mitochondrial factors, Parkin must degrade FBXW7β at the MOM, hence 
promoting Mcl-1 stabilisation and cell-protection. Here, Parkin translocation may be 
triggered by the GSK3/FBXW7β-dependent reduction in Mcl-1 levels.  
 
Presumably, FBXW7 siRNA targets the cytosolic β isoform, as well as the nuclear α 
and γ isoforms. However, the predicted increase in lipid synthesis resulting from 
FBXW7α/γ silencing and subsequent stabilisation of mSREBP is unlikely to override 
the loss of FBXW7β, as this is anticipated to act further downstream in the 
PINK1/Parkin-pathway.  
 
 
7.5  MODEL 
 
Despite a number of unresolved questions regarding the interaction between the 
PINK1/Parkin- and SREBP-pathways, a general picture of how these proteins interact 
to co-ordinate PINK1/Parkin-mediated mitophagy is beginning to emerge (Figure 7.1). 
First, increased cellular stress by CCCP toxification affects both the mitochondrial 
network (Figure 7.1 A) and the endoplasmic reticulum (Figure 7.1 B) (Bouman et al., 
2011). In the context of the endoplasmic reticulum, CCCP is known to activate the 
unfolded protein response (UPR), involved in degrading misfolded proteins. A master 
regulator of this process is the stress-transducer kinase PERK. PERK acts by 
temporarily inhibiting de novo protein translation via the inactivating phosphorylation of 
eukaryotic translation initiation factor-2 (eIF2α) (Bobrovnikova-Marjon et al., 2008; Ron 
and Walter, 2007). Importantly, a known effect of this translation inhibition is the 
depletion of the SREBP-negative regulator INSIG (Lee and Ye, 2004). Therefore ER-
stress, caused by CCCP, can promote the activation of SREBP and hence its target 
genes, purportedly by reducing the inhibitory effects of INSIG1. Interestingly, the 
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Figure 7.1 Model of novel interactions between the PINK1/Parkin-pathway, SREBP and FBXW7. Schematic of the 
proposed interaction between PINK1/Parkin-mediated mitophagy, SREBP in the endoplasmic reticulum and FBXW7 on 
the mitochondrial outer member. In brief, Parkin-dependent SREBP pathway activation, and CD36 & FASN stabilisation 
following cellular stress produces an increase in the lipid content of the cell. If this reaches a permissive level, Parkin 
undergoes translocation in an FBXW7-dependent manner, in order to prevent apoptosis and induce mitophagy. For cell 
survival, mitochondrial biogenesis replaces lost mitochondria via the utilisation of free lipids. 
 
CCCP-dependent decrease in inactive flSREBP1 is blocked by the loss of Parkin 
(Figure 6.15), suggesting that Parkin is involved in the activation of SREBP1, 
conceivably via the ubiquitination and degradation of the existing INSIG pool (Figure 
7.1 C).  
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Another outcome of the CCCP-induced UPR is the upregulation of parkin expression 
by the PERK-activated transcription factor ATF4 (Figure 7.1 D, Bouman et al., 2011), 
demonstrating a putative positive feedback loop, sustaining the activation of SREBP by 
Parkin. The outcome of SREBP-pathway activation is the upregulation of lipogenesis-
pathway enzymes leading to increased lipid synthesis (Figure 7.1 E). This elevation in 
de novo lipid synthesis is proposed to be necessary for the initiation of PINK1/Parkin-
mediated mitophagy. In support of this, Parkin can produce a local increase in cellular 
fatty acid content by ubiquitinating and stabilising the fatty acid transporter, CD36 
(Figure 7.1 F). Additionally, upon CCCP, Parkin ubiquitinates and stabilises the 
essential lipid synthesis enzyme, FASN (Sarraf et al., 2013), two events presumably 
leading to an increase in intracellular lipid content (Figure 7.1 G). With this, the 
potential to generate replacement mitochondria is anticipated to be a permissive event, 
allowing mitophagy to proceed.  
 
In the event of low intracellular lipids, such is the case following SREBF silencing; this 
model would predict a block of PINK1/Parkin-mediated mitophagy, upstream of PINK1 
stabilisation. Conversely, in the case of ‘permissive’ lipid content, PINK1 is stabilised 
on the MOM (Figure 7.1 A), Parkin is recruited, Parkin substrates are ubiquitinated and 
mitophagy can proceed. Here, Parkin translocation may be dependent on steady-state 
Mcl-1 levels, which are regulated by FBXW7β (Figure 7.1 H). In this scenario, a CCCP-
dependent reduction in Mcl-1 levels through the coordinated action of GSK3 and 
FBXW7β could trigger Parkin relocation. Consequently at the MOM, Parkin 
ubiquitinates FBXW7β leading to its removal by the proteasome, thus preventing 
initiation of apoptosis (Figure 7.1 I). 
 
7.5.1  REVISED PINK1/PARKIN PATHWAY 
 
If the proposed model is correct, this study has achieved its original aim of identifying 
novel members of the PINK1/Parkin-pathway. Here, I surmise that the role of the 
pathway is not only in the degradation of dysfunctional mitochondria, but also in the 
prevention of toxin-induced apoptosis via Mcl-1 stabilisation, and the increase in 
cellular lipid content for mitochondrial biogenesis. Support for the latter function of the 
PINK/Parkin-pathway comes from a study showing that Parkin promotes mitochondrial 
biogenesis by causing the degradation of PARIS - a transcriptional repressor of the 
mitochondrial biogenesis gene, PGC-1A (Shin et al., 2011). Additionally, high levels of 
dietary fat cause an increase in parkin expression (Kim et al., 2011), suggesting that 
excess cellular lipids may permit basal degradation and replacement of failing 
mitochondria. Finally, CD36 has been found on the MOM (Smith et al., 2011), 
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Figure 7.2 Revised PINK1/Parkin pathway containing SREBP, GSK3A and FBXW7. Schematic of the revised 
PINK1/Parkin pathway showing SREBP1 and SREBP1-depedent lipid synthesis upstream of PINK1; and GSK3A and 
cytoplasmic FBXW7 (FBXW7β) downstream of PINK1. Here, GSK3A and FBXW7β co-ordinate the removal of the pro-
apoptotic factor, Mcl-1 from mitochondria following toxification. Parkin translocates to the nucleus and degrades 
FBXW7β, promoting the stabilisation of Mcl-1 and survival of the cell. Mfn and Miro are also degraded in a Parkin-
dependent manner, leading the sequestering and isolation of damaged mitochondria. Finally, Parkin ubiquitinates and 
stabilises FASN and CD36 causing a local increase in lipid levels. Together with SREBP1-dependent lipogenesis, 
mitochondrial biogenesis can proceed. 
 
suggesting that Parkin may also regulate the uptake of fatty acids into mitochondria for 
the initiation of mitochondrial biogenesis. 
 
In summary, I have identified two novel promoters of PINK1/Parkin-mediated 
mitophagy upstream of Parkin translocation. Here, SREBP and SREBP-dependent 
lipid synthesis act upstream of PINK1 stabilisation, and FBXW7 acts downstream of 
PINK1 stabilisation (Figure 7.2). Despite a lack of full understanding of the regulatory 
mechanisms involved in these processes, this screen has identified a novel interaction 
between two well-studied pathways, the PINK1/Parkin-pathway, and the SREBP-
pathway, both of which have been genetically linked to Parkinson’s disease. This 
demonstrates a significant advance in our understanding of the way that mitochondrial 
turnover is regulated, and also highlights the possibility of a common, mitochondrial 
etiology for both familial and sporadic forms of Parkinson’s disease.  
SREBP1 
Fatty acids & Cholesterol 
PINK1 
Parkin 
GSK3A 
FBXW7β 
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9.1  ASSESSING siRNA SILENCING 
 
In order to understand the relationship between SREBP- and PINK1/Parkin-pathways, 
both cellular and in vivo approaches were utilised. From a cellular point of view, the 
main tool at our disposal was the transient silencing of pathway genes using siRNA. In 
Chapter 6, low-throughout analysis of screen hits utilised HeLa and YFP-Parkin.HeLa 
cell lines in combination with PINK1, parkin, FBXW7 and SREBF1 siRNAs. To assess 
the efficiency of gene silencing qRT-PCR methods were employed (Figure 9.1). These 
data demonstrate the efficient knockdown of all genes tested in both HeLa cells (Figure 
9.1 A-D), and YFP-Parkin.HeLa cells (Figure 9.1 E-H). Importantly, in agreement with 
published data, HeLa cells lack detectable levels of endogenous parkin (Figure 9.1 B), 
hence the requirement for Parkin overexpression when utilising these cells in pathway 
analysis (Denison et al, 2003).    
 
 
9.2  PARKIN TRANSLOCATION RESCUE WITH LIPIDS 
 
As outlined in section 6.3.6, Parkin translocation following SREBF1 siRNA treatment 
could be rescued by the addition of exogenous cholesterol and/or fatty acids. Here, 
Figure 9.2 represents accompanying control data, demonstrating an absence of effect 
on Parkin translocation following the application of fatty acids and cholesterol in non-
toxified control and SREBF1 siRNA samples (Figure 9.2 A). These data confirm that 
cholesterol and fatty acids are unable to trigger Parkin translocation in the absence of 
CCCP, suggesting a lack of general toxicity conferred by their presence. Additionally, 
there was an absence of effect following fatty acid and/or cholesterol application in 
CCCP-treated control siRNA samples (Figure 9.2 B). Together, these control assays 
suggest that the observed rescue of Parkin translocation in SREBF1-silenced cells 
following CCCP (Figure 6.11) is specific to the reinstatement of SREBF1 pathway 
products, and not due to general cellular or mitochondrial toxicity. 
 
 
9.3  SREBP1 (2A4) ANTIBODY ANALYSIS 
 
The SREBP-pathway has been studied in great detail since its discovery in 1993 
(Briggs et al, 1993; Wang et al, 1993). As a consequence, many antibodies for SREBP 
protein analysis are available. One of the most widely used SREBP1 antibodies 
originates from the lab of Goldstein and Brown, raised against an epitope known as 
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2A4 (Figure 9.3 A, Sato et al, 1994). This epitope is available from a number of 
different companies, and recognises both flSREBP1a and c, and mSREBP1a and c. In 
order to test the specificity of the antibody, YFP-Parkin.HeLa cells were treated with 
either control or SREBF1 siRNA. Under control conditions, only flSREBP1 was visible, 
forming a band at ~125 kDa (Figure 9.3 B). Following SREBF1 siRNA treatment, this 
high molecular weight band greatly reduced in strength, indicating that the antibody 
specifically recognised flSREBP1. To ascertain why the activated mSREBP1 form was 
not visible, cells were treated with control siRNA plus the proteasomal inhibitor MG-132 
(Figure 9.3 C). Here, as nuclear mSREBP1 is known to be rapidly turned over by the 
proteasome, a block at this level should reveal a lower molecular weight band of ~68 
kDa. Indeed, a relatively faint band of this weight was now visible, demonstrating that 
prior experiments probably failed to detect mSREBP1 due to its instability. Another way 
to inhibit mSREBP1 turnover was to silence FBXW7 – a SCF-complex protein involved 
in its turnover in the nucleus (Figure 9.3 D). Once again, a lower molecular weight 
band of ~68 kDa was visible, albeit at even lower levels than that observed with MG-
132 treatment. This may have been due to incomplete silencing of FBXW7, as qRT-
PCR data suggests that FBXW7 knockdown reduces expression to ~30% (Figure 9.1 
H), indicating residual FBXW7 activity within the cell. 
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Figure 9.1 qRT-PCR analysis of gene expression following siRNA treatment. HeLa cells (A - D) or YFP-
Parkin.HeLa cells (E-H) were exposed to 25 nM of control (A - H), PINK1 (A & E), parkin (B & F), FBXW7 (C & G) or 
SREBF1 (D & H) siRNA for 4 days. Gene expression levels were analysed using qRT-PCR against the housekeeping 
gene RNA18S5. Graphs represent the mean of 3 biological repeats. Error bars represent the standard deviation. 
**P<0.01, ***P<0.0001 (Student’s T-test). 
 
 
 
1.00 
0.31 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA FBXW7 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
** 
1.00 
0.20 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA SREBP1 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
*** 
1.00 
0.11 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA PINK1 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
*** 
0.00 0.00 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA PARK2 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
FBXW7 SREBF1 PINK1 parkin A B C D 
H
eLa 
N
or
m
al
is
ed
 m
R
N
A 
Le
ve
ls
 
1.00 
0.27 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA FBXW7 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
*** 
1.00 
0.19 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA SREBP1 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
*** 
1.00 
0.10 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA PINK1 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
*** 
1.00 
0.12 
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
Scramble siRNA PARK2 siRNA 
N
or
m
al
is
ed
 F
ol
d 
E
xp
re
ss
io
n 
*** 
E F G H 
FBXW7 SREBP-1 PINK1 parkin 
Y
FP
-P
arkin.H
eLa 
N
or
m
al
is
ed
 m
R
N
A 
le
ve
ls
 
Control 
siRNA 
PINK1 
siRNA 
Control 
siRNA 
parkin 
siRNA 
Control 
siRNA 
SREBF1 
siRNA 
Control 
siRNA 
FBXW7 
siRNA 
Control 
siRNA 
PINK1 
siRNA 
Control 
siRNA 
park n 
siRNA 
Control 
siRNA 
SREBF1 
siRNA 
Control 
siRNA 
FBXW7 
siRNA 
 292 
 
 
Figure 9.2 Parkin translocation with fatty acids and cholesterol – controls analysis. Assay performed as in Figure 
6.12. (A) Graphical representation of Parkin translocation following control or SREBF1 siRNA application in the absence 
of CCCP. (B) Graphical representation of Parkin translocation following control siRNA application after CCCP 
toxification for 4 hours. Data represent 1 biological repeat with 5 FOV per condition. FA - fatty acids; Chol – cholesterol. 
High – high concentration; Low – low concentration. 
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Figure 9.3 SREBP1 (2A4) antibody analysis. (A) Protein sequence of SREBP1a, with flSREBP1 (whole sequence 
including black, green and red), mSREBP1c (green and red) and the SREBP1 (2A4) epitope (red) highlighted. The 
SREBP1 (2A4) epitope also recognises flSREBP1c, and mSREBP1c (data not shown). (B) Western blot analysis of 
SREBP1 protein levels in YFP-Parkin.HeLa cell samples exposed to control or SREBF1 siRNA, and 10 µM CCCP for 0 
- 6 hours. In this assay, SREBP1 is visualised using the SREBP1 (2A4) antibody in (A) from Santa Cruz. (C) Analysis of 
SREBP1 protein levels in the presence of the proteasome inhibitor MG-132 (25 µM). (D) Analysis of SREBP1 protein 
levels in the presence of FBXW7 siRNA. (B – D) loading control – tubulin. 
 
  
